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Abstract 
The mechanisms underlying the development of insulin resistance in skeletal 
muscle are very complex and are not completely understood. Insulin resistance 
in skeletal muscle is of particular importance because muscle is the major site of 
insulin stimulated glucose uptake. Skeletal muscle is one of the major insulin 
sensitive organs and it is responsible for 80% of insulin stimulated glucose 
disposal as well as fatty acid oxidation. Elevated circulating free fatty acids 
(FFAs) and their derivatives such as endocannabinoids (ECs) have been 
described in obesity and are thought to be influential in the development of 
muscle insulin resistance. While several hypotheses have been put forward to 
explain the mechanisms by which FFAs and ECs may cause insulin resistance, 
there are still many potential signalling pathways which may be involved that 
have not yet been examined.   The main aim of this thesis was to characterize 
the role of the cannabinoid receptors and free fatty acid receptor 1 (GPR40) in 
cell signalling in human and rat skeletal muscle tissue and primary cultured 
myotubes. Gene expression profiling of human skeletal muscle and cultured 
myotubes and myoblasts indicated that the cannabinoid receptor CB1 and GPR40 
were expressed at low levels and these results were confirmed using Taqman 
QRTPCR. CB2 receptor expression was only detected in rat tissue and as a result 
was not further studied in cell culture systems.  When global gene expression 
profiles were further examined it was evident that whilst cultured myotubes 
retained many characteristics of skeletal muscle tissue, the phenotype appeared 
to be closer to fetal than adult muscle. Furthermore, when metabolic gene 
expression networks were analysed using pathway based analysis, it was 
apparent that expression of genes involved in oxidative phosphorylation, insulin 
signalling and glucose transport were markedly reduced in cultured cells. The 
most striking example being GLUT4 which was expressed at approximately 
3000-fold lower levels in cell culture as compared to tissue. 
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The functionality of CB1 and GPR40 receptors was demonstrated using selective 
agonists and antagonists. CB1 activation by both synthetic and endogenous 
ligands was confirmed using phosphorylation of ERK1 and 2 as was the presence 
of functional GPR40 protein in myotubes. Neither agonists nor antagonists of 
CB1 or GPR40 receptors were found to modulate insulin signalling as determined 
E\SKRVSKRU\ODWLRQRIGRZQVWUHDPWDUJHWV$NWDQG*6.ĮE 
Global expression profiling was also carried out on myotubes treated with GPR40 
agonists and antagonists obtained from AstraZeneca.  No changes in metabolic 
or insulin signalling genes were observed. Rather, antagonists of GPR40 appear 
to activate gene expression networks involved in cell proliferation ± in particular 
an elevation in the ERBB2 signalling pathway. 
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CHAPTER 1. General Introduction 
 
1.1. Insulin resistance in skeletal muscle 
1.1.1. Introduction 
Diabetes is a chronic disease that occurs either when the pancreas does 
not produce enough insulin or when the body cannot effectively use the insulin it 
produces. The World Health Organization (WHO) in March 2013 reported that 
347 million people worldwide have diabetes. Type 2 diabetes comprises 90% of 
people with diabetes around the world and is largely the result of excess body 
weight and physical inactivity. Obesity is now considered as an epidemic disease, 
decreasing life expectancy because of adverse consequences such as type 2 
diabetes. In 2008, 10% of men and 14% of women in the world were obese 
%0,NJPFRPSDUHGZLWKIRUPHQDQGIRUZRPHQLQ,Q
fact, 80% of diabetes cases can be attributed to weight gain. Obesity causes a 
predisposition to developing diabetes because a high body mass index of >40 is 
associated with an almost 100% risk for the disease (Sell et al. 2006). The 
pathophysiology of type 2 diabetes involves defects in tissue sensitivity to insulin 
and decreased insulin secretion. Insulin resistance starts with an inability of 
peripheral target tissues (liver, adipose and skeletal muscle) to respond properly 
to insulin which is followed by a compensation state through increasing insulin 
VHFUHWLRQ DQG HQGHG E\ SDQFUHDWLF ǃ FHOO IDLOXUH UHVXOWLQJ LQ GHFUHDVHG LQVXOLQ
secretion. Insulin resistance precedes the onset of overt diabetes by 1 to 2 
decades (Dipl-Pharm & Zierath 2005). Communication between the tissues 
responsible for insulin resistance (particularly adipose tissue and skeletal muscle) 
occurs through metabolic mediators of Free Fatty acids (FFAs) and their 
metabolites and endocrine mediators in the form of adipokines and possibly 
myokines.  
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Insulin resistance especially in skeletal muscle which is responsible for 70-
80%  of peripheral glucose disposal, is an early sign and cause of type two 
diabetes (Di-Marzo & Matias 2005; Edfalk et al. 2008). Skeletal muscle is the 
primary site of insulin-mediated glucose uptake defects in insulin action on 
glucose uptake and metabolism. Skeletal muscle insulin resistance precedes the 
manifestation of type 2 diabetes. Circulating levels of FFAs, which are markedly 
increased in obesity and associated-diseases, has a core role in the development 
of skeletal muscle insulin resistance. Among the different types of fatty acids, 
saturated long-chain fatty acids such as palmitic and stearic acids were 
demonstrated to be potent inducers of insulin resistance. Several mechanisms 
have been suggested to explain the mechanism through which saturated fatty 
acids impair insulin actions such as the Randle cycle, accumulation of 
intracellular lipid derivatives, defect in insulin signalling, oxidative stress, 
modulation of gene transcription, inflammation and mitochondrial dysfunction.  
1.1.2. Mechanisms underlying the insulin resistance induced by 
saturated fatty acids 
1.1.2.1. The Randle cycle 
Around 50 years ago Randle and his colleagues hypothesised that 
increased fatty acid oxidation raises the production of acetyl-CoA resulting in 
inhibition of pyruvate dehydrogenase activity and elevation of citrate levels at 
the tricarboxylic acid cycle (Error! Reference source not found.) (Samuel et al. 2010; 
Randle 1998). Citrate together with an increased ATP/ADP ratio reduces the 
activity of phosphofructokinase and consequently glucose flux through the 
glycolytic pathway, resulting in glucose 6-phosphate accumulation, hexokinase II 
inhibition, increase in intracellular glucose content and, consequently, reduction 
in glucose uptake (Petersen & Shulman 2002; Boden & Shulman 2002). 
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Figure 1-1: Glucose-fatty-acid cycle proposed by Randle and colleagues CoA=coenzyme A. 
PDH=pyruvate dehydrogenase. PFK=phosphofructokinase. G6P=glucose-6-phosphate. 
HK=hexokinase. Red circle with minus sign represents inhibition. Black line with arrowhead 
represents increase or accumulation of substrate. Blue dotted line with arrowhead indicates a 
pathway that is inhibited. Adapted from Pender et al. (2005) 
 
Further studies demonstrated that the insulin resistance induced by fatty 
acids is primarily associated with impaired glucose uptake rather than changes in 
hexose metabolism (Arner 2002). Roden et al. (1996) demonstrated that the 
reduction in muscle glycogen synthesis is preceded by a decrease in 
intramuscular glucose 6-phosphate, suggesting that inhibition of glucose 
transport or its phosphorylation are the main reasons of insulin resistance. Other 
studies also demonstrated that lipid infusion decreases intracellular glucose and 
glucose 6-phosphate content, due to inhibition of glucose uptake by skeletal 
muscle (Petersen & Shulman 2002). However, Tsintzas et al. (2007) 
demonstrated that lipid induced decrease in insulin-stimulated glucose uptake 
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happened after a reduction in carbohydrate oxidation. Thompson et al. (2000) 
reported that the reduction of basal and insulin stimulated glucose uptake by 
palmitate in rat muscle occurred after reduction in glycogen synthesis. Moreover, 
the role of PDK4 in skeletal muscle insulin resistance induced by high FFA was 
addressed by Tsintzas et al. (2007) and Chokkalingam et al. (2007). They 
observed an early upregulation of PDK4 content in skeletal muscle biopsy from 
healthy humans after 6 days of high fat diet, which was associated with a 
reduction in skeletal muscle PDC activation and hence glucose oxidation but not 
glucose disposal mediated skeletal muscle insulin resistance. A high level of 
muscle PDK4 protein expression was observed in starved and diabetic rats (Wu 
et al. 1999). Upregulation of muscle PDK4 protein and mRNA expression in 
starved humans may mediate the insulin resistance induced by the  high  fatty 
acids level in fasting (Tsintzas et al. 2006).  
 
1.1.2.2. Inhibition of skeletal muscle insulin signalling  
Under physiological conditions, insulin activates glucose uptake by 
stimulating the canonical IRS-PI3K-Akt pathway and by phosphorylating and 
inactivating Akt substrate 160 (AS160), a protein that, when activated, prevents 
glucose transporter (GLUT) 4 translocation to the membrane (Martins et al. 2012) 
(Figure 1-2). Saturated fatty acids were demonstrated to affect insulin 
intracellular signalling pathways in skeletal muscle and myocytes. Thompson et 
al. (2000) and Yu et al. (2002) have demonstrated a marked reduction in IRS-1 
tyrosine phosphorylation, PI3-kinase activity and Akt phosphorylation and 
activity in skeletal muscle after lipid infusion in euglycemic hyperinsulinemic 
clamp. However, Tsintzas et al. (2007) did not observe any alteration in muscle 
Akt after lipid infusion. As reviewed by Schmitz-Peiffer (2000), palmitic acid was 
shown to decrease insulin receptor expression and activity and  phosphorylation 
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of IRS-1 and -2 at tyrosine residues, Akt and GSK-3 in isolated soleus muscle, 
primary culture of rat myocytes, pmi28 myotubes, C2C12 and L6 myocytes. 
Activation of various kinases by FFAs such as PKCs, JNK and p38 MAP kinase 
catalyse the phosphorylation of serine residues in IRS-1 instead of tyrosine 
phosphorylation leading to blocking of its downstream signal transduction. Ruiz-
Alcaraz et al. (2013) observed a significantly reduced insulin-induced activation 
of p42/44 MAP kinase in volunteers with poor insulin sensitivity. It is now known 
that FFAs interfere with insulin signaling in skeletal muscle at the level of IRS-1 
serine phosphorylation, involving the activation of protein kinase C. Various PKC 
isoforms have been shown to be involved in lipid-induced insulin resistance in 
skeletal muscle (Griffin et al. 1999). 
 
Figure 1-2: Overview of insulin signalling pathways downstream of the insulin receptor in skeletal 
muscle. 
Activation of insulin receptor leads to tyrosine phosphorylation of IRS family, SHC and Cbl.  Tyrosine  
phosphorylation of IRS results  in the activation of a variety of signalling pathways; the RAS/ MAPK 
pathway which involved in gene regulation, CAP/ Cbl pathway which participate in insulin mediated 
glucose transporter through activation of TC10 and PI3-kinase which phosphorylate AKT (PDK1 
dependent) and in turn phosphorylate  GSK3,  activate the  mTOR and glucose uptake. AS160 = 
160-kDa Akt substrate, CAP = Cbl-associated protein,  GLUT4 = glucose transporter 4, GSK3 
=glycogen synthase kinase 3   Grb2 = growth factor receptor-bound protein 2,  IRS = insulin 
receptor substrate, MAPK = mitogen-activated protein kinase, PDK-1 = 3-phosphoinositide-
dependent protein kinase-1,  PI3 = phosphatidylinositol 3, PKC zeta/lambda = protein kinase C 
zeta/lambda,  RAS = retrovirus-associated DNA sequences,  Shc = Src homology 2 domain-
containing protein, SOS = son-of-sevenless protein. Adapted with modification from (Dipl-Pharm & 
Zierath 2005) 
TC10
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1.1.2.3. Lipotoxic intramyocellular lipid accumulation  
Elevation of plasma FFAs and its metabolites leads to ectopic fat stores 
which have lipotoxic effects on skeletal muscle and other peripheral tissues 
(Martins et al. 2012). Genetic deletion of lipoprotein lipase, fatty acid 
transporters, and diacylglycerol acyl transferase-1 inhibited the accumulation of 
intramyocellular diacylglycerol and triacylglycerol induced by high fat diet (Wang 
et al. 2009). Diacylglycerol directly activates 3.&Ǉ WKDW FDWDO\]HV WKH
phosphorylation of serine-307 residue at IRS-1, reducing its tyrosine 
phosphorylation and activation by insulin (Schmitz-Peiffer C et al. 1997). 
Increased production of ceramide and sphingosines in skeletal muscle cells due 
to high fat diet is associated with glucose intolerance and insulin resistance 
(Chavez et al. 2005). In addition, Han et al. (2011)  demonstrated that 
increased lysophosphatidylcholine content in myocytes leads to serine 
phosphorylation IRS-1 and induce insulin resistance. 
1.1.2.4. Activation of inflammatory signaling pathways  
A close relationship between chronic inflammation and skeletal muscle 
insulin resistance has recently been established. Saturated fatty acids activate 
inflammatory signaling pathways directly through interaction with members of 
Toll-like receptor (TLR) family and indirectly through the secretion of cytokines 
LQFOXGLQJ 71)Į,/-ǃ DQG ,/-6 (Sell et al. 2006; Martins et al. 2012). This is 
supported by increased macrophages and increased inflammatory molecules. 
$FWLYDWLRQRI-1.DQG,..ǃE\VDWXUDWHGIDWW\DFLGVLVDVVRFLDWHGZLWKDPDUNHG
inhibition of insulin action due to serine phosphorylation IRS-1(Wei et al. 2008). 
Diabetic and obese mice have increased skeletal muscle IKK and JNK activities, 
whose pharmacological and genetic inhibition leads to an improvement in insulin 
sensitivity and glucose tolerance (Solinas et al. 2006). Skeletal muscle generates 
and secretes several inflammatory cytokines named myokines including 71)Į
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IL-6, IL-1, IL-5Į,/-8, IL-10, IL-15, and monocyte chemotatic protein (MCP)-1 
which possibly modulate insulin sensitivity (Pedersen et al. 2007). The role of IL6 
in insulin sensitivity is controversial.  Increased levels of IL6 after exercise or 
after short-term treatment increase insulin sensitivity, whereas chronically 
increased levels are associated with insulin resistance (Weigert et al. 2005). 
,QFUHDVHGOHYHOVRI71)ĮKDYHEHHQQRWHGLQVNHOHWDOPXVFOHWLVVXHDQGFXOWXUHG
skeletal muscle cells from humans and animals with insulin resistance and/or 
diabetes (Saghizadeh & Ong 1996)*HQHWLFGHOHWLRQRI71)ĮDQGVXSSUHVVLRQRI
71)Į E\ DQWL-71)Į DQWLERGLHV RU 71)Į FRQYHUWLQJ HQ]\PH LQKLELWRUV LPSURYHV
insulin sensitivity in obese or nonobese insulin-resistant models (Wei et al. 2008). 
71)Į GHFUHDVHV W\URVLQH SKRVSKRU\ODWLRQ RI ,56-1 and increases IRS-1 serine 
phosphorylation (Eckardt et al. 2008). It is worth mentioning that Petersen et al. 
(2007) and Dietze et al. (2002) found that insulin resistance was independent of 
71)Į DQG ,/-6 in insulin resistance subjects and Storz et al. (1999) observed  
WKDW71)Į GLGQRW LQWHUIHUHZLWK$.7NLQDVHVLJQDOOLQJDQG LW increased GLUT1 
content suggesting a protective mechanism by increasing basal glucose uptake.  
2YHUIHHGLQJLQKHDOWK\KXPDQVUHVXOWHGLQVLJQL¿FDQWO\LQFUHDVHGLQSHULSKHUDO
LQVXOLQUHVLVWDQFHZLWKRXWFKDQJHVLQ LQÀDPPDWRU\JHQHH[SUHVVLRQ,/ (Tam 
et al. 2010).  
1.1.2.5. Oxidative stress and mitochondrial dysfunction  
Type 2 diabetes mellitus, obesity and the metabolic syndrome are strongly 
correlated with increased skeletal muscle content of reactive oxygen species 
(ROS) (Abdul-Ghani et al. 2008). Chronic elevation in plasma lipids levels and 
excessive accumulation of intramyocellular lipid content are characterized by 
increased reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
production. ROS lead to impaired insulin response by inducing IRS 
serine/threonine phosphorylation, decreasing GLUT4 gene transcription, and 
decreasing mitochondrial activity. Several studies have shown that mitochondrial 
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content, mitochondrial function, and oxidative capacity are decreased in insulin-
resistant obese and type 2 diabetic individuals (Holloway et al. 2007; Martins et 
al. 2012). Impaired mitochondrial function and reduced fatty acid oxidative 
capacity were found in isolated primary myocytes from insulin resistant obese 
and type 2 diabetic patients (B et al. 2005). High fatty acid availability in  type 2 
diabetes myotubes caused  an impaired mitochondrial capacity for fatty acid 
oxidation and glucose GXHWRGHIHFWVRIIDWW\DFLGǃR[LGDWLRQ(AJ et al. 2009). 
Exposure of rat L6 myotubes to high fatty acid levels lead to excessive but 
LQFRPSOHWH ǃ R[LGDWLRQ ZKLFK OHDG WR PLWRFKRQGULDO VWUHVV  DQG XOWLPDWHO\ WR
insulin resistance in skeletal muscle (Koves et al. 2008). 
A decrease in succinate dehydrogenase (a mitochondrial dysfunction 
marker) activity in insulin-resistant and  diabetic patients skeletal muscle cells 
indicates a possible role of decreased oxidative capacity in the initiation of 
adipocyte-derived muscle insulin resistance (Sell et al. 2006). Impairment of 
mitochondrial function leads to production of ROS and accumulation of fatty acid-
derived metabolites which lead to insulin resistance through activation of several 
kinases, such as NF kB, p38 MAP kinase, JNK, PKC-ǅ DQG 3.&-İ  DQG
subsequently serine phosphorylation in IRS-1 (Hirabara et al. 2010) (Figure 1-3). 
However, the role of  mitochondria dysfunction in skeletal muscle insulin 
resistance is still debatable as recently Galgani et al. (2013)  found no evidence 
of impaired muscle mitochondrial oxidative capacity in insulin-resistant vs 
insulin-sensitive individuals. Induction of skeletal muscle  insulin resistance by 
overfeeding in healthy individuals without a reduction in  mitochondrial content 
was observed by Samocha-Bonet et al. (2012).   
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Figure 1-3: Mechanisms underlying insulin resistance by impaired mitochondrial function as 
suggested by Martins et al. (2012). 
Mitochondria dysfunction leads to increase in FFAs derivatives, reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) which lead to decrease in IRS1 serine phosphorylation and content 
and eventually lead to insulin resistance adapted from Martins et al. (2012).  
 
1.1.2.6. Skeletal muscle fibre types and insulin resistance 
Skeletal muscle contains a unique composition of different muscle fibres 
UHIHUUHG WR DV µµVORZ-WZLWFK¶¶ DQG µµIDVW-twitch¶¶ 2Q WKH EDVLV RI PHWDEROLF DQG
contractile properties and myosin heavy chain (MyHC) isoforms, muscle fibres 
can be broadly classified as type I, oxidative, slow-twitch fibres and type II, fast-
twitch fibres which can be  further classified into type IIa, type IIx and IIb fibres, 
(Shi et al. 2007). Generally, type I and type IIa fibres utilize oxidative 
phosphorylation as their primary metabolic activity, whereas type IIx and IIb 
fibres primarily harness glycolysis to generate ATP. In response to environmental 
signals such as aging, atrophy, exercise, and diabetes, however, muscle can 
modify its functional characteristics by changing its fibre type (Pette & Staron 
2001). Conversion of fibre type happens both in vivo and in vitro (Zebedin et al. 
2004). An association between muscle fibres types and insulin resistance has 
been reported. Patients with central obesity, which is associated with insulin 
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resistance, had  higher proportions of type IIb fibres (Lillioja et al. 1987). Layne 
et al. (2011) observed   diminished type I fibre content in muscle biopsies from 
patients with type 2 diabetes and nondiabetic subjects with the metabolic 
syndrome. Skeletal muscle from obese patients also contains a smaller number 
of mitochondria because of a lower ratio of type I to type II muscle fibres 
(Martins et al. 2012).  
The reason that a higher proportion of type I fibres leads to better insulin 
responsiveness or higher utilization of oxygen during exercise remains elusive. 
Shi et al. (2008) and Shi et al. (2007) suggested that ERK1/2 pathway may play 
an important role in the maintenance of fast fibre phenotype and ERK1/2 activity 
was more than 2-fold higher in fast-twitch muscles than in slow-twitch muscle. 
In contrast, Murgia et al. (2000) and Higginson et al (2002) reported that 
Ras/MEK/ERK play a pivotal role in re-establishing the slow muscle programming 
as ablation of the ERK1/2 pathway increases MyHC IIx and IIb transcripts, 
whereas it decreases MyHC I expression in cultured rat fetal myocytes. 
Interestingly, Stuart et al. (2013) found a 21% fewer Type I muscle fibres, but a 
more than two-fold increase in the mixed Type IIa fibres in men and women with 
central obesity and a family history of type 2 diabetes. Moreover, down-
regulation of myogenin (transcription factor mainly found in type I) and IL-6 ( 
mainly expressed in type I fibres) in condition media treated myotubes might be 
indicative of the formation of less oxidative myotubes more similar to type II 
fibres in the presence of high concentration of fatty acids (Eckardt et al. 2008).  
Thus, the full explanation of the mechanism of insulin resistance in skeletal 
muscle remains elusive, but the search may be narrowed by examining the role 
of free fatty receptors and cannabinoid receptors. 
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1.2. The endocannabinoid system 
1.2.1. Introduction 
The endocannabinoid system is a complex endogenous signalling system 
which influences multiple metabolic pathways and takes its name from the 
cannabis plant. Even though the use of compounds containing cannabinoids to 
stimulate appetite and increase body weight is a traditional treatment, the 
understanding of their metabolism and action is quiet recent (Kunos 2007; 
Bellocchio et al. 2008) 7KH SV\FKRWURSLF FRPSRXQG RI PDULMXDQD Ʃ-
tetrahydrocannabinol (THC) was identified in 1964. Since then considerable 
research has been carried out to clarify the mechanisms of cannabinoid action.  
In the 1990s, receptors for THC were identified. The receptors CB1 and 
CB2 are G protein coupled membrane receptors (GPCR), the Gi/o family (Matias 
et al. 2008) which act through the adenyl cyclase pathway (Di-Marzo & Matias 
2005). CB1 receptors are the most common GPCR in the brain while CB2 
receptors are predominantly found in the immune system. In 2003 Cota et al. 
identified the presence of CB1 receptors in peripheral tissues such as adipose 
tissue, liver, pancreas and skeletal muscle, which are the major organs involved 
in energy metabolism. Even though most research has demonstrated the 
presence of CB2 in immune system solely, Engeli (2008b) has also found them in 
brain stem and Rajesh et al. (2008) found them in human myocardium and 
skeletal muscle.  
1.2.2. Endocannabinoids synthesis and degradation 
A number of ligands (ECs) for these receptors have been identified such as 
N-arachidononyl ethanolamine (anandamide) and 2 arachidonoyl glycerol (2AG) 
which are arachidonic acid derivatives. They are produced on demand as 
metabolic stress and cellular damage lead to an increase in EC synthesis 
(Bellocchio et al. 2008; Engeli 2008b; Matias et al. 2008). Enzymes for EC 
CHAPTER ONE 
 
 
 
  12 
 
 
  
biosynthesis have been identified; ethanolamine-selective phospholipase D for 
anandamide formation and Sn-1-selective diacylglycerol lipase for 2AG formation. 
EC are highly lipophilic compounds and they are rapidly hydrolyzed by fatty acid 
amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) into arachidonic 
acid (Burstein 2005; Bellocchio et al. 2008). 
The formation of anandamide involves a calcium dependent mechanism 
and occurs through the cleavage of NAPE, the precursor for anandamide, by a 
specific phospholipase D (NAPE-PLD). The activity of PLD is regulated by the 
activation of G protein coupled receptors, ionotropic receptors such as glutamate, 
N methyl-D aspartate and metabotropic receptors such as glutamate and 
acetylcholine (Piomelli 2003; Eckardt et al. 2008) (Figure 1-4). 
 The formation of 2AG is also a calcium dependent process. First, 
diacylglycerol is formed through the action of phosphatidylinositol specific PLC 
and then by the action of DAGL, 2AG is formed. The activation of metabotropic 
P2Y receptors as well as ionotropic P2X receptors, for example, facilitates 2 AG 
formation as the activation of these receptors leads to an increase in calcium 
entry into the cell, activation of DAGL and inhibition of MAGL (Eckardt et al. 2008) 
(Figure 1-4). 
 
Figure 1-4:  Factors regulating ECs synthesis. 
(a) The formation of anandamide occurs through the activation of the Calcium dependent N-
acyltransferas (NAT) and Phospholipase D, the former activity increases by the phosphorylation of 
cAMP protein kinase A (PKA). The degradation of anandamide is mediated by fatty acid amide 
hydrolase (FAAH). (b) The activation of metabotropic purinergic P2Y and ionotropic purinergic P2X 
receptors lead to the activation of phospholipase C (PLC) and diacylglycerol lipase (DAGL) and 
inhibition of monoacylglycerol lipase (MAGL), respectively. (Adapted from Eckardt K, 2008)  
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1.2.3. Mechanism of action of endocannabinoids 
The endogenous binding activity of EC to CB receptors is different. 
Anandamide is a partial agonist at CB1 and CB2 receptors with higher affinity for 
CB1 receptors, while 2AG is a full agonist at both receptors. Similar to 
anandamide, 2AG has higher affinity for CB1 receptors. CB1 and CB2 receptors 
activation lead to inhibition of adenyl cyclase and decrease in PKA. CB1 receptor 
activation is also associated with activation of K influx and inhibition of voltage-
Ca channels Figure 1-5. However, CB2 receptors activation is not associated with 
the modulation of ion channel functions. CB receptors activation: 
 Leads to phosphorylation of p42 & p44 MAPK, p38 MAPK and JNK which 
regulate nuclear transport factor (Howlett 2005). 
 and is coupled to phospotidylinositol 3 kinase and Focal adhesion kinase 
(Rodríguez de Fonseca et al. 2005)  
 
Figure 1-5: CB1 receptor intracellular signalling cascades. 
Activation of CB1 receptors leads to inhibition of adenyl cyclase and decrease in cAMP which 
stimulates K+A through inactivation of PKA. Through modulation of PKC, CB1 activation leads to 
inhibition of Ca++ channel and activation of inward rectifying of K+ ion channels. Activation of PKC will 
phosphorylate CB1 and prevent its effect on ion channels. CB1 activation also stimulates intracellular 
kinases, such as Focal Adhesion Kinase (FAK), Phosphatidyl inositol 3-kinase (PI3-K), Protein Kinase 
B (PKB), extracellular signal-regulated kinase (ERK), C-jun N-terminal Kinase (c-JNK) and p38 MAPK 
(p38). Adapted from Pagotto et al. (2006) 
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1.2.4. Other Potential endocannabinoid receptors: 
Not all ECs actions can be explained through activation of CB1 and CB2 
receptor-mediated pathways. Using CB1 and CB2 receptor antagonists, 
researchers have suggested the presence of other non CB receptors (Rodríguez 
de Fonseca et al. 2005) such as the nuclear receptor PPAR, Transmitter gated 
channel transient receptors vanilloid (TRPV1) and GPR55 which may also be 
activated by ECs. 
1.2.4.1. GPR 119 
GPR119 is thought to play an important role in metabolic disease and its 
modulators may influence parameters related to both diabetes and obesity. 
GPR119 is GPCR (class I rhodopsin-type) which increases cAMP levels (Overton 
et al. 2008). The major sites of expression in humans are pancreas, fetal liver 
and GIT as reported by Overton et al. (2008) while Bonini et al. (2001) & Bonini 
et al. (2002) reported that it is present in most rat tissues including brain.  
Oleoylethanolamide (OEA), a structural analogue of the cannabinoid 
anandamide, is a potent natural agonist for GPR119. Anandamide, 
Lysophosphotidyl choline (LPC) also activates GPR119. PSN375693 and 
PSN632408 are synthetic GPR119 agonists which stimulate insulin secretion in a 
glucose-dependent manner. The latter also decreases food intake and body 
weight in rats (Overton et al. 2008).  
,QWKHǃFHOORISDQFUeas GPR119 activation stimulates insulin secretion as 
well as that of glucagon like peptide (GLP) and gastric inhibitory polypeptide (GIP) 
in a glucose dependent manner (Figure 1-6). GPR119 controls glucose 
homeosWDVLVLQWZRZD\VILUVWO\E\VWLPXODWLQJLQVXOLQUHOHDVHIURPWKHǃFHOOVRI
the pancreas and secondly through the release of antihyperglycaemic agents 
such as GIP from enteroendocrine cells (Drucker 2001; Meier et al. 2002; 
Gromada et al. 2004). 
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Figure 1-6:  Proposed mechanisms of GPR119 agonist action. 
GPR119 agonists may affect food intake through direct action or by increase the concentration of 
Glucagon Like peptide 1 (GLp1) and Gastric Inhibitory polypeptide (GIP). GP5DOVROHDGWRǃFHOO
protection and prevention of diabetes. (Adapted from Overton HA et al 2008)  
 
1.2.4.2. Nuclear receptor PPAR;  
 2¶6XOOLYDQ  reported that inflammation, feeding behaviour and 
analgesic roles of ECs can be mediated through nuclear receptors. 2¶6XOOLYDQ
(2007) also reported that the synthetic CB1 and CB2 receptor agonist, Win55212, 
ELQGV WR 33$5Į ZKHUHDV DQDQGDPLGH ELQGV WR 33$5Ǆ GLUHFWO\ DQG VWLPXODWHV
differentiation of pre-adipocytes into adipocytes. It has been found that 2AG and 
$MXOHPLFDFLGDFWLYDWH33$5ǄZKLFKH[KLELWVVLPLODUDFWLRQ WR WKH&%DQG&%
agonist (Burstein 2005). 
1.2.4.3. Transmitter gated channel transient receptors Vanilloid 
1 (TRPV1)  
TRPV1 was cloned in 1997 (Cavuoto et al. 2007). Anandamide stimulates 
TRPV1 and causes calcium influx which leads to neurotransmitter release. 
Burstein (2005) suggested that the vasodilation effect of anandamide is 
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mediated through these receptors as it was not inhibited by a CB receptor 
antagonist (rimonabant), whereas the use of a selective TRPV1 antagonist 
abolished vasodilation. 
1.2.4.4. GPR55;  
Recently, GPR55 has been considered as a cannabinoid receptor. GPR55 is 
only 13.5% identical to CB1 and 14.4% identical to CB2, and its mRNA is present 
in the brain and peripheral tissues. Lauckner et al. (2008) reported that GPR55 is 
an additional cannabinoid receptor that activates signaling pathways distinct 
from CB1 or CB2, and that it may increase neuronal excitability. Anandamide 
and virodhamine activate GTPJS binding via GPR55 and ligands such as 
cannabidiol and abnormal cannabidiol which exhibit no CB1 or CB2 activity are 
believed to function through GPR55 (Ryberg et al. 2007) 
1.2.5. The roles of Endocannabinoids  
1.2.5.1. Central mechanisms. 
The presence of CB1 receptors has been established and they are the most 
abundant GPCR in the brain. The presence of CB2 receptor is still under 
investigation even though Van Sickle et al. (2005) demonstrated their presence 
in rat and ferret brainstem neurons. The production of ECs in the brain is under 
tight control as endocannabinoid levels are regulated by both synthesis and 
degradation. Leptin, which is a known negative regulator of orexigenic peptides, 
decreases the ECs level while ghrelin increases their level (Di-Marzo & Matias 
2005). 
The main role of ECs in brain is mediated through retrograde signalling 
(Figure 1-7) and the subsequent inhibition of neurotransmitters such as GABA, 
serotonin, acetylcholine and other neuropeptides. This might be one of ECs 
possible mechanism in controlling food intake as inhibition of GABA leads to 
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stimulation of MCH (Bellocchio et al. 2008). Another possible explanation for ECs 
action on the central nervous system is through the dopaminergic system, as 
dopamine receptors antagonists reduce the orexigenic stimulation of THC (Liu et 
al. 2005). CB1 can form a heterodimer with dopamine D2 receptor and this 
complex, unlike CB1, stimulates adenyl cyclase.   
  
Figure 1-7: Retrograde signalling by endocannabinoids. 
Depolarization of postsynaptic cell leads to opening of calcium channels and activation of 
metabotropic glutamate receptors (mGluR) which leads to increased endocannabinoid synthesis. 
Presynapticly, the activation of CB1 receptor liberDWHV *ǃǄ ZKLFK EORFNV &D++ channel and 
subsequently results in a decrease in intracellular calcium and the release of neurotransmitters. 
(Adapted from Wilson & Nicoll (2002)) 
 
In the brain, ECs control feeding behaviour in both human and animals by 
increasing appetite (Figure 1-8). It has been found that stimulation of 
cannabinoid receptors leads to an increase in food consumption and the blockade 
of CB1 receptors by antagonists such as Rimonabant leads to a decrease in 
appetite (Di-Marzo & Matias 2005). The effect of ECs on food intake starts from 
the early stages of life. Chan (2004) found that blockade of CB1 receptors in 
newborn mice leads to decrease in the suckling of milk. Similar findings were 
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reported in young rodents by Cota et al. (2003). Cannabinoid receptors are 
overactivated in animal models of genetic- and diet-induced obesity (Kunos 2007; 
Liu et al. 2005). Bellocchio et al. (2008) reported that Cannabinoid receptor 
stimulation in the brain leads to an increase in FA synthase gene expression. ECs 
also affect emotional state, motor function and pain perception. In addition they 
play a role in the control of neurexcitability, neuroprotection, nausea and emisis 
(Van Sickle et al. 2005). 
1.2.5.2. Peripheral effects 
It has been reported that the effect of ECs is mediated not only through 
central but also through peripheral mechanisms. ECs functions in adipose tissue, 
liver, pancreas and skeletal muscle are an attractive field for research 
(Figure 1-8). 
1.2.5.2.1. Liver 
CB1 receptors are present in mouse liver and their expression increases in 
response to a high fat diet. An increase in anandamide and a decrease in FAAH 
activity with no change in 2AG were also observed after a high fat diet (Eckardt 
et al. 2008)(&VVWLPXODWHDGLSRJHQHVLVWKURXJKWKHDFWLYDWLRQRI33$5ǄZKLFK
leads to maturation of adipocytes, inhibition of adenylate cyclase (Bellocchio et al. 
2008) and upregulation of LPL and SREBP-1C expression (Rajesh et al. 2008; 
Engeli 2008b). Activation of CB1 receptors in liver leads to inhibition of AMPK 
and stimulation of acetyl co-enzyme A carboxylase {ACC1} along with an 
increase in de novo fatty acid synthesis (Eckardt et al. 2008). Blocking of CB1 
receptors in cirrhotic liver, which exhibits a high level of CB1 expression, leads to 
a decrease in the fibrotic activity of hepatic myofibroblasts which may be due to 
WKHGHFUHDVHLQWUDQVIRUPLQJJURZWKIDFWRUVǃH[SUHVVLRQ(Engeli 2008b). 
1.2.5.2.2. Adipose tissue  
All genes responsible for biosynthesis and degradation of ECs are present 
CHAPTER ONE 
 
 
 
  19 
 
 
  
in adipocytes. The presence of CB2 receptors is not fully confirmed yet even 
though Pagano et al. (2007) reported the presence of both CB1 and CB2 
receptors. The enzymes NAPE-PLD, DAGL, FAAH, and MAGL have been found in 
adipose tissue (Roche et al. 2006). In addition adipocytes have the ability to 
synthesize 2AG and anandamide (Gonthier et al. 2007). High fat diets increase 
tissue levels of ECs (Artmann et al. 2008). Di Marzo & Matias (2005) found that 
ECs have a role in fat accumulation independent of the amount of dietary fat 
intake by acting directly on adipose tissue. ECs stimulate de novo FA synthesis 
through stimulation of glucose uptake, LPL activation and glycolysis (Eckardt et 
al. 2008) and upregulation of  SREBP-1C, acetyl COA carboxylase and fatty acid 
synthase gene expression (Matias et al. 2008). In cultured mouse adipocytes 
there is a 3-4 fold increase in CB1 protein content during differentiation and an 
increase in 2AG, DAGL, anandamide and NAPE-PLD in the first four days (Matias 
et al. 2006). 
The blockade of CB1 receptors by the antagonist (RIM) leads to stimulation 
of lipolysis and a release of FFA into the circulation and an increase in energy 
expenditure (Liu et al. 2005), a reduction of body weight and an increase in 
adiponectin expression (Eckardt et al. 2008). It has been noticed that stimulation 
and inhibition of adiponectin  gene expression occurs after the use of CB1 
receptor antagonist and agonist, respectively (Hollander 2007). 
1.2.5.2.3. Pancreas 
The expression of CB receptors in pancreas is species specific. In human 
pancreas, CB1 receptors are present in ǃ FHOOV DQG LQ VPDOODPRXQW LQǃ FHOOV
whereas CB2 are present in D cells and exocrine pancreas. DAGL and MAGL are 
present in islet cells while FAAH in E cells (Eckardt et al. 2008). Mouse CB1 
receptors are present in D cells and CB2 present in D and E cells (Engeli 2008b). 
In rat both CB1 and CB2 receptors are present in beta- and non-beta-cells  and  
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the endocannabinoid system modulates glucose homeostasis through the 
coordinated actions of cannabinoid CB1 and CB2 receptors (Bermudez-Silva et al. 
2007). Increased levels of 2AG and anandamide were observed in obese mice. 
Stimulation of CB1 and CB2 receptors leads to inhibition of insulin secretion by 
reduction of glucose-induced calcium oscillation (Eckardt et al. 2008). High 
glucose levels appear to induce ECs production. Indeed, when rat insulinoma 
(RIN- m5F) E-cells were cultured in low glucose medium, insulin led to inhibition 
of glucose induction of ECs, whereas incubation with high glucose medium 
blocked the effect of insulin and increased the level of anandamide and 2 AG 
(Matias et al. 2006).  
1.2.5.2.4. Skeletal muscle 
Skeletal muscle is one of the major insulin sensitive organs and it is 
responsible for 80% of insulin-stimulated glucose disposal as well as fatty acid 
oxidation (Di Marzo & Matias 2005; Engeli 2008). The role of ECs and the 
presence of their receptors in muscle is still under investigation. Engeli (2008) 
reported the presence of CB1, FAAH and MGL in human skeletal muscle. Cavuoto 
et al. (2007) also found CB1 receptors in human skeletal muscle myotubes with 
a similar amount of mRNA expression in obese and lean subjects and they also 
reported the presence of CB2 in human and rodent skeletal muscle. Despite 
these reports, the expression of cannabinoid receptors in primary skeletal muscle 
cells needs more confirmation because human CB1 and CB2  are single exon 
genes in human. The variation in the level of expression in slow, fast and mixed 
muscle fibres in different stages of muscle cell development also needs 
evaluation. 
Insulin resistance in skeletal muscle may be due to impaired insulin signalling, 
lower mitochondrial capacity, increase ceramide content and abnormal secretion 
of myokines (Eckardt et al. 2008). The role of ECs in insulin signalling needs 
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further investigation. A decrease in insulin sensitivity in skeletal muscle, which is 
a primary cause for diabetes, has been linked to an increase in 2AG (Engeli 
2008). The effect of CB1 activation or inactivation in cell signalling cascades in 
skeletal muscle is still under investigation. CB1 receptor blockade enhances AMP-
kinase mRNA expression in myotubes in both obese and lean subjects (Eckardt 
et al. 2008; Cavuoto et al. 2007). Furthermore, ECs modulate energy utilization 
in skeletal muscle as it has been found that Rimonabant increased glucose 
uptake, oxygen consumption and decrease fatty acid oxidation in mouse soleus 
muscle (Cavuoto et al. 2007).   
 
Figure 1-8: Effect of CB1 activation in various tissues. 
In general, endocannabinoid activation leads to an increase in food intake and  lipogenesis and a 
decrease in glucose uptake and insulin secretion. (Adapted from Bellocchio L et al 2008) 
 
1.2.6. Role of endocannabinoids in obesity and  type 2 diabetes 
mellitus (T2D). 
The continuous increase in the prevalence of obesity has led to enormous 
amount of research to understand the underlying causes. Obese people have an 
inability to increase fatty acid oxidation in response to high fat intake, which is 
associated with a decrease in insulin sensitivity (Cavuoto et al. 2007). Obesity 
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plays a major role in the development of insulin resistance and subsequently T2D. 
T2D which is due to beta cell dysfunction and/or peripheral insulin resistance 
affect 150 million people worldwide (Esposito et al. 2008). It is expected that the 
prevalence of T2D will be 4.4% in 2030 worldwide (Hollander 2007).  Genetic 
and functional abnormalities found in obesity are quite similar to those 
abnormalities found in T2D, therefore the possibility of similar underlying 
molecular mechanisms is under investigation  and the focus of much 
contemporary research.  
1.2.6.1. Endocannabinoids in obesity.  
High levels of ECs in both central and peripheral tissues in obese people 
have been found (Engeli 2008). Endogenous and exogenous ECs lead to an 
increase in food intake and weight gain, whereas the use of rimonabant leads to 
a decrease in body weight and an improvement in lipid profiles. High fat diet 
promotes a pathological production of ECs and an increase in the expression of 
ECs receptors in different organs that leads to obesity-associated metabolic 
changes (Engeli 2008; Bellocchio et al. 2008). Engeli (2008) found a higher 
circulating level of ECs in obese women compared with lean subjects. Kunos 
(2007) also found a 3-4 fold increase in CB1 receptor expression in adipose 
tissue, liver and skeletal muscle of obese people. An increase in mRNA 
expression of CB1 in adipose tissue, skeletal muscle and liver of diet induced 
obese rodents was also reported by Eckardt et al. (2008) (Figure 1-9). Matias et 
al. (2006) reported high levels of 2AG and anandamide in visceral adipose tissue 
of obese and diabetic individuals. Besides the abnormal CB1 receptor expression, 
a relation between FAAH and obesity has also been reported by Osei-hyiaman et 
al. (2005) who found an 80% reduction in FAAH and unchanged levels of AEA in 
mice maintained on a high fat diet. Cavuoto et al. (2007) reported a reduction in 
FAAH, an increase in AEA and a polymorphism in the gene encoding FAAH in 
human obesity.  
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Figure 1-9: Consequences of obesity-related overactivation of the endocannabinoid system in 
peripheral tissues. 
In obesity, ECs level usually increase in most tissues. The role of ECs in skeletal muscle is under 
investigation and its role in the development of insulin resistance in obesity is still debatable. 
(Adapted from Eckardt K etal, 2008)  
 
1.2.6.2. Type 2 diabetes. 
ECs play a major role in controlling glucose uptake by peripheral tissues 
and blockade of CB1 leads to reduction in blood glucose levels (Hollander 2007). 
High levels of ECs and a decrease in insulin sensitivity in T2D. An increase in AEA 
and 2AG in E cell cultured in hyperglycemic conditions have been reported by 
Bellocchio et al. (2008). ECs also modulate glucagon and insulin secretion from 
pancreas. The role of ECs in glucose homeostasis has been studied with the use 
of the CB1 antagonist rimonabant. Liu et al. (2005) reported a significant 
increase in glucose uptake in mouse soleus muscle treated with rimonabant even 
in the presence of low insulin concentrations and Engeli (2008) observed that 
rimonabant leads to the preservation of E cell integrity and cell mass in animal 
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models of T2D. Esposito et al. (2008) reported that in a skeletal muscle culture 
cell model (L6), pharmacological blockade of ECs controls insulin stimulated 
glucose uptake at the level of PI3K as rimonabant increased the expression of 
the regulatory units of PI3k (P85 &110 alpha) with no changes in IRS, PI3 kinase, 
protein kinase C, lipid phosphatase and glucose transporter 1 or 4. Esposito et al. 
(2008) also illustrated the role of CB1 receptors in glucose uptake in skeletal 
muscle as they found that the blockade of CB1, but not CB2 or TRVI, stimulated 
2 deoxyglucose uptakes. The use of rimonabant in diabetes (RIO Diabetes) 
concluded that rimonabant significantly reduced weight, HBA1c, lipid profiles and 
associated metabolic dysfunction in obese and overweight diabetic patients 
(Scheen et al. 2006).  
 The use of CB1 antagonists in treatment of diabetes is still under 
consideration, as obesity is usually associated with psychological problems and 
CB receptor antagonists might exaggerate these symptoms. However, studies in 
north America RIO (rimonabant in obesity) which used rimonabant to control 
obesity and the metabolic syndrome, as well as other studies (RIO-Europe, RIO 
Diabetes and RIO-lipid), reported no significant association between rimonabant 
administration and psychiatric illness. A significant weight loss, improvement in 
lipid profile (decrease in TG and increase in HDL cholesterol) and decrease in 
fasting insulin after one year of treatment and a further increase in HDL 
cholesterol without a further reduction in body weight were reported after 2 
years of treatment (RIO America). Despite this, the use of rimonabant has been 
stopped in most countries and the search for antidiabetic drugs without side 
effects is continuing.   
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1.3. FREE FATTY ACID RECEPTORS 
1.3.1. Introduction  
Obesity-driven type 2 diabetes has become a major health problem. 
Understanding of the molecular abnormalities leading to obesity and T2D is 
under intense research investigation. The search for drugs which overcome the 
current antidiabetic drugs side effects and prevent diabetic complication is also 
continuing. The role of free fatty acids in insulin secretion from WKHǃFHOOVRIWKH
pancreas and their association with insulin resistance in liver, adipose tissue and 
skeletal muscle is a fertile area of research as the underlying molecular 
mechanisms remain elusive.   It is well known that FFAs not only are a fuel for 
cell metabolism but also function as extracellular messengers to activate 
intracellular signalling pathways through membrane receptors (Wang et al. 
2011). In the last decade de-orphanization  of  free fatty acid receptors which 
belong to class A (rhodopsin-like) G protein coupled receptors highlighted the 
importance of FFAs in health and disease (Swaminath 2008). The gene encoding 
the FFAs receptors GPR40, GPR43 and GPR41 (also called FFAR1, FFAR2 & FFAR3) 
were identified by Sawzdargo et al. (1997) as intronless genes coded in tandem 
and located, in human, at chromosome 19q13.1. These receptors represent a 
family of receptors because they are more closely related to each other than to 
any other known GPCR. Despite this, this family exhibits somewhat limited 
similarity: 43% between FFAR2 and FFAR3 and 33 and 34% when FFAR1 is 
compared with FFAR2 and FFAR3, respectively (Stoddart et al. 2008). The FFAR2 
and FFAR3 are activated by short chain fatty acids while FFAR1 is activated by 
medium and long chain saturated and unsaturated fatty acids. Other FFA 
receptors which are activated by medium and long chain fatty acids are GPR120 
(Costanzi et al. 2008) and GPR84 (Pu & Liu 2012). Table 1-1 illustrates some 
biological functions of the FFA receptors. GPR40 (FFAR1) is the only receptor that 
will be discussed in more detail. 
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Table 1-1: Characterization of Free Fatty Acid Receptors 
 
Adapted from (Stoddart et al. 2008 & Swaminath 2008) 
 
1.3.2.  The free fatty receptor 1 (GPR40) 
1.3.2.1.  Structure and Phylogenetic Analysis 
GPR40 is an intronless gene located on CD22 on chromosome  19q13 
(Briscoe et al. 2006). Hydropathy analysis indicates that it contains seven 
hydrophobic regions, consistent with transmembrane (TM) spanning helices and 
is classified as class A GPCR that belongs to the rhodopsin family (Stoddart et al. 
2008) (Figure 1-10). Phylogenetic analysis has clustered GPR40 into a branch of 
class A that contains receptors for lipids and nucleotides (Costanzi et al. 2008). 
The GPR40 receptor contains cysteine residues in the first and second 
extracellular loops that are likely to contribute to structure, proline residues in 
TM domains 5, 6, and 7, an asparagine in TM1, and an aspartate in TM2. It also 
contains an arginine at the bottom of TM3, which is within the highly conserved 
CHAPTER ONE 
 
 
 
  27 
 
 
  
motif Glu-Arg-Tyr. The arginine is known to bind to a carboxylic group of GPR40 
agonists (Costanzi et al. 2008)(Mancini & Poitout 2013). Two N-glycosylation 
consensus sequences (Asn-x-Ser/Thr) were identified in extracellular loop 2 
(Swaminath 2008). The key structural features of FFA1 are exemplified in Fig. 
1.10. At the protein level, human GPR40 is 82%, 83% and 88% similar to rat, 
mouse and dog GPR40, respectively. At the DNA level, rat and mouse GPR40 are 
94% identical to each other and 75% and 76% to human GPR40, respectively.  
Polymorphisms in the open-reading frame of human GPR40 have been 
reported (Milligan et al. 2006; Costanzi et al. 2008). Two nucleotide substitutions 
were found, a replacement of Arg211 by His in the third intracellular loop and a 
second, relatively rare polymorphism, characterised by replacement of Asp175 
by Asn in the second extracellular loop (Ichimura et al. 2009). The functional 
significance of these polymorphisms remains unclear;  a Japanese study has 
suggested they are linked to variability in insulin-secretory capacity (Hirasawa et 
al. 2008). Another GPR40 variant, Gly180Ser, was reported by Vettor et al. 
(2008)  and it is associated with reducHGǃFHOODELOLW\WRVHQVHOLSLGDVDQLQVXOLQ
secretory stimulus. The pharmacological consequences of these variations 
remain to be studied in detail using a range of FFAs. 
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Figure 1-10: Predicted topology of human GPR40. 
The figure shows the important functional residues in different colours as indicated in the legend.(Adapted with modification from Stoddart et al. (2008) and Mancini & 
Poitout (2013) 
CHAPTER ONE 
 
 
 
     29 
 
 
  
1.3.2.2.  Tissue Distribution  
Expression analysis of GPR40 using RT-PCR, Western Blot, Northern blot 
and immunohistochemistry revealed a high level of GPR40 receptor mRNA and 
protein in the pancreas (Briscoe & Tadayyon 2003; Itoh et al. 2003; Kotarsky et 
al. 2003; Ichimura et al. 2009). Closer analysis of the distribution of GPR40 
expression in the pancreas showed high levels in the insulin-producing-cells 
compared to the whole pancreas (Briscoe & Tadayyon 2003; Itoh et al. 2003). 
GPR40 expression has also been found in pancreas-derived cell lines, including 
MIN6, TC-3, HIT-T15, and INS-1E (Shapiro et al. 2005; Briscoe & Tadayyon 
2003; Itoh et al. 2003; Kotarsky et al. 2003). Expression has also been detected 
in rat islets (Salehi et al. 2005; Feng et al. 2006) DQGPRXVHǃFHOOV (Schnell et 
al. 2007). The expression of the GPR40 receptor in glucagon-producing cell was 
also reported  in some studies (Flodgren et al. 2007; Wang et al. 2011) but not 
all studies (Itoh et al. 2003). 
The expression of GPR40 is controversial and not well documented in other 
tissues. GPR40 expression is not only tissue specific but also species specific. 
Kotarsky et al. (2003) and Briscoe et al. (2003) reported the expression of 
GPR40 in human skeletal muscle using Northern blot and RT-PCR, respectively.  
However, Steneberg et al. (2005) using PCR and Itoh et al. (2003) using RT-PCR 
failed to detect the presence of GPR40 in mouse and  rat skeletal muscle tissue, 
respectively. The  expression of GPR40 in human brain appears to be 
ubiquitously expressed with the highest expression in the substantia nigra and 
medulla oblongata (Briscoe & Tadayyon 2003), although Itoh et al. (2003) were 
unable to detect GPR40 mRNA in rat brain. Brownlie et al. (2008) also reported 
the presence of GPR40 in human brain but not in rat brain. The expression of 
GPR40 in monkey brain was also reported by Ma et al. (2007). Kotarsky et al. 
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(2003) detected expression of GPR40 in the human liver and heart, but specific 
expression could not be seen in any of these areas in human or rat tissue by 
Briscoe et al. (2003) or by Itoh et al. (2003). GPR40 expression has also been 
reported in human immune cells, with the highest levels of mRNA detected in 
monocytes (Briscoe & Tadayyon 2003). Hidalgo et al. (2011) detected GPR40 
mRNAin bovine neutrophils. In cultured cell lines, functional GPR40 has been 
detected in human breast cancer cell lines, MCF-7 (Yonezawa et al. 2004) and in 
bovine mammary epithelial cells and lactating mammary glands (Yonezawa et al. 
2008). Expression of GPR40 has been demonstrated within the enteroendocrine 
cells of mice (Edfalk et al. 2008), hypothalamic ventromedial nucleus (Le Foll et 
al. 2009), human bronchial epithelial cells (Gras et al. 2009a), mouse bone cells 
(Wauquier et al. 2013), primary chicken hepatocytes (Suh et al. 2008), mouse 
keratinocytes (Fujita et al. 2011) and human spleen (Ichimura et al. 2009).    
1.3.2.3. Deorphanization of Free Fatty Acid Receptor1 (GPR40) 
GPR40 remained classified as an orphan receptor until 2003 when Briscoe 
et al. (2003); Itoh et al. (2003) and Kotarsky et al. (2003) identified a range of 
medium and long chain saturated and unsaturated fatty acids as ligands for 
GPR40. Briscoe et al. (2003) demonstrated that more than 40 different medium 
and long chain fatty acids (LCFAs) were able to activate GPR40 with micromolar 
range potency and this result was confirmed by Itoh et al. (2003) who also 
reported the importance of the carboxyl group in the agonist function. 
Interestingly, the potency of the saturated fatty acids was dependent on chain 
length, whereas chain length and degree of saturation did not correlate with the 
potency of unsaturated fatty acids (Briscoe & Tadayyon 2003).  
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1.3.2.4. Free Fatty Acid Receptor 1 (GPR40) Synthetic Agonists 
and Antagonists 
The first discovered and most commonly used GPR40 agonist is GW9508. 
It is an arylalkyl derivative of propanoic acid and was identified by 
GlaxoSmithKline as a potent GPR40 agonist that has a potency in the nanomolar 
range compared with the micromolar potencies of LCFAs (Briscoe et al., 2006). 
Costanzi et al. (2008) reported that a carboxylic acid moiety was not essential 
for agonist action although the presence of such a feature resulted in more 
efficacious compounds. The same group also identified the FFA1-selective 
antagonist, GW1100.  Table 2.1 illustrates some other available agonists and 
antagonists.  
Table 1-2: List of synthetic GPR40 agonists and antagonists 
 
* Antiobesity compound 
**A novel and orally available selective GPR40 agonist which is in use in clinical trials.  
[(3S)-6-({2_,6_-dimethyl-4_-[3-(methylsulfonyl)propoxy]biphenyl-3-yl}meth-oxy)-2, 3-
dihydro-1-benzofuran-3-yl]acetic acid hemihydrate)" 
 
1.3.2.5. Signalling mechanisms downstream of GPR40  
The initial studies on FFA1 suggested that the GPR40 receptor couples to 
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WKH*SURWHLQVXEXQLW*ĮT(Tan et al. 2008; Itoh et al. 2003; Kotarsky et al. 
2003) (Schnell et al. 2007) which in turn is predicted to catalyze the 
phospholipase C (PLC) mediated hydrolysis of phosphatidylinositol 4,5-
bisphosphate into diacylglycerol (DAG) and inositol trisphosphate (IP3). DAG and 
IP3 subsequently serve as second messenger molecules to activate protein 
kinase C (PKC) and mobilize ER Ca2+ stores, respectively. Latour et al. (2007) 
and  Shapiro et al. (2005) UHSRUWHGWKDWLQKLELWLRQRI*ĮTRU3/&EORFNVWKH
FFA-mediated potentiation of GSIS in vitro, whereas IP3 generation in response 
to FFA in islets was shown to be GPR40 dependent (Alquier et al. 2009). Multiple 
lines of evidence favour a model in which FFA activation of GPR40 leads to influx 
of extracellular Ca2+ with minimal cytosolic ingress from ER Ca2+ stores (Fujiwara 
et al. 2005). Activation of GPR40 modulates KATP channel and L-type calcium 
channel (LTCC) activity, whereas pharmacological inhibition of LTCC or opening 
of KATP channels attenuates FFA-induced increases in intracellular Ca
2+ (Zhao et 
al. 2008) (Figure 1-11). GPR40 activation increases intracellular Ca2+ levels 
primarily via the coordinated enhancement of extracellular Ca2+ influx through 
LTCC and inhibition of both KATP and delayed rectifier K+ channels (Feng et al. 
2006; Shapiro et al. 2005). Furthermore, although the balance of currently 
available data on GPR40 signal transduction suggests that the IP3 signalling is 
likely to play a minor role in the control of intracellular Ca2+ concentrations (and 
insulin secretion) in response to FFAs. Recent studies have attempted to unravel 
WKH*35PHGLDWHG*ĮT3/&-dependent signalling mechanisms responsible 
for FFA augmentation of 2nd phase GSIS. Ferdaoussi et al. (2012) showed that 
both oleate and exogenous DAG promote the activation/phosphorylation of the 
serine/threonine protein kinase D1 (PKD1). FFA activation of GPR40 results in 
the generation of DAG via PLC-mediated hydrolysis of membrane phospholipids, 
activation of PKD1, cortical actin depolymerization, and potentiation of 2nd 
phase GSIS (Figure 1-12).  
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Figure 1-11: Proposed mechDQLVPIRU*35DFWLRQLQǃFHOOV 
Activation of GPR40 leads to calcium release from endoplasmic stores through Gq-PLC signalling 
pathway.Elevated glucose leads to stimulation of LTCC channel and further increases in intracelluar 
calcium and insulin release. (Adapted from Shapiro H 2005) 
 
 
Figure 1-12: Potentiation of glucose-stimulated insulin secretion (GSIS) via GPR40. 
Protein kinase D1 (PKD1) mediates free fatty acid (FFA) potentiation of glucose-stimulated insulin 
secretion (GSIS) via GPR40. Following FFA stimulation of GPR40, the GTP-ERXQGDFWLYHĮVXEXQLW
activates phospholipase C (PLC), which cleaves phosphatidylinositol-4,5-bisphosphate (PIP2) to 
produce inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers Ca2+ efflux from the 
endoplasmic reticulum (ER). DAG promotes the phosphorylation and activation of PKD1 which 
facilitate (F)-actin filamentous remodelling. Adapted from (Mancini & Poitout 2013) 
 
CHAPTER ONE 
 
 
 
     34 
 
 
  
Data from ,WRK HW DO  VXJJHVWHG WKDW *35 FRXOG FRXSOH WR *ĮL
although these findings were not confirmed by Briscoe et al. (2006). Support for 
the ability of FFA1 to couple weakly to Gi/o comes from studies on the breast 
cancer cell line, MCF-7, in which treatment with pertussis toxin blocked the LCFA 
induced elevation of [Ca2+] (Yonezawa et al. 2004). Yonezawa et al. (2008) 
reported that GPR40 agonists (oleate and linoleate) decreased cAMP production. 
Fujita et al. (2011) reported that GW9508 inhibited CCL17 and CCL5 expression 
in a pertussis toxin-sensitive manner in keratinocytes. To our knowledge, the 
RQO\UHSRUWWKDWSURYLGHGHYLGHQFHIRUFRXSOLQJEHWZHHQ*35DQG*ĮV is  by 
Feng et al. (2006)  who suggested that FFAs may act on GPR40 to activate Gs 
SURWHLQ WKURXJK F$033.$ VLJQDOOLQJ LQ UDW ǃ FHOO /LQROHLF DFLG  Vignificantly 
enhanced cAMP accumulation when combined with IBMX (phosphodiesterase 
inhibitor) or forskolin (adeno cyclase stimulator).  A recent interesting finding 
was reported by Mancini & Poitout (2013) ZKRVWDWHGWKDW³ WUDQVPHPEUDQHV
receptor can couple to multiple heterotrimeric G proteins as well as to G protein-
LQGHSHQGHQW ǃ-arrestin-dependent pathways to promote the activation of 
numerous (potentially cross talking) signalling cascades in a ligand and context 
GHSHQGHQWPDQQHU´:KHWKHUWKLVFDQEHDSSOLHGRUQRWWRWKH*35UHFHSWRUV
requires further investigation. 
1.3.2.6. Regulation of GPR40 expression  
A physiologically important property of GPCRs is their tendency to 
desensitize during exposure to agonists. Desensitization mechanisms include 
³GRZQ-UHJXODWLRQ´ RU UHGXFWLRQ RI UHFHSWRU QXPEHU DSSDUHQW VKLHOGLQJ RI WKH
receptors from interacting ligands and uncoupling from G-proteins 
(Kaplamadzhiev et al. 2010; Xiao et al. 1999). Addition of a GPR40 ligand for 14 
days led to a significant down-regulation of GPR40, i.e., G protein-coupled 
CHAPTER ONE 
 
 
 
     35 
 
 
  
receptor-specific internalization (Kaplamadzhiev et al. 2010). A decreased level 
of  GPR40 mRNA expression in the islets of mice kept on a high fat diet for 
several months and in islet cultured in medium containing high concentrations of 
FFAs for 18h were observed by (Flodgren et al. 2007). A decrease in GPR40 
mRNA  after 6 hours treatment with oleic acid was also observed by  Hu et al. 
(2009). Interestingly, GPR40 transcripts and protein were significantly 
upregulated in bone marrow cell  cultured with fibroblast growth factors  
(Kaplamadzhiev et al. 2010). Expression of the GPR40 gene is reduced under 
glucolipotoxic conditions in rats (Fontés et al. 2010) and in islets from T2D 
patients (Del Guerra et al. 2010). However, Briscoe et al. (2003) detected high 
levels of GPR40 mRNA expression in islets from obese mice (ob/ob) and more 
recently Kebede et al. (2012) detected an upreguation of GPR40 mRNA 
H[SUHVVLRQ LQ PLFH DQG KXPDQ ǃ FHOOV FXOWXUHG LQ PHGLXP FRQWDLQLQJ KLJK
glucose for  6 or 24 hours, respectively.   
The transcription factor pancreatic duodenum homobox-1 (PDX1) is highly 
H[SUHVVHG LQǃFHOOVDQG WKHHQGRFULQHFHOOVof the gastrointestinal tract. PDX1 
FRQWUROV NH\ DVSHFWV RI ǃ FHOO IXQFWLRQ E\ UHJXODWLQJ WKH H[SUHVVLRQ RI JHQHV
involved in glucose sensing, insulin gene expression, and insulin secretion. Loss 
or perturbation of PDX1 function leads to impaired GSIS and consequently 
diabetes or glucose intolerance in both mice and humans (Ahlgren et al. 1998). 
PDX1 is a transcription regulator for GPR40 and it binds to an enhancer element 
within the 5-flanking region of GPR40 (Bartoov-Shifman et al. 2007). Studying 
the mechanism through which glucose regulates the GPR40 gene expression in ǃ
cell, Kebede et al. (2012) established that glucose stimulates GPR40 gene 
WUDQVFULSWLRQLQSDQFUHDWLFǃ-cells via increasing the binding of PDX1 to the A-box 
in the HR2 region of the GPR40 promoter. Moreover, they demonstrated that 
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mutation of the PDX1 binding site abolishes glucose activation of GPR40 
promoter activity. This observation is supported by Edfalk et al. (2008) who 
observed  no GPR40 expression in the endocrine cells of PDX1 knockout mice.  
1.3.2.7. Potential role of GPR40 Receptor in pancreas and 
glucose homeostasis 
A large number of in vivo and in vitro studies have now conclusively 
confirmed the importance of GPR40 in mediating the acute stimulatory effects of 
long chain FFAs on GSIS. GPR40 loss of function via small interfering RNA (Itoh 
et al. 2003; Shapiro et al. 2005), antisense oligonucleotides (Salehi et al. 2005), 
pharmacological inhibition (Briscoe et al. 2006), pharmacological activation (. 
Doshi et al. 2009) or gene deletion in mice  (Kebede et al. 2008; Latour et al. 
2007; Steneberg et al. 2005) consistently resulted in a significant decrease in 
FFA-mediated potentiation of GSIS. Interestingly, Vettor et al. (2008) identified 
a low-frequency mutation in human GPR40 that  is associated with a decrease in  
lipid-mediated enhancement of GSIS. Conversely, transgenic overexpression of 
the human GPR40 gene prevented the development of hyperglycemia in high-fat 
diet (HFD) fed mice, and improved insulin secretion and glucose tolerance in 
genetically diabetic (KK) mice (Nagasumi et al. 2007).  
Acutely, FFAs amplify GSIS, but chronically elevated ))$VSURPRWHǃ FHOO
G\VIXQFWLRQDQGJOXFROLSRWR[LFLW\7KHSRWHQWLDO LQYROYHPHQWRI*35LQǃFHOO
glucolipotoxicity has been studied in GPR40-/- and GPR40 transgenic 
overexpression mice but the result was controversial.  Steneberg et al. (2005) 
demonstrated that HFD fed GPR40íí mice were protected from insulin 
resistance, whereas, conversely, transgenic overexpression of GPR40 exhibited 
GLVUXSWHG LVOHW PRUSKRORJ\ DQG LPSDLUHG ǃ FHOO IXQFWLRQ 7KH\ SURSRVHG WKDW
GPR40 antagonists, rather than agonists, should be developed for therapeutic 
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use. Brownlie et al. (2008) and Duttaroy et al. (2008) also found that  GPR40íí 
mice were protected from the effects of HFD on glucose tolerance and had an 
enhancement in insulin sensitivity. In contrast, Nagasumi et al. (2007), Latour et 
al. (2007) and Tsujihata et al. (2011) concluded that chronic treatment with 
GPR40 agonist improved GSIS and hence a reduction in GPR40 signalling may be 
mechanistically linked to the development of T2D. Authors referred these 
GLVFUHSDQFLHVWRWKH*35ííPRXVHGHULYDWLRQW\SHRI IRRGDQGGXUDWLRQRI
feeding. Moreover, Brownlie et al. (2008), Wu et al. (2010) and Tan et al. (2008) 
reported that  GPR40 does not mediate the chronic toxic effects of FFAs on islet 
function. Accordingly, chronic activation of GPR40 should produce beneficial 
effects on glucose homeostasis. Indeed, administration of synthetic GPR40 
agonists improved glycaemic control in diabetic rodents (Tan et al. 2008; Doshi 
et al. 2009) and in T2D patients (TAK-875 Phase II trials). TAK-875 significantly 
improved glycaemic control in patients with type 2 diabetes with minimum risk of 
hypoglycaemia (Burant et al. 2012).  However, the picture has become less clear 
with a recent study using GPR40 knockout mice conducted by Matsuda-
Nagasumi1 et al. (2013) who reported that even though GPR40/FFAR1 has a 
major role in regulating fatty-acid-mediated insulin secretion; the lack of GPR40 
does not induce diabetes even under insulin resistance conditions induced by 
high fat diet or diabetogenic KK gene. It is worth mentioning that GPR40 
receptors have a role in glucagon secretion.  Flodgren et al. (2007) reported that 
knockdown of GPR40 receptors significantly reduced the ability of linoleic acid to 
increase glucagon exocytosis. In support of this, Wang et al. (2011) reported 
that FFA-induced secretion of glucagon from isolated islets is GPR40 dependent. 
Consistent with these in vitro observations, Lan et al. (2008) found that FFA1-/- 
mice secrete significantly less glucagon than wild-type mice in response to 
elevated plasma fatty acid levels. 
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1.3.2.8. Potential role of GPR40 in tissues involved in energy 
homeostasis 
GPR40 expression has been found in several tissues including 
enteroendocrine cells, the brain and skeletal muscle, all of which contribute to 
glucose homeostasis. Luo et al. (2012) and Edfalk et al. (2008) reported that 
GPR40 induces secretion of gut hormones and GPR40 null mice displayed 
reduced plasma incretin levels in response to high fat feeding. Luo et al. (2012) 
developed GPR40 full agonists that have insulinogenic and incretinogenic 
properties. Collectively, GPR40 modulates FFAs stimulated insulin secretion not 
RQO\GLUHFWO\ IURPǃ FHOOVEXWDOVR LQGLUHFWO\ YLD UHJXODWLRQRI LQFUHWLQ VHFUHWLRQ
from enteroendocrine cells. Moreover, the expression of GPR40 in hypothalamus 
could possibly influence the regulation of energy balance (Ma et al. 2007). 
Interestingly, GPR40 is expressed in taste buds and mediate taste preference to 
fatty acids (Cartoni et al. 2010). Even though skeletal muscle has a vital role in 
glucose homeostasis surprisingly no previous reports have described the role of 
GPR40 in skeletal muscle.  
1.3.2.9. Other potential roles of GPR40  
Skin. GPR40 suppresses immune inflammation in the skin similar to other 
Gi-coupled GPCR such as cannabinoid receptors. GPR40 agonist (GW9508) 
attenuate the induction of critical cytokines (CCL5 and CCL17) by 
SURLQIODPPDWRU\ F\WRNLQHV  71)Į LQ NHUDWLQRF\WHV DQG VXSSUHVVHV DOOHUJLF
inflammation in the skin (Fujita et al. 2011). 
Bone. Cornish et al. (2008) demonstrated the expression of GPR40 in 
osteoblasts and osteoclasts, and suggested that activation of GPR40 might 
mediate the antiosteoclastogenic effects of FFAs. GPR40 receptors might play a 
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role in the induction of osteocyte apoptosis (Mieczkowska A et al. 2012). 
Wauguier et al. (2013) confirmed that GPR40-null mice have lower bone density 
and that GPR40 mediates the FFA-mediated inhibition of osteoclastogenesis. 
Cell proliferation. Currently it is well documented that obesity which is 
accompanied with hyperlipidaemia and elevated circulating free fatty acids is 
associated with increased risk of cancer (Pirgon et al. 2013). A link between free 
fatty acids and incidence of breast cancer has also been reported (Rose 1997). 
GPR40 is expressed in human breast cancer cell line (MCF-7) and its expression 
is significantly higher at the beginning and at the end of proliferation indicating 
that LCFA might play a role in cell proliferation  (Yonezawa et al. 2004). Hardy et 
al. (2005) established that oleic acid-induced proliferation is mediated through 
the GPR40 receptor. In mammary epithelial cells GPR40 mediates LCFA 
signalling and plays an important role in cell proliferation and survival (Yonezawa 
et al. 2008).  In addition, downregulation of GPR40 by small-interfering RNA led 
to a significant inhibition in the proliferative effect of the anti-diabetic drugs 
TZDs in nonmalignant human bronchial epithelial cells. Whether or not chronic 
GPR40 activation might have carcinogenic effects warrants further investigation 
as this might hold the key to the use of GPR40 agonists in near future.  
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1.4. Aim of thesis 
Obesity and diabetes are major health problems worldwide. One of the 
underlying causes of diabetes is insulin resistance and its development appears 
years or even decades before manifestation of diabetes. Skeletal muscle has a 
core role in insulin resistance associated with high levels of circulating free fatty 
acids. The search for safe drugs without side effects to treat diabetic patients has 
been an attractive field for decades. 
The aim of this thesis is to investigate two possible targets for the 
treatment of insulin resistance (cannabinoid receptors specifically CB1 and free 
fatty receptor 1) and downstream signalling in human and rat (Wistar and the 
diabetic model, Zucker) skeletal muscle tissue and cultured cells. The major 
objectives of this thesis are: 
1. To analyse the  transcriptional profiles of  skeletal muscle tissues and 
cultured cells in order to assess the suitability of using cell culture to 
model skeletal muscle metabolism and signalling. 
2. To investigate the expression of the cannabinoid receptors and GPR40 in 
different stages of muscle development as well as in different muscle 
fibre types. 
3. To examine the influence of cannabinoid receptors and GPR40 (GPR40) 
on insulin signalling and skeletal muscle glucose metabolism. 
4. To study the effects of activation and inhibition of GPR40 upon global 
gene expression profiles in human primary skeletal muscle cells.
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CHAPTER 2. GENERAL MATERIALS AND METHODS  
 
2.1. Tissue collection 
Human muscle samples were obtained from the mixed muscle fibre Vastus 
lateralis (VL). The samples were taken from 19 healthy male volunteers with a 
age of 22.78±3.02 (Mean±SDV) and BMI of 24.69±2.52 using the needle biopsy 
technique (Bergstrom needles) under local anaesthetic with medical school 
ethical approval (G/5/2009). 
 Rat muscle samples were obtained from Wistar and Zucker fat and Zucker 
lean rats. Zucker rats were generously provided by Professor Michael Randall. 
Rat muscle samples were taken from fast muscle fibres Soleus (SOL) and the red 
portion of gastrocnemius (GR), slow muscle fibre the white portion of 
gastrocnemius (GW) and the Extensor digitorum longus (EDL) and the mixed 
muscle fibres Vastus Lateralis (VL). The rats were killed by cervical dislocation 
without anaesthesia, a method approved by the University of Nottingham and 
the Animal Scientific Procedures Act (ASPA) and the muscles were carefully 
excised within 10 minutes of death. 
Table 2-1: Rat parameters 
 
WR=Wistar Rat, ZFR=Zucker Fat Rat, ZLR=Zucker Lean Rat 
2.2. Reagents 
 )HWDO%RYLQH6HUXP )%6DQG+DP¶V )PHGLXP IRU FHOO FXOWXUHZHUH
purchased from Sigma and PAA laboratories (Somerset, UK). CB1 agonist ACEA, 
WR ZFR ZLR ZFR ZLR
Age (wks) 4-6 12 12 20 20
Weight(g) 180-200 342 292 408 401
Blood Glucose(mM) 24 6 28 8.5
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GPR40 agonist GW9508, Anandamide (AEA) and PPAR antagonist T0070907 
were from Tocris Biosience. Epidermal growth factor (EGF), horse serum and 
RNA clean up kit were from Invitrogen and MAP kinase inhibitor (U0126) from 
Promega. Oleic acid, Palmitic acid, Rimonabant (Rim) and fatty-acid-free BSA 
were from Sigma. Rim was obtained from the NIMA Chemical Synthesis 
program, via Dr Stephen ALexander. GPR40 agonist and antagonist (AZ921, 
AZ915, AZ836 and AZ468) were provided by Astra Zeneca. Human brain and 
spleen Poly A+ RNA were from Clontech (catalogue numbers 636102 and 
636121, respectively)  
2.3. Muscle cell culture 
Satellite cell isolation and culture were carried out according to the method 
of Blau & Webster (1981) with some modifications. The muscle samples were 
divided into two pieces, one piece was flash frozen in liquid nitrogen for RNA and 
Protein extraction. The second piece was put in ice cold phosphate buffer saline 
(PBS) for primary tissue culture. Under sterilized condition, the sample was 
washed with PBS and minced finely in a Petri dish by using a scalpel (no.22 
blade). The tissue was then transferred to a 50ml Falcon tube containing a 
magnetic stirrer and 5 ml trypsin (0.05% trypsin, 0.02% EDTA in PBS) and 
stirred gently for 15 minutes at 37°C. The supernatant was neutralized by 
adding an equal amount of growth media (HDP¶VF10 supplement with 20% FBS, 
LXPOSHQLFLOOLQDQGǋJPOVWUHSWRP\FLQ$IWer removal of tissue debris by 
filtering through 100µm pore size Nylon mesh the supernatant was transferred 
to a new falcon tube and centrifuged for 10 min at 1700rpm at room 
temperature. The cell pellets were re-VXVSHQGHGLQPORI+DP¶V)FRQWDLQLQJ
20% FBS media, allowed to adhere to tissue culture plastic for 10mins, to 
minimize fibroblast contamination, and subsequently transferred to culture in 
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T25 flasks coated with 0.2% gelatin (W/V).  
The cells were grown in 5% CO2 at 37°C. Feeding of the cells was as 
follows; after 24 hours the cells were washed with PBS and new Hams F10 media 
containing 20% FBS were added. The media were then changed every 2 days, in 
WKH ILUVW  ZHHNV ZLWK +DP¶V ) PHGLD FRQWDLQLQJ  FBS. Once myoblast 
cultures reached approximately 80% confluence, they were induced to 
differentiate by reducing the serum concentration to 10% for 3 days followed by 
changing into 6% horse serum-containing media until the cells had differentiated 
into a fused multinucleated myotube network at which point they were treated. 
 
Figure 2-1: Representative pictures for human satellites, myoblasts and myotubes derived from 
human skeletal muscle  
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Figure 2-2: Representative picture of Wistar and Zuckers rat myotubes (5 weeks). 
 
 
Important observation from skeletal muscle culture: 
x First, serum plays an important role for successful human cell primary 
culture as cells were unable to proliferate properly when PAA serum was 
used and that lead to  culture failure in 4 samples . From our experience in 
muscle culture, we recommended the use of Thermo Scientific Hyclone 
serum (cat no HYC-001-406B). The serum is sterile filtered, not heat 
inactivated, Bovine growth serum and  US origin. 
x Second, there were no observed differences between cells cultured from 
different muscle types (slow and fast) or rat origin (Wistar and Zucker). 
x Third, rat muscle cells proliferate more rapidly than human cells due to the 
smaller number of satellite cells isolated from the small size human samples. 
x Fourth, the maximum time for serum starvation is two hours and we do not 
recommend serum starvation as cells appear stress. 
x Fifth, the appearance of scatter myoblast in day two is a sign of a successful 
culture. 
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2.4. Delipidation of foetal bovine serum 
 Fatty-acid-free serum was prepared according to the method described in  
Hannah et al, (2001). Briefly, 125ml of FBS was mixed with 40:60 volume ratio 
of 100 ml N-butanol and 150ml Di-isopropyl ether. The solutions were mixed 
thoroughly by end to end rotation on a daisy-wheel for 20 minutes followed by 
incubation on ice for another 20 minutes. Separation of the aqueous phase from 
the organic phase was achieved by 5 minutes centrifugation at 2500 rpm. The 
extraction of the aqueous phase (the straw coloured bottom layer) was carefully 
done by pipette. A second solvent extraction step was carried out by adding 
50ml Di-isopropyl ether only. The mixing, centrifugation and extraction was 
repeated and then with the aqueous phase was placed under a gentle stream of 
nitrogen for 30 min in order to remove any remaining solvent. Delipidated 
serums was transferred to a pear shaped flask and freeze dried for at least 24 
hours. The freeze dried serum was dissolved in 50ml HPLC water, dialyzed with 3 
changes of PBS for 12 hours each and finally filter sterilised using 0.2 µm crodisk 
syringe filter. 
2.5. Preparation of Fatty Acids in Complex with BSA 
The 24% (w/v) bovine serum albumin (BSA) was prepared by gradually 
adding 6g of fatty-acid-free BSA (cat. No. A6003; Sigma) into 17.5ml 150mM 
NaCl in a beaker, over a slow period of time at room temperature with stirring. 
The pH was adjusted to 7.4 with 5M NaOH, and the volume made up to 25ml 
with 150mM NaCl. This solution was filtered through a 0.45µm filter and frozen 
in aliquots at ±20°C. 
The  fatty acid/BSA solution was then prepared by a modification of the 
method of Van Harken and Dixon (1969).  Briefly, 39.6 mg Sodium Oleate or 
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36mg palmitic acid was transferred to a glass beaker containing 0.5ml ethanol, 
and the ethanol was evaporated under a stream of nitrogen. Then 7 ml 24% 
(w/v) ice-cold BSA and 48µl of 5M NaOH were added. The solution heated gently 
with stirring on a hot plate  until an emulsion is formed then the fatty acids were 
stored at ±20°C until use. 
2.6. Analysis of Gene Expression at the mRNA level 
2.6.1. Total RNA extraction 
Tissue RNA was extracted using Tri-reagent® (Ambion).  Frozen ~50 mg of 
tissues were homogenized in 2ml tri reagent using a Janke & Kunkel Ultra-Turrax 
T25 homogenizer. The RNA from cell culture samples was extracted by scraping 
the cells in 1ml Tri reagent. The homogenate was allowed to stand for 5 minutes 
at room temperature then 200µl of BCP (1-Bromo-3-chloropropane, Sigma) was 
added per ml of Tri-reagent used. The solution was vortexed and centrifuged at 
10,000 rpm for 15 minutes at 4°C. RNA was precipitated from the upper 
aqueous phase by the addition of 250µl of 2M sodium acetate and 700µl 2-
isopropanol per ml of solution.  After mixing, the solution was chilled at -20oC for 
at least an hour, followed by centrifugation at 10000g for 10 minutes at 4oC. The 
supernatant was discarded and the pellet washed twice with 500µl 70% ethanol 
solution. The supernatant was then removed, and the pellet air dried for 5 
minutes and then re-suspended in 50µl RNAse free water.  
2.6.2. RNA clean up, quantification and quality measurement 
Total RNA clean up and on-column DNAse digestion were performed using 
51HDV\SXULILFDWLRQNLW4LDJHQE\IROORZLQJWKHPDQXIDFWXUHU¶VLQVWUXctions. The 
quality of RNA was initially determined by subjecting samples to agarose gel 
electrophoresis (1.5%). brLHIO\ǋJRI51$ZHUHPL[HGZLWKǋ/RIJO\R[DO
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reaction mixture (1x BPTE buffer,1M deionised glyoxal ,4.8% (v/v) glycerol, 60% 
(v/v) DMSO and 20% (w/v) ethidium bromide), incubated at 55°C for 1 hour and 
then  placed on ice for 10 minutes. Prior to loDGLQJLQWRWKHJHOǋ/RI ORDGLQJ
dye was added to the sample. The gel was run at 90 V (5 V/cm). The RNA 18S 
and 28S bands were visualised with a UV transilluminator, and the photograph 
recorded using Genesnap software. Un-degraded RNA samples showed two 
intact and distinct ribosomal subunits- 28S and 18S.  The RNA and purity and 
concentration were further measured  on a nanodrop spectrophotometer 
(Nanodrop technologies, USA). The ratio of absorbances between 1.8-2.0 at both 
260/280 and 260/230 was taken as an indication of acceptance of RNA purity.  
For microarray studies, RNA quality was also measured by Agilent 
bioanalyzer 2100 which provides concentration, visual inspection of RNA 
integrity, generates a ribosomal ratio and an RNA Integrity number (RIN). RIN is 
a comprehensive estimation of RNA integrity, as it takes the entire 
electrophoretic trace into account (Mueller & Schroeder, 2004). Samples were 
deemed acceptable for microarray studies if they had a RIN value more than 7.5 
(see Figure 2-3 & appendix 1). 
 
Figure 2-3: Electrophoretogram showing 18S and 28S peaks in one sample with RIN=9.5. 
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2.6.3. mRNA purification from total RNA 
Dynabeads® mRNA purification kit (Invitrogen) was used to extract mRNA 
from total RNA to overcome the problem of genomic DNA contamination 
following the manufacturers¶ LQVWUXFWLRQV. As suggested for low total RNA 
concentrations, the amount of reagents used were reduced according to the 
concentration of total RNA used (3.5 to 7.5 µg were used). mRNA was eluted 
from the dynabeads using  11µl 10mM Tris-HCl (pH 7.5) and heating for 2 min at 
70oC.  Dynabeads were reconditioned and used for subsequent mRNA extraction 
according to the manufacturers¶ protocol. 
2.6.4. cDNA synthesis 
cDNA was produced by the reverse transcription of 500ng of total RNA or 
 ǋ/ RI P51$ SUHSDUHG IURP DW OHDVW  ǋJ WRWDO 51$ 7KH IROORZLQJ ZHUH
DGGHG LQWR  PO 3&5 WXEHV WKH WRWDO 51$ RU P51$ ǋ/ UDQGRP SULPHUV
QJǋORIG173¶VP0DORQJZLWKRNase-free water was added to give 
DWRWDOYROXPHRIǋ/7KHWXEHVZHUHEULHIO\YRUWH[HGDQGFHQWULIXJHGEHIRUH
being placed into a thermocycler (MWG-Biotech Primus 96 Plus) at 65°C for 5 
PLQXWHV IROORZHG E\ D UDSLG FKLOO RQ LFH:KLOVW RQ LFH ǋ/ RI  X First-strand 
EXIIHUǋ/RI0'77ǋ/RI51DVH287Xǋ/DQGǋ/RI6XSHUVFULSW,,,
57Xǋ/ZHUHPL[HGDQGWKHQDGGHGWRWKHSULPHU51$PL[7KHFRQWHQWV
of the tube were mixed and incubated at 25°C for 5 minutes, 50°C for 1 hour, 
70°C for 15 minutes and then cooled to 4°C. cDNA was then stored at -20°C 
until RT-QPCR analysis.  
2.6.5. Analysis of mRNA expression by TaqMan® real-time 
quantitative PCR  
The mRNA expression levels of selected genes were quantified using the 
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step one plus real ±time PCR system (Applied Biosystems) based on Taqman 
standard curve method. The Taqman RT-PCR is a very selective and useful 
assay for the amplification of specific sequences encoding the gene of interest. 
It employs the use of a Probe where its ends are labelled with a fluorophore and 
a quencher respectively. During the RT-PCR reaction, the Probe identifies 
amplified targets and binds to them. The intensity of light emitted, which is due 
to the release of the probe, is measured in real time which reflects the 
expression levels of the gene in the sample being analysed. For a reaction with 
a total volume 25µL the following reagents were added to 5µl of cDNA; 
Table 2-2: Sample preparation for QRT-PCR reaction. 
 
 
A negative/No Template Control (NTC) was also included E\UHSODFLQJǋ/
RIF'1$ZLWKǋ/51DVH-free water. Thermo-cycling parameters were 50°C for 2 
minutes, 95°C for 10 minutes (melting temperature) followed by 40 x (95°C for 
15 seconds, 60°C for 1 minute) (annealing temperature). The standard curve 
consisted of two-fold serial dilutions of cDNA reverse transcribed from a known 
quantity of RNA (NEAT). All standards, samples and negative controls were 
assayed in triplicate to ensure accurate results. The threshold cycle (Ct Value) is 
the point at which fluorescence rises to a point considered statistically significant 
above the baseline values. A standard curve was then constructed by plotting Ct 
values versus the logarithm of the serial cDNA dilutions. Any assay which did not 
have a standard curve with a slope between -3.0 and -3.6 (90-100% efficient) 
TaqMan® Universal PCR Mastermix 
Applied Biosystems (4304437)
ǋ/
)RUZDUGSULPHUǋ0 ǋ/
5HYHUVHSULPHUǋ0 ǋ/
3UREHGXDOODEHOOHGǋ0 ǋ/
Water (molecular grade) ǋ/
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was rejected as were any results where the values for the triplicates had a range 
greater than 0.5 Ct Figure 2-4. Maintenance genes were used where appropriate. 
 
Figure 2-4: Serial standard curve with slop of -3.33 and r2 of -0.99 
 
 
The primers and probes (Table 2-3) were designed using Primer Express 3 
software and analysed by NCBI blast.  
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Table 2-3: Oligonucleotide sequences for probes and primers 
 
Type Forward Primer (5'?3') Reverse Primer (5'?3') Probe
18S CGGCTACCACATCCAAGGAA GCTGGAATTACCGCG TGCTGGCACCAGACTTGCCCTC
Human
E -actin CCTGGCACCCAGCACAAT GCCGATCCACACGGAGTACT ATCAAGATCATTGCTCCTCCTGAGCGC
Human
CB1
GCCCATGTGGCTAAAAAAGC CAATGCCAAGTGTATCGGTTCTT AGACAGTGGATGAGACACACAACGGCA
Human
CB2
GCAGCGTGACTATGACCTTCAC GAGCTTTGTAGGAAGGTGGATAGC TGACCGCCATTGACCGATACCTCTG
Human
EGR1
CCGCAGAGTCTTTTCCTGACA CCACAAGGTGTTGCCACTGT TGGAGACCAGTTACCCCAGCCAAACC
Human
GPR  119 
GCGGATGGCATTTGTCACTT GTACCTGTCAAAGGTGATCAGCAT CTCCGCAGCTGCCTCTGTCCTCAC
Human
GPR  55     
AATGACATCTCTCAGCCCTCTCA  CAGCAATTCATGCCCATTGA TGCACCGGACCACCAACAGTTGTG
Human
GPR 40
GCCCGCTTCAGCCTCTCT GAGGCAGCCCACGTAGCA CCTGCTCTTTTTTCTGCCCTTGGCC
Human
IL6
GGCGCTTGTGGAGAAGGAG CGGGAACGAAAGAGAAGCTCTA TCCCCTCCAGGAGCCCAGCTATGA
Human
PDK4
CAAGGATGCTCTGTGATCAGTATTATTT TGTGAATTGGTTGGTCTGGAAA CATCTCCAGAATTAAAGCTTACACAAGTGAATGGA
Human
TBP
GGAGCTGTGATGTGAAGTTTCCTA CCAGGAAATAACTCTGGCTCATAAC TAGAAGGCCTTGTGCTCACCCACCA
Human
TNFa
CCCAGGGACCTCTCTCTAATCA GGTTTGCTACAACATGGGCTACA CTCTGGCCCAGGCAGTCAGATCATCT
RAT
E -actin AGCCATGTACGTAGCCATCCA  TCTCCGGAGTCCATCACAATG TCTCCCTGTATGCCTCTGGTCGTACCAC
Rat
CB1
CCAAAAGTGGAGAGCGACAAC CGTCTCGAAGGTCCCAATGT CATCCAGATCACCATGCCGTTCACA
Rat
CB2
TTGGCCGGAGCTGACTTC CACACCGTGAAAGACATGGAA CGTGATCTTTGCCTGCAACTTCGTCA
Rat
GPR 119
TCCATATTCCAGCAGACCACCTA GCACAAACCTTGGGTGAAACA CATGGGCCCTGCACCTTCTTTGC
Rat
GPR 40
CCTGCCCGACTCAGTTTCTC CGGAGGCAGCCCACATAG TTCTGCTCTTCTTTCTGCCCTTGGTTATCA
Rat
GPR 55
CGCCATCCAGTACCCTCTTC ATGCAGCAGATCCCAAAGGT TCAATCACTTCCGGTCCCCCAGG
RAT
IL6
TCAGGAACAGCTATGAAGTTTCTCTCCG  CGAAACTGGCTGGAAGTCTCT GGCAACTGGCTGGAAGTCTCT
Rat
PDK4
GCTCACACAAGTCAATGGAAAATT ATGTGGTGAAGGTGTGAAGGAA CCAGGCCAACCAATCCACATCGTG
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2.6.6. One-Color Agilent Microarray: 
Agilent's Quick Amp Labelling Kit protocol was followed; briefly, cDNA was 
generated from 500ng of total RNA mixed with Agilent RNA spike-in positive 
control in the presence of T7 promoter primer. Fluorescent cRNA 
(complementary RNA) was generated by using T7 RNA polymerase, which 
simultaneously amplifies target material (approximately 100-fold) and 
LQFRUSRUDWHV F\DQLQH ¶-labeled CTP. According to the manufacturers 
recommendation, RNeasy Mini Kit (Qiagen) was used for cRNA purification and 
NanoDrop spectrophotometer for quantification of of cRNA (ng/µL) and cyanine 3 
(pmol/µL) concentrations to determine the specific activity and cRNA yield. 
5HFRPPHQGHGF51$\LHOGVDQGVSHFLILFDFWLYLWLHVIRUK\EULGL]DWLRQDUHDQG
UHVSHFWLYHO\ )RUK\EULGL]DWLRQHTXDODPRXQWVRIF51$ZHUHK\EULGL]HGWR
Agilent Human Whole Genome Oligo Microarray for 17 hours at 65oC with 
rotation (10 rpm) in a hybridization oven. The hybridized microarrays were 
subjected to washing as recommended by Agilent protocol. Scanning and feature 
extraction were done using Agilent scanner. 
2.6.7. Affymetrix microarray  
Whole-genome Human GeneChip HT PM Array (HG_U133+PM_(HT_HG-
U133_Plus_PM) was used. The RNA was isolated from human myotubes after 
being subjected to different treatments. The labelling and hybridization steps 
were performed at the Nottingham Arabidopsis Stock Centre (NASC).  
2.6.8. Taqman® Low-Density Array  
Taqman® Low-Density Custom Array Micro Fluidic cards (ABI Applied 
Biosystems, UK) were used for the quantification of expression of 48 key 
metabolic genes in human skeletal muscle. Each card allowed for 8 samples to 
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be run in parallel for 48 Taqman gene expression assay targets that were pre-
ORDGHGLQWRHDFKRIWKHZHOOVRQWKHFDUG%ULHIO\ǋORI7DTPDQ8QLYHUVDO3&5
master mix (2x) (ABI Applied Biosystems, UK) was added to 500 ng RNA 
HTXLYDOHQWRIǋOF'1$LQWRDQEppendorf RNAse free tube. RNAse free water 
ǋOZDVWKHQDGGHGWRPDNHWKHWRWDOYROXPHRIWKHUHDFWLRQPL[WXUHXSWR
ǋO7KHUHDFWLRQPL[WXUHZDVWKHQYRUWH[HGFHQWULIXJHGDQGORDGHGLQWRRQH
of the fill reservoirs of the Micro Fluidic card. The cards were then centrifuged 
(MULTIFUGE 3 S-R, Heraeus) and run on a 7900HT Fast Real-Time PCR System 
(ABI Applied Biosystems, UK). The expression of hydroxymethylbilane synthase 
(HMBS) was used to normalise the data to minimize variations in the expression 
of individual housekeeping genes. Gene expression was measured using the 2-
ƩƩ&WPHWKRG 
2.7. Protein Expression Experiments: 
2.7.1. Protein gel electrophoresis and Western blotting  
Reagents  
 
10% Ammonium persulfate (APS) 
0.1g of Ammonium persulfate was dissolved in 1ml of distilled water immediately 
prior to use 
4x Separation Buffer (pH 8.8) 
1.5 M Tris.Cl 
0.4%SDS 
4x Stacking Buffer (pH 6.8) 
0.5 M Tris.Cl 
0.4%SDS 
SDS-PAGE Separating Gel (12% for 2 gels)  
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30% Acrylamide/bisacrylamide:  8 ml 
4x separation buffer: 5ml 
Distilled water: 6.8ml 
$36ǋ/ 
7(0('ǋ/ 
SDS-PAGE Stacking gel (10ml)  
30% Acrylamide/bisacrylamide:  1 ml 
4x stacking buffer: 2.5ml 
Distilled water: 6.5ml 
$36ǋ/ 
7(0('ǋ/ 
5x Protein sample loading buffer (50ml)  
1 M Tris (pH 6.8) :4.5 ml  (90mM) 
5% (v/v) beta-mercaptoethanol 
4% (w/v) SDS:2g  
Bromophenol blue (0.01% w/v) 
7M deionized urea (dissolved in water and deionized by incubation with   
Amberlite Monobed resin for 30 min with gentle stirring)  
SDS-PAGE running buffer (500ml 10x ) 
1.92 M Glycine: 72g 
0.25 M Tris base: 15g  
10% (w/v) SDS: 5g 
Transfer buffer (500ml 10x)  
1.92 M Glycine: 72g 
0.25 M Tris base: 15g  
Tris-Buffered Saline (10xTBS PH 7.4)  
Tris Base: 15g 
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NaCl: 4.4g 
KCL: 1.0g 
pH adjusted to 7.4 and made up to 500 mL with distilled H2O  
TBS-T  
10xTBS 1:10 
YY7ZHHQ 
Blocking buffer  
3% fish gelatine in TBS-T  
Stripping buffer (pH 2.0) 
0.25 M glycine 
2% SDS 
Ponceau Red  
0.1% (w/v) Ponceau S (3-hydroxy-4[2-sulpho-4-(4-sulphophenylazo)-phenyl-
azo]-2, 7-napthalenedisulphoric acid) in 5% (v/v) acetic acid.  
2.7.2. Protein extraction and quantification 
Proteins were precipitated by adding isopropanol to the organic bottom 
layer following the RNA extraction with trizol method, and centrifuging at 
5000rpm for 10 minutes at 4OoC. After removal of supernatant, the pellet was 
washed with 0.3M guanidine HCl/ 95% ethanol and then stored in 2 ml 70% 
ethanol (-20oC). The pellets were dissolved in SDS (Sodium Dodecyl Sulfate)-
Urea sample buffer. For complete dissolving of the proteins, 3x 10 second 
sonication was performed.  
Proteins in RIPA buffer (Radio Immuno Precipitation Assay) [150mM NaCl 
25mM Tris-HCl pH 7.6, Triton X-100, 1% Sodium deoxycholate 0.1% SDS, 1mM 
Na3VO4, 10mM NaF, and stock 25 × Complete Protease inhibitor (Roche)], were 
dissolved by sonicating 3 times for 10 seconds and rotating the homogenate for 
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45 minutes on a daisy wheel in cold room followed by centrifugation at 15000g 
for 10 minutes. The supernatant was then separated from the pellet and assayed 
for total protein concentration was determined using the BCA Protein Assay Kit 
(Pierce, Rockford, IL). Sample loading buffer was used before heating and 
loading of the sample in the polyacrylamide gels for electrophoresis. 
2.7.3. Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE)  
Protein (25 to 45µg/ml) in RIPA buffer was mixed with 5X denaturing 
buffer boiled for 5 minutes and then resolved on 12% SDS-Polyacrylamide gel 
for about an hour under a constant current of 150mA. Proteins were then 
transferred onto pre-soaked nitrocellulose membrane at 105mA, after which the 
membrane was blocked for 1 hour in blocking buffer (3% fish gelatine in 
0.1%TBST) in order to reduce non specific binding to the primary antibody. The 
membrane was subsequently incubated with appropriate polyclonal or 
monoclonal antibodies as listed in table below overnight at 4oC. Blots were 
washed three times for 15 minutes duration each in TBST buffer and incubated 
with IRDye® conjugated anti-rabbit or anti-mouse secondary antibodies (LI-
COR® biosciences) for an hour at room temperature. After subsequent washing 
(3 times 5mins in TBST) the blots were scanning by using a LI-COR® Odyssey 
infrared imaging system (LI-COR® Biosciences, Lincoln, NE/USA). Densitometric 
analysis of protein bands were performed on Odyssey version 3 software. 
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Table 2-4: List of primary and secondary antibodies used in Western Blot experiments 
 
 
2.7.4. Immunocytochemistry  
Rat myoblast cells were grown on a coated cover slip and fixed with 3-4% 
PAF (paraformaldehyde in PBS pH 7.4) for 15 min at room temperature. The 
cells were then washed twice with ice cold PBS. Permeabilization was done by 
incubation of the samples PBS containing 0.25% Triton X-100 for 10 min and 
cells were then washed in PBS three times for 5 min. To block unspecific binding 
of the antibodies cells were incubated with 1% BSA in PBST for 30 min. 
Overnight incubation with the primary antibodies was done at 4°C. The solution 
Antibody
(Catalog number)
Company
Species 
raised in
Concentration Condition Secondary
Approx 
Weight (kDa)
DŽŶŽĐůŽŶĂů ?ƉŚŽƐƉŚŽ ?
p44/42 MAPK 
 ?Z< ? ? ? ? ? ? ? ? ? ? ? ?
Cell Signalling Rabbits 1/1500
Overnight 
incubation
1/10000 44
DŽŶŽĐůŽŶĂů ?Ɖ ? ? ? ? ?DW<
 ?Z< ? ? ? ? ? ? ? ? ? ? ? ?Cell Signalling Mice 1/1500
Overnight 
incubation
1/10000 42
Monclonal--phospho-GSK-
3ɲ ?ɴ ? ? ? ? ? ? ? ? ? Cell Signalling Rabbits 1/500
Overnight 
incubation
1/10000
51 ɲ
 ? ?ɴ
Monoclonal--GSK-3ɲ ?ɴ ? ? ?ƐĐ ?
7291)
Santa Cruz 
Biotechonology
Mice 1/1000
Overnight 
incubation
1/10000
51 ɲ
 ? ?ɴ
Monoclonal--phospho-AKT-
-(#4051)
Cell Signalling Mice 1/500
overnight 
incubation 
using bags
1/10000 60
Polyclonal--AKT--(#9272) Cell Signalling Rabbits 1/1000
overnight 
incubation 
using bags
1/10000 60
Monoclonal--P38--(#9107) Cell Signalling mouse 1/1000
Overnight 
incubation
1/10000 40
Monoclonal--phospho-P38--
(9215)
Cell Signalling Rabbits 1/500
Overnight 
incubation
1/10000 43
Monoclonal--cyclophilin--
(ab74173)
Abcam mouse 1/1500
Overnight 
incubation
1/10000 21
Polyclonal CB1 
(10006590)
Cayman Rabbits 1/500
Overnight 
incubation
1/10000
Polyclonal CB2 
(101550) 
Cayman Rabbits 1/500
Overnight 
incubation
1/10000
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was then decanted and the cell washed three times in PBS (5min each) before 
incubation with the secondary antibody in 1% BSA, PBS for 1 hr at room 
temperature in the dark. The cells were then washed three times with PBS for 5 
min each in the dark. Before mounting the cover slip on a slide the nuclei were 
stained with DAPI for 1 min. Images were obtained using a Leica DMRB 
fluorescent microscope with an oil or glycerol immersion lens at 40x and 64x 
magnification, respectively. Images were captured using Openlab software 
(Improvision-Perkin Elmer, UK). 
Table 2-5: List of primary and secondary antibodies used in immunoflourescence experiments  
 
 
2.8. Calcium imaging 
Single cell intracellular [Ca2+] was quantified  in myoblast and myotube 
clusters by using Ca2+ sensitive fluorescent dye fura-2AM (Cambridge Bioscience, 
Cambridge, UK) and an Andors IQ imaging system. The cells were seeded in 19 
mm glass coverslips (0.2% gelatine coated). Cells  were washed 3 times with 
Ca2+buffer (NaCl 145mM, KCl 5mM, CaCl2 2mM, MgSO4 7H2O 1mM, HEPES 10mM 
DQG*OXFRVHP0ZLWKRUZLWKRXWJ%6$DQGWKHQORDGHGZLWKǋ0)XUD-2-
AM for 30 minutes in the dark at 37ǎC followed by wash and another 15 min 
incubation with buffer. The cover slips were fixed to a Perspex chamber and the 
Primary antibody
(source)
Dilution/conditions Secondary antibody/wavelength Dilution/conditions
Rabbit polyclonal anti- GLUT 4
(Abcam 33780) 1:100, O/N, 4
oC Goat anti-rabbit Alexa Fluoro 488 1:750, 1hrs, RT
0RXVHPRQRFORQDODQWL3.&ǃ
(P-2584 Sigma, UK) 1:500, O/N, 4
oC Anti-mouse Alexa fluoro 568 1:750, 1hrs, RT
Rabbit  monoclonal anti Ki67
(Abcam, UK) 1:200, O/N, 4
oC Goat anti-rabbit Alexa Fluoro 488 1:750, 1hrs, RT
5DEELWSRO\FORQDODQWL3.&į
(P-8333 Sigma, UK) 1:500, O/N, 4
oC Goat anti-rabbit Alexa Fluoro 488 1:750, 1hrs, RT
5DEELWSRO\FORQDODQWL3.&ǅ
(P-0713 Sigma, UK) 1:500, O/N, 4
oC Goat anti-rabbit Alexa Fluoro 488 1:750, 2hrs, RT
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pictures were taken by Retiga chilled digital intensified charge-coupled device 
(CCD) camera. Images were obtained every 5 sec up to 30 min by exciting the 
preparations at 340 and 380 nm. Excitation wavelengths were used to obtain the 
ratio 340/380 with excitation wavelengths set to 500 nm. 
 
Figure 2-5: Myotubes (A) and Myoblasts (B) loaded with fura-2  
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CHAPTER 3. MICROARRAY STUDY OF MUSCLE 
DEVELOPMENT, MYOGENESIS 
 
3.1. Introduction 
Myogenesis, skeletal muscle development, is a multistep process that 
involves commitment of multipotential, mesodermal precursors to a muscle cell 
fate, followed by myoblast proliferation, activation of muscle specific genes, and 
fusion to form multinucleated muscle fibres (Shen et al. 2003). This complex 
process is a highly ordered cascade and is under strict transcriptional control. In 
myogenesis, proliferation of mononucleate myoblasts is followed by irreversible 
cell-cycle withdrawal, cell fusion to form multinucleate myotubes and 
subsequent maturation of myotubes into various classes of myofibres. Myogenic 
differentiation is under the control of two major families of transcription factors; 
the myogenic regulatory factor (MRF) family which includes (Myf5, MyoD, 
myogenin and MRF4) and  the myocyte enhancer factor 2 (MEF2) family which 
consists of MEF2A, MEF2B, MEF2C and MEF2D (Tomczak et al. 2004; Wang et al. 
2004). It is well known that the quiescent satellite cells are activated after 
muscle injury as well as severe exercise, however the fate of these cells is either 
to myogenesis or to a mesenchymal alternative differentiation program (Shefer 
et al. 2004; Yablonka-Reuveni 1988; Beauchamp et al. 1999; Zammit et al. 
2006). Different molecular markers (Pax7, Pax3 & MYOD) have been identified 
which can be used to characterize muscle satellite cells (Parker et al. 2003; 
Siegel et al. 2011; Seale et al. 2000). However,  (Shefer et al. 2004)  reported 
that Pax7 is initially expressed in both myogenic and non-myogenic clones and  
(Yablonka-Reuveni et al. 2008) reported that Pax3 is only present in certain 
muscles such as diaphragm and limb muscles. The activated satellite cells and 
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proliferating myoblasts tend to co-express Pax7 and MyoD, whereas the 
differentiating myocytes start to express myogenin with concomitant 
downregulation of Pax7 (Wang et al. 2008 and Zammit et al. 2006). It  has been 
found that insulin-like growth factors, hepatocyte growth factors, fibroblast 
growth factors (Kudla et al. 1998 and Bhasker & Friedmann 2008)  and  the p38 
mitogen-activated protein kinase (MAPK) pathway are required for myogenesis. 
The extracellular signal-regulated kinase (ERK) pathway plays dual roles: it 
inhibits differentiation at the onset of differentiation and promotes myocyte 
fusion at the late stage of differentiation (Wang et al. 2008). Although 
myogenesis has been widely described, this complex cascade, which involves 
many steps and interactions between various genes is not fully understood. 
Furthermore, there are many genes involved in muscle cell 
proliferation/differentiation that are not yet known. The rapid development of 
expression microarray technology has provided new possibilities to view 
myogenesis in a genome-wide perspective. In skeletal muscle the use of 
microarray studies has focused on the identification of gene expression 
differences between normal and diseased muscle (Haslett & Kunkel 2002; Baker 
et al. 2006; Gonzalez de Aguilar et al. 2008; Han et al. 2003). The 
transcriptional profile differences between myoblasts and myotubes were studied 
in C2C12 mouse cells at limited time points in the glycogenome only (Moran et 
al. 2002 and Janot et al. 2009). In this study microarray was used not only to 
focus on gene expression differences between proliferating and fully 
differentiated stages but also to highlight the importance of the identification of 
suitable reference genes as well as searching for G protein coupled-receptors 
which might have a role in skeletal muscle development.  Changes in mRNA 
transcription levels are crucial during developmental processes. Ideally the 
reference genes should not be regulated or influenced by the experimental 
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procedure, should be resistant to cell cycle fluctuations or nutrient status and be 
expressed early in fetal development and throughout adulthood 5DGRQLüHWDO
2004 and Warrington et al. 2000). 
The superfamily of Gprotein-coupled receptors (GPCRs) is one of the 
largest families of proteins in the mammalian genome which play a key role in 
cellular communication, mediating the efficient coordination of a cell's responses 
to extracellular stimuli  (Lander et al. 2001; New & Wong 2007).  GPCRs share a 
common structural signature of seven hydrophobic trans membrane (7 TM) 
segments, with an extracellular amino terminus and an intracellular carboxyl 
terminus (Kobilka 2007). These receptors can be clustered into 5 families: the 
rhodopsin family, the adhesion family, the frizzled/ taste family, the glutamate 
family, and the secretin family (Fredriksson et al. 2003). When stimulated these 
receptors modulate the activity of a wide range of intracellular signalling 
pathways that facilitate cellular development, cell migration, differentiation, 
proliferation, and survival (Wang et al. 2007). GPCRs transduce signals across 
the plasma membrane through their ability to stimulate guanine nucleotide 
exchange by heterotrimeric G proteins which are grouped into four classes, 
NQRZQDV*ĮT*ĮLR*ĮVDQG*Į(New & Wong 2007). This promotes 
WKHUHOHDVHRI IUHH*ĮDQG*ǃǄVXEXQLWVZKLFKWKHQLQLWLDWHLQWUDFHOOXODUVLJQDO
WUDQVGXFWLRQ0HPEHUVRIDOOIRXUFODVVHVRI*ĮVXEXQLWKDYHEHHQVKRZQWREH
involved in the regulation of cell growth and proliferation. Depending on the type 
of G protein to which the receptor is coupled, a variety of downstream signalling 
pathways can be activated. GPCR-mediated proliferation activate via activation 
of PI3Ks, MAPKs , NF-kB or transactivating of RTKs (Receptor Tyrosine Kinase) 
which is integral to second messenger regulation (Milligan & Kostenis 2006; 
Schäfer et al. 2004; Wang et al. 2007). Signalling is then attenuated 
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(desensitized) by GPCR internalization, which is facilitated by arrestin 
dependent or  arrestin independent pathways (Kroeze et al. 2003; Luttrell & 
Lefkowitz 2002). Very little is known regarding the possible roles of GPCRs in 
regulating the development of skeletal muscle and most studies have used 
myogenic cell lines C2C12 and L6 as models for studying skeletal muscle 
development (Jean-Baptiste et al. 2005; Weiss et al. 2010). 
Skeletal muscle primary cell culture provides a well-established model for 
studying myogenesis as well as the metabolic and molecular functions of skeletal 
muscle. The drawback of cell culture in general is that cells change their 
phenotype and remain relatively immature (Raymond et al. 2010; Baker et al. 
2006).The availability of microarray technology makes it possible to investigate 
the gene expression differences between human myotubes and skeletal muscle 
tissues.  
3.2. Aims 
 The objectives of this study are: 
x   To address the gene expression difference during muscle development.  
x To recognize suitable and stable reference genes during skeletal muscle 
development.  
x To identify GPCRs that might have a role in skeletal muscle development. 
x To study the differences in the global gene expression profiles between 
myotubes and skeletal muscle tissue. 
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3.3. Experiment design and methods 
3.3.1. Sample collection and preparation  
Human skeletal muscle tissues from vastuis lateralis were collected from 
three subjects and samples were divided into two parts, the first part snap 
frozen in liquid nitrogen and the second part was used for isolation and culture 
of satellite cells in gelatinized flasks.  
Total RNA, mRNA, cDNA and protein preparation was performed as 
described in chapter 2 section 2.6. 
3.3.2. One-Color Microarray: 
 Agilent one color whole genome microarrays (4*44K DNA) were used to 
measure the mRNA expression level of 41078 entities in human skeletal muscle 
tissues, myoblasts and myotubes.  The microarray experiment was carried out 
as described in chapter 2 section 2.6.6 .Data were extracted using Agilent 
Feature Extraction Software. Data from arrays which passed the Agilent QC 
report were loaded onto GeneSpring GX 11 software (Appendix 2). 
3.3.3. Pre-processing and normalization of microarray data 
Pre-processing of raw probe intensities is an essential procedure in the 
analysis of gene expression microarray data. Generally, background correction 
and normalization are used to reduce the impact of variations in experimental 
conditions (Gyorffy et al. 2009).  
Normalization requires adjustment of microarray data for effects which 
arise from variation in the technology rather than from biological differences 
between the RNA samples or between the printed probes (Smyth et al. 2003). 
Background Subtraction is an important step in this process as fluorescence of a 
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spot is due not only to spot signal intensity but also background noise which is 
due to a variety of technical factors. The processed signal was generated after 
background subtraction by setting all data with a value of less than 1.0 to 1.0 to 
avoid bias in estimation.  
In order to produce similar scales for fold changes in both the up and down 
directions as well as to produce normal distribution of expression, raw data were 
transformed to log to base 2 followed by 75% quantile normalization. Quality 
control was performed as a first step to identify potential outliers; two 
unsupervised methods were used, Pearson correlation and Principal Component 
Analysis (PCA).  
Ranking of genes involves either ranking the genes in order of expression 
from strongest to weakest or choosing a critical-value above which any value is 
considered to be significant. Agilent flagging rules were applied and all the 
marginal and absent features were sited to be missing before ranking.  Two-way 
Hierarchical clustering was performed on the 3 experimental conditions 
according to their gene expression. A fold change, with a cut off value of plus or 
minus two was also calculated to assess the level and direction of changes in 
gene expression between skeletal muscle tissues, myoblast and myotubes. This 
was followed by applying the Gene ontology (GO) classification system. In GO, 
GeneSpring computes a p value to quantify the significance in the GO by 
applying the Benjamini-Yekutieli correction to quantify the significance and apply 
correction for the large number of hypotheses tested.  
Data were interpreted using Ingenuity Pathways Analysis (IPA) (Ingenuity 
Systems, Redwood City, CA, USA) http://www.ingenuity.com. The list of 
differentially expressed genes selected by the microarray analysis described 
above was loaded onto IPA using the following criteria: Direct and Indirect 
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relationships were included; data were filtered by species (human), and 
subsequently by tissue (skeletal muscle). Then IPA generated lists of genes that 
were associated with particular biological functions, diseases, and molecular 
processes. The IPA output also showed the canonical pathways active in the 
different samples.  
3.3.3.1. Evaluation of microarray data 
To confirm the validity of the microarray data, evaluation was performed 
as follows; 
1) An estimate of the concordance was provided by the percentage of genes 
defined as present (expressed at above marginal levels) between biological 
replicates.  
2) Pearson correlation was used to correlate the normalized expression 
intensity of present entities between biological replicates. 
3.4. Results  
3.4.1. Principle Component Analysis (PCA) and Hierarchal 
Clustering. 
PCA analysis indicated that the samples separated according to tissue/cell 
type and not to the volunteer subject they were obtained from i.e the tissues 
clustered together whereas myobasts and myotubes formed another group 
(Figure 3-1). Two-way hierarchal clustering also showed that tissues were 
clearly separated from culture cells based on their gene expression profile 
(Figure 3-2). Samples that did not pass the agilent QC report and the quality 
metrics were removed from further analysis. The final analysis was performed 
between two biological replicates. 
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Figure 3-1: PCA analysis of human muscle arrays from three biological samples. 
The figure shows the distribution of tissue and cultured cells (myoblasts and myotubes).The 
distribution of subjects along 3 eigenvectors. The samples separated according to tissue/cell type 
and not to the volunteer subject they were obtained from. New parameter = the average. 
 
 
Figure 3-2: Dendrogram of hierarchal clustering from 3 biological samples. 
The figure shows separation of human muscle tissues (TIS) from myoblasts (MB) and myotubes 
(MT). Tissues were clearly separated from culture cells based on their gene expression profile 
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3.4.2. Reproducibility. 
Pearson correlation analysis showed high correlation between two 
biological replicates from whole tissues, myoblasts and myotubes (r=0.92, 
r=0.93, r=0.95, respectively).  Technical replicates e.g. two myoblast replicates 
from the same human tissue had a high correlation coefficient (r=0.98) 
(Figure 3-3). 
 
Figure 3-3: Pearson correlations between two biological replicates. 
A (r=0.92), B (r=0.95) & C (r=0.93) and two technical replicates D (r=0.98).   
 
3.4.3. Concordance. 
Using only the entities called as Flag present, it was found that out of 
41,078 entities; tissues displayed 23,772, myotubes 27,861 and myoblast 
29,090 entities. Concordance rates among biological replicates were 79% in 
tissues (Figure 3-4), 84% in myoblast and 88% in myotube. Technical replicates 
e.g. myoblasts from the same human had a 93% concordance rate. 
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Figure 3-4: Venn diagram showing concordance, the number of similar entities between two human 
muscle tissue samples. 
 
3.4.4. Ranking. 
According to the expression intensity, genes were ranked in a descending 
order.  A similar rank order for most genes was observed between two biological 
replicates (Table 3-1).  
Table 3-1: List of some genes ranking in myoblast, myotube and skeletal muscle tissue. 
 
Human 1 Human 2
1
1
1
1
1
1
Tissues Flag  Present Genes
GeneSymbol
Myoblast
1
Myoblast
2
GeneSymbol
Myotube
1
Myotube
2
GeneSymbol
Tissue
1
Tissue
2
MAT2A 313 313 OAZ1 2 2 MYH7 1 1
NDUFB10 1955 1955 ACTB 29 28 ENO3 3 2
OAZ1 2 1 SOX8 2734 2733 MB 4 5
EIF1 25 24 UBC 15 13 ERBB2IP 4383 4384
FBL 664 662 SLC35E4 265 263 SLC15A2 34600 34601
UBC 13 10 RPLP0 23 20 TNNI2 5 7
CCT7 1347 1343 ITGB5 1754 1750 ACTA1 8 6
UBB 73 78 TPM1 188 183 TNNC2 6 3
ENO1 970 976 RBP4 24119 24112 IL19 35532 35535
RPS4Y1 916 907 TTC3 3622 3613 CCL2 13570 13574
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Among the three biological replicates, two replicates only passed the 
quality control. As the validation of the data was highly acceptable and 
comparative, ranking, intensity value and a fold-FKDQJH FXWRII SRLQWRI
was computed to identify transcriptome differences between muscle tissue and 
cultured myotubes and cultured myoblasts  
3.4.5. Genes involved in myogenesis 
The comparison was carried out using ranking from high to low expression 
when comparing between myoblasts and myotubes, while ranking and fold 
change were used when comparing cultured cell and muscle tissue (Table 3-2). 
The transcriptional regulators MYOD1, MYF5, CDK6 and MYOG were all higher in 
cultured cells than tissue. MYOD1, MYF5 and CDK6 were also higher in 
myoblasts than myotubes, whereas MYOG was higher in myotubes than 
myoblasts. In contrast to transcriptional regulators, the myocyte enhancer 
family had higher expression in tissue compared to cultured cells. Comparison 
between myoblasts and myotubes revealed that expression of MEF2a and MEF2b 
was higher in myoblasts, whereas MEF2c and MEF2d were higher in myotubes. 
Genes that have a role in adhesion (MGAT1, HES6, ITGb1, ITGa1, ITGb7, ITGa4, 
NCAM1 and VCAM1) were higher in myotubes compared to myoblasts. 
Furthermore, STAT1, STAT2 and STAT4, genes that have a role in 
differentiation, were slightly higher in myotubes than myoblasts, whereas the 
growth factors FGFR2, IGFbp3 and IGFbp4 were higher in myoblasts compared 
to myotubes. Not surprisingly, genes responsible for muscle structure proteins 
and phenotypes (Desmin, Tropomyosin, Troponin, Tropomodulin and myosin 
lLJKW DQG KHDY\ FKDLQ ZHUH KLJKHU IROG FKDQJH   LQ WLVVXH WKDQ FXOWXUHG
cells. It is worth mentioning that the embryonic type myosin heavy chain gene 
(MYH3) was higher in myotubes compared to skeletal muscle tissue. 
Interestingly, most genes associated with both slow and fast muscle fibres 
phenotype were lower in cultured cells than muscle tissue.   
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Table 3-2: List of genes involved in myogenesis 
 
Gene 
Symbol
Rank 
MYOBLAST 
Rank 
MYOTUBE
Rank 
TISSUE 
Description
ACTA1 1000 256 7 Homo sapiens actin, alpha 1, skeletal muscle 
(ACTA1), mRNA [NM_001100]
CDH15 489 809 1958
Homo sapiens cadherin 15, M-cadherin (myotubule) 
(CDH15), mRNA [NM_004933]
CDK6 1490 1929 7824
Homo sapiens cyclin-dependent kinase 6 (CDK6), 
mRNA [NM_001259]
CKMT2 17904 17846 191
Homo sapiens creatine kinase, mitochondrial 2 
(sarcomeric) (CKMT2), nuclear gene encoding 
mitochondrial protein, mRNA [NM_001825]
DES 760 542 48 Homo sapiens desmin (DES), mRNA [NM_001927]
DMD 4779 4069 1671 Homo sapiens dystrophin transcript variant 
Dp427p2, mRNA [NM_004010]
FGFR2 14141 16309 27743
Homo sapiens fibroblast growth factor receptor 2  
transcript variant 2, mRNA [NM_022970]
HES6 10731 8055 20607
Homo sapiens hairy and enhancer of split 6 
(Drosophila) (HES6), mRNA [NM_018645]
IGF2 825 682 977
Homo sapiens insulin-like growth factor 2 
(somatomedin A) (IGF2), transcript variant 2, mRNA 
[NM_001007139]
IGFBP3 355 331 11078
Homo sapiens insulin-like growth factor binding 
protein 3 (IGFBP3), transcript variant 1, mRNA 
[NM_001013398]
IGFBP4 6697 5800 16045
Homo sapiens insulin-like growth factor binding 
protein 4 (IGFBP4), mRNA [NM_001552]
INSR 25948 22471 24169 Homo sapiens insulin receptor (INSR), transcript 
variant 1, mRNA [NM_000208]
ITGA3 10364 9354 20617
Homo sapiens integrin, alpha 3 (ITGA3), transcript 
variant a, mRNA [NM_002204]
ITGA4 17660 15852 28149
Homo sapiens integrin, alpha 4 (ITGA4), mRNA 
[NM_000885]
ITGB1 48 29 674
Homo sapiens integrin, beta 1  (ITGB1), transcript 
variant 1A, mRNA [NM_002211]
ITGB7 8626 13513 16076
Homo sapiens integrin, beta 7 (ITGB7), mRNA 
[NM_000889]
JAK1 7794 6946 8376 Homo sapiens Janus kinase 1 (a protein tyrosine 
kinase) (JAK1), mRNA [NM_002227]
JAK2 15326 14802 12002 Homo sapiens Janus kinase 2 (a protein tyrosine 
kinase) (JAK2), mRNA [NM_004972]
JAK3 11160 9856 14610
Homo sapiens Janus kinase 3, mRNA (cDNA clone 
MGC:39993 IMAGE:5212575), complete cds. 
[BC028068]
LEPR 12573 8131 25386 Homo sapiens leptin receptor (LEPR), transcript 
variant 2, mRNA [NM_001003679]
MAPK1 10202 10565 9613
Homo sapiens mitogen-activated protein kinase 1 
(MAPK1), transcript variant 1, mRNA [NM_002745]
MEF2A 15349 15563 13714 Homo sapiens MADS box transcription enhancer 
factor 2, polypeptide A (MEF2A), mRNA [NM_005587]
MEF2B 7341 9312 9338
Homo sapiens MADS box transcription enhancer 
factor 2, polypeptide B mRNA (cDNA clone 
IMAGE:4280324), complete cds. [BC010931]
MEF2C 4267 2944 1001
Homo sapiens MADS box transcription enhancer 
factor 2, polypeptide C (MEF2C), mRNA 
[NM_002397]
MEF2D 9103 7058 8045
Homo sapiens MADS box transcription enhancer 
factor 2, polypeptide D (MEF2D), mRNA 
[NM_005920]
MYBPC1 31944 31122 107
Homo sapiens myosin binding protein C, slow type 
(MYBPC1), transcript variant 2, mRNA [NM_206819]
MYF5 2548 2888 10407
Homo sapiens myogenic factor 5 (MYF5), mRNA 
[NM_005593]
MYH1 4893 3394 521
Homo sapiens myosin, heavy chain 1, skeletal 
muscle, adult (MYH1), mRNA [NM_005963]
MYH2 3057 1721 13
Homo sapiens myosin, heavy chain 2, skeletal 
muscle, adult (MYH2), mRNA [NM_017534]
MYH3 1265 322 8166 Homo sapiens myosin, heavy chain 3, skeletal 
muscle, embryonic (MYH3), mRNA [NM_002470]
MYH7 1905 303 1
Homo sapiens myosin, heavy chain 7, cardiac 
muscle, beta (MYH7), mRNA [NM_000257]
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Table 3-2: (Continued) 
 
Gene 
Symbol
Rank 
MYOBLAST 
Rank 
MYOTUBE
Rank 
TISSUE 
Description
MYL1 3510 1668 56
Homo sapiens myosin, light chain 1, alkali; skeletal, 
fast (MYL1), transcript variant 3f, mRNA 
[NM_079422]
MYL2 6040 3111 27
Homo sapiens myosin, light chain 2, regulatory, 
cardiac, slow (MYL2), mRNA [NM_000432]
MYL3 10717 7054 827
Homo sapiens myosin, light chain 3, alkali; 
ventricular, skeletal, slow (MYL3), mRNA 
[NM_000258]
MYLK2 21057 24226 161 Homo sapiens myosin light chain kinase 2, skeletal 
muscle (MYLK2), mRNA [NM_033118]
MYOD1 8456 8734 12377
Homo sapiens myogenic differentiation 1 (MYOD1), 
mRNA [NM_002478]
MYOG 10756 8997 12531
Homo sapiens myogenin (myogenic factor 4) 
(MYOG), mRNA [NM_002479]
MYOZ1 25911 28386 275
Homo sapiens myozenin 1 (MYOZ1), mRNA 
[NM_021245]
MYOZ3 21309 21329 412
Homo sapiens myozenin 3 (MYOZ3), mRNA 
[NM_133371]
NCAM1 16479 13133 28905
Homo sapiens neural cell adhesion molecule 1 
(NCAM1), transcript variant 3, mRNA 
[NM_001076682]
PAX3 16647 20649 15077 Homo sapiens paired box gene 7 (PAX7), transcript 
variant 2, mRNA [NM_013945]
PAX7 15503 16575 22617
Homo sapiens paired box gene 7 (PAX7), transcript 
variant 2, mRNA [NM_013945]
RYR1 12680 11523 1261 Homo sapiens ryanodine receptor 1 (skeletal) 
(RYR1), transcript variant 1, mRNA [NM_000540]
RYR2 31602 32575 31553 Homo sapiens ryanodine receptor 2 (cardiac) 
(RYR2), mRNA [NM_001035]
RYR3 18317 26195 9456 Homo sapiens ryanodine receptor 3 (RYR3), mRNA 
[NM_001036]
STAT1 6561 6118 10188
Homo sapiens signal transducer and activator of 
transcription 1, 91kDa (STAT1), transcript variant 
alpha, mRNA [NM_007315]
STAT2 17191 15859 23891
Homo sapiens signal transducer and activator of 
transcription 2, 113kDa (STAT2), mRNA 
[NM_005419]
STAT3 16223 15053 14539
Homo sapiens signal transducer and activator of 
transcription 3 (STAT3), transcript variant 3, mRNA 
[NM_213662]
STAT4 19467 16823 21558 Homo sapiens signal transducer and activator of 
transcription 4 (STAT4), mRNA [NM_003151]
STAT6 2232 2354 5638
Homo sapiens signal transducer and activator of 
transcription 6, interleukin-4 induced (STAT6), 
mRNA [NM_003153]
TCEAL7 8147 9514 15268
Homo sapiens transcription elongation factor A (SII)-
like 7 (TCEAL7), mRNA [NM_152278]
TMOD4 21647 23413 193 Homo sapiens tropomodulin 4 (muscle) (TMOD4), 
mRNA [NM_013353]
TMOD4 21647 23413 193 Homo sapiens tropomodulin 4 (muscle) (TMOD4), 
mRNA [NM_013353]
TNNC1 3339 1402 39
Homo sapiens troponin C type 1 (slow) (TNNC1), 
mRNA [NM_003280]
TNNC2 1944 747 5
Homo sapiens troponin C type 2 (fast) (TNNC2), 
mRNA [NM_003279]
TNNI1 10099 5781 1962
Homo sapiens troponin I type 1 (skeletal, slow) 
(TNNI1), mRNA [NM_003281]
TNNI2 5868 3512 6
Homo sapiens troponin I type 2 (skeletal, fast) 
(TNNI2), mRNA [NM_003282]
TNNT1 691 701 18
Homo sapiens troponin T type 1 (skeletal, slow), 
mRNA (cDNA clone MGC:104241 IMAGE:4247379), 
complete cds. [BC107798]
TNNT3 3185 1265 39
Homo sapiens troponin T type 3 (skeletal, fast) 
(TNNT3), transcript variant 2, mRNA [NM_006757]
TPM1 119 175 42
Homo sapiens tropomyosin 1 (alpha) (TPM1), 
transcript variant 5, mRNA [NM_000366]
TPM3 1870 1956 98
Homo sapiens tropomyosin 3 (TPM3), transcript 
variant 2, mRNA [NM_153649]
VCAM1 11760 7113 20836
Homo sapiens vascular cell adhesion molecule 1 
(VCAM1), transcript variant 1, mRNA [NM_001078]
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3.4.6. Reference genes 
The reference genes must be expressed at a constant level between 
individuals and different samples, and have amplification efficiency and 
abundance similar to that of the genes of interest. In this study a list of 
common reference genes were chosen according to Eisenberg & Levanon 
(2003). TBP was found to be the most stable gene as it had a similar 
rank and intensity at all stages of development in agreement with Stern-
Straeter et al. (2009) (Table 3-3). 
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Table 3-3: List of reference genes in skeletal muscle tissue and cultured cells. 
 
MB=myoblast, MT=myotube, TIS=tissue, FC=fold change & N/A=no difference 
MB MT TIS MB MT TIS 
ACTB 17 29 368 8.19 7.87 6.90
Homo sapiens actin, beta (ACTB), mRNA 
[NM_001101]
GAPDH 367 242 76 6.33 6.69 8.39
Homo sapiens glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), mRNA [NM_002046]
RPS18 107 101 230 7.38 7.33 7.49
Homo sapiens ribosomal protein S18 (RPS18), 
mRNA [NM_022551]
TBP 13154 13198 12816 -0.91 -0.90 -0.80
Homo sapiens TATA box binding protein (TBP), 
mRNA [NM_003194]
TAPBP 6882 6114 7200 1.20 1.49 1.12
Homo sapiens TAP binding protein (tapasin) 
(TAPBP), transcript variant 1, mRNA 
[NM_003190]
RPL18 338 269 647 6.38 6.59 6.17
Homo sapiens ribosomal protein L18 (RPL18), 
mRNA [NM_000979]
TUBB 2108 1904 5144 3.85 3.95 2.03
Homo sapiens tubulin, beta (TUBB), mRNA 
[NM_178014]
TRFP 10262 10915 10492 0.01 -0.20 -0.08
Homo sapiens Trf (TATA binding protein-
related factor)-proximal homolog (Drosophila) 
(TRFP), mRNA [NM_004275]
UBC 12 14 18 8.24 8.04 9.22
Homo sapiens ubiquitin C (UBC), mRNA 
[NM_021009]
ALDOA 787 605 74 5.38 5.67 8.55
Homo sapiens aldolase A, fructose-
bisphosphate (ALDOA), transcript variant 1, 
mRNA [NM_000034]
PGK1 439 491 442 6.14 5.96 6.69
Homo sapiens phosphoglycerate kinase 1 
(PGK1), mRNA [NM_000291]
LDHA 604 680 604 5.75 5.53 6.28
Homo sapiens lactate dehydrogenase A 
(LDHA), mRNA [NM_005566]
ENSA 13013 14248 10636 -0.87 -1.21 -0.07
Homo sapiens endosulfine alpha (ENSA), 
transcript variant 3, mRNA [NM_004436]
BTF3 361 367 494 6.30 6.29 6.56
Homo sapiens basic transcription factor 3 
(BTF3), transcript variant 2, mRNA 
[NM_001207]
YARS 11185 9266 15731 -0.32 0.33 -1.66
Homo sapiens tyrosyl-tRNA synthetase (YARS), 
mRNA [NM_003680]
CSTB 2297 2266 3115 3.65 3.62 3.20
Homo sapiens cystatin B (stefin B) (CSTB), 
mRNA [NM_000100]
RAB1A 2848 2740 5464 3.24 3.26 1.86
Homo sapiens RAB1A, member RAS oncogene 
family (RAB1A), mRNA [NM_004161]
TKT 2511 2281 7860 3.49 3.65 0.87
Homo sapiens transketolase (Wernicke-
Korsakoff syndrome) (TKT), mRNA 
[NM_001064]
YARS 11185 9266 15731 -0.32 0.33 -1.66
Homo sapiens tyrosyl-tRNA synthetase (YARS), 
mRNA [NM_003680]
ZFP36L1 722 582 1703 5.49 5.75 4.47
Homo sapiens zinc finger protein 36, C3H type-
like 1 (ZFP36L1), mRNA [NM_004926]
BTBD2 13963 12689 11090 -1.17 -0.74 -0.26
Homo sapiens BTB (POZ) domain containing 2 
(BTBD2), mRNA [NM_017797]
CDC2L2 24256 23909 23652 -4.62 -4.33 -4.03
Homo sapiens cell division cycle 2-like 2 
(PITSLRE proteins) (CDC2L2), transcript variant 
6, mRNA [NM_033532]
HYOU1 16368 14825 23718 -1.91 -1.39 -4.04
Homo sapiens hypoxia up-regulated 1 
(HYOU1), mRNA [NM_006389]
GSK3A 1705 1940 1335 4.18 3.90 4.99
Homo sapiens glycogen synthase kinase 3 
alpha (GSK3A), mRNA [NM_019884]
ATP5H 399 460 117 6.22 6.04 8.11
Homo sapiens ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit d (ATP5H), 
transcript variant 1, mRNA [NM_006356]
NDUFA7 2077 2277 711 3.83 3.61 6.00
Homo sapiens NADH dehydrogenase 
(ubiquinone) 1 alpha subcomplex, 7, 14.5kDa 
(NDUFA7), mRNA [NM_005001]
CLSTN1 4990 4937 7687 2.04 2.01 0.93
Homo sapiens calsyntenin 1 (CLSTN1), 
transcript variant 1, mRNA [NM_001009566]
NDUFV2 1893 1793 359 4.01 4.04 6.98
Homo sapiens NADH dehydrogenase 
(ubiquinone) flavoprotein 2, 24kDa (NDUFV2), 
mRNA [NM_021074]
NDUFS5 308 336 137 6.52 6.42 7.98
Homo sapiens NADH dehydrogenase 
(ubiquinone) Fe-S protein 5, 15kDa ( 
(NDUFS5), mRNA [NM_004552]
B2M 518 453 536 5.92 6.06 6.47
Homo sapiens beta-2-microglobulin (B2M), 
mRNA [NM_004048]
Gene 
Symbol
Rank Intensity
Description
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3.4.7. GPR receptors and Endoannabinoid metabolism genes. 
 Targeting of G-protein coupled receptors (cannabinoid and free fatty acids 
receptors in particular) in different tissues has been the focus of recent research 
in an attempt to discover new therapies for metabolic diseases (Fredriksson et 
al. 2003). The expression of CB1, CB2, GPR55 and GPR119 were observed in 
both culture skeletal muscle cells and skeletal muscle tissue. The gene 
expression for most of the enzymes responsible for endocannabinoid synthesis 
and degradation (FAAH, MGLL, DAGLA & NAPE-PLD) was higher in skeletal 
muscle tissue than cultured cells. DAGLB was the only enzyme for which the 
gene expression was higher in myotubes than skeletal muscle tissue (Table 3-4). 
The expression of the free fatty acid receptors (GPR40, GPR120, GPR84 and 
GPR43) was also observed. A considerable number (87 out of 329, taken from 
The International Union of Basic and Clinical Pharmacology) of GPCR receptors in 
tissue were observed and 72 had a fold change of >± 2 when skeletal muscle 
tissue was compared to cultured cells. Among the 87 GPCR receptors observed, 
only 4 transcripts were higher in cultured cells when compared to skeletal 
muscle tissue (ADRA2A, ADRA2C, HRT2B and GPR126) (Table 3-5). 
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Table 3-4: Cannabinoid receptors and Endoannabinoid metabolism genes. 
 
MB=myoblast, MT=myotube, TIS=tissue, FC=fold change & N/A=no difference 
 
MB MT TIS MB MT TIS 
MB
vs
MT
MT
vs
TIS
MB
VS
TIS
CNR1 34339 32628 28149 -7.51 -6.72 -5.82 #N/A -6.40 -8.09
Homo sapiens cannabinoid 
receptor 1 (brain) (CNR1), mRNA 
[NM_033181]
CNR2 31846 30571 28967 -7.00 -6.68 -5.50 #N/A -2.31 -2.37
Homo sapiens cannabinoid 
receptor 2 (macrophage) (CNR2), 
mRNA [NM_001841]
GPR119 25291 24315 21455 -4.88 -4.44 -3.35 #N/A -2.13 -2.89
Homo sapiens G protein-coupled 
receptor 119 (GPR119), mRNA 
[NM_178471]
GPR55 34813 32689 30692 -7.78 -6.83 -5.62 #N/A -2.31 -4.46
Homo sapiens G protein-coupled 
receptor 55 (GPR55), mRNA 
[NM_005683]
FAAH 31349 30314 23612 -7.10 -6.68 -4.00 #N/A -6.40 -8.53
Homo sapiens fatty acid amide 
hydrolase (FAAH), mRNA 
[NM_001441]
MGLL 3757 3570 2086 2.66 2.73 4.06 #N/A -2.51 -2.63
Homo sapiens monoglyceride 
lipase (MGLL), mRNA [NM_007283]
DAGLB 15932 13985 17888 -1.78 -1.12 -2.28 #N/A 2.24 #N/A
Homo sapiens diacylglycerol lipase, 
beta (DAGLB), mRNA [NM_139179]
DAGLA 25539 24691 23579 -4.95 -4.59 -4.00 #N/A #N/A #N/A
Homo sapiens diacylglycerol lipase, 
alpha (DAGLA), mRNA [NM_006133]
NAPE-PLD 11207 10147 8119 -0.32 0.04 0.78 #N/A #N/A #N/A
N-acyl-phosphatidylethanolamine-
hydrolyzing phospholipase D 
[RefSeq_peptide;Acc:NP_945341] 
Gene 
Symbol
Rank Intensity Fold Change
Description
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Table 3-5: List of GPCR receptors in cultured cells and skeletal muscle tissue. The genes are 
arranged according to tissue ranking 
 
Gene 
Symbol
Rank 
MB 
Rank 
MT
Rank 
TIS
FC MB 
VS MT
FC MT 
VS TIS
FC MB 
VS TIS
Description
GPRc5c 7666 3348 1384 -3.1 -4.9 -9.6
Homo sapiens  G protein-coupled receptor, fami ly C, group 5, 
member C (GPRC5C), transcript variant 1, mRNA [NM_022036]
P2RY2 18349 21274 1938 #N/A -201 -108.1
Homo sapiens  purinergic receptor P2Y, G-protein coupled, 2 
(P2RY2), transcript variant 1, mRNA [NM_176072]
GPR125 2863 3576 2404 #N/A -2.2 -4.5
Homo sapiens  G protein-coupled receptor 125 (GPR125), 
mRNA [NM_145290]
GPR153 5675 931 2464 -5.9 #N/A -3.3
Homo sapiens  G protein-coupled receptor 153 (GPR153), 
mRNA [NM_207370]
GPR56 3573 2838 3387 #N/A #N/A #N/A
Homo sapiens  G protein-coupled receptor 56 (GPR56), 
transcript variant 3, mRNA [NM_201525]
ADRB2 7692 8928 4628 #N/A -3.7 -2.7
Homo sapiens  adrenergic, beta-2-, receptor, surface 
(ADRB2), mRNA [NM_000024]
GPRC5B 8034 9967 5922 #N/A -3.0 #N/A
Homo sapiens  G protein-coupled receptor, fami ly C, group 5, 
member B (GPRC5B), mRNA [NM_016235]
LGR4 5356 6085 6715 -2.3 #N/A #N/A
Homo sapiens  leucine-rich repeat-conta ining G protein-
coupled receptor 4 (LGR4), mRNA [NM_018490]
ADRA2C 1988 4348 7062 3.1 2.2 6.9
Homo sapiens  adrenergic, a lpha-2C-, receptor (ADRA2C), 
mRNA [NM_000683]
MRGPRF 11655 9634 7298 #N/A 2.6 -2.9
Homo sapiens  MAS-related GPR, member F (MRGPRF), mRNA 
[NM_145015]
P2RY14 35436 38374 10482 #N/A -140.1 -169.9
Homo sapiens  purinergic receptor P2Y, G-protein coupled, 
14 (P2RY14), transcript variant 2, mRNA [NM_014879]
GPR157 18386 19218 10560 #N/A -18.1 -13.2
Homo sapiens  G protein-coupled receptor 157, mRNA (cDNA 
clone IMAGE:4720622), complete cds . [BC018691]
ADRA1D 20282 19561 10632 #N/A -6.9 -8.3
Homo sapiens  adrenergic, a lpha-1D-, receptor (ADRA1D), 
mRNA [NM_000678]
Lphn1 9353 7814 10665 #N/A #N/A #N/A
Homo sapiens  latrophi l in 1 (LPHN1), transcript variant 1, 
mRNA [NM_001008701]
TBXA2R 13694 16716 11085 #N/A -3.4 -2.0
Homo sapiens  thromboxane A2 receptor (TBXA2R), transcript 
variant 1, mRNA [NM_201636]
Gpr18 36277 34545 32714 -2.6 #N/A -4.8
Homo sapiens  G protein-coupled receptor 18 (GPR18), mRNA 
[NM_005292]
Gpr84 31977 29064 29610 -2.1 #N/A -3.4
Homo sapiens  G protein-coupled receptor 84 (GPR84), mRNA 
[NM_020370]
Gpr120 32499 30315 26555 #N/A #N/A #N/A
Homo sapiens  G protein-coupled receptor 120 (GPR120), 
mRNA [NM_181745]
CXCR4 5510 8883 11353 2.7 #N/A 4.7
Homo sapiens  chemokine (C-X-C moti f) receptor 4 (CXCR4), 
transcript variant 1, mRNA [NM_001008540]
EDNRB 16815 20018 11467 #N/A -6.2 -3.2
Homo sapiens  endothel in receptor type B (EDNRB), 
transcript variant 2, mRNA [NM_003991]
Gpr116 35032 35411 11739 #N/A -106.8 -173.3
Homo sapiens  G protein-coupled receptor 116 (GPR116), 
mRNA [NM_015234]
EDG6 27201 31771 12924 #N/A #N/A #N/A
Homo sapiens  endothel ia l  di fferentiation, 
lysophosphatidic acid G-protein-coupled receptor, 6 (EDG6), 
mRNA [NM_003775]
P2RY1 33830 33221 13035 #N/A -64.1 -114.4
Homo sapiens  purinergic receptor P2Y, G-protein coupled, 1 
(P2RY1), mRNA [NM_002563]
Eltd1 17101 16911 13206 #N/A -2.1 -2.3
Homo sapiens  EGF, latrophi l in and seven transmembrane 
domain conta ining 1, mRNA (cDNA clone MGC:34204 
IMAGE:5229055), complete cds . [BC025721]
VIPR2 27981 28850 13404 #N/A -5.0 -5.5
Homo sapiens  vasoactive intestina l  peptide receptor 2 
(VIPR2), mRNA [NM_003382]
AVPR2 14236 19094 13748 2.6 -2.1 #N/A
Homo sapiens  arginine vasopress in receptor 2 
(nephrogenic diabetes  ins ipidus) (AVPR2), mRNA 
[NM_000054]
GPR20 17363 13769 14023 -2.3 -10.0 -8.2
Homo sapiens  G protein-coupled receptor 20 (GPR20), mRNA 
[NM_005293]
GPR4 29738 31124 14184 #N/A -9.6 -18.6
Homo sapiens  G protein-coupled receptor 4 (GPR4), mRNA 
[NM_005282]
EDG5 10463 8907 16106 #N/A #N/A #N/A
Homo sapiens  endothel ia l  di fferentiation, sphingol ipid G-
protein-coupled receptor, 5 (EDG5), mRNA [NM_004230]
GPR162 23523 23779 16962 #N/A -4.8 -3.4
Homo sapiens  G protein-coupled receptor 162 (GPR162), 
transcript variant A-2, mRNA [NM_019858]
ADRA2B 25557 30826 17290 3.2 -24.5 -7.6
Homo sapiens  adrenergic, a lpha-2B-, receptor (ADRA2B), 
mRNA [NM_000682]
ADORA2A 21563 20315 17310 #N/A #N/A -2.7
Homo sapiens  adenos ine A2a receptor (ADORA2A), mRNA 
[NM_000675]
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Table 3-5: (Continued) 
 
Gene 
Symbol
Rank 
MB 
Rank 
MT
Rank 
TIS
FC MB 
VS MT
FC MT 
VS TIS
FC MB 
VS TIS
Description
ADORA2A 21563 20315 17310 #N/A #N/A -2.7
Homo sapiens  adenos ine A2a receptor (ADORA2A), mRNA 
[NM_000675]
HTR7 9775 10758 17343 #N/A 3.9 4.9
Homo sapiens  5-hydroxytryptamine (serotonin) receptor 7 
(adenylate cyclase-coupled) (HTR7), transcript variant d, 
mRNA [NM_019859]
CALCR 34753 35559 17906 #N/A -22.6 -37.5
Homo sapiens  ca lci tonin receptor (CALCR), mRNA 
[NM_001742]
BDKRB2 6570 6580 17999 #N/A 13.2 12.8
Homo sapiens  bradykinin receptor B2 (BDKRB2), mRNA 
[NM_000623]
GPR68 5493 5153 18338 #N/A 21.0 -2.1
Homo sapiens  G protein-coupled receptor 68 (GPR68), mRNA 
[NM_003485]
CCRL2 24161 25064 18852 #N/A -4.5 -3.7
Homo sapiens  chemokine (C-C moti f) receptor-l ike 2 (CCRL2), 
mRNA [NM_003965]
LPHN2 13142 11933 19745 #N/A 4.9 3.8 Homo sapiens  latrophi l in 2 (LPHN2), mRNA [NM_012302]
TACR2 22237 21701 20120 #N/A #N/A #N/A
Homo sapiens  tachykinin receptor 2 (TACR2), mRNA 
[NM_001057]
CCR1 33102 31669 20472 #N/A -13.3 -24.4
Homo sapiens  chemokine (C-C moti f) receptor 1 (CCR1), 
mRNA [NM_001295]
GABBR1 21716 21340 21410 #N/A #N/A #N/A
Homo sapiens  gamma-aminobutyric acid (GABA) B receptor, 
1 (GABBR1), transcript variant 1, mRNA [NM_001470]
NPY1R 32643 33382 21728 #N/A -10.8 -16.8
Homo sapiens  neuropeptide Y receptor Y1 (NPY1R), mRNA 
[NM_000909]
ADORA2B 11428 11369 21815 #N/A 8.6 8.4
Homo sapiens  adenos ine A2b receptor (ADORA2B), mRNA 
[NM_000676]
GPR126 18236 16073 21988 #N/A 3.4 2.0
Homo sapiens  G protein-coupled receptor 126 (GPR126), 
transcript variant b1, mRNA [NM_198569]
ADRA2A 10860 11718 22464 #N/A 9.6 12.6
Homo sapiens  adrenergic, a lpha-2A-, receptor (ADRA2A), 
mRNA [NM_000681]
GPR114 21105 19708 22763 #N/A -2.4 -3.6
Homo sapiens  G protein-coupled receptor 114 (GPR114), 
mRNA [NM_153837]
PTAFR 35488 33848 22895 #N/A -3.3 -6.6
Homo sapiens  platelet-activating factor receptor (PTAFR), 
mRNA [NM_000952]
PTHR1 20355 19752 22934 #N/A #N/A #N/A
Homo sapiens  parathyroid hormone receptor 1 (PTHR1), 
mRNA [NM_000316]
P2RY6 17981 17176 23661 #N/A 3.9 3.0
Homo sapiens  pyrimidinergic receptor P2Y, G-protein 
coupled, 6 (P2RY6), transcript variant 2, mRNA [NM_176798]
GPR3 28878 33144 24208 #N/A -4.2 -3.7
Homo sapiens  G protein-coupled receptor 3 (GPR3), mRNA 
[NM_005281]
Edg2 12958 12767 24625 #N/A #N/A #N/A
Homo sapiens  endothel ia l  di fferentiation, 
lysophosphatidic acid G-protein-coupled receptor, 2 (EDG2), 
transcript variant 2, mRNA [NM_057159]
AGTRL1 33644 34763 24951 #N/A #N/A #N/A
Homo sapiens  angiotens in II  receptor-l ike 1 (AGTRL1), 
mRNA [NM_005161]
GPR45 30585 28962 26475 #N/A -2.5 -3.7
Homo sapiens  G protein-coupled receptor 45 (GPR45), mRNA 
[NM_007227]
GPR120 32499 30315 26555 #N/A #N/A #N/A
Homo sapiens  G protein-coupled receptor 120 (GPR120), 
mRNA [NM_181745]
AVPR1A 38504 37645 27556 #N/A -4.4 -8.5
Homo sapiens  arginine vasopress in receptor 1A (AVPR1A), 
mRNA [NM_000706]
GABBR2 30663 30561 28416 #N/A -2.3 -2.7
Homo sapiens  gamma-aminobutyric acid (GABA) B receptor, 
2 (GABBR2), mRNA [NM_005458]
DRD3 31541 30430 28600 #N/A -2.3 -2.9
Homo sapiens  dopamine receptor D3 (DRD3), transcript 
variant e, mRNA [NM_033663]
GCGR 19872 27908 29167 7.0 #N/A 5.5 Homo sapiens  glucagon receptor (GCGR), mRNA [NM_000160]
FFAR2 33532 31388 29225 #N/A -2.3 -4.5
Homo sapiens  free fatty acid receptor 2 (FFAR2), mRNA 
[NM_005306]
CRHR2 31621 29060 29314 -2.1 #N/A -3.2
Homo sapiens  corticotropin releas ing hormone receptor 2 
(CRHR2), mRNA [NM_001883]
GPR84 31977 29064 29610 -2.1 #N/A -3.4
Homo sapiens  G protein-coupled receptor 84 (GPR84), mRNA 
[NM_020370]
NTSR2 33927 32038 29882 #N/A -2.3 -4.4
Homo sapiens  neurotens in receptor 2 (NTSR2), mRNA 
[NM_012344]
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Table 3-5: (Continued) 
 
 
Further analysis of the data was performed using GeneSpring and 
Ingenuity Pathway Analysis (IPA) to examine the differences between myotubes 
and tissue; myoblasts and myotubes; myoblasts and tissue.  
3.4.8.  Cultured Myotubes vs. Muscle Tissue 
Close examination of the fold-change ratio between myotubes vs muscle 
tissue showed that 12,851 enWLWLHVRXWRIKDGDIROGFKDQJHRIWKHUH
was a considerable number (2,417) of genes whose annotation was unidentified. 
Gene 
Symbol
Rank 
MB 
Rank 
MT
Rank 
TIS
FC MB 
VS MT
FC MT 
VS TIS
FC MB 
VS TIS
Description
GALR2 33763 31728 30620 #N/A -2.2 -4.3
Homo sapiens  ga lanin receptor 2 (GALR2), mRNA 
[NM_003857]
PTGER1 22896 22946 30695 #N/A 2.7 2.6
Homo sapiens  prostaglandin E receptor 1 (subtype EP1), 
42kDa (PTGER1), mRNA [NM_000955]
FFAR1 28375 29027 32595 #N/A #N/A #N/A
Homo sapiens  free fatty acid receptor 1 (FFAR1), mRNA 
[NM_005303]
SSTR3 27175 27011 32810 #N/A #N/A #N/A
Homo sapiens  somatostatin receptor 3 (SSTR3), mRNA 
[NM_001051]
ADRB1 33509 33588 33017 #N/A -2.2 -3.6
Homo sapiens  adrenergic, beta-1-, receptor (ADRB1), mRNA 
[NM_000684]
MRGPRD 36324 34856 33799 #N/A -2.3 -4.4
Homo sapiens  MAS-related GPR, member D (MRGPRD), 
mRNA [NM_198923]
SSTR5 31132 34979 33921 #N/A -2.3 -2.6
Homo sapiens  somatostatin receptor 5 (SSTR5), mRNA 
[NM_001053]
ADORA1 21595 15364 33977 -4.6 18.5 4.0
Homo sapiens  adenos ine A1 receptor (ADORA1), transcript 
variant 1, mRNA [NM_000674]
CELSR3 24863 29218 34552 #N/A #N/A 2.1
Homo sapiens  cadherin, EGF LAG seven-pass  G-type 
receptor 3 (flamingo homolog, Drosophi la) (CELSR3), mRNA 
[NM_001407]
P2RY12 37667 36463 35323 #N/A -2.3 -4.4
Homo sapiens  purinergic receptor P2Y, G-protein coupled, 
12 (P2RY12), transcript variant 1, mRNA [NM_022788]
OPRD1 27534 31714 35687 #N/A #N/A #N/A
Homo sapiens  opioid receptor, del ta  1 (OPRD1), mRNA 
[NM_000911]
HRH4 38027 37115 35846 #N/A -2.3 -4.4
Homo sapiens  his tamine receptor H4 (HRH4), mRNA 
[NM_021624]
DRD5 24648 36868 36431 3.2 -2.3 -2.8
Homo sapiens  dopamine receptor D5 (DRD5), mRNA 
[NM_000798]
CHRM3 28874 30983 37040 #N/A -2.3 -2.2
Homo sapiens  chol inergic receptor, muscarinic 3 (CHRM3), 
mRNA [NM_000740]
EMR1 38131 36041 37418 -2.0 -2.1 -4.3
Homo sapiens  egf-l ike module containing, mucin-l ike, 
hormone receptor-l ike 1 (EMR1), mRNA [NM_001974]
BAI2 18027 15226 37626 #N/A 21.8 11.4
Homo sapiens  bra in-speci fic angiogenes is  inhibi tor 2 
(BAI2), mRNA [NM_001703]
GPR19 25556 32913 37781 2.2 #N/A #N/A
Homo sapiens  G protein-coupled receptor 19 (GPR19), mRNA 
[NM_006143]
GPR149 38288 39089 38077 #N/A -2.4 -4.2
Homo sapiens  G protein-coupled receptor 149 (GPR149), 
mRNA [NM_001038705]
ADMR 37097 40733 40586 #N/A #N/A #N/A
Homo sapiens  adrenomedul l in receptor (ADMR), mRNA 
[NM_007264]
HTR2B 22553 19637 40838 -2.1 9.4 4.4
Homo sapiens  5-hydroxytryptamine (serotonin) receptor 2B 
(HTR2B), mRNA [NM_000867]
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The number of downregulated genes was almost twice the number of 
upregulated genes (8,363 & 4,489 respectively). These genes were further 
analysed with the GO classification system, in which the genes were divided into 
three categories (cellular component, biological process and molecular function). 
Most genes that were downregulated in cultured myotubes compared to skeletal 
muscle tissue (Figure 3-5) were in cellular component (41.9%) mainly 
associated with cytoplasm and mitochondria (43.7%). With respect to biological 
processes (39.9% of all downregulated genes), a significant number of genes 
was associated with cellular metabolic processes (19.4%), response to stimulus 
(18.2%) and biological regulation (13.7%).  The molecular function category 
(18.2% of all downregulated genes), included genes involved in receptor activity 
(28.7%) and membrane transducer activity (25.6%). Among the genes that 
were upregulated (Figure 3-5) in cultured myotubes, genes in the cellular 
components category (35.3% of all upregulated genes) were primarily 
associated with endoplasmic reticulum (57.7%). In the molecular function 
category (containing 31.4% of all upregulated genes) most genes were in 
associated with binding (64.5%), mainly protein binding. The augmented 
biological processes category (33.7% of all upregulated genes) included genes 
involved in cellular processes (21.2%), biological regulation (15.7%) and 
metabolic processes (12.1%). Overall, the over-represented GO annotations 
were associated with cytoskeletal protein binding (molecular function); fatty acid 
beta oxidation and organic acid metabolism-related terms (metabolic 
processes); and muscle development (biological process).  
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Figure 3-5: Gene Ontology analysis in skeletal muscle Tissue vs. Myotubes. 
The figure shows that the molecular functions and cellular components categories had the highest 
percentage of downregulated and upregulated genes, respectively. 
 
3.4.8.1. Downregulated genes.  
IPA analysis was used for further analysis of the low expressed 
(downregulated) genes in myotubes vs skeletal muscle tissue.  Interestingly, the 
low expressed genes were associated with carbohydrate, protein and lipid 
metabolism as well as energy production and molecular transport.  Genes 
encoding metabolic proteins were included in this group: phosphorylase, 
glycogen, muscle (PYGM), citrate synthase (CS), lipoprotein lipase (LPL), 
carnitine palmitoyltransferase 1B (muscle) (CPT1B), phosphoglycerate mutase 2 
(muscle)(PGAM2), fatty acid binding protein 3, muscle and heart    (FABP3), 
adenosine monophosphate deaminase 1 (AMPD1), and fructose-1,6-
bisphosphatase 2 (FBP2)  (see Appendix 3 tables 1, 2 and 3). Mitochondrial 
dysfunction, TCA Cycle and calcium signalling were among the top canonical 
pathways. Interestingly, all the enzymes in TCA Cycle (Figure 3-6) as well as 
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JHQHVUHVSRQVLEOHIRUǃR[LGDWLRQFigure 3-7) were downregulated in myotubes.  
Furthermore, genes that are involved in transcriptional control of fatty acid 
oxidation and glucose homeostasis sucKDV33$5Į33$5ǃ33$5į33$5*&,Į	
33$5*&ǃ ZHUH DOVR ORZ H[SUHVVHG LQ P\RWXEHV ,3$ DQDO\VLV VKRZHG WKHVH
transcription factors were among the upstream regulators and  as most of 
downstream transcripts were low expressed, they are predicted to be inhibited. 
The prediction of inhibition is due to the fact that the genes controlled by these 
transcription factors are inhibited in the database. This indicates that the genes 
involved in fatty acid and glucose oxidation were decreased in myotubes 
compared to skeletal muscle tissue.   For example, the downstream transcripts 
of PPARGC1E (Figure 3-8) are responsible for; Glucose Transport [solute carrier 
family 2 member 4 (SLC2A4)]; Glucogenogesis [phosphoenolpyruvate 
carboxykinase 1 (PCK1)]; Glucogenogesis and Glycogenolysis [glucose-6-
phosphatase (G6PC)]; cholesterol synthesis  [farnesyl-
diphosphatefarnesyltransferase 1 (FDFT1)] and [acetyl-CoA carboxylase beta 
(ABCA1)]; Triglyceride synthesis [diacylglycerol O-acyltransferase 1 (DGAT1)]; 
7&$F\FOH>FLWUDWHV\QWKDVH&6ǃR[LGDWLRQ>FDUQLWLQHSDOPLWR\OWUDQVIHUDVH%
(CPT1B)], [acyl-CoA dehydrogenase very long, long and medium chains 
(ACADVL,  ACADM   ACAADL  )] and [acetyl-CoA carboxylase beta (ACACB)] ; 
Oxidative Phosphorylation [cytochrome c oxidase (COX5A & COX4II)] and [ATP 
synthase, H+ transporting, mitochondrial complex (ATP512 & ATP5B)].
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Figure 3-6: TCA CYCLE, Graphical representation of the downregulated genes in cultured myotubes compared to SM tissue and their molecular relationships. 
Genes are represented as green diamond shapes. The colour intensity corresponds to the magnitude of change.  The fold changes appear in green numbers. The pathway 
image was created using the IPA software. 
-9.1
-9.1
-13.4
-12.3
-11.1
-10.2
-4.9
-10.7
TCA CYCLE
2.3.3.1 citrate synthase
4.2.1.3 aconitase 
1.1.1.41 isocitrate dehydrogenase
6.2.1.5 succinate-CoA ligase
1.3.5.1 succinate dehydrogenase complex
4.2.1.2 fumarate hydratase
1.1.1.37 malate dehydrogenase 
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Figure 3-7: ǃ-oxidation, Graphical representation of the downregulated genes in cultured myotubes compared to SM tissue and their molecular relationships. 
Genes are represented as green diamond shapes. The colour intensity corresponds to the magnitude of change.  The fold changes appear in green numbers. The pathway 
image was created using the IPA software. 
-26.6
-4.8
-4.9
-12.7
-2.1
ɴ-OXIDATION
6.2.1.3 acyl-CoA synthetase 
5.3.3.8 enoyl-CoA delta isomerase 1
4.2.1.1.7 enoyl-CoA hydratase 
1.1.1.35 hydroxyacyl-CoA dehydrogenase
2.3.1.16 acetyl-CoA acyltransferase 1
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Figure 3-8: Graphical representation of the transcriptional regulator PPARGC1ǃ and the downstream 
genes in cultured myotubes compared to skeletal muscle tissue. 
Genes are represented in green colour.  The colour intensity corresponds to the magnitude of 
change.  The lines in between genes represent known interactions. The downstream transcripts of 
PPARGC1B are responsible for; Glucose Transport (SLC2A4); Glucogenogesis (PCK1); Glucogenogesis 
and Glycogenolysis (G6PC); cholesterol synthesis (FDFT1) and (ABCA1); Triglyceride synthesis 
('*$77&$F\FOH&6ǃoxidation (CPT1B, ACADVL, ACADM   ACAADL and (ACACB); Oxidative 
Phosphorylation (COX5A & COX4II) and [ATP (ATP512 & ATP5B). The pathway image was created 
using the IPA software. For genes symbol and fold change see appendix 3. 
 
Moreover, most genes for the insulin signalling pathway had lower 
expression in myotubes compare to skeletal muscle tissue. As illustrated in 
Figure 3-9 the MAPKs pathway was not affected whereas the PI3K/AKT pathway 
and GLUT4 translocation were affected. Interestingly, most of the negative 
regulators of insulin transduction pathway had higher expression in myotubes 
compare to skeletal muscle tissue such as PTEN, SHIP2, SOSC3 and LAR. It is 
worth mentioning that not only the expression of GLUT4 (SLC2A4) but also 
genes responsible for GLUT4 trafficking, such as VAMP2 and TC10 had lower 
expression in myotubes than skeletal muscle tissue Table 3-6.  Mitochondria 
dysfunction was also among the top canonical pathways as most complexes 
enzymes (NADH dehydrogenase, succinate dehydrogenase), cytochromes 
(CYC1, CYTB, COX1 & COX7A1) and monoamine oxidase (MAOB & MAOA) were 
downregulated (Figure 3-10) (Appendix 3 table 5). 
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Figure 3-9: Graphical representation of insulin signalling pathway showing the regulated genes in cultured myotubes compared to SM tissue. 
An expression is shown using green (down regulated) and red (up regulated). All transcripts shown had a fold-FKDQJH  7KH FRORXU LQWHQVLW\ FRUUHVSRQGV WR WKH
magnitude of change. The MAPKs pathway was not affected whereas the PI3K/AKT pathway, the GLUT4 and genes responsible for GLUT4 trafficking such as VAM2 and TC10 
had lower expression in myotubes than skeletal muscle tissue. Most of the negative regulators of insulin transduction pathway (PTEN, SHIP2, SOSC3 and LAR) had higher 
expression in myotubes compare to skeletal muscle tissue. The pathway image was created by IPA software with modification. For genes name and fold changes see 
Table 3-6 
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Table 3-6: List of genes involved in insulin signalling pathway. 
Symbol Entrez Gene Name Fold Change
ACLY ATP citrate lyase 6.427
AKT2 v-akt murine thymoma viral oncogene homolog 2 -2.477
CBL Cbl proto-oncogene, E3 ubiquitin protein ligase 3.523
EIF4E eukaryotic translation initiation factor 4E -2.373
EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1 3.339
FOXO4 forkhead box O4 -2.324
FYN FYN oncogene related to SRC, FGR, YES 7.054
GAB1 GRB2-associated binding protein 1 -4.888
GRB10 growth factor receptor-bound protein 10 -2.316
INPP5D inositol polyphosphate-5-phosphatase, 145kDa -12.031
IRS1 insulin receptor substrate 1 2.429
IRS2 insulin receptor substrate 2 -2.787
IRS4 insulin receptor substrate 4 -2.372
LIPE lipase, hormone-sensitive -10.644
PDE3B phosphodiesterase 3B, cGMP-inhibited -2.471
PRKCZ protein kinase C, zeta 3.100
PTEN phosphatase and tensin homolog 2.048
PTPN11 protein tyrosine phosphatase, non-receptor type 11 2.485
PTPRF (LAR) protein tyrosine phosphatase, receptor type, F 35.321
RAF1 v-raf-1 murine leukemia viral oncogene homolog 1 -3.125
RHOQ ras homolog family member Q -4.767
SHC1 SHC (Src homology 2 domain containing) transforming protein 1 5.685
SLC2A4 solute carrier family 2 (facilitated glucose transporter), member 4 -3329.000
SOCS3 suppressor of cytokine signaling 3 5.694
STXBP4 syntaxin binding protein 4 3.458
TRIP10 thyroid hormone receptor interactor 10 -6.084
TSC1 tuberous sclerosis 1 -2.541
VAMP2 vesicle-associated membrane protein 2 (synaptobrevin 2) -3.036
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Figure 3-10: Mitochondria dysfunction. Graphical representation of the downregulated genes in cultured myotubes compared to SM tissue and their molecular relationships. 
Genes are represented in green colour and.the colour intensity corresponds to the magnitude of change. All genes has a Fold cKDQJHRI -2 with a range from -2 for 
PPP3CA to -2485 for MAOB   The lines in between genes represent known interactions. The pathway image was created using the IPA software. For genes symbol and fold 
change see appendix 3 table 5.  
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The genes responsible for calcium signalling and muscle contraction and 
relaxation were also downregulated (including SERCA, CASQ, RYR, TROPONIN, 
TROPMYOSIN, MYOSIN, CALM & CREB)   (Figure 3-11) (Appendix 3 table 6). A 
closer examination of the downregulated groups revealed several genes 
encoding proteins of myofilaments MYL3; associated/regulatory proteins TMOD4, 
MYBPC1, and XIRP2; the regulator of the muscle sarcomere CAPN3 and skeletal 
muscle phenotypes (MYL3, TNNC1, TNNI1 & TNNT1 for slow phenotype and 
MYL1, TNNC2, TNNI2, and TNNT3 for fast phenotype). The top downregulated 
genes were myoglobin (MB-29166), myosin binding protein ,slow type (MYBPC1 
-25444), fructose1,6 biosphosphate 2 (FBP2 -6480), adenosine monophosphate 
deaminase 1 (AMPD1 -6150), myozenin 1 (MYOZ1 -4595), phosphorylase 
glycogen muscle (PYGM -4374) and solute carrier family 2 , member 4 (SLC2A4 
{GLUT4} -3329). This indicates that genes involved in various highly regulated 
biological functions (energy metabolism and muscle contraction) were the most 
downregulated genes. 
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Figure 3-11: Calcium signalling. Graphical representation of the downregulated genes in cultured 
myotubes compared to SM tissue and their molecular relationships. 
Genes are represented as green diamond shapes. The intensity corresponds to the magnitude of 
change.  The lines in between genes represent known interactions. The pathway image was created 
using the IPA software. For gene symbol see appendix 3 table 6.   
 
3.4.8.2. Upregulated genes.  
As expected, the top biological functions in the upregulated genes were 
associated with Cellular Movement, Cellular Growth and Proliferation, Cellular 
Development, Cellular Assembly and Organization and Cellular Function and 
Maintenance.  Table 3-7 shows the most important functions annotation of the 
upregulated genes. Among the upregulated genes detected in skeletal muscle 
proliferation and differentiation category  were well-known regulatory factors 
such as MYOD1, MYOG, MYF5, FGFR2, ITGB1, CDKN, TOP2A, and HIF1A  
(Appendix 4). The top canonical pathway includes the Epithelial Adherens 
Junction Signalling and the Remodelling of Epithelial Adherence. Several genes 
that have a regulatory function in cell attachment and adherence were included 
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in the upregulated category such as CDH2 (Cadherin2) & POSTN (Periostin/ 
Osteoclast Specific Factor) with fold-changes of 167 and 2,432 respectively.  
Other genes such as ABL1, ANTXR1, CCND1, PTBP1 had a fold change less than 
20 and were also involved in cell adherence.  Interestingly, around 200 genes 
were related to extracellular matrix, such as those encoding: isoforms of lysyl 
hydroxylase (PLOD3, PLOD2) , an enzyme that catalyzes the formation of 
hydroxylysine in collagens; CSGlcA-T, which is involved in the synthesis of 
chondroitin sulphate as a glucuronyltransferase ; the metalloproteinase MMP14; 
TIMP2, an inhibitor of the metalloproteinase type IV; the protease inhibitor 
SERPINE2; insulin like growth factor IGFBP; connective tissue growth factor 
CTGF; growth differentiation factor GDF1s and interleukin 6 (IL6).  The 
upregulated metabolic genes are involved in accumulation of glycosaminoglycan 
& hyaluronic acid and the release of ATP.  The most elevated genes included 
PTX3 (Pentraxin) which has a role in phagocytosis and inflammatory response; 
POSTN (Periostin) which has a role in cell adhesion and migration; DMBT1 
(Deleted in malignant brain tumors) that plays a role in cell differentiation and 
migration; IL6 (Interleukin 6) an important cytokine which has a role in cell 
proliferation, differentiation, apoptosis and growth; FOXD1 (Forkhead box D1) 
that plays a role in cell activation; GERM1 (Germlin 1) that has a role in 
proliferation, differentiation, growth and assembly; TNNT2 (Cardiac troponin) 
that has a role in abnormal morphology and relaxation. It is worth mentioning 
that cyclin-dependent kinase inhibitor which has an important role in cell 
proliferation, cell cycle arrest and initiation of differentiation was also among the 
XSVWUHDP UHJXODWRUV 71)Į ZDV DQRWKHU XSVWUHDP UHJXODWRU DQG LWV DFWLYDWLRQ
through the TNFR1 leads to induction of cell survival and the activation of the 
NF-ǉ%SDWKZD\Figure 3-12). Overall, upregulated genes were associated with 
an increase in cell movement and proliferation.  
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Table 3-7: Top up regulatory functions in myotubes compared to skeletal muscle tissue.  
 
Category Functions Annotation Predicted Activation State
Carbohydrate Metabolism
accumulation of 
glycosaminoglycan 
&hyaluronic acid
Increased
Cell Death and Survival
apoptosis of embryonic 
cell lines, epithelial cell 
lines & macrophafes
Increased
Cell Death and Survival cell viability Increased
Cell Death and Survival cell death & apoptosis Decreased
Cell Signaling hydrolysis of GTP Increased
Cell-To-Cell Signaling and Interaction
adhesion & attachment 
of cells  (blood , immune 
& connective tissue 
cells)
Increased
Cellular Assembly and Organization
d velopment of 
cytoplasm & formation of 
cytoskeletonformation of 
cytoskeleton
Increased
Cellular Development differentiation of cells Increased
Cellular Growth and Proliferation formation of cells Increased
Cellular Movement cell movement Increased
Connective Tissue Disorders congenital anomaly of 
skeletal bone Decreased
DNA Replication, Recombination, and 
Repair synthesis of DNA Increased
Hematological System Development and 
Function
accumulation of 
leukocytes, myeloid 
cells, neutrophils & 
phagocytes
Increased
Hematological System Development and 
Function
aggregation of blood 
platelets Increased
Inflammatory Response accumulation of granulocytes Increased
Molecular Transport release of ATP Increased
Organismal Injury and Abnormalities Bleeding Decreased
Organismal Survival organismal death Decreased
Skeletal and Muscular Disorders congenital anomaly of 
musculoskeletal system Decreased
Small Molecule Biochemistry
quantity of 
glycosphingolipid, 
ceramide & sphingolipid
Increased
Tissue Morphology quantity of blood cells Increased
Tissue Morphology quantity of blood platelets Increased
Tumor Morphology proliferation of cancer 
cells Increased
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Figure 3-12: TNFR1 signalling. Graphical representation of the unregulated genes in cultured 
myotubes compared to SM tissue and their molecular relationships. 
The red colour intensity corresponds to the magnitude of change.  The lines in between genes 
represent known interactions. The pathway image was created using the IPA software. For gene 
symbol see appendix 4.   
 
3.4.9. Myoblast versus myotubes.  
Comparison of the gene expression differences between myoblasts and 
myotubes in culture, showed 2,774 entities with a fold change range greater 
than two. 2,091 were expressed at a lower level whereas 683 genes were 
increased in myoblasts. GO analysis of the low expressed  genes showed a high 
percentage of those genes to be associated with biological processes (43.3%) 
followed by cellular components (36.4%) and molecular function (20.7%). The 
genes expressed at higher levels in myotubes had a similar pattern of 
distribution across the 3 categories; 54, 4% were associated with biological 
processes, 43.5% with cellular components and 2.1% with molecular functions 
(Figure 3-13). 
CHAPTER THREE 
 
 
 
    96 
 
 
   
 
Figure 3-13: Gene Ontology analysis in Myoblasts vs. Myotubes. 
The figure showed that the biological processes category had the highest percentage of 
downregulated and upregulated genes. 
 
Closer inspection of the biological function category revealed a decrease in genes 
responsible for muscle contraction and cytoskeletal organization (CASQ2, MYLPF, 
TNNT2, CACNG1, MYH3, MYH8, TNNT3, CSRP3 & ANK1), a decrease in 
carbohydrates and lipid metabolism genes (ABCB4, ACADS, CD36, CEBPA, CRAT, 
EGFR, INSR, PDK4, PPARG, SLC2A1 & UCP3), a decrease in cell movement and 
binding (ACHE, CASP1, CCBP2, CCL11 ,CCL5, CD74, CMKLR1, FOS, IGF1, 
IKBKB, IL16, IL1B, IL1RL1, NCAM1 & VCAM1) and an increase in  organismal 
death  
Table 3-8) in myoblast compared to myotubes. Among the top upregulated 
genes were protein disulphide isomerase family A member 3 (PDIA3  FC 16.9) 
that has a role in apoptosis and folding in; Solute carrier family 24 member 4 
(SLC24A4  FC 10.5) that has a role in Na+, Ca2+, K+ binding and transport; 
Fms-related tyrosine Kinase 4 (FLT4  FC  7.17) that is a growth factor receptor 
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and has a role in proliferation, migration, apoptosis and growth;  ryanodine 
receptor 3  (RYR3 FC  6.5),  a calcium ion transport; chemokine (C-X-C motif) 
ligand 14 cytokine (CXCL14 FC  6.4) that has a role in signalling, proliferation & 
mobilization; cell adhesion molecule 1 (CADM1 FC 5.9) that plays a role in 
abnormal morphology, cell-cell adhesion, & apoptosis. The top  downregulated 
genes include  Sarcolipin  (SLN FC -8.2) which plays a role in calcium ion 
transport and relaxation; (C-C motif) ligand 11 (CCL11 FC -8.1 ) that has a role 
in migration, adhesion & chemokine; tumor necrosis factor receptor superfamily, 
member 13C (TNFRSF13C  FC -7.1) that has a role in development, proliferation 
and  differentiation; Sema domain  (SEMA6A FC -6.4) that plays a role in protein 
binding, migration, growth; and cell differentiation and (sex determining region 
Y)-box 17 ( SOX FC -5.8) that has a role in cell growth, differentiation and  
proliferation. LXR/RXR (retinoid X receptors) and FXR/RXR (farnesoid X receptor) 
pathways were among the top canonical pathways. Most of genes in these 
patways were down regulated (Figure 3-14). LXR/RXR and FXR/RXR pathways 
play an important role in lipid metabolism and molecular transport.  
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Table 3-8: Top regulatory functions in myoblasts compared to myotubes  
 
 
Category Functions Annotation Predicted Activation State
Cellular Movement cell movement Decreased
Cell-To-Cell Signaling and Interaction binding of cells Decreased
Cell-To-Cell Signaling and Interaction activation of cells Decreased
Cellular Movement leukocyte migration Decreased
Molecular Transport quantity of metal ion Decreased
Cell-To-Cell Signaling and Interaction interaction of cells Decreased
Molecular Transport quantity of Ca2+ Decreased
Cellular Development differentiation of cells Decreased
Carbohydrate Metabolism uptake of carbohydrate Decreased
Cellular Movement migration of cells Decreased
Molecular Transport concentration of lipid Decreased
Cellular Movement recruitment of cells Decreased
Inflammatory Response inflammatory response Decreased
Molecular Transport uptake of 2-deoxyglucose Decreased
Cellular Growth and Proliferation proliferation of cells Decreased
Cell Cycle mitogenesis Decreased
Molecular Transport release of Ca2+ Decreased
Lipid Metabolism fatty acid metabolism Decreased
Cell-To-Cell Signaling and Interaction binding of blood cells Decreased
Molecular Transport secretion of lipid Decreased
Connective Tissue Development and 
Function adipogenesis Decreased
Organismal Survival organismal death Increased
Cell Morphology mineralization of cells Increased
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Figure 3-14: Graphical representation of FXR/RXR signalling pathway showing the regulated genes in cultured myoblasts compared to myotubes related to glucose and lipid 
metabolism.  
An expression is shown using green (down regulated) and red (up regulated). All transcripts shown had a fold-FKDQJH7KHFRORXULQWHQVLW\FRUUHVSRQGVWRWKH
magnitude of change. The pathway image was created with modification by using the IPA software. 
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3.5. Discussion 
Myogenesis is a complex cascade of discrete developmental steps that are 
under strict transcriptional control. Successful myogenic differentiation requires 
numerous interactions between diverse cellular processes involving growth 
factors, hormones, receptors and transcription factors. Although myogenesis has 
been widely described, there are certainly many genes involved in muscle cell 
proliferation/differentiation that are not yet known. The use of microarrays to 
identify genes involved in skeletal muscle function and pathology has been 
limited to studies investigating disease states and myogenesis in cell lines. In the 
present study high-density oligonucleotide arrays were used to (a) characterize 
changes in global mRNA expression patterns during human myogenesis, (b) 
investigate potential differences in the expression of metabolic genes and GPCR 
receptors between skeletal muscle tissue and primary cultured cells in a 
genome-wide perspective and (c) identify suitable reference genes for each 
developmental stage. The use of primary cell cultures and other cell models 
provides a well-established and reproducible model in myogenesis.  However 
their use in studying insulin signalling is controversial.  Human skeletal muscle 
cell culture has been used extensively for the investigation of the biochemical 
and genetic basis of peripheral insulin resistance in type 2 diabetes. Importantly, 
cultured human muscle cells appear to maintain the biochemical and metabolic 
properties of skeletal muscle tissue (Jackson et al. 2000; Henry & Ciaraldi 1996; 
Halse & Bonavaud 2001). Interestingly, Brozinick et al. (2003), Eckardt et al. 
(2008), Pender et al. (2005) and Berggren et al. (2005) have shown that insulin 
resistance disappears in cultured skeletal muscle cells obtained from biopsies 
from obese, insulin-resistant patients demonstrating that insulin resistance might 
be a reversible feature that can be acquired with obesity. Previous studies 
indicate that the genetic basis of muscle function and metabolism for each 
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individual is maintained in cell culture however, muscle from obese or diabetic 
individuals cease to be insulin resistant and this is because the cells are no 
longer being subjected to the external signals such as increased FFA and 
inflammatory cytokines that are present in obese and diabetic subjects.  
This study investigated the global gene expression changes in human 
skeletal muscle tissue compared to cells in culture. The high levels of 
reproducibility, concordance and correlation between replicates confirmed the 
reliability of the microarray data. Moreover, the findings were found to be in 
general agreement with the findings from the published literature. PAX7, a 
molecular marker for muscle satellite cells, had higher expression in myoblasts 
than myotubes and showed very low expression in skeletal muscle tissue (Parker 
et al. 2003; Siegel et al. 2011; Seale et al. 2000; Wang et al. 2008). The 
transcriptional elongated factors Tceal was higher in myotubes compared to 
tissue in line with previous observations (Shi & Garry 2010). The expression of 
the THY1 gene, which is mainly expressed in human fibroblasts, neurons and 
endothelial cells, was higher in cultured cells than skeletal muscle tissue in 
agreement with (Raymond et al. 2010). The contamination with fibroblasts can 
be improved by using Percoll density centrifugation as reported by (Yablonka-
Reuveni & Nameroff 1987) culturing satellite cell from a living single fibre 
(Rosenblatt & Lunt 1995) however, nonmyogenic differentiation of satellite cell 
commonly happens and 100% pure myogenic cell is almost impossible (Duguez 
et al. 2003; Shefer et al. 2004; Rosenblatt & Lunt 1995).The glucose 
transporter GLUT1 (SLC2A1) was also higher in skeletal muscle cultured cells 
than skeletal muscle tissue (Al-Khalili et al. 2003; Jackson et al. 2000).  In line 
with Guigal et al. (2002), uncoupling protein-3 (UCP3), which is a mitochondrial 
membrane protein in human skeletal muscle, showed a low expression in 
cultured muscle cells. Collectively, these observations confirmed the validity of 
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the microarray data. 
Skeletal muscle differentiation is a complex, highly coordinated process 
that relies on precise temporal gene expression patterns (Tomczak et al. 2004). 
In order to provide a useful database of genes that are differentially expressed 
throughout the myogenic process, all the  genes described in the present study 
were compared and were found to be in general agreement with findings from 
previous studies (Kislinger et al. 2005; Janot et al. 2009; Moran et al. 2002; 
Shen et al. 2003; Tomczak et al. 2004; Raymond et al. 2010). The expression of 
the transcriptional regulators MYOD1, MYF5, CDK6 and Myogenin was higher in 
cultured cells than tissue (Yablonka-Reuveni 1988; Yablonka-Reuveni et al. 
2008).  Higher expression of MYOD1 and MYF5 were found  in myoblasts; 
differentiating myocytes start to express myogenin with concomitant 
downregulation of MYOD1 (Tomczak et al. 2004; Wang et al. 2004). MyoD and 
MEF2 are known to be involved in myogenin induction at the start of 
differentiation (Wang et al. 2008). In this study MEF2a and MEF2b were higher in 
myoblasts whereas MEF2c and MEF2d were higher in myotubes indicating that 
not all members of the MEF family have a role in differentiation (Biressi et al. 
2007). Cyclin-dependent kinase, CDK is  a cell cycle inhibitor that has a role in 
normal cell growth during myocyte development  as it inhibits proliferation and 
helps in the initiation of differentation (Shen et al. 2003). The level of CDK was 
high in myoblasts and then gradually decreased indicating that after 3 weeks 
cultured myoblasts are at the stage of starting differentiation. Genes encoding 
cell adhesion molecules are highly expressed in early myotubes  providing a 
clearer indication of how the plasma membrane and extracellular matrix may be 
modified prior to cell fusion and suggesting their potential role during the initial 
steps of myogenic differentiation (Janot et al. 2009). In line with Janot et al., 
(2009) and Shen et al. (2003), we found higher expression of genes involved in 
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adhesion  (MGAT1, HES6, ITGb1, ITGa1, ITGb7, ITGa4, NCAM1 and VCAM1) in 
myotubes compared to myoblasts and whole tissue. Furthermore, STAT1, STAT2 
and STAT4 that play a role in differentiation (Wang et al. 2008) were also slightly 
higher in myotubes than myoblasts whereas genes for the growth factors FGFR2, 
IGFbp3 and IGFbp4 were higher in myoblasts compared to myotubes. Skeletal 
muscle differentiation is regulated by fibroblast growth factors in most skeletal 
muscle cell lines and in skeletal muscle primary cultures (Kudla et al. 1998). 
IGF-1 influences the development and maintenance of muscle cells at least 
partly through the induction of specific transcription factors and knockout of the 
IGF-IR gene causes severe skeletal muscle growth impairment (Kuninger et al. 
2004; Bhasker & Friedmann 2008). 
Not surprisingly, genes responsible for muscle structure subunit and 
phenotypes (Desmin, Tropomyosin, Troponin, Tropomodulin and myosin light 
DQGKHDY\FKDLQZHUHKLJKHULQWLVVXHWKDQFXOWXUHGFHOOVZLWKDIROGFKDQJH
in agreement with previously published data (Raymond et al. 2010). It is worth 
mentioning that the embryonic type myosin heavy chain (MYH3) was higher in 
myotubes compared to skeletal muscle tissue.  Myofibres are not fixed units but 
are capable of responding to functional demands by changing their phenotypic 
profile. Variation between the fibre-type phenotype of myotube cultures and that 
of the muscle tissue from which they were derived occurs through  the increased 
expression of slow phenotype, Myosin heavy 7 (Myh7) (Chemello et al. 2011; 
Baker et al. 2006). In this study we used a mixed type muscle (VL) that 
expresses both slow and fast genes.  Interestingly, the expression of genes 
associated with both slow and fast muscle fibre phenotypes was decreased in 
cultured cells when compared to skeletal muscle tissue. These data suggest that 
specific transcriptional programs generating mature muscle phenotype are 
activated in vivo but not in cultured muscle cells. Collectively, these data are 
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broadly consistent with the findings reported in previous microarray-based 
studies of myogenic gene expression in skeletal muscle cell lines and confirm 
that human skeletal muscle cultured cells is a valuable cell model in studying 
myogenesis.  
The role of G-protein coupled receptors in different tissues has been the 
focus of intense research in an attempt to discover new therapies for metabolic 
diseases. The microarray data revealed the presence of cannabinoid and 
potential cannabinoid receptors and most of the enzymes responsible for 
endocannabinoid synthesis and degradation in both skeletal muscle cultured cells 
and skeletal muscle tissue. The expression of most receptors (CB1, CB2, GPR55 
and GPR119) and enzymes (FAAH, MGLL, DAGLA & NAPE-PLD) was higher in 
skeletal muscle tissue than cultured cells. GPCR in tissue were found to have a 
fold change of + 2 when compared to culture cells, however,  4 transcripts were 
higher in cultured cell compared to skeletal muscle tissue [ADRA2A, ADRA2C, 
HRT2B (serotonin) and GPR126]. Serotonin (HRT2B) is another possible target in 
skeletal muscle proliferation and glucose homeostasis. Identification and 
localization of a functional skeletal muscle serotonin 5-HT2A receptor in rat fetal 
myoblasts was reported by Guillet-Deniau (1997) who also observed an 
upregulation of the transcription factor myogenin by serotonin. Both  rat and 
human skeletal muscle express the 5-HT2A receptor and 5-HT2B and specific 5-
HT2A agonists can rapidly stimulate glucose uptake in skeletal muscle (Wappler 
et al. 2001; Hajduch 1999). Fischer et al., (1995) reported a 1.8  and 1.5-fold 
increase in the amounts of glucose transporters GLUTI and GLUT4 at the cell 
surface of the cardiomyocytes with 90min treatment with 5HT. Guillet-Deniau 
(1997) demonstrated a 2±3-fold increase in GLUT3 mRNA level at 1.5 h, 
maximal level at 3 h and  decreased to reach the control level after 9h after 
addition of serotonin to the cultured rat myoblast. Interestingly, microarray data 
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revealed the presence of GLUT3 (SLC2A3) with a rank order 17684 (myoblast), 
17082 (myotube) and 28829 (tissue). The 5HT2b (HTR2b) receptor had a fold 
change of +9.41 (myotubes vs. tissue) and +4.39 (myoblasts vs. tissue).The 
orphan GPR126, has an essential role in muscle development (Soranzo et al. 
2009; Waller-Evans et al. 2010), has been isolated from human umbilical vein 
endothelial cell cultures and whole-genome association studies have identified 
genetic variation at the GPR126 locus as a determinant of trunk length and body 
height in the human population (Waller-Evans et al. 2010).  
Based on these interesting data regarding the differences in transcript 
expression between tissue and cultured cells, further analysis of the data by 
Genespring and IPA was carried out. IPA computed the data to generate 
significant networks and canonical pathways  
The fold-change ratio between myotubes and muscle tissue showed that 
more than 12 thousand genes displayed differential expression between cultured 
myotubes and SM tissue. The number of genes with low expression was almost 
twice the number of genes with high expression genes (8,363 & 4,489 
respectively). Ontology analysis of regulated genes in SM cultures revealed that 
with regard to cellular components a large number of genes encoding 
mitochondrial proteins were expressed at a lower level and endoplasmic 
reticulum components at a higher level in myotubes as compared to tissue. The 
downregulated genes in myotubes when compared to skeletal muscle tissue 
were genes associated with carbohydrate, protein and lipid metabolism as well 
as energy production. The genes that had the lowest expression included those 
encoding key regulators of glycogenolysis (PYGM), fatty acid oxidation (CPT1B) 
and ATP production. Various genes involved in glycolysis and oxidative 
phosphorylation (complexes I, II, III and IV) were also repressed. Mitochondrial 
dysfunction, TCA Cycle and calcium signalling were among the top canonical 
CHAPTER THREE 
 
 
 
    106 
 
   
  
SDWKZD\V DQG DOO WKH HQ]\PHV LQ 7&$ &\FOH DV ZHOO DV ǃ R[LGDWLRQ KDG D ORZ
expression in myotubes compare to skeletal muscle tissue. Interestingly, genes 
that are involved in the transcriptional control of fatty acid oxidation and glucose 
homeostasis (such as PPARA, PPARG, PPARGCIA & PPARGC1B) (Semple 2006; 
Wahli & Michalik 2012; Lefebvre & Chinetti 2006) were decreased in myotubes 
compared to skeletal muscle tissue. Moreover, most fatty acid and glucose 
transporters were lower in cultured cells compared to skeletal muscle tissues. 
The GLUT4 (SLC2A4) was one of the most downregulated genes (FC -3329) 
however, GLUT1 was upregulated (FC 87). A decrease in protein and mRNA 
expression of GLUT4 and an increase in GlUT1 expression  in  cultured muscle 
cells was also reported by Michael et al. (2001), Jackson et al. (2000) and Al-
Khalili et al. (2003). In this study, decreases in proteins involved in translocation 
of GLUT4 (VAMP2 and TC10) were also found. The importance of VAMP2 in 
trafficking of GLUT4 in 3T3 L1 adipocyte and rat cultured skeletal muscle cells 
was reported by Martin et al., (1996) and Braiman et al., (2001), respectively. 
JeBailey et al., (2004), Chang, Chiang, & Saltiel, (2005) and (Chiang et al. 2006) 
reported that TC10 plays an important role in actin remodelling process which is 
required for GLUT4 translocation to the plasma membrane in response to insulin. 
Collectively, a decrease in PI3k/AKT pathway was seen with an increase in 
negative regulator of insulin signal transduction pathway (SHIP2, PTEN and 
SOCS). Giving that there was little or no GLUT4 and higher levels of GLUT1 may 
indicate (in cultured cell) there is little insulin stimulated glucose uptake. Human 
skeletal muscle culture has been used extensively for the investigation of the 
biochemical and genetic basis of peripheral insulin resistance. However, its use in 
studying insulin-stimulated glucose transport must be interpreted with caution as 
a decrease in insulin induced GLUT4 translocation in cultured cell compare to 
insulin responsiveness typically observed in human forearm muscle balance 
studies has also been reported (Perriott et al. 2001).   
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Genes that encode myofilaments and calcium-binding proteins were also 
expressed at a lower level in cultured cells. Slow type isoforms such as MYL3, 
MYBPC1 and MYOZ1 and isoforms that are expressed in fast type muscle fibres 
such as TMOD4, CASQ1 and MYOZ3 showed decreased expression. Vastus 
lateralis (VL) muscle in humans is described as containing a mixture of type I 
(slow) and type II (fast) fibres.  In contrast, Baker et al. (2006) observed 
upregulation of slow muscle genes only in cell culture. It can be seen that  
muscle cell cultures in general remain relatively immature, in terms of their 
phenotype in line with previous observations by Raymond et al. (2010).  As 
genes responsible for skeletal muscle development and function were also 
decreased in cultured cells, pathways involving skeletal muscle disorders and 
muscle myopathies were identified by Ingenuity analysis as being elevated in 
cultured cells. The decrease in metabolic genes and genes involved in muscle 
contraction  in cultured cells, also indicated a phenotype associated with disuse 
atrophy and Duchenne muscular dystrophy (Noguchi et al. 2003; Chen et al. 
2007; Baker et al. 2006). 
As expected, genes showing elevated expression in myotubes compared to 
skeletal muscle tissue were associated with Cellular Movement, Cellular Growth 
and Proliferation, Cellular Function and Maintenance.  Among the upregulated 
genes detected in skeletal muscle proliferation and differentiation category were 
the regulatory factors MYOD1, MYOG, MYF5, FGFR2, ITGB1, CDKN, TOP2A, and 
HIF1A. Moreover, several genes that have a regulatory function in cell 
attachment and adherence as well as around 200 genes related to extracellular 
matrix such as those encoding for accumulation of glycosaminoglycan and 
hyaluronic acid were also included in this list. This provides an indication of how 
the plasma membrane and extracellular matrix may be modified prior to cell 
maturation. Growth related genes were also upregulated in myotubes compared 
to skeletal muscle tissue (including insulin like growth factor, connective tissue 
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growth factor and growth differentiation factor).  Overall, upregulated genes 
were associated with an increase in cell movement, adhesion, inflammation and 
proliferation. Gene expression changes during myoblast differentiation were 
previously studied in mouse C2C12 cells (Janot et al. 2009; Moran et al. 2002; 
Kislinger et al. 2005; Shen et al. 2003; Tomczak et al. 2004).  The present study 
is the first study using human primary cultured cells. When myoblasts were 
compared to myotubes, 2,774 entities had fold change of ± 2 and among them 
around a thousand genes (1,091) were downregulated. IPA analysis showed that 
the top biological functions were Cellular Movement, Cell-To-Cell Signalling and 
Interaction. Close examination of the regulated functions revealed a decrease in 
genes responsible for muscle contraction and cytoskeletal organization in 
myoblasts compared to myotubes, which was also reported by Moran et al. 
(2002), a decrease in carbohydrate and lipid metabolism genes, a decrease in 
cell movement and binding indicating a modification changes prior to cells fusion 
in line with (Shen et al. 2003). LXR/RXR (retinoid X receptors) and FXR/RXR 
(farnesoid X receptor) pathways were among the top canonical pathways and 
was predicted to be inhibited, as most genes in the networks had lower 
expression in myoblast than myotubes. Even though It is well known that 
LXR/RXR and FXR/RXR play a crucial role in the regulation of bile acid catabolism 
(Goodwin et al. 2000) other studies reported their role in  lipid and glucose 
metabolism. Ma et al. (2006) reported that FXR is a key regulator of glucose 
metabolism as they observed that FXR-null mice developed severe fatty liver and 
elevated circulating FFAs, which was associated with elevated serum glucose and 
impaired glucose and insulin tolerance. FXR also plays an important role in 
lipoprotein metabolism. Lambert et al., (2003) observed an elevated plasma 
cholesterol and triglyceride levels and excessive accumulation of fat in the liver 
in FXR±/± mice. Collectively, the higher level of metabolic genes in myotubes is 
an essential modification changes (i.e cell are differentiation and gaining muscle 
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phenotype) prior to cells fusion.  
In conclusion, these data indicate that whilst primary human skeletal 
muscle myotube culture is at present the most physiologically relevant cell model 
for studying skeletal muscle development and metabolism, at the transcriptional 
level there are many differences between cell culture and muscle tissue. The 
decrease in expression of genes in the insulin signalling cascade, glucose 
metabolism, oxidative phosphorylation and beta oxidation suggests that primary 
myotube cell culture may be at least partially compromised in terms of being a 
cellular model for intermediary metabolism.  
The expression of GPR40, 55, 119 and CB1 & CB2 were detected at the 
mRNA level by microarray, but the levels of expression were low. In fact all of 
these receptors were found to be expressed at levels below that of marginally 
expressed genes. However, this was also true of other receptors expressed at 
low levels, such as the insulin receptor, which has been definitively shown to be 
both present and functional in skeletal muscle. Thus microarray technology, 
whilst effective as a tool for analysis of global gene expression changes, can lack 
the sensitivity to detect transcripts expressed at low but functional levels. 
In the next chapters, the expression of GPCRs will be further investigated 
using QRTPCR which is a more sensitive technique for the detection of mRNA. 
The functionality of these receptors in terms of activation of signal transduction 
pathways and effects upon metabolic pathways will also be described. 
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CHAPTER 4. MOLECULAR CHARACTERISATION OF 
CANNABINOID RECEPTORS IN 
SKELETAL MUSCLE 
 
4.1. Introduction 
Insulin resistance, especially in skeletal muscle which is responsible for 70-
80%  of peripheral glucose disposal, is an early sign and cause of type two 
diabetes. As insulin resistance develops years before overt diabetes, many 
researchers have focused on understanding the underlying molecular 
mechanisms with a view to identify targets for future antidiabetic therapies. 
GProtein-Coupled Receptors (GPCRs) activation or inhibition in skeletal muscle is 
a fertile area of research to achieve this goal as they may be involved in  cross 
talk with various tyrosine receptors including the insulin receptor (Seale et al. 
2000). 
The cannabinoid receptors are GPCRs that are coupled to the Gi/o family 
predominantly and act through the adenyl cyclase pathway (Di-Marzo & Matias 
2005; Matias et al. 2008; Engeli 2008a). CB1 and CB2 receptor activation by 
endogenous endocannabinoids such as N-arachidononyl ethanolamine 
(anandamide) and 2 arachidonoyl glycerol (2AG) lead to a decrease in cAMP and 
subsequent PKA, phosphorylation of p42 & p44 MAPK, p38 MAPK and JNK 
(Howlett 2005). They are also coupled to phosphotidylinositol 3 kinase and Focal 
adhesion kinase (Rodríguez de Fonseca et al. 2005). CB1 receptor only is 
associated with K+ influx and inhibition of voltage-gated Ca+2 channels. Although 
CB1 and CB2 receptors are most highly expressed in brain and spleen, 
respectively, their presence in other tissues such as liver, pancreas, adipose 
tissue, myocardium and skeletal muscle has been reported (Engeli 2008a; Rajesh 
et al. 2008; Paul Cavuoto et al. 2007).  The role of endcannabinoids and the 
potential presence of functional CB receptors in skeletal muscle is still under 
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investigation.  Cavuoto et al. (2007)reported the presence of CB1 and CB2 mRNA 
in human and rodent skeletal muscle, respectively. CB1 (human and rat) and 
CB2 (human) open reading frames contain a single exon and  Cavuoto et al. 
(2007) used DNAse treated total RNA (not mRNA) for cDNA synthsis and 10 
times over the standard loading amount for RT-PCR were used for CB2. 
 A growing body of evidence shows that obese and diabetic patients have 
high levels of circulating endocannabinoids (Engeli 2008b; Bellocchio et al. 2008; 
Kunos 2007; Matias et DO2¶6XOOLYDQ2VHL-Hyiaman 2005). However 
their role in glucose homeostasis in skeletal muscle is still controversial and 
requires further investigation. An increase in glucose uptake has been reported 
with the use of CB1 antagonist Rimonabant (Cavuoto et al. 2007; Esposito et al. 
2008; Liu et al. 2005), whereas Eckardt et al. (2009) observed an increase in 
glucose uptake with Anandamide (AEA), a CB1 agonist. A decrease in skeletal 
muscle insulin sensitivity as a result of an increase in 2AG in obesity and 
diabetes was reported by Engeli (2008b) and by (Bellocchio et al. 2008), which 
might be due to an increase in IRS-1 (Ser307) phosphorylation and a decrease 
in Akt (Ser473) phosphorylation as observed by Eckardt et al. (2009). The same 
authors also reported an activation of ERK1/2 and MAPK p38 which are 
downstream targets of insulin signalling. Furthermore, Esposito et al. (2008) 
reported that CB1 antagonist (RIM) induced insulin stimulated glucose uptake in 
mice primary cultured cells and L6 cell module . As slow twitch skeletal muscle 
fibres are more sensitive to insulin and changing of muscle phenotype from fast 
to slow improves glycemic control (Kubis et al. 2003; Lillioja et al. 1987; Wang 
et al. 2004), the role of CB1 and CB2 in insulin signalling in slow and fast muscle 
requires further investigation.  
In addition to the classical cannabinoid receptors, there is a suggestion 
that GPR55 and GPR119 are potential cannabinoid receptors and may play a role 
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in glucose homeostasis. GPR55 is coupled to the Gs family and acts through a 
signalling pathway distinct from CB1 and CB2; for example it does not lead to 
ERK1/2 phosphorylation or an increase in calcium release (Lauckner et al. 2008; 
Ryberg et al. 2007). GPR119 is a GPCR (class I rhodopsin-type) that increases 
cAMP levels (Overton et al. 2008). GPR119 activation stimulates insulin secretion 
from the pancreas and glucagon like peptide (GLP) and gastric inhibitory 
polypeptide (GIP) secretion from enteroendocrine cells in a glucose dependent 
manner (Drucker 2001; Meier et al. 2002; Gromada et al. 2004). Chu et al. 
(2007) reported that the use of GPR119 agonists such as oleoylethanolamine do 
not decrease circulating glucose in GPR119 deficient mice. Again, their role in 
skeletal muscle has not been explored yet. 
Another attractive area for research in GPCR biology is their association 
with cell development and differentiation (such as neurons, red blood cell, 
neutrophil, osteoblast and smooth muscle cell) (Wang et al. 2004). The role of 
CB1 in adipogenesis and neurogenesis has been reported by Matias et al. 
(2008), Pagano et al. (2007). The role of cannabinoid receptors in myogenesis 
remains to be elucidated. 
4.2. Aims 
 The main objectives of this study are: 
x To investigate and confirm the presence of CB1, CB2, GPR55 and GPR119 in 
human and rat skeletal muscle tissues and primary skeletal muscle cells 
culture.   
x To compare the level of cannabinoid receptor mRNA expression between 
human and rat skeletal muscle.  
x To compare the level of cannabinoid receptor mRNA expression in different 
muscle types at various stages of differentiation. 
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x To compare the level of cannabinoid receptors mRNA expression between 
Zucker Fat Rat (ZFR), Zucker Lean Rat (ZLR) and Wistar rat (WR) in 
different muscle types, heart, spleen, adipose tissue and liver.   
x To assess the functionality of these GPCRs and determine whether their 
activation or inhibition may have a role to play in the control of blood 
glucose homeostasis.   
4.3. Experiment design and methods 
4.3.1. Sample collection and preparation  
Human skeletal muscle tissues from vastus lateralis were collected from 8 
subjects. Each sample was divided into two parts; the first part was snap frozen 
in liquid nitrogen and stored at -80oC and the second part was used for isolation 
and culture of satellite cells in gelatinized flasks.  
Slow (SOL & GR), fast (EDL & GW) and mixed (VL) muscle tissue was 
collected from Wistar, Zucker lean and fat rats.  Liver, epididymal adipose, 
spleen, pancreas and heart tissues were also collected and snap frozen in liquid 
nitrogen. Isolation and culture of satellite cells was performed from all 3 muscle 
types obtained from both Wistar and Zucker rats. 
Total RNA, mRNA, cDNA and protein preparation was performed as 
described in chapter 2 section 2.6. 
4.3.2. Determination of GPCR mRNA expression levels 
4.3.2.1. QRT-PCR 
Quantitative Taqman RTPCR was performed using the step one plus real±
time PCR system (Applied Biosystems). A standard protocol as described in 
chapter 2 was followed.  In the initial experiments, in both human and rat 
(myoblasts and myotubes), the results were analysed using the absolute mean 
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values. The reason for this was the significant differences observed in the 
UHIHUHQFH JHQH ǃ-actin and 18s) values between different tissues (brain, 
muscle, spleen and pancreas) as well as the various stages of muscle 
development (myoblasts, myotubes and tissues) (Tables 4.1 and 4.2). This 
result was similar to the microarray analysis described in Chapter 3 and to 
previous results reported by Stern-Straeter et al. (2009). 5DGRQLüHWDO 
mentioned that the 18s gene cannot to be used as a reference gene when mRNA 
instead of total RNA is used in cDNA synthesis. Habets et al. (1999) observed a 
difference in total RNA and 28S rRNA between slow and fast muscles; in slow 
muscle the 28S rRNA was 5-6 fold higher than fast muscle. In later experiments, 
normalization was performed using TATA binding protein (TBP) as a reference 
gene (microarray data showed no significant differences in gene ranking 
between tissue and cultured cells). Stern-Straeter et al. (2009) & Warrington et 
al. (2000) reported that TBP is a suitable gene to use as a reference gene in cell 
development studies. 
Table 4-1: Human reference gene CT values 
 
MB=Myoblast, MT=Myotube, M TIS =muscle tissue. % values describe the confluence of 
myoblast cells in culture 
 
Table 4-2: 5DWǃDFWLQ&7YDOues 
 
MB=Myoblast, MT=Myotube, M TIS =muscle tissue, GR=Gastrocnemius Red, GW= 
Gastrocnemius White, SOL=Soleus, VL= Vastus Lateralis, EDL= Extensor Digitorum Longus 
 
HUMAN ɴ-actin 18s 
50%MB 25 28 
100%MB 17 23 
MT 15 24 
MTIS 15 24 
BRAIN 22 31 
SPLEEN 
 
27 
5$7ȕDFWLQ GR GW EDL SOL 
MB 16 22 18 20 
MT 17 14 16 14 
MTIS 16 21 20 20 
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4.3.3. Protein phosphorylation experiments 
Western blotting was used to study the effect of CB1 agonists and 
antagonists, MEK inhibitor and pertussis toxin on the phosphorylation state and 
total content of selected cell signalling proteins using procedures described in 
detail in Chapter 2 section 2.7. 
4.3.3.1. ERK1/2 and MAPK38 
Human and rat (Wistar and Zucker) myotubes were treated with either 10 
nM ACEA, 10nM EGF (Epidermal Growth Factor) or 10µM AEA for 5, 10 and 15 
min.  Myotubes were also pretreated with either 100nM RIM, 10 µM U0126 or 
50nM PTX 30min prior to the addition of ACEA, AEA or EGF for 10min.  Wistar rat 
myotubes were also treated with ACEA and/or RIM for 24 hours in the absence 
or presence of 100 nM insulin. After treatments, cells were washed with ice-cold 
PBS and lysed with RIPA buffer. Densitometry was used to measure the degree 
of phosphorylation.   
4.3.3.2. $.7DQG*6.Įǃ 
Wistar rat myotubes were cultured in fatty acid free serum and treated 
with 100nM ACEA or 100nM RIM for 24hrs followed by 10 min stimulation of AKT 
DQG*6.ĮǃZLWKQ0LQVXOLQ$IWHUWUHDWPHQWVFHOOVZHUHZDVKHGZLWKLFH-
cold PBS and lysed with RIPA buffer.  
4.3.4. Protein expression experiments   
 Western blotting was used to examine the expression of CB1 and CB2. 
Immunocytochemistry was used to examine the expression of Ki67 and GLUT4.  
4.3.4.1. Ki67 
Wistar rat myoblasts were cultured in fatty acid free serum for 24 hrs 
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followed by 24hrs incubation with vehicle (0.01% ethanol) or 10nM ACEA.  
4.3.4.2.  GLUT4 
Wistar rat myotubes were cultured in fatty acid free serum for 24 hrs 
followed by 24hrs incubation with vehicle (0.01% ethanol) or 100nM ACEA. Cells 
were also treated with 100nM insulin (5, 10, 30 min) in presence or absence of 
100nM ACEA (24hrs before).  
4.4. Statistical analysis 
Statistical analysis was performed using GraphPad Prism software. RT-PCR 
and Western blot values were expressed as mean ± S.E.M. Statistical 
comparisons of different groups were made by one-way analysis of variance 
$129$ DQG %RQIHUURQL¶V PXOWLSOH FRPSDULVRQ SRVW-hoc test  Unpaired two-
tailed t-test was also used to compare between two variable. A P value <0.05 
was taken as the level of significance.  
4.5. Results 
4.5.1. CB1 mRNA expression 
4.5.1.1. Human  
The microarray data (chapter 3) revealed very low level expression of CB1 
in skeletal muscle tissue and cultured cells Figure 4-1. The expression of CB1 in 
human skeletal muscle tissue and cultured myoblast and myotubes was 
assessed by Taqman QRT-PCR. Compared with the level of CB1 expression in 
the brain, the expression of CB1 in human skeletal muscle is very low 
(Figure 4-2). Skeletal muscle tissues and 100% myoblasts had significantly 
higher CB1 mRNA levels than 50% myoblast (P<0.001) and myotubes (P<0.01) 
(Figure 4-3).   
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Figure 4-1: Microarray normalized intensity value (Log base 2) of CB1 mRNA expression in human 
skeletal muscle Tissue, Myoblast and Myotube (data from chapter 3). 
 
 
Figure 4-2: QRT-PCR analysis of CB1 expression in human skeletal muscle and brain tissues. 
Values are mean±SEM; data are non-normalized and just uses CB1 standard curve for quantification 
(n= 3 subjects for skeletal muscle tissue and brain mRNA were from Clontech). MTIS=muscle tissue, 
brainTIS= brain tissue. ***denotes P<0.0001. 
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Figure 4-3: QRT-PCR analysis of CB1 mRNA expression in human skeletal muscle tissue and 
cultured cells. 
Values are mean±SEM data is non-normalized and just uses CB1 standard curve for quantification 
(n=3 human). MB=Myoblast, MT=Myotube, MTIS =muscle tissue. * denotes P<0.05, ** denotes 
P<0.01, *** denotes P<0.0001.  
4.5.1.2. Wistar rat 
QRT-PCR was used to characterize gene expression differences between 
fast and slow skeletal muscle fibres in rat at different stages of differentiation in 
cell culture. CB1 was expressed in all rat tissues and cells tested. Rat skeletal 
muscle tissue had a higher CB1 mRNA expression than cultured cells in all 
muscle types tested (Table 4-3). Brain tissue had a significantly higher level of 
CB1 mRNA than muscle tissues (P<0.01) but the difference between brain and 
muscle was much less pronounced than in human samples (Figure 4-4). In both 
tissue and cultured cells, with the exception of GW myoblasts, the fast muscles 
(GW & EDL) had a trend for  higher CB1 expression than slow muscles (GR & 
SOL) but the difference was only significant between GR and GW myotubes (P 
<0.05) (Figure 4-5). Furthermore, skeletal muscle tissues (slow and fast) had a 
higher level of expression than cultured myoblasts and myotubes (Table 4-3). 
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Figure 4-4: Quantitative analysis QRT-PCR of CB1mRNA expression in rat skeletal muscle and brain 
tissues. 
** denote P<0.01 of brain compare to GR and SOL. Values are mean±SEM. Data were normalized to 
TBP (n=6). GR=Gastrocnemius Red, GW= Gastrocnemius White, SOL=Soleus, VL= Vastus Lateralis, 
EDL= Extensor Digitorum Longus. 
 
 
Figure 4-5: QRT-PCR analysis of CB1 mRNA expression in rat myotubes. 
* denotes P<0.05. Values are mean±SEM, data are non-normalized and just uses CB1 standard 
curve for quantification (n= 6 rats) GR=Gastrocnemius Red, GW= Gastrocnemius White, 
SOL=Soleus, VL= Vastus Lateralis, EDL= Extensor Digitorum Longus. 
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Table 4-3: Rat skeletal muscle tissue and cultured cell CB1 mRNA expression 
 
 Values are mean±SEM (n=12samples from 6 rats). GR=Gastrocnemius Red, GW= 
Gastrocnemius White, SOL=Soleus, VL= Vastus Lateralis, EDL= Extensor Digitorum 
Longus. 
  
4.5.1.3. Zucker Lean and Zucker Fat Rats 
4.5.1.3.1. CB1 mRNA expression in skeletal muscle 
Expression levels of CB1 in muscle tissues from VL, EDL, GR and SOL 
muscles were similar at 12 weeks for Zucker Fat Rat (ZFR) and Zucker Lean Rat 
(ZLR) (Figure 4-6). At 20 weeks ZFR had higher (p<0.01) expression of CB1 
than ZLR. Interestingly, Wistar rat skeletal muscle tissues (GR, GW, EDL, Vl & 
SOL) had higher levels of CB1 expression than either ZFR and ZLR (Figure 4-6). 
There was no difference in CB1 expression on cultured myotubes between ZFR, 
ZLR and Wistar rats (Figure 4-6). 
 
Figure 4-6: Comparisons of CB1 mRNA expression in rat skeletal muscle tissues between ZFR 
(Zucker Fat Rat), ZLR (Zucker Lean Rat) and WR (Wistar Rat). 
A & B) *denote P<0.05 compared to ZLR and ZFR P<0.01 higher CB1 expression in WR GW than ZFR 
&ZLR GW. D) *** denotes P<0.001 compared to ZLR and ZFR, * denotes P<0.05 ZFR compared to 
ZLR (20wks). Data were normalized to TBP. Values are mean ± SEM (n=5 rats, 2 samples from 
each)  
GR GW EDL SOL
Tissue 0.0309±0.0235 0.0947±0.0526 0.1084±0.0803 0.0302±0.0172
Myotube 0.0021±0.0009 0.0084±0.0020 0.0111±0.0061 0.0025±0.0010
Myoblast 0.0068±0.0038 0.0002±0.0001 0.0095±0.0022 0.0049±0.0018
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4.5.1.3.2. CB1 mRNA expression in other tissues 
20wk old ZFR had significantly higher CB1 expression in Epididymal 
Adipose Tissue (EAT) (P<0.01) than ZLR. Similar to skeletal muscle, Wistar rat 
EAT had also higher CB1 expression (P<0.001) than ZFR and ZLR (12 & 20 wks) 
Figure 4-7. In liver, no differences between ZLR and ZFR CB1 expression were 
observed and again Wistar rats had higher expression of CB1 than ZFR and ZLR 
. CB1 expression in spleen and heart showed no significant differences between 
the different types of rats (Figure 4-7). 
 
Figure 4-7: QRT-PCR analysis represents comparisons of CB1 mRNA expression in rat tissues 
between ZFR (Zucker Fat Rat), ZLR (Zucker Lean Rat) and WR (Wistar Rat). 
A) Epididymal Adipose tissue (EAT) **denotes P<0.01. B) Liver * denotes P<0.05 compared to ZLR 
and ZFR higher. C) Heart. D) Spleen. Data were normalized to TBP. Values are mean ± SEM (n=3 
rats). 
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4.5.2. CB2 mRNA expression 
4.5.2.1. Human 
The microarray data presented in Chapter 3 also revealed the low level 
expression of CB2 in skeletal muscle tissue, myoblasts and myotubes.  QRT-PCR 
analysis confirmed the expression of CB2 in cultured cells but not in human 
skeletal muscle tissue. 100% myoblasts had a higher level of expression than 
myotubes (P<0.05). Skeletal muscle CB2 expression was very low particularly 
when compared with expression in spleen (P<0.001) (Table 4-4).  
Table 4-4:  Human CB2 mRNA expression in skeletal muscle tissue, cultured cells and spleen. 
 
*** denotes (P<0.001) compared to MB and MT. * denotes P<0.05 MB 
compared MT. Values are mean ± SEM. Data were normalized to TBP (n=3-6). 
NED=No Expression Detected, MB=Myoblasts, MT=Myotubes, MTIS =muscle 
tissue.  
 
4.5.2.2. Wistar Rat 
RT-PCR analysis demonstrated the expression of CB2 in rat skeletal muscle 
tissue and cultured cells. Tissue levels of CB2 expression were higher than 
myoblasts and myotubes in all muscle types tested (P <0.05). Skeletal muscle 
CB2 expression was very low when compared with the spleen CB2 expression 
(P<0.001) (Table 4-5). 
Table 4-5:  Rat skeletal muscle tissue, spleen and cultured cells CB2 mRNA expression 
 
* P<0.05 denotes tissues compared to myotubes and myoblasts. ***denotes P<0.001 Spleen 
compared to skeletal muscle tissue. Data were normalized to TBP. Values are mean ± SEM (n=3-6). 
GR=Gastrocnemius Red, GW= Gastrocnemius White, SOL=Soleus, VL= Vastus Lateralis, EDL= 
Extensor Digitorum Longus. 
MB 50% MB 100% MT MTIS spleen
MEAN 0.004377* 0.000821 0.3634***
SEM 0.001988 0.0002192 0.08643
NED NED
  
GR GW EDL SOL SPLEEN 
TISSUE  0.0101±0.0003* 0.0157±0.0087*  0.0454±0.0123*  0.0248±0.0148*  1.5420±0.1815***  
MYOTUBE  0.0055±0.0012  0.0052±0.0007  0.0087±0.0011  0.0051±0.0017    
MYOBLAST  0.0052±0.0029  0.0039±0.0019  0.0029±0.0009  0.0018±0.0009    
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4.5.2.3. Zucker Fat and Lean Rat  
The expression of CB2 was also investigated in fast and slow muscle tissue 
from ZFR and ZLR. ZFR skeletal muscle tissue had similar CB2 expression to ZLR 
in all types of muscle tested. CB2 expression was higher in Wistar rat skeletal 
muscle tissues than ZLR and ZFR skeletal muscle tissues but this reached 
statistical significance in GR and GW only (Figure 4-8).  
 
Figure 4-8: Comparisons of CB2 mRNA expression in rat skeletal muscle tissues between ZFR 
(Zucker Fat Rat), ZLR (Zucker Lean Rat) and WR (Wistar Rat). 
* denotes (P<0.05) WR (GR &GW) compared to ZLR and ZFR. Data were normalized to TBP. Values 
are mean ± SEM (n=5-7).GR=Gastrocnemius Red, GW= Gastrocnemius White, SOL=Soleus, VL= 
Vastus Lateralis, EDL= Extensor Digitorum Longus.  
 
4.5.3. GPR55 mRNA expression 
The microarray analysis presented in Chapter 3 indicated the presence of 
GPR55 in human Skeletal muscle tissue and cultured cells (TIS=30527, 
MT=34893, MB=35826 ranking out 41078). However, the RT-PCR analysis 
revealed that neither human nor rat skeletal muscle tissues or cultured cells had 
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a detectable level of GPR55 expression. GPR55 expression was found in rat 
pancreas, spleen, and human brain (0.014± 0.001) and spleen (1.517 ± 
0.3519).  
4.5.4. GPR119 mRNA expression 
4.5.4.1. Human 
The microarray data presented in Chapter 3 revealed the expression of 
GPR119 in skeletal muscle tissue, myoblasts and myotubes (TIS= 22132, 
MB=24726, MT=24725 ranking out 41078) (Figure 4-9). The expression of 
GPR119 was significantly higher (P<0.05) in 100% MB and MT than 50% 
myoblasts, skeletal muscle tissue and spleen (Figure 4-10). There was no 
detectable level of GPR119 expression in human brain tissue (Data not shown).  
 
Figure 4-9: Microarray normalized intensity value (Log base 2) of GPR119 mRNA expression in 
human skeletal muscle Tissue, Myoblast and Myotube. 
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Figure 4-10: RT- PCR analysis of human GPR119 in skeletal muscle tissue (MTIS), myoblast (MB) 
and myotubes (MT) and spleen. 
* denotes (P<0.05). Data was normalized to TBP. Values are mean ± SEM (n=6-12). MB=Myoblast, 
MT=Myotube, MTIS =muscle tissue. 
 
4.5.4.2. Rat  
RT-PCR analysis revealed the expression of GPR119 mRNA in all muscle 
types of both Wistar and Zucker rats (Figure 4-11). RT-PCR analysis also 
revealed that ZLR (12wks) had a trend for higher GPR119 expression than ZFR 
(12wks) in most of the muscles tested and  this reached statistical significance in 
SOL muscle (P<0.05). RT-PCR also revealed the presence of GPR119 in brain, 
spleen and pancreas of Wistar rats (data not shown). 
GPR119 EXPRESSION IN HUMAN
MB50% MB100% MT MTIS SPLEEN
0.00
0.05
0.10
0.15
0.20
*
LE
V
E
L 
O
F 
E
X
P
R
E
SS
IO
N
*
CHAPTER Four 
 
 
 
    127 
 
   
  
 
Figure 4-11: Comparisons of GPR119 mRNA expression in rat  skeletal muscle tissues between ZFR 
(Zucker Fat Rat), ZLR (Zucker Lean Rat) and WR (Wistar Rat). 
Data were normalized to TBP (n=5-7). Values are mean ± SEM. GR=Gastrocnemius Red, GW= 
Gastrocnemius White, SOL=Soleus, VL= Vastus Lateralis, EDL= Extensor Digitorum Longus. 
 
Figure 4-12: QRT-PCR analysis represent a comparisons of GPR119 mRNA expression in rat SOL 
tissues between ZFR (Zucker Fat Rat), ZLR (Zucker Lean Rat) and WR (Wistar Rat). 
* denotes P<0.05 in ZLR than ZFR and WR.  Data were normalized to TBP (n=5).Values are mean ± 
SEM  
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4.5.5. Effect of ACEA, AEA, U0126 and RIM on ERK 
phosphorylation 
RTPCR analysis showed that human and rat (Zucker and Wistar) myotubes 
had detectable levels of CB1. To address the functionality of CB1, the effect of 
CB1 activation or inhibiton on ERK1/2 phosphorylation was investigated. 
4.5.5.1.  Human  
Treatment of human VL myotubes with 10nM ACEA showed a time 
dependent increase in ERK1/2 phosphorylation (Figure 4-13). Treatment with 
AEA (10µM) also showed a time dependent increase in ERK1/2 phosphorylation 
with a significant peak (P<0.05) at 10min (Figure 4-14). EGF was used as a 
positive control for ERK phosphorylation. Pretreatment of myotubes with the 
MEK inhibitor U0126 (10µM) significantly inhibited ERK phosphorylation induced 
by EGF and ACEA (Figure 4-15).  
 
Figure 4-13: Representative blot showing the effect of time course treatment of 10nM ACEA on 
phosphorylation of ERK in human myotubes. 
Quantified values of PERK1/CYCL, PERk2/CYCL are shown in the lower panel. Values are mean ± 
SEM .Data were analysed by one way ANOVA with Bonferroni post-hoc test (n=3).  
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Figure 4-14: Representative blot showing the effect of time course treatment of 10µM AEA on 
phosphorylation of ERK in human myotubes. 
Quantified values of PERK1/TERK1, PERk2/TERK2 are shown in the lower panel. * denotes P<0.05 
FRPSDUHGWRYHKLFOHDQG$($¶9DOXHVDUHPHDQ6(0'DWDZHUHDQDO\VHGE\RQHZD\$129$
with Bonferroni post-hoc test (n=3).  
 
Figure 4-15: Representative blot showing the effect of 10µM U0126 on ERK phosphorylation 
induced by EGF (10nM) and ACEA (10nM) in human myotubes. 
Quantified values of PERK2/CYC are shown in the lower panel. * denotes P<0.05 and ** denotes 
P<0/01. Phospho ERK1/2 (PERK) is shown in red band and total ERK1/2 (TERK) in green. Values are 
mean ± SEM (n=3). 
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4.5.5.2. Wistar Rat 
Treatment of rat myotubes with 10 nM ACEA showed a rapid induction of 
ERK1/2 phosphorylation within 5 min and reached peak values at 10 min that 
was followed by a decline at 20 min (Figure 4-16). Treatment of the myotubes 
with 10µM AEA for 10 min led to a significant (P<0.01) induction of ERK1/2 
phosphorylation. Pre-treatment (30 min) of the cells with 100 nM RIM or 10µM 
U0126 significantly inhibited (P<0.01) the ACEA and AEA induction of ERK1/2 
phosphorylation (P<0.01) (Figure 4-17, Figure 4-18, Figure 4-19, respectively). 
It is worth mentioning that the experiments were performed in muscles 
consisting of different types of fibres (slow and fast) and no difference was found 
between the two types. The pattern of ERK1 and ERK2 phosphorylation change 
was also similar, thus quantification of ERK2 phosphorylation only was used as 
an indicator in some experiments.   
 
Figure 4-16:  Representative blot showing the effect of time course treatment of 10nM ACEA on 
phosphorylation of ERK in Wistar rat myotubes. 
Quantified values of PERK1/TERK1, PERk2/TERK2 are shown in the lower panel. * denotes P<0.05 
compared to vehicle. Cyclophilin was used as a loading control. Values are mean ± SEM. Data were 
analysed by one way ANOVA with Bonferroni post-hoc test (n=3). 
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Figure 4-17: Representative blot showing the effect of 100nM RIM on ERK phosphorylation induced 
ACEA(10nM) in Wistar rat myotubes. 
Pretretment (30min) with 100nM RIM significantly inhibited ERK1/2 phosphorylation induced by 
10nM ACEA (** denotes P<0.01). Quantified values of PERK2/TERk2 are shown in the lower panel. 
Values are mean ± SEM.  Data were analysed by one way ANOVA with Bonferroni post-hoc test. 
Phospho ERK1/2 (PERK) is shown in red band and total ERK1/2 (TERK) in green. Cyclophilin was 
used as a loading control (n=3). 
 
 
Figure 4-18: Representative blot showing the effect of 10µM AEA and 100nM RIM (30min prior) on 
ERK phosphorylation in Wistar rat myotubes. 
Quantified values of PERK2/TERk2 are shown in the lower panel (** denotes P<0.01). Data were 
analysed by one way ANOVA with Bonferroni post-hoc test. Cyclophilin was used as a loading control 
(n=3). 
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Figure 4-19: Representative blot showing the effect of 10µM U0126 (30 min pre-treatment) on ERK 
phosphorylation induced by AEA (10µM) and ACEA (10nM) in Wistar rat myotubes. 
Quantified values of PERK2/TERk2 are shown in the lower panel. * denotes P<0.05 and ** denotes 
P<0/01. Data were analysed by one way ANOVA with Bonferroni post-hoc test. Phospho ERK1/2 
(PERK) is shown in red band and total ERK1/2 (TERK) in green.  Cyclophilin was used as a loading 
control (n=3). 
4.5.5.3. Zucker Lean and Fat Rats 
As CB1 mRNA expression was detected in both ZLR and ZFR, its 
functionality was investigated by studying the activation (phosphorylation) of the 
ERK1/2 signalling pathway. Treatment of myotubes cultured from ZLR with 
10nM ACEA and 10µM AEA led to a significant induction of ERK1/2 
phosphorylation at 10 and 15 min (P<0.01). Pretreatment with 100nM Rim for 
30min significantly inhibited ERK1/2 phosphorylation induced by ACEA and AEA 
(Figure 4-20 & Figure 4-21) 
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Figure 4-20: Representative blot showing the effect of 10nM ACEA and 100nM RIM (30min prior) on 
ERK phosphorylation in ZLR myotubes. 
Quantified values of PERK2/TERk2 are shown in the lower panel (* denotes P<0.05 compared to 
vehicle and ** denotes P<0.01 compared to ACEA +RIM).   Data were analysed by one way ANOVA 
with Bonferroni post-hoc test. Cyclophilin was used as a loading control.Phospho ERK1/2 (PERK) is 
shown in green band and total ERK1/2 (TERK) in red (n=2). 
  
 
Figure 4-21: Representative blot showing the effect of 10µM ACEA and 100nM RIM (30min pre-
treatment) on ERK phosphorylation in ZLR myotubes. 
Quantified values of PERK2/TERK2 are shown in the lower panel (** denotes P<0.01 compared to 
vehicle and ACEA +RIM).   Data were analysed by one way ANOVA with Bonferroni post-hoc test. 
Phospho ERK1/2 (PERK) is shown in green band and total ERK1/2 (TERK) in red.  Cyclophilin used as 
a loading control (n=2) 
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In ZFR, the time course treatment with 10nM ACEA showed time 
dependent increase in ERK phosphorylation with a significant peak at 15 min 
(P<0.05) compared to vehicle (0.01% ethanol) (Figure 4-22A). Similarly, 
treatment of ZFR myotubes with 10 µM AEA induced a time dependent increase 
in ERK1/2 phosphorylation with a significant peak at 10min compared to vehicle 
(P<0.05) (Figure 4-22B). Interestingly, pre-treatment of ZFR myotubes with 
100nM RIM did not inhibit ERK1/2 phosphorylation induced by ACEA 
(Figure 4-22C). 
 
Figure 4-22: Representative blots showing the effect of 10µM ACEA, 10µM AEA and 100nM RIM 
(30min prior) on ERK phosphorylation in ZFR myotubes in upper panels. 
Quantified values are shown in the lower panels (n=2). A) Time course treatment with 10 nM ACEA 
(* denotes P<0.05 compared to vehicle). B) Time course treatment with 10 µM AEA (* denotes 
P<0.05 compared to vehicle) C) Pre-treatment with 100nM RIM(* denotes P<0.05 compared to 
vehicle. Data were analysed by one way ANOVA with Bonferroni post-hoc test. Phospho ERK1/2 
(PERK) is shown in red band and total ERK1/2 (TERK) in green.  Cyclophilin was used as a loading 
control. 
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4.5.6. Effect of ACEA on MAPK38 (p38 MAPK) phosphorylation 
As MAPK38 is another key signalling protein which can play a role in insulin 
resistance (Koistinen et al. 2003), the activation of the CB1 receptor with 10nM 
ACEA on MAPK38 was studied. Treatment of Wistar rat myotubes with 10nM 
ACEA induced MAPK38 phosphorylation at 5min (P<0.05) compared to vehicle 
(0.01%ethanol) followed by reduction at 15min (Figure 4-23). The molecular 
weight of Phospho and total MAPk38 were detected at 43KDa. 
 
Figure 4-23: Representative blot showing the effect of 10µM ACEA on MAPK38 phosphorylation in 
rat myotubes.  
Quantified values of PMAPK38/TMAPK38 are shown (* denotes P<0.05 compared to vehicle and 
$&($¶ Data were analysed by one way ANOVA with Bonferroni post-hoc test (n=2). 
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4.5.7. Effect of ACEA and RIM on insulin stimulated AKT 
phosphorylation 
As AKT is a key protein in insulin signalling, AKT phosphorylation following 
acute insulin (100nM for 10 min) stimulation of Wistar rat myotubes which had 
been pre-treated with either 100nM ACEA or 100nM RIM for 24 hours was 
studied. Pretreatment with ACEA and RIM had no significant effect on insulin 
induced AKT phosphorylation (Figure 4-23). The molecular weight of the bands 
of Phospho AKT and Total AKT were detected at 62 KDa. 
   
 
Figure 4-24:  Representative blot showing the effect of 24 hours treatment with 100 nM ACEA and 
RIM on insulin stimulated AKT phosphorylation in Wistar rat myotubes. 
Quantified values of PAKT/TAKT are shown in lower panels A) Pre-treatment (24 hours) of myotubes 
with 100nM ACEA ** denotes P<0.01 compared to vehicle (0.01% ethanol). B) Pre-treatment (24 
hours) of myotubes with 100nM RIM *** denotes P<0.001 compared to vehicle.  Data were analysed 
by one way ANOVA with Bonferroni post-hoc test (n=2).  
 
4.5.8. (IIHFWRI$&($DQG5,0RQLQVXOLQVWLPXODWHG*6.ĮDQG
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under acute insulin stimulation after treatment with ACEA and Rim was carried 
out.  Pretreatment (24hours) with 100nM ACEA and 100 nM RIM had no 
VLJQLILFDQW HIIHFW RQ LQVXOLQ LQGXFHG *6.Į DQG *6.ǃ SKRVSKRU\ODWLRQ
(Figure 4-257KHPROHFXODUZHLJKWRIWKHEDQGVRISKRVSKRDQGWRWDO*6.Į
DQG*6.ǃZHUHGHWHFWHGDWDQG.'DUHspectively. 
 
Figure 4-25: Representative blot showing the effect of 24 hours treatment with 100 nM ACEA and 
5,0RQLQVXOLQVWLPXODWHG*6.ĮDQG*6.ǃSKRVSKRU\ODWLRQLQ:LVWDUUDWP\RWXEHV 
Quantified valueVRI3*6.Į7*6.ĮDQG3*6.ǃ7*6.ǃDUHVKRZQLQORZHUSDQHOVGHQRWHV
P<0.01 compared to vehicle (0.01% ethanol). Data were analysed by one way ANOVA with 
Bonferroni post-hoc test (n=2).  
 
4.5.9. Effect of ACEA and RIM on insulin stimulated ERK 
phosphorylation 
Previous data in this Chapter showed activation and inhibition of ERK 
phosphorylation by CB1 receptor agonists and antagonists, respectively. A 24 
hour incubation of Wistar rat myotubes with 100 nM ACEA or 100nM RIM prior to 
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administration of 100nM insulin for 10 min did not alter insulin induction of ERK 
phosphorylation (Figure 4.26). 
 
Figure 4-26: Representative blot showing the effect of 24 hours treatment with 100 nM ACEA and 
RIM on insulin stimulated ERK1/2 phosphorylation in Wistar rat myotubes. 
Quantified values of PERK2/TERK2 are shown in lower panels. ** denotes P<0.01 compared to 
vehicle (0.01% ethanol). Data were analysed by one way ANOVA with Bonferroni post-hoc test 
(n=2). 
 
4.5.10. Effect of ACEA and RIM on insulin stimulated MAPK 38 
phosphorylation 
In order to investigate the possible signalling pathways that might be 
involved in skeletal muscle insulin resistance, the effect of 24 hours incubation of 
Wistar rat myotubes with 100nM ACEA and 100nM RIM on insulin-induced 
MAPK38 phosphorylation was examined. 100nM ACEA in the presence or 
absence of insulin led to significantly higher phosphorylation of MAPK38 
(P<0.01) compared to vehicle (0.01% ethanol). Insulin also induced significant 
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MAPK38 phosphorylation (P<0.05) compared to vehicle (0.01% ethanol) 
(Figure 4-27).  
 
Figure 4-27: Representative blot showing the effect of 24 hours treatment with 100 nM ACEA and 
RIM on insulin stimulated MAPK38 phosphorylation in Wistar rat myotubes.  
Quantified values of PMAPK38/TMAPK38 are shown in lower panels. * denotes P<0.05 and ** 
denotes P<0.01 compared to vehicle (0.01% ethanol). Data were analysed by one way ANOVA with 
Bonferroni post-hoc test (n=2).  
 
4.5.11. Effect of Pertussis Toxin (PTX) on ERK phosphorylation 
induced by ACEA 
It is well documented that the cannabinoid receptors are coupled to Gi/o 
SURWHLQDOWKRXJKUHFHQWO\VRPHVWXGLHVVXJJHVWHGWKHSRVVLEOHFRXSOLQJWR*T»
11 (Dalton et al. 2009)(Matias et al. 2008). In this study, pretreatment of Wistar 
rat myotubes with the Gi/o inhibitor (50 nM PTX) for 30 min did not block the 
stimulatory effect of 10 nM ACEA on ERK phosphorylation (Figure 4-28).  
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Figure 4-28: Representative blot showing the effect of 50 nM Pertusis Toxin (PTX) on ERK 
phosphorylation induced by 10nM ACEA in Wistar rat myotubes.  
Quantified values of PERK2/TERK2 are shown in lower panels. * denotes P<0.05 and ** denotes 
P<0.01 compared to vehicle (0.01% ethanol). Data were analysed by one way ANOVA with 
Bonferroni post-hoc test (n=3). 
 
4.5.12. Effect of CB1 receptor activation on cell proliferation  
CB1 receptor activation has been reported to play an important role in 
cellular proliferation and differentiation (Wang et al. 2004). Incubation of 10-day 
myoblasts with 10nM ACEA or Vehicle (0.01% ethanol) for 24 hours showed a 2-
fold increase in cell number in ACEA treated myoblasts when compared to 
vehicle (Fig 4.29). The percentage of Ki67 positive cells was 73.9% in ACEA 
treated cells and 48.3% in vehicle suggesting that ACEA increases cellular 
proliferation in myoblasts.  
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Figure 4-29: Ki67 immunofluorescence in myoblasts obtained from VL Wistar rats. 
A) Cells were treated with vehicle (0.01% ethanol). B)  Cells were treated with 10nM ACEA. Images 
were taken at 40x magnification. Scale bar 20µm. Ki67 green and DAPI blue (n=3). 
 
4.5.13. Glucose transporters in skeletal muscle tissue and 
cultured cells 
In this study immunofluorescence of GLUT4 in Wistar rat skeletal muscle 
cultured cells showed that treatment of myotubes with 100nM insulin for 10 min 
did not induce significant changes in GLUT4 cellular distribution between insulin 
and vehicle (0.01% ethanol) treated cells. Interestingly, a low level of 
recruitment of GLUT4 to the cell membrane was observed in some 
undifferentiated myoblasts (Figure 4-30C). Time course treatment (5, 10, 30 
min) of rat myotubes with 100nM insulin in presence or absence of 10nM ACEA 
(24hours incubation prior to insulin) demonstrated no significant difference in 
GLUT4 cellular distribution compared to vehicle (data not shown). It is worth 
mentioning that the human microarray data presented in Chapter 3 showed a 
high level of GLUT1 (SLC2A1) expression in myoblasts and myotubes compared 
to muscle tissue (Table 4.6). In contrast, GLUT4 (SLC2A4) expression was much 
higher in tissue compared to myoblasts and myotubes (Table 4-6). 
A BA
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Figure 4-30: GLUT 4 immunofluorescence in Wistar rat myotubes and myoblasts. 
A) Myotubes treated with vehicle (0.01% ethanol). B)  Myotubes treated with 100nM insulin. C) 
Myoblasts treated with 100nM insulin. Images were taken at 64x magnification. Scale bar 40µm. 
GLUT4 green fluorescent and DAPI red fluorescence (n=3). 
 
Table 4-6: Glucose transporters in human skeletal muscle tissue and cultured cell. 
 
MB=myoblast, MT=myotube, TIS=tissue, FC=fold change & N/A=no difference 
 
4.6. Discussion 
4.6.1. Characterisation of cannabinoid receptors. 
 Skeletal muscle is one of the major insulin sensitive organs and it is 
responsible for 80% of insulin stimulated glucose disposal. Even though high 
circulating levels of endocannabinoids have been reported in obese and diabetic 
individuals, their tissue expression levels and the link between cannabinoid 
receptors and insulin signalling in skeletal muscle (skeletal muscle) are still 
controversial (Bensaid et al. 2003; Pagotto et al. 2006; Lindborg et al. 2010). 
The aim of this study was to characterize the cannabinoid receptors CB1 and 
CA B
MB MT TIS MB MT TIS 
MB
vs
MT
MT
vs
TIS
MB
VS
TIS
SLC2A1 2709 2980 21461 3.6 3.1 -3.3 2.4 87.1 121.2
Homo sapiens solute carrier 
family 2 (facilitated glucose 
transporter), member 1 
(SLC2A1), mRNA 
[NM_006516]
SLC2A4 35015 32232 1719 -7.8 -6.8 4.7 #N/A -3329.2 -6342.5
Homo sapiens solute carrier 
family 2 (facilitated glucose 
transporter), member 4 
(SLC2A4), mRNA 
[NM_001042]
Gene 
Symbol
Rank Intensity Fold Change
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CB2 and identify their role in cell signalling in human and rat skeletal muscle 
tissue and primary cultured skeletal muscle cells. The expression and 
functionality of other potential cannabinoid-related receptors, GPR 119 and 
GPR55 was also investigated.  
The microarray analysis performed in Chapter 3 indicated the expression of 
CB1 and CB2 receptors as well as FAAH, MGLL, DAGLA, DAGLB and NAPE-PLD in 
human skeletal muscle tissue and primary cultured myoblasts and myotubes 
indicating that this expression is muscle specific and not the result of 
contaminating adipocytes or other infiltrating cell types. However, the levels of 
cannabinoid receptor mRNA detected by microarray was extremely low and 
provided no direct evidence that functional CB1 or CB2 receptors were present. 
This is further complicated by the fact that antibodies used to detect CB 
receptors in immunohistochemistry or western blots are notoriously unreliable 
and often give false positive results (A. Bennett, unpublished observations). 
QRT-PCR analysis, which is considerably more sensitive than microarray, 
performed in this Chapter confirmed the expression of CB1 at the mRNA level in 
both human and rat muscle tissues and cultured cells in agreement with Eckardt 
et al. (2009) and Cavuoto et al. (2007). Furthermore, human myoblasts and 
skeletal muscle tissue had higher CB1 expression than myotubes. In rat, a trend 
for a higher level of CB1 expression in fast muscles (EDL and GW) compared to 
slow muscles (SOL and GR) was observed which essentially agrees with results 
observed in a study investigating CB1 expression in different frog muscle types 
(Huerta et al. 2009). The QRT-PCR findings from the present study also revealed 
CB2 mRNA expression in rat skeletal muscle tissue and cultured cells in 
agreement with Cavuoto et al. (2007). Interestingly, human CB2 mRNA 
expression was considerable in 100% myoblasts, whereas it decreased in 
myotubes and was undetected in muscle tissues.  
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The presence of GPR119 was observed in human skeletal muscle tissue 
and cultured cells using both microarrays and QRT-PCR. This is an important 
finding as only one previous study reported the presence of GPR119 in human 
skeletal muscle using Northern blot (Soga et al. 2005). GPR119 mRNA 
expression was also detected in various rat tissues (brain, spleen, pancreas, and 
skeletal muscle), which is in agreement with Bonini et al. (2001) & Bonini et al. 
(2002). The present study is the first to investigate the presence of GPR119 in 
skeletal muscle cultured cells in an attempt to identify its role in cell 
development and signalling cascade. Even though the microarray analysis 
detected the expression of GPR55 in human skeletal muscle tissue and cultured 
cells, RT-PCR analysis failed to detect the presence of GPR55 in both human and 
rat skeletal muscle tissue and cultures cells. The expression of  GPR55 proteins 
in rat skeletal muscle tissue  and GPR55 mRNA in C2C12 has been reported by 
Simcocks et al. (2011) and Roy et al. (2010), respectively. 
High levels of circulatory endocannabinoids are well documented in obese 
and diabetic subjects (Serrano et al. 2008). However, the presence and role of 
Skeletal muscle CB1 receptors in obesity and diabetes is poorly described. 
Pagotto et al. (2006) reported a high level of mRNA CB1 expression in soleus 
muscles from mice fed a high fat diet whereas Lindborg et al. (2010) observed a 
low CB1 protein expression in SOL from ZFR. The adipose tissue CB1 mRNA 
expression was upregulated in obese Zucker fat rats compared to lean 
littermates (Vickers et al. 2003; Pagano et al. 2007; Bensaid et al. 2003). In 
contrast  Engeli et al. (2005) and Blüher et al. (2006) demonstrated a down 
regulation of CB1 mRNA in adipose tissue taken from obese subjects. High levels 
of CB1 mRNA and protein were observed in renal cortex of diabetic mice when 
compared with nondiabetic control animals (Barutta et al. 2010).  In the present 
study, the expression levels of CB1, CB2 and GPR119 in muscle, liver, heart, 
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spleen and adipose tissues were similar between 12 week old Zucker Fat Rats 
(ZFR) and Zucker Lean Rats (ZLR), however at 20 weeks ZFR muscle and 
adipose tissues had a significantly higher expression of CB1 than ZLR. GPR119 is 
a potential cannabinoid receptor that might play a role in glucose homeostasis 
by two ways; firstly by stimulating insulin release from the ǃ FHOOV RI WKH
pancreas and secondly through the release of antihyperglycaemic agents such as 
glucagon like peptide (GLP) and gastric inhibitory polypeptide (GIP) from 
enteroendocrine cells (Drucker 2001; Meier et al. 2002; Gromada et al. 2004). 
In this study the expression of GPR119 in skeletal muscle tissues was higher in 
Zucker than Wistar rats in contrast to CB1 which has higher expression in Wistar 
compared to Zuckers, however the difference disappeared in myotubes cultured 
from the same animal, which indicates that removal of the physiological factors 
that differentiate the two strains of rat in cultured cells may cause the 
equalization of GPR119 and CB1 expressions.  This hypothesis is supported by 
the fact that Brozinick, Roberts, & Dohm, (2003), Pender et al. (2005) and 
Berggren et al. (2005) did not observe a difference in insulin resistance between 
cultured cells from obese (insulin-resistant patients) and control subjects.   
Interestingly, muscle, liver and adipose tissues obtained from Wistar rats had 
significantly higher levels of CB1 (but not CB2) mRNA content than Zucker obese 
and lean rats. This finding may be due to downregulation of the CB receptors in 
insulin resistant states caused by elevated endogenous circulating cannabinoids. 
Down-regulation or reduction of receptor number, apparent shielding of the 
receptors from interacting ligands, and uncoupling from G-proteins in response 
to stimulation by cannabinoid ligands have all been previously described 
(Freedman and Lrfkowitz 1996 & Xiao et al. 1999). Prolonged stimulation 
generally leads to a significant receptor loss from the cell surface (Gainetdinov et 
al. 2004). 
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It is widely assumed that cannabinoid receptors are Gi/o protein coupled 
(Pertwee & Ross 2002; McAllister & Glass 2002; Matsuda et al. 1990; Dalton et 
al. 2009; Bellocchio et al. 2008). However Ahn et al. (2012) found that 
activation of ERK via a CB1 allosteric modulator was Gi independent in HEK293 
and neuronal cells. Matias et al. (2008) reported that CB1 and CB2 in RIN-m5F 
ǃ-FHOOV DUH *T »  FRXSOHG DQG LQVHQVLWLYH WR SHUWXVVLV WR[LQ 6Wimulation of 
cAMP was observed in rat cultured striatal neurons and in CB1 transfected CHO 
cells in response to activation by the CB1 agonist HU210 suggesting that under 
certain circumstances, the CB1 receptors can couple to Gs proteins (Glass & 
Felder 1997; Turu & Hunyady 2010). The interaction of CB1 with Gs was also 
demonstrated in CHO cells expressing human CB1 (Demuth & Molleman 2006). 
In the present study PTX had no effect on ACEA stimulated MAPK 
phosphorylation potentially indicating that CB1 is not Gi/o coupled in skeletal 
muscle. However, a PTX sensitive GPCR would need to be shown to be sensitive 
and inhibited by PTX in myotubes in culture in order to be confident that PTX 
was having no effect on CB1. It is worth mentioning that unpublished data from 
our laboratory also demonstrated no effect of ACEA, AEA or RIM on cAMP 
production ± if CB1 was Gi/o coupled then CB1 agonists would be expected to 
decrease cAMP levels. These results indicate that there is specificity between 
CB1 receptor coupling and tissue type. 
4.6.2. Functionality of cannabinoid receptors.  
The functionality of CB1 in human and rat cultured cells was assessed by 
studying the effect of an endogenous (AEA) and a synthetic (ACEA) agonist. As 
AEA is a nonspecific ligand which may act via a number of receptors including 
CB1, CB2 and TRPV1 (Matias et al. 2008; Cavuoto et al. 2007), ACEA was also 
used as it is a CB1 selective agonist (Hillard et al. 1999; Pertwee & Howlett 
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2010). In this study, treatment of human and rat myotubes with AEA and ACEA 
increased ERK1/ERK2 and p38 MAPK phosphorylation.  Increased  
phosphorylation of MAPK by AEA and ACEA was previously reported by Eckardt 
et al. (2009) and Tedesco et al. (2010). Interestingly, treatment with a CB1 
selective antagonist (RIM) attenuated the ERK activation induced by AEA and 
ACEA in cells obtained from Wistar and ZLR but not ZFR.  This may indicate that 
CB1 agonists signalling are altered in ZFR derived cells, or that antagonists are 
for some reason ineffective.   Previous studies indicate that CB1 antagonist 
AM251 was in fact more effective in high fat diet fed and/or obese rats than in 
lean controls, which is in potential contrast to our data (Bellocchio et al. 2008). 
Furthermore, rimonabant has been previously described as having a more 
pronounced effect upon glucose uptake in skeletal muscle myotubes obtained 
from obese as compared to lean individuals (Cavuoto 2010) However, the same 
study reported no effect of either RIM or AEA upon ERK phosphorylation. It is 
possible that the effects of endocannabinoid signalling upon ERK signalling are 
unrelated to their metabolic effects and rather, are associated with cell 
proliferation or differentiation (Roux & Blenis 2004). The disappearance of RIM 
effect on ZFR needs further investigation in terms of effects on metabolic gene 
expression and cell proliferation.  
To further investigate the role of CB1 receptor activation in the acute modulation 
of insulin signalling in rat and human myotubes, the effects of CB1 agonists and 
antagonists on key proteins in the insulin signalling cascade were studied. 
Previous findings in the literature regarding the role of the cannabinoid receptor 
activation or inhibition on AKT are controversial. Eckardt et al. (2009) found that 
AEA impaired insulin-VWLPXODWHG$.7EXWQRW*6.ĮǃSKRVSKRU\ODWLRQDQGSUH-
treatment with RIM completely abolished the AEA effect in human primary 
cultured cell. However Lindborg et al. (2010) reported that neither CB1 receptor 
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DJRQLVWVQRUDQWDJRQLVWVDOWHUHG$NWDQG*6.ǃSKRVSKRU\ODWLRQin soleus muscle 
from lean and obese Zucker rats. Song et al. (2011) reported that the CB1 
agonist HU210 induced insulin resistance in muscle of wild-type C57BL/6 mice 
through inhibition of AKT phosphorylation which was prevented by pretreatment 
with the CB1 antagonist AM251. Esposito et al. (2008) also demonstrated that 
RIM increased AKT phosphorylation and glucose uptake in L6 skeletal muscle 
cells. Pharmacological activation or inhibition of CB1 receptor activity exerts a 
differential effect with regard to MAP kinase and PKB-directed signalling in L6 
module (Lipina et al. 2010). In this study, neither ACEA nor RIM affected insulin-
VWLPXODWHGSKRVSKRU\ODWLRQRI$NWRU*6.Įǃ, indicating that modulation of CB1 
receptor in skeletal muscle cultured cell does not have a role in insulin signalling. 
The discrepancy between this study and some earlier studies may be due to the 
different time point and the cell model. This can be due the difference in; 
concentration and duration of treatment with RIM as this study used 100nM for 
30 min while Eckardt et al. (2009) used  ǋPROO 5LP IRU KUV GLIIHUHQFH LQ
treatment as this study used ACEA and RIM while Song et al. (2011) used 
HU210 and AM251; and different in cell types as Wistar skeletal muscle primary 
cultured cells were used in the current study while human skeletal muscle 
cultured cells were used in  Eckardt et al. (2009) study and L6 module was used 
in Lipina et al. (2010b) and Esposito et al. (2008) studies. Moreover, none of the 
previous studies used free fatty acid free serum in culture medium prior to the 
treatments.     
Transport instead of phosphorylation of glucose may be the rate limiting 
process in the uptake of glucose by cultured human muscle cells (Jacobs et al. 
1990)( Perriott et al. 2001). The role of CB1 inhibition in glucose uptake was 
reported by Esposito et al. (2008) who found that RIM increased glucose uptake 
in L6 cells and  Liu et al. (2005) who observed similar findings in soleus muscle 
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isolated from female Lepob/Lepob mice treated with RIM. It was suggested that 
RIM increased glucose uptake in soleus muscle through the GLUT1 glucose 
transporter as a low dose of insulin (10nM) was used. In the present study 
immunofluorescence of GLUT4 in rat skeletal muscle cultured cells showed that 
treatment of rat myotubes with 100nM insulin in the presence or absence of 
ACEA (24hours incubation prior to insulin) resulted in no difference in GLUT4 
cellular distribution compared to vehicle. This result may be due to the low level 
of GLUT4 expression and the high level of GLUT1 expression observed in culture 
in Chapter 3 and previous studies in the literature (Bouché et al. 2004; Jackson 
et al. 2000; Al-Khalili et al. 2003). A slight recruitment of GLUT4 to cell 
membrane was observed in some undifferentiated myoblasts in line with a 
previous study by Jackson et al. (2000) who reported that the greatest 
stimulatory effect of insulin on glucose uptake was seen in myoblasts, and this 
was diminished after myoblast fusion and disappeared in fused myotubes. 
Photolabelling of cell surface glucose receptors is recommended for better 
visualization (Ijuin & Takenawa 2012; Al-Khalili et al. 2003). Insulin-dependent 
GLUT4 exocytosis includes several steps, including recruitment, docking and/or 
fusion of GLUT4-containing vesicles to the plasma membrane (Sakamoto & 
Holman 2008). GLUT4 exocytosis in the skeletal muscle cells is dependent on the 
actin cytoskeletal rearrangement occurring at the membrane ruffles (Saltiel & 
Kahn 2001). This indicates that not only a reduction of GLUT4 content but also a 
decrease in the expression of genes involved in cytoskeletal rearrangement, as 
observed in chapter 3, might explain the inability of insulin to affect GLUT4 
cellular distribution compared to vehicle in the present study.      
GPCR receptors are associated with cell lineage development  and play an 
important role in cellular proliferation and differentiation (Wang et al. 2004). The 
role of CB1 in adipogenesis and neurogenesis has been reported by Matias et al. 
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(2008), Pagano et al. (2007) and Jin et al. (2004). Gary-bobo et al. (2006) 
reported that RIM can lead to a decrease in cell proliferation in mouse 3T3 cells.   
In this study the role of the synthetic CB1 agonist ACEA was investigated in 
skeletal muscle cells proliferation using the proliferation marker Ki67. This well-
established proliferation marker has a distinctive distribution pattern that 
exclusively identifies proliferating cells (Kumai et al. 2007). Even though Ki67 is 
constantly present in cell cycling, its pattern of expression is variable. Depending 
on the stage of the cell cycle, it might appear in the small nuclei, nuclear area or 
disappear in resting cells as well as terminally differentiated cells (Ross & Hall 
1995). The results from the present study showed that CB1 activation leads to 
increased expression of nuclear Ki67, indicating an increase in myoblast 
proliferation.  
In conclusion, the expression of the CB1 cannabinoid receptor in skeletal 
muscle has been confirmed at the mRNA level in skeletal muscle tissue and in 
cultured cells. Expression of GPR119 was also confirmed in both tissue and cell 
cultured whereas CB2 was only found in cell culture and GPR55 expression was 
not detected in either tissue or cells.  Subsequent studies using CB1 agonists 
and antagonists demonstrated that activation of CB1 robustly induced ERK and 
p38 MAPK phosphorylation which was inhibited by the specific antagonist 
rimonabant. These data demonstrate functional expression of CB1 in skeletal 
muscle tissue culture.   The inability of rimonabant to inhibit CB1 agonist 
mediated ERK phosphorylation suggests altered ECS signalling in obesity 
however this finding requires further investigation. This study, in contrast to 
previous work, did not find any evidence that CB1 activation or inhibition 
influenced insulin signalling or glucose uptake in skeletal muscle. However the 
levels of proteins involved in insulin signalling and glucose uptake (in particular 
Glut4) are drastically reduced in cultured cells as compared to tissue and this 
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may account for the lack of effect of cannabinoids to influence insulin signalling 
and glucose uptake in this model. Further refinement of the cell culture model is 
needed to promote a more adult phenotype, turn on oxidative phosphorylation 
and increase insulin sensitive glucose uptake.  A potential role for CB1 in 
promoting myoblast proliferation was identified ± possibly involving activation of 
ERK signalling. Further studies looking at the effects of CB1 receptor agonists 
and antagonists upon markers of cell proliferation and differentiation are 
warranted. 
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CHAPTER 5. MOLECULAR CHARACTERISATION OF 
FREE FATTY ACID RECEPTOR 1 (GPR40) 
IN SKELETAL MUSCLE 
5.1. Introduction 
Free fatty acids (FFAs) have been implicated in the pathogenesis of insulin 
resistance however the molecular mechanism by which FFAs reduce insulin 
sensitivity is not fully understood. Since the Randle hypothesis (excessive FFAs 
reduce glucose oxidation due to substrate competition)  was published 40 years 
ago, a number of subsequent theories have been put forward to explain the role 
of fatty acids in the development of insulin resistance (Costanzi et al. 2008). 
Roden et al. (1996) suggested that inhibition of glucose transport or its 
phosphorylation is the main reason of insulin resistance. Tsintzas et al. (2007) 
and Chokkalingam et al. (2007) addressed the role of PDK4 in skeletal muscle 
insulin resistance induced by high FFAs. Saturated fatty acids were 
demonstrated to affect insulin intracellular signalling pathways in skeletal muscle 
and myocytes (Thompson AL et al. 2000; Yu et al. 2002). Various PKC isoforms 
have been shown to be involved in lipid-induced insulin resistance in skeletal 
muscle (Griffin et al. 1999). The role of inflammatory cytokines in insulin 
resistance induction have been also postulated (Sell et al. 2006; Martins et al. 
2012). More recently, deorphanization of free fatty acid receptors {GPR40 
(FFAR1), GPR120, GPR84, GPR42 & GPR43} provided an alternative molecular 
target for FFA, however the exact role of these receptors is still under 
investigation and little is known about their functionality in skeletal muscle. 
GPR40 is a promising target for diabetes treatment. It mainly binds to GPRq and 
weakly binds to Gi/o (Itoh et al. 2003; Kotarsky et al. 2003) and is activated by 
medium to long chain saturated and unsaturated fatty acids. GPR40 is expressed 
LQ D YDULHW\ RI WLVVXHV LQFOXGLQJ ǃ FHOOV RI WKH SDQFUHDV EUDLQ PRQRF\WHV
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splenocytes, intestinal tract, skeletal muscle, liver and heart (Kotarsky et al. 
2003; Swaminath 2008; Ichimura et al. 2009; Briscoe & Tadayyon 2003). The 
binding of FFA and esterified forms of FAs (Stewart et al. 2006) WR*35LQǃ
cells leads to phospholipase c activation which is followed by calcium release, 
activation of MAPK and increased insulin secretion (Ichimura et al. 2009; 
Overton et al. 2008). The activation of GPR40 receptors and the release of 
insulin is a glucose dependent process, GPR40 activation increases intracellular 
Ca2+ levels primarily via the coordinated enhancement of extracellular Ca2+ 
influx through LTCC and inhibition of KATP channels by glucose as well as 
stimulation of calcium release from endoplasmic stores through Gq-PLC 
signalling pathway (Feng et al. 2006; Shapiro et al. 2005). It is well documented 
that the acute effect of FFA in ǃcells is different from the chronic effect as the 
IRUPHU OHDGV WR LQVXOLQ VHFUHWLRQ DQG WKH ODWWHU OHDGV WR LPSDLUPHQW LQ ǃ FHOO
function and apoptosis (Swaminath 2008). As previously discussed in the 
general LQWURGXFWLRQ FKDSWHU WKH SRWHQWLDO LQYROYHPHQW RI *35 LQ ǃ FHOO
glucolipotoxicity has been studied in GPR40-/- and GPR40 transgenic 
overexpression mice but the result was controversial. Steneberg et al. (2005), 
Brownlie et al. (2008) and Duttaroy et al. (2008) reported that GPR40  mediates 
both acute and chronic effects of FFA on insulin secretion. In contrast, Nagasumi 
et al. (2007), Latour et al. (2007), Tsujihata et al. (2011), Brownlie et al. 
(2008), Wu et al. (2010) and Tan et al. (2008) indicated that the lipotoxic effect 
of FFA is not mediated by GPR40 receptors. Authors account for these 
discrepancies in WKH*35ííPRXVHJHQHWic back ground, type of foods and 
duration of feeding. Whilst a considerable amount of work has been carried out 
examining the role of GPR40 in the pancreas, the mechanism of action and 
physiological role of GPR40 in skeletal muscle is largely unknown.   
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5.2. Aims 
The main objectives of this study are: 
x To confirm the presence of GPR40 receptors in human and rat skeletal 
muscle tissues and primary skeletal muscle cell culture.   
x To compare the level of GPR40 receptor mRNA expression between Zucker 
Leans, Zucker Fat and Wistar rats in different muscle types. 
x To establish the functionality of GPR40 receptor and to determine whether 
activation or inactivation of GPR40 receptors may have a role to play in 
insulin resistance. 
x To compare gene expression profiles in human primary skeletal muscle cells 
in response to the GPR40 agonists and antagonists using DNA microarray. 
5.3. Experiment design and methods 
5.3.1. Sample collection and preparation  
Human vastus lateralis samples were collected and divided into two parts, 
first part snap frozen in liquid nitrogen and the second part was used for 
isolation and culture of satellite cells (chapter 2 section 2.3) 
Wistar, Zucker lean and fat rats skeletal muscle tissues were collected from 
slow (SOL & GR), fast (EDL & GW) and mixed (VL) muscle.  liver, epididydmal 
adipose, spleen, pancreas and heart tissues were also collected and snap frozen 
in liquid nitrogen. Isolation and culture of satellite cells was carried out using the 
different muscle tissue types from both Wistar and Zucker rats. 
Total RNA, mRNA, cDNA and protein preparation was performed as 
described in chapter 2 section 2.6. 
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5.3.2. QRT-PCR 
Quantitative Taqman PCR was performed in the step one plus real ±time 
PCR system (Applied Biosystems). Standard protocol as described in chapter 2 
section 2.6.5 was followed. Normalization was carried out by using TATA binding 
protein (TBP) and RPLPO as invariant reference genes.  
5.3.3. Microarray 
5.3.3.1. Expirement design, procedure and data processing 
 Human myotubes were cultured until confluent and then incubated with 
100nM AZ921 (GPR40 agonist), 5µM AZ836 (GPR40 antagonist in horse or fatty 
acid free serum) and AZ921+AZ836 for 24 hrs. DMSO 0.001% was used as a 
vehicle. Five replicates were used for each treatment condition and four 
replicates for the vehicle.  
The cells were lysed with Trizol then total RNA was extracted and cleaned 
up as described in chapter 2 section 2.6. The integrity of the RNA was assessed 
using an Agilent Bioanalyzer. All samples subjected to microarray experiment 
had a RIN value greater than 8 (Appendix 5). 
Whole-genome Human GeneChip HT PM Array (HG_U133+PM) was used to 
detect the global changes in gene expression in response to different conditions. 
Synthesis of labelled cRNA, hybridization and scanning of microarray were 
performed by Nottingham Arabidopsis Stock Centre staff according to the 
PDQXIDFWXUHU¶VSURWRFROV$II\PHWUL[6DQWD&ODUD&$ 
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5.3.3.2. Data preprocessing 
The RMA (Robust Multichip Averaging) was used for preprocessing. RMA 
corrects arrays for background using transformation, quantile normalization 
based on a normal distribution and then estimation of expression values on a log 
scale (Allison et al. 2006) . 
A) Background correction on affymetrix is based on the distribution of the 
perfect match (PM) values among probes. The Affymetrix software computes 
a background-corrected intensity by subtracting the probe background 
signal from the estimated all probes median background intensity.  
B) Quantile normalization is used to equalize the distribution of measurements 
on all arrays and is computed by ranking of probe intensities for each array 
and then taking the corresponding average value of the probe intensities. 
C) Log transformation to the base 2 was taken for the normalized data after 
background subtraction to adjust the distribution. Then, summarization of 
LQWHQVLWLHVYDOXHRI LQGLYLGXDOSUREHVZDVFDUULHGRXWXVLQJ7XNH\¶VPHGLDQ
polish.    
5.3.4. Protein phosphorylation experiments 
Western blots were utilized to study the effect of GPR40 agonists and 
antagonists, MEK inhibitor and pertussis toxin on cell signalling pathways. 
5.3.4.1. (5.0$3.$.7DQG*6.Įǃ 
Human and rat myotubes were treated with either 10 nM GW9508, 100nM 
AZ921, 100 & 250 µM Oleic acid or 250 & 500 µM Palmitic acid  for 5, 10,15, 20 
or 30 min. GPR40 antagonists (30 nM AZ915, 100 µM AZ468 or 5 µM AZ836) , 
10 µM U0126 or 50nM PTX  were added 30min prior to the addition of the 
agonists. Human and Wistar rat myotubes were also treated with GPR40 
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agonists and/or antagonists for 24 hours in the absence or presence of 100 nM 
insulin. After treatments, cells were washed with ice-cold PBS and lysed with 
RIPA buffer.  
5.3.5. Immunocytochemistry experiments   
Wistar rat myoblasts and myotubes were cultured in fatty acid free serum 
for 24 hrs followed by 24h incubation with vehicle (0.001% DMSO), 100nM 
AZ921 or with 100nM insulin in presence or absence of 100nM AZ921 (24hrs 
before). Then, cells were incubated overnight with 1:100 GLUT4  or 1:500 PKC 
ǃ į 	 ǅ DQWLERGLHV IROORZHG ZLWK DQ KRXU LQFXEDWLRQ ZLWK WKH VHFRQGDU\
antibodies described in chapter 2 section 2.7.4. 
5.3.6. Calcium imaging 
Wistar rat myoblasts and myotubes cultured on cover slips were used to 
measure the intracellular calcium levels after the addition of GPR40 agonists 
AZ921 (1 or 3 µM ) or 1 µM GW9508 for up to 30 min. 10 µM ATP for 1min was 
used as positive control. The cells were cultured in fatty acid free medium for 
24hrs with either 6mM glucose or 25mM glucose. Calcium imaging was carried 
out as described in chapter 2 section 2.8. 
5.4.    Statistical analysis 
Statistical analysis was performed with GraphPad Prism software. RT-PCR 
and Western blot values are expressed as mean ± S. E. M. Statistical 
comparisons of different groups were made by one-way analysis of variance 
$129$ DQG %RQIHUURQL¶V PXOWLSOH FRPSDULVRQV SRVW-hoc test. Unpaired two-
tailed T tests were also used. A P value <0.05 was taken as the level of 
significance.  
Microarray preprocessed data were analysed with GeneSpring GX 11 
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VRIWZDUH7UDQVFULSWVZLWKIROGFKDQJHRIDQG38QSDLUHG77HVWZLWK
multiple correction) were then uploaded into the Ingenuity Pathway Analysis 
,3$IRUIXUWKHUDQDO\VLV,Q,3$&RUHDQDO\VLVWKH)LVKHU¶V([DFW7HVW)(7 was 
used to calculate the P value in function and canonical analysis. FET calculates 
the proportion of significant molecules from the data set that map to a function 
similar to the proportion of the function in the reference set. Z-score and 
corrected bias Z-score were used in downstream effects and upstream regulator 
analysis. Z-score is designed to reduce the chance that random data will 
generate significant predictions as it identifies the biological functions that are 
expected to be increased or decreased given the observed gene expression 
change in the datasets. A significant Z-VFRUH LV RU  ZKLFK LQGLFDWH DQ
increase or decrease, respectively in the predicted functions.   
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5.5. Results 
5.5.1. GPR40 mRNA expression 
5.5.1.1. Human  
The expression of GPR40 in human skeletal muscle tissue and cultured 
myoblasts and myotubes was detected by Agilent microarray with a ranking 
order of 32595, 29027 and 28375 out of 41078, respectively.  Taqman RT-PCR 
confirmed the expression of GPR40 in skeletal muscle tissue and cultured cells. 
Higher levels of GPR40 were found in   myoblasts than myotubes (P<0.05) 
Figure 5-1.  Brain tissue had the highest level of GPR40 mRNA expression as 
compared to spleen and skeletal muscle tissue and myotubes.     
 
Figure 5-1: RT-PCR analysis of GPR40 relative expression in human tissues and cultured skeletal 
muscle cells. 
TBP=TATA Binding Protein, MB=Myoblast, MT=Myotube, M=muscle, TIS=tissue. Values are 
mean±SEM *denotes P<0.05,**P<0.01 (N=6 samples from 3 subjects).  
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5.5.1.2. Wistar and Zucker rats 
In Wistar, Zucker lean and Zucker fat rats in all skeletal muscle tissues and 
myotubes tested (Gastrocnemius, Vastus Lateralis, Soleus & Extensor digitroum 
longus) the expression of GPR40 mRNA was observed. Wistar rat pancreas, 
spleen, adipose tissue, heart and liver tissues also had detectable level of GPR40 
mRNA expression. Pancreas had the highest level and was statistically significant 
(P<0.05) compared to skeletal muscle tissue, heart and liver (Figure 5-2). 
Zucker fat and lean spleen, adipose, heart and liver tissues also expressed 
GPR40 mRNA at varying levels (n=2 animals, data not shown) 
 
Figure 5-2: Taqman RT-PCR of GPR40 mRNA expression in rat tissues. 
Data were normalized to TBP. Values are mean±SEM *denotes P<0.05, (n=3 rats).  
 
GPR40 mRNA expression levels in 12 week old and 20week old Zucker fat 
and lean rats was also examined. There were no significant differences in GPR40 
mRNA expression between ZLR and ZFR at 12 weeks. However, in 20 week old 
Zucker fat rats GPR40 mRNA was significantly increased in the VL (P<0.01) as 
compared to 20 week old Zucker lean rats. It is worth mentioning that Zucker 
rats VL and SOL had higher level of GPR40 mRNA expression than Wistar rat 
PA
N
 
SP
LE
EN
AD
IPO
SE
MU
SC
LE
HE
AR
T
 
LIV
ER
0.0
0.1
0.2
0.3
0.4
*
G
PR
40
 
RE
LA
TI
VE
 
EX
PR
ES
SI
O
N
CHAPTER Five 
 
 
 
    162 
 
   
  
(P<0.01). However, VL and SOL cultured myotubes had no significant difference 
in GPR40 expression between ZFR and ZLR as well as Wistar rats.  The ZFR (12 
and 20wks) had higher blood glucose level than ZLR (P<0.001) (table 2.1). 
Expecting that removal of the hyperglycemic condition in culture alters the 
GPR40 expression level in ZLR and ZFR, the cells were cultured in 6mM and 
25mM glucose for 6 hours.  Our result showed a significant higher expression 
level in cells cultured in 25mM compared to those cultured in 6mM glucose at 6 
hours (P<0.05)  however, the difference disappeared  at 24hours (Figure 5-4).  
 
Figure 5-3: Comparative analysis of GPR40 mRNA expression in rat skeletal muscle tissues. 
(A) 12 weeks  Soleus * denotes P<0.05 WR compare to ZFR and ** denotes P<0,01 WR compare to 
ZLR. (B)12 +20 weeks Vastus lateralis ** denotes P<0,01 ZFR compare to WR and ***denotes 
P<0.001 ZFR compare to ZLR .. ZFR (Zucker Fat Rat), ZLR (Zucker Lean Rat) and WR (Wistar Rat). 
Data were normalized to TBP. Values are mean ± SEM (n=5 rats) 
 
 
Figure 5-4: RT-PCR analysis of GPR40 mRNA expression in rat myotubes taken from ZFR (Zucker 
Fat Rat), ZLR (Zucker Lean Rat) and WR (Wistar Rat). 
A) Cultured myotubes from different rats P>0.05. B) glucose treatment of cultured myotubes for 6 
and 24 hours * denotes P<0.05 . Data were normalized to TBP. Values are mean ± SEM (n=2 
independent experiments).  
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5.5.2. Effect GPR40 agonists and antagonists on ERK 
phosphorylation 
Taqman QRTPCR analysis showed that human and rat  myotubes had a 
detectable level of GPR40. To address the functionality of GPR40, we studied the 
effect of GPR40 activation or inhibiton on ERK1/2 phosphorylation. Cyclophilin 
was used as an invariant reference protein for normalization.   
5.5.2.1. GW9508 and Oleic acid 
Treatment of Myotubes with 10nM GW9508 cultured from both Wistar and 
Zucker (Fat and Lean) showed time dependent changes in ERK phosphorylation. 
Representative blots are shown in Figure 5-5 	 Figure 5-6.  
 
Figure 5-5: Representative blot showing the Effect of GPR40 agonist (10nM GW9508) treatment on 
ERK1/2 phosphorylation in Wistar rat myotubes on the upper panel. 
Quantified values of PERK1/TERK1and PERK2/TERK2 on the lower panel. *denotes P<0.05 and ** 
denotes <0.01. Data were analysed by one way ANOVA with Bonferroni post-hoc test (N=3). 
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Figure 5-6: Representative blot showing the effect of GPR40 agonist (10nM GW9508) treatment on 
ERK1/2 phosphorylation in Zucker Fat Rat myotubes on the upper panel. 
Quantified values of PERK1/TERK1 and PERK2/TERK2 on the lower panel.*denotes P<0.05 compare 
to vehicle. Data were analysed by one way ANOVA with Bonferroni post-hoc test (N=2). 
 
Treatment of rat myotubes with 100 and 250 µM Oleic acid also showed a 
time dependent increase in ERK1/2 phosphorylation however significance 
(p<0.001) was  observed with the  250µM Oleic acid concentration.  
Representative blots are shown in Figure 5-7 & Figure 5-8.   
 
Figure 5-7: Representative blot showing the effect of 100µM Oleic acid treatment on ERK1/2 
phosphorylation in rat myotubes on the upper panel. 
Quantified values of PERK1/CYC and PERK2/CYC on the lower panel. Data were analysed by one way 
ANOVA with Bonferroni post-hoc test (N=3) 
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Figure 5-8: Representative blot showing the effect of 250µM Oleic acid treatment on ERK1/2 
phosphorylation in Zucker Fat Rat  myotubes on the upper panel. 
Quantified values of PERK1/TERK1 and PERK2/TERK2 on the lower panel. *denotes P<0.05 and 
***denotes <0.001. Data were analysed by one way ANOVA with Bonferroni post-hoc test (N=3) 
 
Human myotubes treated with 10nM GW9508 and 100µM Oleic acid showed a 
time dependent increase in ERK1/2 phosphorylation Figure 5-9. Pre-treatment 
with MEK inhibitor (10µM U0126) significantly inhibited ERK phosphorylation by 
GW9508 Figure 5-10. Treatment of rats and human myotubes with 100, 250 and 
500 µM Palmitic acid did not alter the level of ERK1/2 phosphorylation. 
K>/ ? ? K>/ ? ? ? K>/ ? ? ?
TERK1/2
PERK1/2
CYC
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Figure 5-9: Representative blot showing the effect of 10 nM GW9508 and 100 µM Oleic acid 
treatment on ERK1/2 phosphorylation in human myotubes on the upper panel. 
Quantified values of PERK1/CYC and PERK2/CYC on the lower panel. *denotes P<0.05 and 
**denotes P<0.01 compare to vehicle. Data were analysed by one way ANOVA with Bonferroni post-
hoc test (N=3) 
 
 
Figure 5-10: Western blot showing the effect of MEK inhibitor (10 µM U0126) on ERK1/2 
phosphorylation induced by GPR40 agonist (10 nM GW9598) on human myotubes (N=3). 
Phospho ERK1/2 (PERK) is shown in green band and total ERK1/2 (TERK) in red.  Cyclophilin used as 
a loading control. 
   
TERK1/2
PERK1/2
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GW9508 GW9508+U0126
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5.5.2.2. Determining the effects of GPR40 ligands AZ921 
(agonist) and the antagonists (AZ915, AZ468 &AZ836) 
upon ERK phosphorylation 
 Even though GW9508 is a selective partial agonist for GPR40 with pEC50 
values of 7.32, it also activates GPR42 and GPR43 (pEC50< 4.3 and < 4.3 
respectively). In this study the more potent and full GPR40 agonist (AZ921 EC50 
22nM) and antagonists (AZ915 IC50 6nM, AZ468 IC50 20µM & AZ836 IC50 1µM) 
were used to confirm the functionality of GPR40 in skeletal muscle. Treatment of 
human, Wistar and Zucker rats myotubes with 100nM AZ921 induced a time 
dependent increase in ERK1/2 phosphorylation with a significant (P<0.01) peak 
at 15- 20min followed by a significiant (P<0.05) reduction at 30min(Figure 5-11 
& Figure 5-12). Pre-treatment of human and rat myotubes with 100 µM AZ468 
and 5 µM AZ836 significantly reduced ERK1/2 phosphorylation induced by 
AZ921. However the human specific antagonist AZ915 did not suppress the 
ERK1/2 induction by AZ921. Representative blots are shown in Figure 5-13and
Figure 5-14. Pre-treatment with MEK inhibitor (10µM U0126) significantly 
inhibited ERK phosphorylation by AZ921. Interestingly, the GPR40 antagonists 
had no effect on ERK1/2 phosphorylation induced by GW9508 and Oleic acid in 
both human and rats myotubes. 
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Figure 5-11: Representative blot showing the effect the GPR40 agonist (100nM AZ921) treatment 
on ERK1/2 phosphorylation in Wistar rat myotubes on the upper panel. 
Quantified values of PERK1/TERK1 and PERK2/TERK2 on the lower panel. ***denotes P<0.001 
FRPSDUHWR¶DQG¶.Data were analysed by one way ANOVA with Bonferroni post-hoc test (N=3). 
Phospho ERK1/2 (PERK) is shown in green band and total ERK1/2 (TERK) in red.  Cyclophilin used as 
a loading control. 
 
 
 
Figure 5-12: Representative blot showing the effect the GPR40 agonist (100nM AZ921) treatment 
on ERK1/2 phosphorylation in human myotubes on the upper panel. 
Quantified values of PERK1/TERK1 and PERK2/TERK2 on the lower panel. ** denotes P<0. 01 and 
GHQRWHV 3 FRPSDUH WR YHKLFOH DQG ¶ 'DWD ZHUH DQDO\VHG E\ RQH ZD\ $129$ ZLWK
Bonferroni post-hoc test (N=3) Phospho ERK1/2 (PERK) is shown in red band and total ERK1/2 
(TERK) in green.  Cyclophilin used as a loading control (N=3). 
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Figure 5-13: Representative blot showing the effect the GPR40 antagonist (100 µM AZ468) on 
ERK1/2 phosphorylation induced by GPR40 agonist (100 nM AZ921) in Wistar rat myotubes on the 
upper panel. 
Quantified values of PERK1/TERK1 and PERK2/TERK2 on the lower panel. ** denotes P<0.01 AZ921 
¶FRPSDUHWR$=$=¶DQGGHQRWHV3$=¶FRPSDUHWR$=$=¶
Data were analysed by one way ANOVA with Bonferroni post-hoc test (N=3). Phospho ERK1/2 
(PERK) is shown in green band and total ERK1/2 (TERK) in red.  Cyclophilin used as a loading control 
(N=3). 
   
 
Figure 5-14: : Representative blot showing the effect the GPR40 antagonist (5µM AZ836) on 
ERK1/2 phosphorylation induced by GPR40 agonist (100 nM AZ921) in Zucker lean rat myotubes on 
the upper panel. 
Quantified values of PERK1/TERK1 and PERK2/TERK2 on the lower panel. * denotes P<0.05 AZ921 
¶FRPSDUHWR$=$=¶DQGGHQRWHV3$=¶FRPSDUHWR$=$=¶
Data were analysed by one way ANOVA with Bonferroni post-hoc test (N=3). Phospho ERK1/2 
(PERK) is shown in green band and total ERK1/2 (TERK) in red.  Cyclophilin used as a loading control 
(N=3). 
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 ? ? ?
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Figure 5-15: Representative blot showing the effect the GPR40 antagonist (5µM AZ836) on ERK1/2 
phosphorylation induced by 250 µM OLEIC ACID (OL) and 10 nM GW9508 (GW)) in rat myotubes on 
the upper panel. 
Quantified values of PERK1/TERK1 and PERK2/TERK2 on the lower panel. * denotes P<0.05 and 
**denotes compare to vehicle. Data were analysed by one way ANOVA with Bonferroni post-hoc test 
(N=3). Phospho ERK1/2 (PERK) is shown in red band and total ERK1/2 (TERK) in green.  Cyclophilin 
used as a loading control (N=3). 
 
5.5.3. Effect of GPR40 agonists and antagonists on insulin 
stimulated AKT phosphorylation 
AKT is a key signalling protein in insulin signalling  (Lindborg et al. 2010). 
It has been found that insulin has a diverse role in its  action along metabolic 
and mitogenic signalling pathways (Koistinen et al. 2003). AKT phosphorylation 
under acute insulin (100nM for 10 min) stimulation of Wistar rat and human 
myotubes pre-treated with 100nM AZ921,10nM GW9508, 250 µM Oleic acid for 
24 hours with or without 5 µM AZ836 (antagonist)was studied. Pretreatment 
with 100nM AZ921 significantly (P<0.01) decreased insulin induced AKT 
phosphorylation in human myotubes (Figure 5-16) but the difference did not 
reach significance (P=0.07) in rat myotubes (Figure 5-17). Interestingly, 10nM 
GW9508 had no effect on insulin stimulated AKT phosphorylation while 250 µM 
TERK1/2
PERK1/2
CYC
VEHICLE OLEIC GW9508 OL+AZ836 GW+AZ836
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Oleic acid increased it (P<0.05) Figure 5-18.The GPR40 antagonist AZ836 
abolished the effect of the agonist (AZ921) and had no effect on Oleic acid 
induction of AKT phosphorylation.   The molecular weight of the bands of 
Phospho AKT and Total AKT were detected at 62 KDa. 
 
Figure 5-16: Representative blot showing the effect of GPR40 agonist (100nM AZ921) and 
antagonist (5 µM AZ836) on insulin stimulated AKT phosphorylation in human myotubes. 
Pre-treatment (24 hours) of myotubes with 100nM AZ921 significantly reduce the acute (10min) 
stimulatory effect of 100 nM INS (insulin) on AKT phosphorylation. *** denotes P<0.001 compare to 
vehicle and * denotes P<0.05 compare to insulin. Data were analysed by one way ANOVA with 
Bonferroni post-hoc test (n=4 samples /2 subjects). 
PAKT
TAKT
Vehicle INS AZ921 AZ921+INS AZ921+AZ836+INS
INS - + - + +
AZ921 - - + + +
AZ836 - - - - +
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Figure 5-17: Representative blot showing the effect of GPR40 agonist (100nM AZ921) and 
antagonist (5 µM AZ836) on insulin stimulated AKT in Wistar rat myotubes.  
Pre-treatment (24 hours) of myotubes with AZ921 and AZ836 had a trend of reduction on the acute 
(10min) stimulatory effect of 100 nM INS (insulin) on AKT phosphorylation. Data were analysed by 
one way ANOVA with Bonferroni post-hoc test (n=4 samples/2rats). 
 
 
Figure 5-18: Representative blot showing the effect of GPR40 agonist (250 µM Oleic acid) and 
antagonist (5 µM AZ836) on insulin stimulated AKT phosphorylation in Wistar rat myotubes (n= 4 
samples/2rats). 
Pre-treatment (24 hours) of myotubes with 100 µM Oleic acid increase the acute (10min) stimulatory 
effect of 100 nM INS (insulin) on AKT phosphorylation. * denotes P<0.05 compare to insulin. Data 
were analysed by one way ANOVA with Bonferroni post-hoc test. 
Vehicle INS AZ921 AZ921+ INS
AZ921+AZ836+ 
INS
PAKT
TAKT
INS - + - + +
AZ921 - - + + +
AZ836 - - - - +
INS OL+INS OL+AZ836+INSVehicle
PAKT
TAKT
INS OL+INS OL+AZ836+INS
CHAPTER Five 
 
 
 
    173 
 
   
  
5.5.4. Effect of AZ921 and AZ836 on LQVXOLQ VWLPXODWHG*6.ǃ
phosphorylation 
GSK is another key signalling protein in insulin signalling that regulates 
glycogen synthesis (Lindborg et al. 2010):HH[DPLQHG*6.ǃSKRVSKRU\ODWLRQ
under acute insulin stimulation after treatment with 100nM AZ921 and 5 µM 
AZ836.  Pretreatment (24 hours) with 100nM AZ921 had no significant effect on 
LQVXOLQ LQGXFHG*6.ǃSKRVSKRU\ODWLRQKRZHYHUWKHDGGLWLRQRIWKHDQWDJRQLVW
AZ836 30 mins before the agonist increased insulin induction of GSK 
phosphorylation (P<0.01) (Figure 5-19). The molecular weight of the bands of 
3KRVSKRDQG7RWDO*6.ǃZHUHGHWHFWHGDW.'D 
 
 
Figure 5-19: Effect of GPR40 agonist (100nM AZ921) and antagonist (5 µM AZ836) on insulin 
VWLPXODWHG*6.ǃSKRVSKRU\ODWLRQLQKXPDQP\RWXEHV.  
Pre-treatment (24 hours) of myotubes with 100nM AZ921 had no effect on the acute (10min) 
VWLPXODWRU\HIIHFWRIQ0,16LQVXOLQRQ*6.ǃSKRVSKRU\ODWLRQZKLOHWKHDQWDJRQLVW$=
significantly increase it. ** denotes P<0.01 compare to insulin. PhRVSKR*6.ǃLVVKRZQLQUHGEDQG
DQG WRWDO *6.ǃ LQ UHG 'DWD ZHUH DQDO\VHG E\ RQH ZD\ $129$ ZLWK %RQIHUURQL SRVW-hoc test 
(n=4samples/2 subjects). 
 
Vehicle INS AZ921+INS AZ921+AZ836+INS
PGSK3ß
TGSK3ß
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5.5.5. Effect of AZ921, GW9508, Oleic acid and Palmitic acid on 
MAPK38 phosphorylation 
MAPK38 is another key signalling protein which might play a role in insulin 
resistance (Koistinen et al. 2003). incubation of Wistar rat and human myotubes 
with 100 nM AZ921, 250 µM Oleic acid and 250 µM Palmitic acid had no  effect 
on insulin induction of MAPK38 phosphorylation however, 10nM GW9508 
significantly induced it (P<0.01) (Figure 5-20).  
 
Figure 5-20: Representative blot showing the effect 10 min treatment of 10 nM GW9508, AZ921 
(100nM),Palmitic acid (250µM PAL) or 250 µM OLEIC ACID (OL) on MAPK38 phosphorylation on 
human myotubes. 
** P<0.01 compared to vehicle. Data were analysed by one way ANOVA with Bonferroni post-hoc 
test (n=3. 
5.5.6. Effect of Pertussis Toxin (PTX) on ERK and MAPK38 
phosphorylation induced by GPR40 agonists 
GPR40 has previously been described as being mainly linked to Gq 
although it can be weakly coupled to Gi/o (Itoh et al. 2003; Kotarsky et al. 
2003). In this study, pretreatment of Wistar rat myotubes with Gi/o specific  
inhibitor PTX (50 nM) for 30 min (P<0.05) reduced the effect of 250 µM Oleic 
acid, 10nM GW9508 (P<0.05) and 100nM AZ921 on ERK1/2  phosphorylation, 
however,  the latter did not reach statistical  significance (Figure 5-21). PTX also 
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reduced the effect of 10nM GW9508 (P<0.05) on MAPK38 phosphorylation 
(Figure 5-22).   
 
Figure 5-21: Representative blots showing the Effect of Pertussis toxin (50nM PTX) on ERK 
phosphorylation induced by 100 nM AZ921 & 250 µM Oleic acid on Wistar rat myotubes. 
* denotes P<0.05. Phospho ERK1/2 (PERK) is shown in red band and total ERK1/2 (TERK) in green.  
Cyclophilin was used as a loading control. Data were analysed by one way ANOVA with Bonferroni 
post-hoc test (n=3). 
 
Figure 5-22: Representative blots showing the Effect of Pertussis toxin (50nM PTX) on MAPK38 
phosphorylation induced by 10 nM GW9508 Wistar rat myotubes. 
* denotes P<0.05. Cyclophilin was used as a loading control. Data were analysed by one way ANOVA 
with Bonferroni post-hoc test (n=3). 
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5.5.7. Effect of GPR40 agonists (AZ921 and GW9508) on 
intracellular  calcium ion  release 
As GPR40 is predominanWO\D*ĮTFRXSOHGUHFHSWRUanticipated to increase 
intracellular calcium, calcium mobilization is used a functional read out in the 
majority of publications.  The addition of  AZ921 (1 & 3 µM) or GW9508 (1 µM)  
for 5, 10 and 30 min to cells cultured (myoblasts and myotubes) in 6mM or 
25mM glucose for 6hrs did not produce any change in calcium ion levels 
(Figure 5-23). However, the addition of 10 µM ATP produced a rapid elevation of 
calcium in almost 96% of the cells. The experiment was done 3 times using 
cells from different animals.  
 
Figure 5-23: A representative trace showing the effect of GPR40 agonist. 
A) 1 µM of AZ921, B) 10nM GW9805 and 10 µM ATP in the 340/380 nm excitation length wave ratios 
in Wistar rat myotubes (n=3 independent experiments).  
 
5.5.8. Effect of GPR40 agonist (AZ921), MEK inhibitor (U0126) 
and 3DOPLWLF DFLG RQ &\WRNLQH 71)Į DQG ,/ P51$
expression 
There is now a strong appreciation that the secretory products of muscle, 
also referred to as myokines, are part of a muscle-to-fat signalling possibly 
modulating insulin sensitivity in skeletal muscle  (Eckardt et al. 2008). 
Treatment of human myotubes with 100nM AZ921 alone for 24hrs did not have 
DQ\ VLJQLILFDQW FKDQJHV LQ ,/ DQG 71)Į P51$ H[SUHVVLRQ 3! KRZHYHU
pretreatment with U0126 (30 min) before the addition of AZ921 had a 
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significant effect on IL6 mRNA expression only (Figure 5-24). However, 250µM 
Palmitic acid had a significant (P<0.05) effect on ERWK ,/ DQG 71)Į P51$
expression. Interestingly, the MEK inhibitor and GPR40 antagonist did not block 
WKHHIIHFWRI3DOPLWLFDFLGRQ,/DQG71)ĮP51$H[SUHVVLRQ,QIDFt, the MEK 
LQKLELWRUKDGDV\QHUJLVWLFHIIHFWRQ71)ĮP51$H[SUHVVLRQFigure 5-25.  
 
Figure 5-24: Quantitative analysis RT-3&5 RI 71)Į $ RU ,/ % P51$ H[SUHVVLon in human 
myotubes. 
Cells were treated with GPR40 agonist (100 nM AZ921) with or without 10 µM MEK inhibitor (U0126) 
for 24 hrs.  * denotes P<0.05. Data were normalized by TBP and RPLPO.  Values are mean±SEM 
Bonferroni's Multiple Comparison Test (n=3 independent experiments)  
 
Figure 5-25: Quantitative analysis RT-PCR of IL6 mRNA expression in human myotubes. 
(A) Cells were treated with 250 µM Palmitic acid with or without 30 nM GPR40 antagonist (AZ915) 
for 24 hrs. (B) Cells were treated with 250 µM Palmitic acid with or without 10 µM MEK inhibitor 
(U0126) for 24 hrs.  * denotes P<0.05  & *** denote P<0.001. Data were normalized by TBP and 
RPLPO. Values are mean±SEM Bonferroni's Multiple Comparison Test (n=3 independent 
experiments)   
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Figure 5-26: Quantitative analysis RT-3&5RI71)ĮP51$H[SUHVVLRQLQKXPDQP\RWXEHV 
(A) Cells were treated with 250 µM Palmitic acid with or without 30 nM GPR40 antagonist (AZ915) 
for 24 hrs. (B) Cells were treated with 250 µM Palmitic acid with or without 10 µM MEK inhibitor 
(U0126) for 24 hrs.  * denotes P<0.05  & *** denote P<0.001. Data were normalized by TBP and 
RPLPO. Values are mean±SEM Bonferroni's Multiple Comparison Test (n=3 independent 
experiments)   
 
5.5.9. Effect of GPR40 agonist (AZ921), antagonist (AZ915), 
MEK inhibitor (U0126), Oleic and Palmitic acids on PKD4 
mRNA expression 
Substrate competition between fatty acids and glucose occurs at the level 
of the pyruvate dehydrogenase complex which is regulated by pyruvate de- 
hydrogenase kinase (PDK), which plays an important role in the development of 
insulin resistance (Sugden 2003). Treatment of human and Wistar rat myotubes 
with 100nM AZ921, 250 µM Oleic acid and 30nM AZ915 for 24hrs did not have 
any significant (P>0.05) effect on PDK4 mRNA expression Figure 5-27. 
However, 250µM Palmitic acid and 10 µM U0126 caused a significant (P<0.01) 
change in PDK4 mRNA expression. Interestingly, the MEK inhibitor and the 
GPR40 antagonist did not block the effect of Palmitic acid but Oleic acid did 
block it.  
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Figure 5-27: Quantitative analysis RT-PCR of PDK4 mRNA expression in human myotubes. 
A) Cells were treated with 100 nM AZ921, 30nM AZ915, AZ921+AZ915 or 10µM MEK inhibitor 
(U0126)   for 24 hrs. B) Cells were treated with 250 µM Palmitic acid with or without or GPR40 
antagonist (AZ915 30nM) for 24 hrs. C) Cell were 24 hrs treated with 250 µM Palmitic acid, 250 µM 
Oleic  acid  or  Oleic (OL)+ Palmitic acids (PAL).  Cells were treated with 250 µM Palmitic acid with or 
without 10 µM MEK inhibitor (U0126) for 24 hrs. * denotes P<0.05 & ** denote P<0.01. Data were 
normalized by TBP and RPLPO.  Values are mean±SEM Bonferroni's Multiple Comparison Test (n=3 
independent experiments) 
 
5.5.10. Microarray result 
Previous findings in this chapter indicate that GPR40 is expressed and 
functional in rat and human skeletal muscle cultured myotubes. However the 
exact role of GPR40 in metabolism could not be clearly stated. As this is the 
first study carried out in skeletal muscle, the influence of GPR40 agonists and 
antagonists on global gene expression was investigated using Affymetrix 
microarray.  
Human myotubes were cultured in 25cm2 flasks and incubated with 
vehicle (0.01% DMSO), GPR40 agonist (AZ921 100nM), GPR40 antagonist 
(AZ836 5µM) or the agonist with antagonist for 24 hours. The antagonist was 
used 30 min prior to the addition of the agonist. The cells were cultured in fatty 
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acid free serum or horse serum (for the antagonist only) containing media 
before performing the treatments.    
5.5.10.1.  Initial characterisation of microarray gene expression 
data 
Principal component analysis (PCA) of global gene expression profiles 
revealed two distinct populations where the control, agonist and agonist with 
antagonist  form a group and the antagonist (horse and free fatty acid) form 
another group (Figure 5-28). Two ways hierarchal clustering based on 
conditions and entities showed similar result to the PCA analysis. Hierarchal 
clustering showed that control and agonist with antagonist are the closest 
groups Figure 5-29. The reproducibility of the data was assessed by the 
correlation coefficients of the normalized data. The correlation coefficient 
between the replicates in each treatment condition was 0.99 across all the 
samples.   
 
Figure 5-28: Principal component analysis (PCA) plot showing the distribution of subjects along 3 
eigenvectors.  
The plot showing two distinct  groups, the first group formed from  Vehicle (CON) 0 .001 DMSO, 
GPR40  agonist (AGO) 100nM AZ921, GPR40 antagonist 5µM AZ836 with the agonist (AGOANT)and 
the second group includes the antagonist groups (cells cultured in 5% fatty acid free medium 
(ANTFFA) or 6%horse (ANTH) serum medium). Samples were displayed in respect to the first 
components and coloured by the treatment parameter. (4-5 flasks from 1 subject) 
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Figure 5-29: Dendrogram showing the hierarchical cluster analysis of gene expression profile. 
The agonist, the agonist with the antagonist and the vehicle clustering in one group and the 
antagonist form another group. Each row corresponds to a single gene, and each column 
corresponds to a single condition. The branch lengths indicate the correlation with which genes or 
samples were joined, with longer branches indicating a lower correlation. Color represents different 
transcript expression levels.  
  
5.5.10.2. The effect of GPR40 agonists and antagonists on gene 
expression profiles  
Treatment of human myotubes with 100nM AZ921 for 24 hours did not 
appear to produce significant differences in gene expression. When applying a 
two fold cut off change (agonist vs vehicle), p<0.05 and the Benjamini- 
Hochberg multiple testing comparison, only 4 transcripts appeared to be 
significantly up regulated; MALAT1 (metastasis associated lung adenocarcinoma 
transcript 1),  CENPF (centromere protein F),  AHSA2 (activator of heat shock  
protein ATPase homolog 2) and NEAT (nuclear paraspeckle assembly transcript 
Applying 1.5 fold change cut off (agonist vs vehicle), 154 transcripts were found 
to be statistically significantly altered (appendix 6). These transcripts were then 
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uploaded into the Ingenuity pathway (IPA) software in order to identify 
metabolic processes and signalling pathways that may be influenced by the 
activation of GPR40. The IPA network function analysis revealed that most 
genes in this data set are associated with cell cycle and cellular assembly and 
organization network. However, there were no significant canonical pathways. 
As the z score was insignificant, no prediction states could be addressed in 
downstream and upstream regulators. Almost similar results were found when 
the gene differences between the effects of the agonist/antagonist in the human 
myotubes were compared to vehicle. The 64 transcripts with a fold change of 
1.5 showed no significant pathways or prediction states as the Z-score was 
insignificant. The PCA blot and the hierarchical clustering showed the similarities 
between the agonist, antagonist with agonist and vehicle.   
A confirmation of GPR40 agonist effect on the metabolic genes was done 
by using Taqman® Low-Density Custom Array using Micro Fluidic cards (ABI 
Applied Bio systems, UK) where a quantification of expression of 45 key 
metabolic genes in human skeletal muscle genes including; transcriptional 
activators, cells signalling proteins, substrate transporters, lipogenic enzymes, 
and proteins catalysing glucose and fat oxidation. As listed in Table 5-1 most 
genes had a fold change of <1.5 except PDK4 (pyruvate dehydrogenase kinase, 
isozyme 4) and PYGM (phosphorylase glycogen, muscle) which had a fold 
change of 1.6 and -1.5, respectively. It is worth mentioning that the RT-PCR 
showed no significant difference on PDK4 expression between the GPR40 
agonist and the vehicle Figure 5-27. 
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Table 5-1: Gene card analysis for the effect of the GPR40 agonist on the metabolic genes 
 
ID Fold Change Entrez Gene Name Location Type(s)
PDK4 1.615 pyruvate dehydrogenase kinase, isozyme 4 Cytoplasm kinase
MLXIPL 1.239 MLX interacting protein-like Nucleus transcription regulator
SURF1 1.155 surfeit 1 Cytoplasm enzyme
NR1H3 1.132 nuclear receptor subfamily 1, group H, member 3 Nucleus ligand-dependent nuclear 
receptor
IRS1 1.124 insulin receptor substrate 1 Cytoplasm enzyme
TALDO1 1.118 transaldolase 1 Cytoplasm enzyme
ACADL 1.092 acyl-CoA dehydrogenase, long chain Cytoplasm enzyme
HMBS 1.092 hydroxymethylbilane synthase Cytoplasm enzyme
PPP1CC 1.056 protein phosphatase 1, catalytic subunit, gamma isozyme Cytoplasm phosphatase
PIK3R1 1.044 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) Cytoplasm kinase
HK2 1.041 hexokinase 2 Cytoplasm kinase
DGAT1 1.014 diacylglycerol O-acyltransferase 1 Cytoplasm enzyme
NDUFS4 -1.015 NADH dehydrogenase (ubiquinone) Fe-S protein 4, 18kDa Cytoplasm enzyme
GYG1 -1.038 glycogenin 1 Cytoplasm enzyme
LDHB -1.044 lactate dehydrogenase B Cytoplasm enzyme
SCD -1.055 stearoyl-CoA desaturase (delta-9-desaturase) Cytoplasm enzyme
FOXO3 -1.067 forkhead box O3 Nucleus transcription regulator
DGKA -1.073 diacylglycerol kinase, alpha 80kDa Cytoplasm kinase
APOE -1.076 apolipoprotein E Extracellular Space transporter
SDHB -1.081 succinate dehydrogenase complex, subunit B, iron 
sulfur (Ip) Cytoplasm enzyme
SREBF1 -1.086 sterol regulatory element binding transcription factor 1 Nucleus transcription regulator
DGKD -1.098 diacylglycerol kinase, delta 130kDa Cytoplasm kinase
COX7A2 -1.099 cytochrome c oxidase subunit VIIa polypeptide 2 (liver) Cytoplasm enzyme
TKT -1.099 transketolase Cytoplasm enzyme
FOXO1 -1.108 forkhead box O1 Nucleus transcription regulator
NR1H2 -1.110 nuclear receptor subfamily 1, group H, member 2 Nucleus ligand-dependent nuclear 
receptor
PDK2 -1.112 pyruvate dehydrogenase kinase, isozyme 2 Cytoplasm kinase
IRS2 -1.121 insulin receptor substrate 2 Cytoplasm enzyme
PDP2 -1.139 pyruvate dehyrogenase phosphatase catalytic subunit 2 Cytoplasm phosphatase
ALDOA -1.141 aldolase A, fructose-bisphosphate Cytoplasm enzyme
G6PD -1.145 glucose-6-phosphate dehydrogenase Cytoplasm enzyme
ABCA1 -1.152 ATP-binding cassette, sub-family A (ABC1), member 1
Plasma 
Membrane transporter
CPT1B -1.156 carnitine palmitoyltransferase 1B (muscle) Cytoplasm enzyme
AKT2 -1.180 v-akt murine thymoma viral oncogene homolog 2 Cytoplasm kinase
SLC2A4 -1.183 solute carrier family 2 (facilitated glucose transporter), 
member 4
Plasma 
Membrane transporter
SLC27A1 -1.189 solute carrier family 27 (fatty acid transporter), 
member 1
Plasma 
Membrane transporter
PFKM -1.193 phosphofructokinase, muscle Cytoplasm kinase
PPM2C -1.209 pyruvate dehyrogenase phosphatase catalytic subunit 1 Cytoplasm phosphatase
ADFP -1.222 perilipin 2 Plasma Membrane other
ACACB -1.277 acetyl-CoA carboxylase beta Cytoplasm enzyme
ACLY -1.294 ATP citrate lyase Cytoplasm enzyme
CD36 -1.300 CD36 molecule (thrombospondin receptor) Plasma Membrane transmembrane receptor
FASN -1.301 fatty acid synthase Cytoplasm enzyme
PPARGC1A -1.381 peroxisome proliferator-activated receptor gamma, 
coactivator 1 alpha Nucleus transcription regulator
PKM2 -1.387 pyruvate kinase, muscle Cytoplasm kinase
PYGM -1.508 phosphorylase, glycogen, muscle Cytoplasm enzyme
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GPR40 Antagonist effects, Human myotubes were treated with GPR40 
antagonist AZ836 for 24 hours in Ham-F 10 media containing 5% free fatty acid 
serum or 6% horse serum to study global gene change in the presence and 
absence of fatty acids. There was no significant difference in the transcripts 
between the two conditions (FFA serum and Horse serum). Applying a 2 fold 
change (antagonist vs vehicle) with unpaired TTEST with correction (Benjamin- 
Hochberg) showed 178 regulated transcripts. The transcripts were then loaded 
into the IPA where all species, molecules and/or relationships were considered. 
IPA analysis showed that most genes are associated with development and cell 
death and survival in the downstream functions however the Z-score was 
insignificant. The upstream regulators and canonical pathways were also with 
insignificant z score or with bias.  
Further analysis of transcripts (2538) with a fold change of 1.5 and 
multiple correction test (FDR) were carried out. In the biological functions 
(Table 5-2), large numbers of genes were associated with cell cycle, cell death 
and survival, cell assembly and organization and development disorder. 
Prediction of activation with Z-VFRUHZHUHIRXQGLQFHOOVXUYival, proliferation 
of cells, organization of cytoplasm and cytoskeletal, cell growth, differentiation 
of cells and cell movement. Predictions of inhibition were associated with the 
following functions annotation: apoptosis, organismal death, congenital 
anomalies, developmental disorders and growth failure (Table 5-4). The number 
of genes associated with metabolism was low and their functions were not 
predictable. The function networks and the canonical pathways had insignificant 
Z score or with bias. Interesting findings were found when the upstream 
regulators with significant bias corrected Z- score were correlated with functions 
which also have significant Z score. The analysis was carried out as follows:  
1. The genes which are responsible for functions with significant Z 
scores were identified.   
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2. The upstream regulators with significant bias corrected Z score 
were identified (Table 5-3). 
3. Correlation of downstream genes for the upstream regulators with 
the significant functions (Table 5-4).   
4. Ranking of the genes with significant functions involved in the 
upstream. 
5. Further analysis of some upstream regulators from different types 
with high bias corrected Z scores was carried (Table 5-5).   
The upstream regulators ERBB2, PPARD, MAPK8 (JUNC1) and IL3 were 
further analysed. In all these regulators the highest number of downstream 
transcripts was associated with cell proliferation (70%, 57%, 82% and 80%). 
Other significant functions such as organization of cytoskeletal, cell survival, cell 
movement and cell differentiation also have a considerable numbers of 
downstream transcripts (Table 5-4). A closer look for genes regulated by ERBB2 
revealed that most genes which have a role of cell proliferation and survival 
were upregulated such as (BCL2, HES1, HES2, LTBP3, NOTCH1, TNC,  ERBB3, 
ESR1, ESR2, ETV6 and MAPKBP3) while genes arrest cell cycle and inhibit 
proliferation were down regulated (RECK, PDCD4, ITGA2, CUL3, CDKNIB, 
CAPZA2, DPT & JAG1) (Table 5-5). The transcription factor PPARD (peroxisome 
proliferator-activated receptor delta) was predicted to be activated as most 
downstream transcripts in the data set which are regulated by PPARD were 
activated. Most of PPARD downstream transcripts were associated with fatty 
acid metabolism however BCL2 (antiapoptotic factor) were among them. BCL2 
and CDKNIB (cyclin-dependent kinase inhibitor) were downstream transcripts of 
MAPK8 (JUNC1). The up regulated cytokines IL3 is a potent growth promoting 
cytokines which has a role in cell proliferation and cell death and survival. The 
anti-apoptotic factors BCL2, ATF (activation transcription factor) as well as 
CDKNIB were among downstream transcripts of IL3 (Table 5-5). 
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Table 5-2: The biological functions ascribed to genes that were altered by treatment with GPR40 
antagonist. 
 
Category Functions Annotation
Activation z-
score
p-Value Predicted Activation State
# 
Molecules
1 Cellular Movement cell movement 4.685 1.40E-07 Increased 359
2 Cell Death and Survival cell survival 4.64 1.02E-07 Increased 250
3 Gene Expression transactivation 4.289 4.16E-05 Increased 119
4 Cellular Development differentiation of cells 4.149 3.15E-05 Increased 339
5 Cellular Growth and Proliferation proliferation of cells 3.718 1.34E-11 Increased 630
6 Inflammatory Response phagocytosis 3.599 3.70E-03 Increased 50
7 Cellular Function 
and Maintenance
organization of 
cytoplasm 3.22 1.03E-09 Increased 263
8 Cellular Function 
and Maintenance
organization of 
cytoskeleton 3.16 9.42E-09 Increased 240
9 Post-Translational Modification
phosphorylation of 
protein 3.091 2.00E-03 Increased 129
10 Immune Cell Trafficking
adhesion of 
lymphocytes 3.084 1.21E-03 Increased 25
11 Cellular Movement
cell movement of 
tumor cell lines
2.921 6.16E-03 Increased 121
12 Cell Morphology formation of cellular protrusions 2.742 2.85E-07 Increased 151
13 Cellular Function 
and Maintenance microtubule dynamics 2.729 3.70E-09 Increased 211
14 Cellular Movement invasion of cells 2.67 3.86E-03 Increased 124
15
Cardiovascular 
System 
Development and 
Function
development of 
vascular system 2.665 5.71E-09 Increased 208
16 Behavior behavior 2.577 3.67E-06 Increased 179
17
Hematological 
System 
Development and 
Function
differentiation of blood 
cells 2.49 2.66E-03 Increased 133
18 Cellular Function 
and Maintenance endocytosis 2.421 2.68E-05 Increased 57
19 Cellular Development
differentiation of 
endothelial cells 2.326 3.84E-03 Increased 24
20
Connective Tissue 
Development and 
Function
proliferation of 
fibroblast cell lines 2.288 3.51E-04 Increased 81
21 Cellular Function 
and Maintenance cellular homeostasis 2.287 5.59E-04 Increased 237
22 Small Molecule Biochemistry
quantity of cyclic 
nucleotides 2.28 5.75E-03 Increased 37
23 Tissue Development skin development 2.198 2.03E-03 Increased 49
24 Cell Death and Survival
cell viability of tumor 
cell lines 2.161 2.37E-05 Increased 134
25 Gene Expression expression of RNA 2.074 9.31E-08 Increased 384
26
Cell-To-Cell 
Signaling and 
Interaction
interaction of 
lymphocytes 2.034 2.46E-03 Increased 22
27 Cellular Growth and Proliferation
proliferation of 
epithelial cells 2.001 4.31E-03 Increased 70
28 Organismal Injury 
and Abnormalities injury of lung -2.067 5.04E-03 Decreased 23
29 Cardiovascular Disease Cardiac Fibrosis -2.139 8.00E-04 Decreased 26
30 Cell Death and Survival
apoptosis of 
hematopoietic cell 
lines
-2.622 1.51E-03 Decreased 42
31 Cardiovascular Disease Hypertension -2.784 1.85E-03 Decreased 59
32 Cardiovascular Disease Heart Disease -2.973 4.84E-04 Decreased 167
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Table 5-3: The upstream regulators  
 
Symbol z scor Entrez Gene Name Type(s)
ERBB2 4.168 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 kinase
BDNF 3.505 brain-derived neurotrophic factor growth factor
IL3 3.489 interleukin 3 (colony-stimulating factor, multiple) cytokine
Ins1 3.372 insulin I other
PPARD 3.326 peroxisome proliferator-activated receptor delta ligand-dependent nuclear receptor
CEBPB 3.256 CCAAT/enhancer binding protein (C/EBP), beta transcription regulator
MAPK8 3.124 mitogen-activated protein kinase 8 kinase
TCF3 3.067 transcription factor 3 transcription regulator
STAT5B 2.809 signal transducer and activator of transcription 5B transcription regulator
RUNX2 2.7 runt-related transcription factor 2 transcription regulator
FGF7 2.671 fibroblast growth factor 7 growth factor
MAPK1 2.582 mitogen-activated protein kinase 1 kinase
AKT1 2.577 v-akt murine thymoma viral oncogene homolog 1 kinase
STAT5A 2.561 signal transducer and activator of transcription 5A transcription regulator
IL12A 2.548 interleukin 12A (natural killer cell stimulatory factor 1) cytokine
NR1H3 2.42 nuclear receptor subfamily 1, group H, member 3 ligand-dependent nuclear receptor
ADORA2A 2.228 adenosine A2a receptor G-protein coupled receptor
HMOX1 2.142 heme oxygenase (decycling) 1 enzyme
FABP4 -2 fatty acid binding protein 4, adipocyte transporter
KIAA1524 -2.121 KIAA1524 other
ACACB -2.213 acetyl-CoA carboxylase beta enzyme
IFNB1 -2.227 interferon, beta 1, fibroblast cytokine
IRF4 -2.383 interferon regulatory factor 4 transcription regulator
FGF19 -2.401 fibroblast growth factor 19 growth factor
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Table 5-4: The biological function releated to the upstream regulators 
 
 
Cellular Growth 
and 
Proliferation
Cellular 
Function and 
Maintenance
Cell Death and 
Survival
Cellular 
Movement
Cellular 
Development
proliferation of 
cells
organization of 
cytoskeleton
cell survival cell movement
differentiation 
of cells
48 16 28 37 35
70% 23% 41% 54% 51%
13 6 6 8 9
57% 26% 26% 35% 39%
14 6 10 14 8
82% 35% 59% 82% 47%
36 15 17 22 25
80% 33% 38% 49% 56%
IL3 
(45)
26439
Upstream Regulator
(# downstream transcripts)
Rank (out of 
42413)
PPARD 
(23)
ERBB2 
(69)
MAPK8
(17)
3793
11117
1162
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Table 5-5: list of downstream transcripts of the activated upstream regulators ERBB2, PPARD, 
MAPK8 and Il3 
  
Sympol
Rank (out of 
42413)
fold 
change
Entrez Gene Name
ABHD5 2541 -1.700 abhydrolase domain containing 5
ACAA2 14630 2.279 acetyl-CoA acyltransferase 2
ADAM8 32890 1.944 ADAM metallopeptidase domain 8
AHNAK 3176 1.780 AHNAK nucleoprotein
ANGPTL4 39127 1.885 angiopoietin-like 4
BACE1 18802 1.643 beta-site APP-cleaving enzyme 1
BARD1 6884 -1.521 BRCA1 associated RING domain 1
BCL2 21143 1.767 B-cell CLL/lymphoma 2
BMP7 30496 1.545 bone morphogenetic protein 7
CAPZA2 1626 -1.516 capping protein (actin filament) muscle Z-line, alpha 2
CDC42SE1 9613 1.578 CDC42 small effector 1
CDKN1B 74 -1.751 cyclin-dependent kinase inhibitor 1B (p27, Kip1)
CDKN2B 934 1.599 cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)
COL1A1 12590 1.965 collagen, type I, alpha 1
CSF2 6181 1.520 colony stimulating factor 2 (granulocyte-macrophage)
CUL3 385 -2.206 cullin 3
CYB561 862 1.569 cytochrome b561
DPT 40 -2.054 dermatopontin
DZIP3 2688 -1.632 DAZ interacting protein 3, zinc finger
EDN1 259 -1.708 endothelin 1
ERBB3 1604 1.539 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)
ESR1 9062 1.729 estrogen receptor 1
ESR2 19888 1.724 estrogen receptor 2 (ER beta)
ETV6 546 1.691 ets variant 6
FASN 13229 1.575 fatty acid synthase
FOLR1 39796 1.730 folate receptor 1 (adult)
GNAI1 971 -1.727
guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 
1
GPC1 31733 1.566 glypican 1
HBB 31701 1.546 hemoglobin, beta
HES1 28725 2.367 hairy and enhancer of split 1, (Drosophila)
HES2 31636 1.657 hairy and enhancer of split 2 (Drosophila)
HMGB2 12249 1.603 high mobility group box 2
IGF2R 8473 1.525 insulin-like growth factor 2 receptor
IGFBP5 2098 1.604 insulin-like growth factor binding protein 5
ITGA2 2297 -1.587 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)
ITGB1 4594 1.540
integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes 
MDF2, MSK12)
JAG1 50 -1.519 jagged 1
KIFC3 10791 1.694 kinesin family member C3
KLK3 22064 1.512 kallikrein-related peptidase 3
LTBP3 3266 1.759 latent transforming growth factor beta binding protein 3
MAP1B 38828 1.939 microtubule-associated protein 1B
MAPK8IP3 17850 1.546 mitogen-activated protein kinase 8 interacting protein 3
MARCKS 8273 1.622 myristoylated alanine-rich protein kinase C substrate
MMP11 23175 1.577 matrix metallopeptidase 11 (stromelysin 3)
MMP13 28630 1.554 matrix metallopeptidase 13 (collagenase 3)
MYBL2 40936 1.619 v-myb myeloblastosis viral oncogene homolog (avian)-like 2
ERBB2
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Table 5-5: (Continued) 
  
 
Sympol
Rank (out of 
42413)
fold 
change
Entrez Gene Name
MYCN 8252 1.658 v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian)
NDUFV1 19232 1.632 NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kDa
NEDD9 58 -1.599 neural precursor cell expressed, developmentally down-regulated 9
NFKB2 26777 1.577 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)
NOTCH1 6928 1.553 notch 1
NRBP1 27326 1.553 nuclear receptor binding protein 1
PDCD4 413 -1.538 programmed cell death 4 (neoplastic transformation inhibitor)
PDLIM4 4760 1.717 PDZ and LIM domain 4
PHLDB1 20337 1.501 pleckstrin homology-like domain, family B, member 1
PTPRB 532 1.551 protein tyrosine phosphatase, receptor type, B
RAD51AP1 4159 -1.585 RAD51 associated protein 1
RECK 398 -1.504 reversion-inducing-cysteine-rich protein with kazal motifs
SMAD2 805 -1.506 SMAD family member 2
SOX4 18098 1.766 SRY (sex determining region Y)-box 4
SPDEF 32544 1.838 SAM pointed domain containing ets transcription factor
SQLE 4228 1.841 squalene epoxidase
TAPBP 5601 1.531 TAP binding protein (tapasin)
TGM1 36781 1.504
transglutaminase 1 (K polypeptide epidermal type I, protein-glutamine-gamma-
glutamyltransferase)
TNC 8987 1.619 tenascin C
TSC22D1 6000 -1.515 TSC22 domain family, member 1
VWF 33081 1.550 von Willebrand factor
ZEB1 4497 -1.512 zinc finger E-box binding homeobox 1
ZFP36L2 12914 1.568 ZFP36 ring finger protein-like 2
ACSL6 14686 1.522 acyl-CoA synthetase long-chain family member 6
ADORA1 21524 1.751 adenosine A1 receptor
ANGPTL4 39127 1.885 angiopoietin-like 4
APOE 15270 1.588 apolipoprotein E
BCL2 21143 1.767 B-cell CLL/lymphoma 2
C10orf35 40329 1.536 chromosome 10 open reading frame 35
DNASE1L2 39735 1.596 deoxyribonuclease I-like 2
FAM131C 35062 1.524 family with sequence similarity 131, member C
FASN 13229 1.575 fatty acid synthase
LGALS4 34618 1.588 lectin, galactoside-binding, soluble, 4
LIPE 14721 1.503 lipase, hormone-sensitive
MDFI 38204 1.577 MyoD family inhibitor
MERTK 15837 1.539 c-mer proto-oncogene tyrosine kinase
MFGE8 27161 1.552 milk fat globule-EGF factor 8 protein
PDE4C 25508 1.749 phosphodiesterase 4C, cAMP-specific
PKLR 37387 1.729 pyruvate kinase, liver and RBC
PNPLA2 22659 1.897 patatin-like phospholipase domain containing 2
PPARD 3793 1.650 peroxisome proliferator-activated receptor delta
SCD 2975 1.680 stearoyl-CoA desaturase (delta-9-desaturase)
SFI1 3393 1.534 Sfi1 homolog, spindle assembly associated (yeast)
SIRT5 9246 1.592 sirtuin 5
PPARD
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Table 5-5: (Continued) 
 
Sympol
Rank (out of 
42413)
fold 
change
Entrez Gene Name
ABCA1 16186 1.531 ATP-binding cassette, sub-family A (ABC1), member 1
ADARB1 4234 1.690 adenosine deaminase, RNA-specific, B1
APOE 15270 1.588 apolipoprotein E
B4GALT1 8289 1.634 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1
BCL2 21143 1.767 B-cell CLL/lymphoma 2
CDKN1B 74 -1.751 cyclin-dependent kinase inhibitor 1B (p27, Kip1)
COL1A1 12590 1.965 collagen, type I, alpha 1
FASLG 27081 1.746 Fas ligand (TNF superfamily, member 6)
FUS 25083 1.663 fused in sarcoma
HDAC6 21612 1.643 histone deacetylase 6
HMOX1 41664 1.503 heme oxygenase (decycling) 1
LHB 41626 1.550 luteinizing hormone beta polypeptide
MMP13 28630 1.554 matrix metallopeptidase 13 (collagenase 3)
MTHFR 18698 1.687 methylenetetrahydrofolate reductase (NAD(P)H)
NPPB 36493 1.628 natriuretic peptide B
PPARD 3793 1.650 peroxisome proliferator-activated receptor delta
ATF5 14193 2.008 activating transcription factor 5
BCL2 21143 1.767 B-cell CLL/lymphoma 2
BRD4 9200 1.695 bromodomain containing 4
CALR 7641 1.647 calreticulin
CD86 18463 1.502 CD86 molecule
CDKN1B 74 -1.751 cyclin-dependent kinase inhibitor 1B (p27, Kip1)
CITED2 20 -1.698 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2
CREM 545 -1.860 cAMP responsive element modulator
CSF2 6181 1.520 colony stimulating factor 2 (granulocyte-macrophage)
CTLA4 21903 1.658 cytotoxic T-lymphocyte-associated protein 4
DOK2 41089 1.554 docking protein 2, 56kDa
EIF1AY 238 -1.511 eukaryotic translation initiation factor 1A, Y-linked
ELAVL3 21278 1.792 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 3 (Hu antigen C)
ELK4 12144 1.520 ELK4, ETS-domain protein (SRF accessory protein 1)
FASN 13229 1.575 fatty acid synthase
FUS 25083 1.663 fused in sarcoma
GADD45B 8746 1.540 growth arrest and DNA-damage-inducible, beta
GNA13 4528 -1.552 guanine nucleotide binding protein (G protein), alpha 13
GPRIN1 35608 1.691 G protein regulated inducer of neurite outgrowth 1
HNF1A 25673 1.551 HNF1 homeobox A
HNF4A 17649 1.657 hepatocyte nuclear factor 4, alpha
HNRNPA2B1 28705 1.658 heterogeneous nuclear ribonucleoprotein A2/B1
HSP90B1 8246 1.525 heat shock protein 90kDa beta (Grp94), member 1
IL3RA 26750 1.561 interleukin 3 receptor, alpha (low affinity)
ITGB7 38078 1.691 integrin, beta 7
KLF9 2909 -1.516 Kruppel-like factor 9
MID1 857 -1.766 midline 1 (Opitz/BBB syndrome)
NEDD9 58 -1.599 neural precursor cell expressed, developmentally down-regulated 9
NOTCH1 6928 1.553 notch 1
OSM 14303 1.551 oncostatin M
PAPPA2 903 1.709 pappalysin 2
PFKL 31867 1.517 phosphofructokinase, liver
PIWIL1 38444 1.524 piwi-like RNA-mediated gene silencing 1
PROX1 27589 1.795 prospero homeobox 1
RB1 688 -1.640 retinoblastoma 1
RPL7 10007 1.845 ribosomal protein L7
RPS12 19618 1.767 ribosomal protein S12
SH3BP1 27923 1.531 SH3-domain binding protein 1
SMAD5 4356 1.642 SMAD family member 5
SOCS3 11892 1.621 suppressor of cytokine signaling 3
SOX4 18098 1.766 SRY (sex determining region Y)-box 4
SPI1 34675 1.720 spleen focus forming virus (SFFV) proviral integration oncogene spi1
TAX1BP1 446 -1.860 Tax1 (human T-cell leukemia virus type I) binding protein 1
VAV2 12604 1.839 vav 2 guanine nucleotide exchange factor
WNK1 25979 1.674 WNK lysine deficient protein kinase 1
MAPK8
IL3
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5.6. Discussion 
There is a gathering body of evidence linking elevated FFA and the 
development of insulin resistance. The pathology of insulin resistance is complex 
and it must be multifactorial.  The possibility that the activation or the inhibition 
of the GPR40 receptor may play a part in the role of FFAs in insulin resistance 
has sparked considerable interest in the experimentation on this receptor, from 
basic research to potential drug discovery efforts.  The roles of GPR40 in the 
pancreas have been extensively studied (Wu et al. 2010; Tsujihata et al. 
2011;Doshi et al. 2009) however, the relationship between the well-documented 
detrimental chronic effects of fatty acids on pancreatic islets and GPR40 is under 
debate. Steneberg et al. (2005) suggests that GPR40 mediates both the acute 
and chronic effects of FFAs in pancreatic islet and that antagonist rather than 
agonist might be useful in diabetes treatment while Tan et al. (2008) and 
Costanzi et al. (2008) suggest that an agonist could be useful in treatment of 
diabetes. Hence, GPR40 antagonists or agonists may represent a useful 
therapeutic strategy for the prevention and treatment of obesity-associated type 
2 diabetes. Given the number of fatty acids that are agonists for GPR40 it is 
conceivable that the physiologically relevant FFAs for GPR40 may vary in a tissue 
dependent fashion. As skeletal muscle plays a core role in glucose disposal and 
insulin resistance, the goal of this study was to characterise the mechanisms of 
action and the functionality of GPR40 receptor in human and rat skeletal muscle 
at the molecular level. 
5.6.1.  Characterization of GPR40 in human and rat skeletal 
muscle tissue and cultured cells  
The expression of GPR40 is well documented in pancreas however its 
expression in other tissues is controversial. In this study, microarray and RT-PCR 
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data revealed the expression of GPR40 in human skeletal muscle tissue and 
primary cultured cells. This is in agreement with Kotarsky et al. (2003) and 
Briscoe et al. (2003) who reported the expression of GPR40 in human skeletal 
muscle by using Northern blot and RT-PCR, respectively. The RT-PCR data 
showed a higher level of GPR40 mRNA expression in myoblasts in comparison to 
myotubes and tissue. Human brain and spleen tissues also expressed GPR40 in 
agreement with Swaminath (2008), Brownlie et al. (2008) and Hirasawa et al. 
(2008).  
The expression of GPR40 is not only tissue specific but may also be species 
specific. Rat RT-PCR data showed the expression of GPR40 mRNA in Wistar rat 
fast and slow muscle fibres without any significant difference between the two 
types. In contrast, Steneberg et al. (2005) and Itoh et al. (2003) could not find 
GPR40 mRNA expression in either mouse or rat skeletal muscle tissue. GPR40 
expression was also found in rat pancreas, spleen, adipose, heart and liver but 
not in rat brain in agreement with  Itoh et al. (2003) and Brownlie et al. (2008). 
Decrease in GPR40 expression in high fat diet fed mice (11 weeks) was observed 
by Kebede et al. (2012)  while Briscoe et al. (2003) detected a significant 
increase in expression of GPR40 mRNA in whole pancreas of ob/ob mice 
compared with control lean mice. In the current study, expression levels of 
GPR40 were similar at 12 weeks for Zucker fat Rat (ZFR) and Zucker Lean Rat 
(ZLR), however at 20 weeks ZFR had a significantly (p<0.01) higher expression 
of GPR40 than ZLR. Interstingly, ZFR and ZLR slow (SOL) and mixed (VL) 
muscle fibres but not the fast (GR and EDL) had higher expression of GPR40 
compared to Wistar rats muscle fibres. This may indicate strain specific 
differences and a relationship between GPR40 expression and insulin sensitivity 
as slow fibres are more sensitive to insulin.  Cultured myotubes from ZFR, ZLR 
and Wistar rats had no significant difference in GPR40 expression. Insulin 
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resistance has previously been shown to disappear in cultured myotubes from 
obese and diabetic patients (Sell et al. 2008; Pender et al. 2005; Brozinick et al. 
2003) indicating that removal from the obese environment restores normal 
insulin signalling to cultured cells.  Hence, the cells were cultured in high 
(25mM) glucose for 6 and 24 hours. Interestingly, cells cultured in 25mM 
glucose had a significantly higher level of GPR40 expression. Kebede et al. 
(2012) also observed a higher GPR40 mRNA expression in human and rat 
pancreatic islets cultured in high glucose and they concluded that the main effect 
of glucose on GPR40 expression does not lie at the level of mRNA stability but, 
rather, at the transcriptional level. Moreover, the addition GPR40 ligand for 6 
hours, led to a significant down-regulation of cell surface expressed GPR40, 
presumably via receptor-specific internalization (Kaplamadzhiev et al. 2010; Hu 
et al. 2009). Expression of the GPR40 has also been shown to be reduced under 
glucolipotoxic conditions in rats (Fontés et al. 2010) and in islets from T2D 
patients (Del Guerra et al. 2010). Therefore, further investigation is needed to 
determine the mechanisms involved in the effects of high glucose as well as 
GPR40 ligands on GPR40 mRNA expression in skeletal muscle. 
5.6.2. Effector mechanisms 
A gathering body of evidence suggests that the GPR40 receptor couples to 
tKH*ĮTVXEXQLWRI*SURWHLQ (Shapiro et al. 2005; Tan et al. 2008). MAPK 
activation can occur downstream of signaling pathways initiated by receptors 
coupled to either Gi  or Gq (Itoh et al. 2003; Kotarsky et al. 2003). Studying the 
signalling mechanisms downstream of GPR40, we found that PTX (Gi inhibitor) 
significantly decreased MAPK phosphorylation induced by GW9508 and oleic acid 
suggesting that GPR40 is a Gi coupled receptor in skeletal muscle.  In support of 
this finding are the studies conducted by Fujita et al. (2011), Hidalgo et al. 
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(2011) and Yonezawa et al. (2008) who found that activation of GPR40 was PTX 
sensitive in skin, PTX decreased calcium release  in  bovine neutrophils and 
decreased cAMP production in bovine mammary epithelial cell, respectively. In 
this study PTX only partially decreased the ERK1/2 phosphorylation induced by 
AZ921 suggesting that GPR40 may not only be Gi coupled in skeletal muscle.  
Itoh et al. (2003) found that GPR40 activation in CHO cells transfected with 
human GPR40 decreased cAMP production with no effect of PTX, a finding which 
was not detected in CHO cells transfected with mouse GPR40 suggesting that 
human GPR40 couples mainly with Gq and partially with Gi However, mouse 
GPR40 couples with Gq only in CHO cells indicating species difference in the 
coupling of GPR40 with G proteins. Furthermore, research by 2012 Nobel 
Laureate in Chemistry Robert J. Lefkowitz and his colleagues has clearly 
demonstrated that 7TMRs can couple to multiple heterotrimeric G proteins as 
well as to G protein-independent and/or dependent pathways to promote the 
activation of numerous signaling cascades in a ligand and context dependent 
manner (Mancini & Poitout 2013).  
Stimulation of calcium release via receptor coupling to Gq with subsequent 
activation of phospholipase C and release of IP3 is frequently use as a functional 
read out. However, stimulation of calcium release via coupling to Gi in an IP3-
independent manner has been reported by Dorn et al,  (1997). In this study 1µM 
GW9508 and 3 µM AZ921 were used to evaluate the role of GPR40 in calcium 
release in Wistar rat myotubes and myoblasts cultured in 6mM or 25mM glucose. 
Neither GW9508 nor AZ921 had any effect on intracellular calcium release. As a 
reduction of expression in cultured cells of genes involved in calcium signalling 
was detected by our microarray data (chapter 3) we used 10 µM ATP as a 
positive control. ATP produced a rapid response even though microarray data 
showed a low expression of the ryanodine receptors in cultured myotube and 
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myoblast compare to skeletal muscle tissue. The increase in calcium release 
upon G35 DFWLYDWLRQ LQ ǃ FHOOV LV ZHOO GRFXPHQWHG 7KH HOHYDWLRQ RI
LQWUDFHOOXODUFDOFLXPLQǃFHOOVRFFXUVQRWRQO\WKURXJKD3/&SDWKZD\EXWDOVR
through L-W\SHFDOFLXPFKDQQHOVDQGǃFHOOVHFUHWDJRJXHV which have little or no 
effect in the presence of low concentrations of glucose (Fujiwara et al. 2005; 
Yonezawa et al. 2004; Yonezawa et al. 2008). Induction of calcium release from 
other cell types  has also been reported,  e.g. oleic acid (500µM) and GW9508 
(50µM)  induced calcium release in bovine neutrophil and HEK-GPR40 cells 
(Hidalgo et al. 2011). In this study GW9508 was used as the potency of GW9508 
(pEC50 7.32±0.03)  was greater than that observed for the long chain fatty acid 
linoleic acid (pEC50 5.65±0.06) (Briscoe et al. 2006). The discrepancy between 
our results and  certain previous reports might be explained by the complexity of 
the role of the FFAs on calcium release in skeletal muscle (Gamberucci et al. 
2003), the dependence on high glucose levels in other tissue types (Berchtold et 
al. 2000), the very high concentrations of GPR40 agonists used by some 
researchers (Hidalgo et al. 2011) and/or the type of cell used.  Moreover, 
LQFUHDVHGFDOFLXPUHOHDVHE\ROHLFDQGOLQROHLFDFLGVLQSULPDU\PRXVHǃFHOOVDQG
INS1 cells was reported by (Schnell et al. 2007) however Briscoe et al. (2006) 
were able to observe  increases in calcium release in GPR40-expressing HEK-293 
cells but not in isolated rat or mouse islets following incubation with GW9508. 
Collectively, this indicates that physiological differences between the cell lines 
and primary cells could be contributory factors.  
5.6.3. Functionality of skeletal muscle GPR40  
The functionality of GPR40 was investigated by assessing the direct effect 
of the endogenous GPR40 agonists (oleic and palmitic acids), synthetic agonists 
(GW9508 and AZ921) and synthetic antagonists (AZ915, AZ836 and AZ468) on 
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the activation of key proteins involved in insulin signalling cascades in human 
and rat (Wistar and Zucker) myotubes.  The main findings from these 
experiments showed that time course treatment with 10nM GW9508 and 250µM 
oleic but not palmitic acid induced ERK1/2 phosphorylation in human, Wistar rat, 
ZLR and ZFR myotubes. Time course treatment with 100nM AZ921 also induced 
ERK1/2 phosphorylation in both human and rat myotubes. The MEK inhibitor (10 
µM U0126) abolished the effects of all agonists while the GPR40 antagonist 
(AZ836 and AZ468) decreased the induction produced by AZ921 only. This may 
indicate that the agonists work through different sites. Even though this study is 
the first study to investigate the role of GPR40 in skeletal muscle, the results are 
in line with previous reports in other cell types. Zhang et al. (2007) indicated 
WKDWROHDWHEXWQRWSDOPLWDWHFRXOGDFWLYDWH(5.YLD*35 LQPRXVHǃ-cell 
line NIT-1. Itoh et al. (2003) found that oleic acid increased ERK1/2 
phosphorylation in Chinese hamster ovary (CHO) transfected with human 
GPR40. The effect of the AZ antagonists on AZ921 suggests that the specificity 
of the Astra Zeneca compounds is limited to activation by certain ligands only. 
This is in general agreement with previous studies, Briscoe et al. (2006) 
reported  that the GPR40 antagonist GW1100 prevented the effects of GW9508 
but not linoleic acid on GPR40. Hu et al. (2009) reported that the antagonist 
DC26126 decreased ERK phosphorylation induced by oleic and linolelic acid in 
GPR40 expressing CHO cells. The effect of GPR40 agonists on MAPK38 was 
different to those observed with ERK as GW9508 only induced MAPK38 
phosphorylation in agreement with Zhang et al. (2007) and Yonezawa et al. 
(2008)  who reported that oleate had no effect on phosphorylation of Jun and 
MAPK38. This apparent discrepancy between effects of different FFAs is most 
likely attributable to activation of distinct allosteric sites on the receptor by 
different molecules. Interestingly, Lin et al. (2012) described three novel GPR40 
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allosteric agonists that bind to separate sites and display complex binding and 
functional cooperativity with one another and with the endogenous GPR40 
ligands docosahexaenoic acid and linoleic acid. Positive allosteric modulation of 
GPR40 activity presents an attractive therapeutic avenue that would offer 
additional advantages over orthosteric GPR40 agonists (Mancini & Poitout 2013).  
One of the most important downstream targets of insulin action is Akt, a 
serine/threonine kinase which plays a major role in insulin signalling pathway. In 
this study the effect of GPR40 agonists on the insulin stimulation of AKT 
phosphorylation in human and Wistar rat myotubes was inconsistent; GW9508 
had no effect, oleic acid increased, and AZ921 decreased the effect of insulin 
stimulation upon AKT phosphorylation and the GPR40 antagonists abolished the 
effect of AZ921 only. Furthermore, the GPR40 agonists had no effect on insulin 
VWLPXODWLRQ RI*6.ǃSKRVSKRU\ODWLRQZKLOH WKH*35 DQWDJRQLVW VLJQLILFDQWO\
increased it. In support of our results, an increase in Akt phosphorylation levels 
in liver of obese Zucker rats treated with the GPR40 antagonist DC260126 was 
reported by Zhang et al. (2010) and increased Akt phosphorylation by oleate in 
bovine mammary epithelial cells (bMEC) was observed by Yonezawa et al. 
(2008). In contrast, Briscoe et al. (2006) did not observe any effect  of oleate on 
Akt phosphorylation. Collectively this observation indicates that the GPR40 
antagonist not the agonist might play a role in insulin signalling. In fact, the use 
of GPR40 antagonist rather than agonist in treatment of diabetes was suggested 
by Steneberg et al. (2005), Zhang et al. (2010), Brownlie et al. (2008) and 
(Duttaroy et al.2008.). In contrast, Nagasumi et al. (2007), Latour et al. (2007) 
and Tsujihata et al. (2011) suggested the use of GPR40 agonists in treatment of 
diabetes. GPR40 agonists are insulinotropic agents because they stimulate 
LQVXOLQ VHFUHWLRQDQGFRXQWHU WKHDGYHUVHHIIHFWVRQǃ-cell survival (Wagner et 
al. 2013). In addition, the GPR40 agonist TAK-875 significantly augmented 
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plasma insulin levels and reduced fasting hyperglycaemia in male Zucker 
diabetic fatty rats without any risk of hypoglycaemia (Tsujihata et al. 2011). In 
fact, in May 2013, the Takeda Pharmaceutical Company Limited ("Takeda") 
announced the results of a Phase III clinical trial 24 weeks treatment with 
fasiglifam (TAK-875) which showed a statistically significant and clinically 
relevant reduction in HbA1c levels in type 2 diabetes patients. Interestingly, 
Nagasumi et al. (2013) observed that the lack of GPR40 does not exacerbate 
glucose intolerance and insulin resistance induced by high-fat diet. The role of 
the GPR40 receptor in insulin signalling effects upon glucose metabolism in 
skeletal muscle cell culture cannot be accurately studied as GLUT4 translocation 
and glucose uptake experiments could not be performed on our cell model. As 
previously mentioned in Chapters 3 and 4, cultured cells have very low GLUT4 
and high GLUT1. Thus, other possible roles through which  FFA induce insulin 
resistance were studied. 
5.6.4. GPR40 activation and Cytokines  
Obesity induced inflammation which is characterized by infiltration of 
macrophages and the secretion of inflammatory cytokines in metabolically active 
tissues is critical for the development of insulin resistance. In this study, a 
GPR40 agonist (100nM AZ921 for 24 hours) had no effect on TNF-Į DQG ,/
mRNA expression in cultured myotubes, however, 250µM palmitic acid caused a 
significant (P<0.05) increase in both IL-DQG71)ĮP51$H[SUHVVLRQ7KHHIIHFW
of palmitic acid was not altered by a MEK inhibitor (U0126) or a GPR40 
antagonist in either human or Wistar rat myotubes. This indicates that GPR40 
recHSWRUDFWLYDWLRQGRHVQRWDIIHFW VNHOHWDOPXVFOHH[SUHVVLRQRI71)ĮDQG ,/
and that the effects of palmitic acid are also unlikely to be mediated by GPR40.    
Indeed, Wu et al. (2010) have previously reported that the palmitate mediated 
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increase in IL-6  does not occur as a result of GPR40 activation. In addition, 
Fujita et al. (2011) found that stimulation of GPR40 by GW9508 actually 
attenuates the induction of inflammatory cytokines and chemokines in 
keratinocytes and suppresses allergic inflammation in the skin. The result of this 
study and some previous reports indicate that GPR40 has no role in the 
elevation of cytokine production observed in obesity where circulating FFA levels 
are elevated.  
5.6.5. GPR40 activation and PDK4  
Pyruvate dehydrogenase kinases (PDK) phosphorylate and inactivate 
pyruvate dehydrogenase complex (PDH) which catalyzes the conversion of 
pyruvate to acetyl CoA. PDK4 expression can be induced by starvation, high-fat 
diet and diabetes (Wu et al. 1999). Regulation of the activity of the pyruvate 
dehydrogenase complex in skeletal muscle plays an important role in fuel 
selection and glucose homeostasis. Insulin resistance is associated with 
increased skeletal muscle PDK expression (Kim et al. 2006). In this study 
treatment of human and Wistar rat myotubes with AZ921, Oleic acid and  AZ915 
for 24hrs did not have any significant effect upon PDK4 mRNA expression. 
However, Palmitic acid and U0126 caused a significant (P<0.01) change in PDK4 
mRNA expression. Grassian et al. (2011) and Johnson & Denton (2003) reported 
that the MEK inhibitors (UO126 and PD98059) increased PDK4 mRNA and 
protein levels and decreased relative PDH flux.   Interestingly, the MEK inhibitor 
and the GPR40 antagonist did not block the effect of Palmitic acid but Oleic acid  
was effective in blocking palmitate induced increases in PDK4 expression. The 
protective effect of oleic acid on palmitic acid induced inflammation, apoptosis 
and insulin resistance in skeletal muscle  has been observed by many 
researchers (Coll et al. 2008; Chavez et al. 2003; Peng et al. 2011; Hardy et al. 
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2005). Overall the presented data suggest that palmitic acid does not exert its 
effects via GPR40, and the role of oleate in reducing the detrimental effects of 
palmitate are also unlikely to involve GPR40 signalling 
5.6.6. Effects of modulating GPR40 activity upon transcriptional 
networks 
This study is the first study to explore the functionality of GPR40 receptor 
in skeletal muscle. Global expression profiling with oligonucleotide microarray 
and Taqman® Low-Density Array were used to systematically characterize gene 
expression profiles in myotubes treated with GPR40 agonists and antagonists. 
The effects of GPR40 activation or inhibition on gene expression were studied to 
further understanding and provide new insight of GPR40 mechanisms in skeletal 
muscle.  
Treatment of human myotubes with the GPR40 agonist (AZ921) alone or in 
combination with the GPR40 antagonist (AZ836) did not produce any significant 
alteration in biological functions or  canonical  pathways when data with a fold 
change >1.5 and analysed using IPA. However, the GPR40 antagonist (AZ836) 
produced significant changes in a number of gene regulatory pathways. 
Interestingly, the effects of the antagonist in cells cultured in lipid-free medium 
were similar to those cultured in horse serum which may contain lipid species 
that are capable of binding to and activating GPR40. This may indicate that 
GPR40 is at least constitutively active, or that myotubes produce GPR40 ligands 
which then act in an autocrine manner. It is now accepted that constitutive 
activity is a feature associated with many G protein-coupled receptors, the 
majority of GPCRs show some level of spontaneous activity in the absence of 
agonists (Milligan 2003) and that the majority of antagonists are actually inverse 
agonists which can reduce the basal activity a receptor (Kenakin 2001).  A high-
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level of constitutive activity of GPR40 was indicated by experiments employing 
cell membrane preparations aQG WKH ELQGLQJ RI >6@JXDQRVLQH ¶-O->Ǆ-thio] 
triphosphate (Stoddart & Milligan 2010).   
Analysis of the effects of the GPR40 antagonist by IPA revealed that most 
genes were associated with cell proliferation, differentiation, cytoskeleton 
organization, movement and survival. IPA analysis indicated that the increased 
expression of several upstream regulators of transcription. Among the upstream 
regulators ERBB2, PPARD, MAPK8 and IL3 were chosen for further analysis to 
highlight their role in cell proliferation as they have a high predicted Z-score.  
ERBB2 is a member of the EGF receptor (EGFR) family of receptor tyrosine 
kinases (RTK), composed of 4 closely related type 1 RTKs including the EGFR 
(ERBB1/HER1), ERBB2 (Neu/HER2), ERBB3 (HER3), and ERBB4 (HER4) (Lahlou 
et al. 2012; Olayioye et al. 2000). In different cell types, EGFR transactivation 
can mediate GPCR-induced Ras/Raf/MEK/ERK and PI3-kinase/Akt activation and 
thereby contributes to the coupling between GPCRs and cell cycle progression 
(Rozengurt 2007). Moreover, ERBB RTKs integrate signalling events emanating 
from other receptor classes, such as G-protein-coupled receptors and cytokine 
receptors (Olayioye et al. 2000). In this study, the expression of ERBB2 in 
cultured myotubes was revealed by microarray with a rank of 11117 out of 
42413. The role of ERBB2 receptors  in skeletal muscle was studied by Leu 
(2003) who reported that ERBB2 signalling is an essential regulator for the 
formation of both neuromuscular synapses and muscle spindles in mice. A 
similar findings were reported by Andrechek et al. (2002) who found ERBB2 
receptors in  skeletal muscle tissue and cultured myoblasts and highlighted the 
importance of ERBB2 signalling in regeneration of muscle fibres.  
The microarray data showed that treatment with a GPR40 antagonist led to 
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increased expression of ERBB2 in cultured skeletal muscle cells. Ingenuity 
pathway analysis demonstrated that the expression of 46 genes known to be 
transcriptionally regulated by ERBB2 was altered by GPR40 antagonist 
treatment. The majority of these downstream transcripts were found to be 
associated with cell proliferation and development. Under normal conditions, 
ErbB receptors are expressed at very low levels in a variety of tissues and cells 
of epithelial, mesothelium, endothelial, and neuronal origin where they elicit 
broad biological functions, including organ development, maintenance of cell 
proliferative and differentiation states, and the regulation of tissue homeostasis 
(Alaoui-Jamali et al. 2003). Overexpression of ERBB2 increases cell proliferation 
and survival (Kurokawa & Arteaga 2001).  Overexpression of ERBB2 has also 
been reported in numerous cancers, including breast, lung, gastric, oral and 
ovarian tumors (Olayioye et al. 2000). Overexpression of the human ERBB2 
gene correlates with a lower survival rate in breast cancer patients (Yang et al. 
2000). Besides their role cancer pathology, ERBB2 and ERBB3 are also required 
for normal development as ablation of ERBB2 or ERBB3 causes embryonic 
lethality (Ponomareva et al. 2006; Lahlou et al. 2012). 
Unlike other members of the family, ERBB2 is not directly ligand activated, 
it does however interact with other ligand-bound EGF receptor family members 
to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated 
activation of downstream signalling pathways. ErbB2 is the preferred 
heterodimerization partner for all other ERBB family members and plays a role in 
the potentiation of ERBB receptor signalling (Graus-Porta et al. 1997). In fact, 
the ErbB2-ErbB3 heterodimer is the most potent ErbB signalling complex in 
terms of cell growth and transformation (Olayioye et al. 2000). It is worth 
mentioning that homodimers are weakly active or are devoid of kinase activity 
(Benlimame et al. 2005). Inactivation of ERBB2 by blocking antibodies decreases 
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ERBB3 tyrosine phosphorylation and inhibits cell proliferation whereas 
transcriptional repression of ERBB3 expression blocks ERBB2-induced 
proliferation in mouse  mammary epithelial cell culture (Lahlou et al. 2012). 
ERBB3 was found to be elevated following GPR40 antagonist treatment which 
indicates that ErbB2/ErbB3 heterodimer activity may be increased.  
If the increased expression of ErbB2 and ErbB3 observed in GPR40 
antagonist treated cells leads to physiologically significant changes in cell 
behaviour, then the expression of genes downstream of the ErbB heterodimer 
would be expected to alter accordingly. The section that follows describes 
changes in expression of genes regulated by ErbB2:ErbB3 and discusses how the 
pattern of gene expression changes may lead to increased cell proliferation and 
reduced apoptosis. 
The estrogen receptor (ER) belongs to a nuclear receptor superfamily of 
ligand-activated transcription factors that play a central role in cell proliferation 
(Stoica, Franke, Wellstein, et al. 2003). The estrogen-mediated signalling plays a 
central role in ERBB2/PI-3K/Akt signalling in hormone-dependent breast cancer 
(Stoica, Franke, Moroni, et al. 2003). ERBB2 activation by heregulin leads to cell 
growth and ER regulation in breast cancer cells (Pietras et al. 1995). 
Interestingly, the ER (ESR1 & ESR2) were among the upregulated downstream 
transcripts of ERBB2 in the current study which indicates that they also might 
play a role in skeletal muscle proliferation induced by GPR40 antagonist 
treatment. The apoptotic resistance factor BCL2 (B-cell CLL/lymphoma 2) (Zhou 
et al. 2002) was also one of the upregulated downstream transcripts of ERBB2. 
Studies using MCF-7 cells with or without ErbB2 expression, Guo et al. (2004) 
showed an enhancement in Bcl-2 levels in ErbB2-overexpressing cells.  
ETS factors are known to act as positive or negative regulators of cell 
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proliferation, differentiation and apoptosis (Watson et al. 2010). One ETS family 
member, ETV6, was another upregulated transcript in the current study. Galang 
et al. (2004) reported an elevated expression of ETV6 in mammary tumours 
compared to normal mammary tissue.  
Transforming growth factor beta (TGF-ǃ LV D cytokine which potently 
inhibits the growth of normal epithelial cells as well as some breast cancer cell 
lines in culture (Wilson et al. 2005). Latent TGF-beta binding protein (LTBP) 
attaches to TGF-ǃDQGSUHYHQWVELQGLQJWR7*)-ǃ receptors leading to increased 
cell proliferation. LTBP3 expression was found to be elevated in the GPR40 
antagonist treated cells.  LTBP-3 knockdown via siRNA mediated silencing 
resulted in reduced cell proliferation and reduced osteogenic differentiation (Koil 
et al. 2008). Furthermore,  ERBB2/HER-2 overexpression promotes the growth 
and malignancy of mammary epithelial cells, in part, by conferring resistance to 
the growth inhibitory effects of TGF-ǃ(Wilson et al. 2005).  
The Notch family includes four conserved transmembrane receptors 
(Notch1 - Notch4) and five surface localized ligands (Jagged1, Jagged2, Delta-
like1, Delta-like2 and  Delta-like3), which play fundamental roles in self-renewal, 
proliferation, adhesion and migration (Le Friec et al. 2012). Notch1 and JAG1 
expression were altered by GPR40 antagonist treatment (Notch1 increased and 
JAG decreased). JAG1 has been reported to significantly reduce endothelial cell 
proliferation by Liebler et al. (2012) and an increase in Notch1 coupled with 
reduced JAG1 expression may contribute to increased myoblast proliferation. 
The cell cycle is regulated by both the positive (cyclin-dependent kinase 
CDK1) and negative (cyclin-dependent dependent kinase inhibitors CDKN1B) 
regulators (Aleem et al. 2005).  CDKN1B is one of the transcripts that is 
downregulated by ERBB2. Down-regulation of CDKN1B (p27) has been described 
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in cells in which ERBB2 was overexpressed (Yang et al. 2000). It was by this 
group that the HER-2/Grb2/Ras/MAPK pathway was demonstrated to be involved 
in the down-regulation of p27.  
The E3 ligase (Cul3) and the adhesive protein Dermatopontin (DPT) were 
also among the downregulated transcripts that have been previously been 
described as being  under the regulation of ERBB2. CUL3 is a crucial regulator of 
cell proliferation, and has been reported to be responsible for the degradation of 
Cyclin E (McEvoy & Kossatz 2007). When Cul3 levels are reduced, CyclinE 
activity increases, driving cells into S phase and promoting cell proliferation. DPT 
is an extracellular matrix protein and is assumed to play important roles in cell-
matrix interactions and matrix assembly (Kuroda et al. 1999). DPT has been 
shown to interact with, and enhance the activity of TGF-ǃ (OKAMOTO et al. 
1999) Thus the decrease in DPT may further decrease the anti-proliferative 
effects of TGF-ǃ 
7KH DGKHVLRQ PROHFXOH  Į-integrin (ITGA2) was also a downregulated 
downstream transcript of ERBB2 in this study, in agreement with Ye et al. 
(1996) who reported that overexpression of the ERBB2 gene in a non-
tumorigenic human mammary epithelial cell line, MTSV1-7, induced a 
downregulation of transcription of the genes coding for adhesion molecules E-
FDGKHULQDQGĮ-integrin. The activation of Į2ǃ integrin has been demonstrated 
previously to inhibit ERBB2-mediated cell proliferation in mammary epithelial 
cells (Baeckstro et al. 2000). 
Matrix metalloproteinases (MMPs) play a major role in cell 
proliferation, migration ,differentiation and apoptosis and are negatively 
regulated by MMP inhibitory proteins such as RECK (reversion-inducing-cysteine-
rich protein with kazal motifs) (Noda et al. 2003). Hsu et al. (2006) 
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demonstrated that the over expression of ERBB2 inhibits the expression of the 
RECK in B104-1-1 cells, NIH/3T3 (cells expressing constitutively active HER-
2/neu) and human HaCaT keratinocytes cells via the ERK signalling pathway.  
RECK can inhibit cell proliferation by downregulation of a ubiquitin ligase 
component, S-phase kinase-associated protein 2 (SKP2), and upregulation of its 
substrate, p27 (KIP1). p27 acts by inhibiting Cdk2 and instigates a blockade at 
G1 (Yoshida et al. 2011). As ERBB2 also directly decreases p27/Cdk2 interaction 
(Lane et al. 2000) this should lead to a decrease in Cdk2 activity and subsequent 
increase in cellular proliferation.  
PDCD4 (programmed cell death 4) is a tumour suppressor gene and the 
expression of PDCD4 in rat skeletal muscle tissue and myoblasts was reported 
by Zargar et al. (2011). Our data indicate that PDCD4 is downregulated by 
GPR40 antagonist treatment. Huang et al. (2009) found that PDCD4 is down-
regulated by miR-21 in breast cancer cells expressing ERBB2 and as PDCD4 is 
positively regulated by the TGF-ǃ pathway (Baeckstro et al. 2000) it is possible 
that ERBB2 suppression of TGF-ǃ signalling may be responsible for the reduction 
of PCDC4 mRNA in this study.  
The capping protein (CPAZA2) which tightly binds to the fast growing ends 
of actin filaments in skeletal muscle and regulates its growth (Eckert et al. 2012) 
was found to be inhibited by the GPR40 antagonist in this study and it is one of 
the downstreams of ERBB2. The expression of CPAZA2 and many of the genes 
mentioned above were found to be altered in a similar manner by a   microarray 
study in which ERBB receptors were stably overexpressed in a polyclonal cell 
population as single or paired combinations using murine and human breast cell 
models (Alaoui-Jamali et al. 2003).  
It worth mentioning that another microarray study was carried out by 
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Mackay et al. (2003) to evaluate the role of ERBB2 overexpression in the 
ERBB2-transfected breast luminal epithelial cell line C5.2, the ERBB2-amplicon-
containing breast cancer cell line BT474, and ERBB2-overexpressing invasive 
ductal breast carcinomas.  The results of our microarray regarding the 
downstream transcripts of ERBB2 were in agreement with the Mackay study for 
both downregulation  (RECK, PDCD4, ITGA2, CUL3, CDKNIB, CAPZA2, DPT, 
JAG1) )or upregulation (BCL2, HES1, HES2, LTBP3, NOTCH1, TNC,  ERBB3, 
ESR1, ESR2, ETV6 and MAPKBP3) of genes by increased ERBB2 expression 
induced by the GPR40 antagonist in human myotubes.  The following figure 
shows a suggested pathway through which elevated ERBB2 expression caused 
by GPR40 antagonist treatment may lead to increased cell proliferation. The 
figure illustrates that the GPR40 proliferative and anti-apoptotic effects are 
through the activation of ERBB2. The ERBB3/ERBB2 heterodimer generate a 
spectrum of signalling pathway through, 1) AKT pathway to activate BCL2, 
ESR1 and ESR2. 2) Notch pathway, to activate HES1 and HES2 as well as to 
LQKLELW -$*  0$3. SDWKZD\V WR LQKLELW 7*)ǃ &'.1,% 5(&. 32&' DQG
ITGA2 as well as to activate ETV6. 4) Direct or indirect pathways to inhibit 
CUL3, CAPZA2 and DPT as well as to activate LTBP3. These pathways modulate 
cell proliferation and apoptosis by; 
1. ,QKLELWLRQ RI 7*)ǃ ZKLFK VXEVHTXHQWO\ OHDGV WR DQ LQFUHDVH LQ FHOO
proliferation via the downregulation  of CUL3 and  DPT as well as through 
the upregulation of LTBP. 
2. Activation of CDK which leads to increase in cell proliferation via the 
upregulation of JUN1, HES1, HES2, Notch1, ESR1 and ESR2 as well as 
through the downregulation of CDKNIB (p27) and RECK. 
3. Upregulation of BCL2 which is a powerful anti-apoptotic factor.
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Figure 5-30: A proposed molecular mechanism through which the activated ERBB2 upstream leads to cell proliferation. 
ERBB2 associated with ERBB3 to form a functional heterodimer which generated a diverse spectrum of signaling pathways  such as 1) PI3K/AKT pathway to activate BCL2, 
ESR1 and ESR2. 2) Notch pathway, to activate HES1 and HES2 as well as to inhibit JAG1. 3) RAS/MEK/ERK SDWKZD\VWRLQKLELW7*)ǃ&'.1,%5(&.32&'DQG,7*$DV
well as to activate ETV6. 4) Direct or indirect pathways to inhibit CUL3, CAPZA2 and DPT as well as to activate LTBP3. The ERBB2/ERBB3 seems to modulate apoptosis and 
cell SUROLIHUDWLRQLQDGLUHFWRULQGLUHFWZD\VE\WKHDFWLYDWLRQRI%&/DQG&'.DVZHOODVE\LQKLELWLRQRI7*)ǃ.The human myotubes were  treat with 5µM AZ836 (GPR40 
antagonist) for 24 hours. All transcripts shown had a fold-change of >1.5, and P<0.05. 
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ID Entrez Gene Name Reference 
BCL2 B-cell CLL/lymphoma 2 (Zhou et al. 2002)(Guo et al. 2004) (Lobenhofer et al. 2000) 
CAPZA2 capping protein (actin filament) muscle Z-line, alpha 2 (Alaoui-jamali et al. 2003)(Eckert et al. 2012) 
CDK1 cyclin-dependent kinase 1 (Le Friec et al. 2012)(Aleem et al. 2005)
CDKN1B cyclin-dependent kinase inhibitor 1B (p27, Kip1) (Yang et al. 2000)(Lane et al. 2000)
cMYC avian myelocytomatosis viral (Le Friec et al. 2012)(Frederick et al. 2004)
CUL3 cullin 3 (Sumara et al. 2007)(Mcevoy et al. 2007)
DPT dermatopontin (Kuroda et al. 1999)(Okamoto et al. 1999)
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (HER2/NEU) (Rozengurt 2007)(Olayioye et al. 2000)(Alaoui-jamali et al. 2003) (Riese et al. 1995)
ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (Olayioye et al. 2000)(Graus-Porta et al. 1997)(Graus-Porta et al. 1997)(Mackay et al. 2003)
ESR1 estrogen receptor 1 (Stoica, Franke, Wellstein, et al. 2003)(Pietras et al. 1995)
ESR2 estrogen receptor 2 (ER beta) (Stoica, Franke, Moroni, et al. 2003).
ETV6 ets variant 6 (Watson et al. 2010)(Watson et al. 2010)
HES1 hairy and enhancer of split 1 (Pradeep et al. 2012)
HES2 hairy and enhancer of split 2 (Pradeep et al. 2012)
ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) (Ye et al. 1996)(Baekstrom et al 2000). 
JAG1 jagged 1 (Liebler et al. 2012)
LTBP3 latent transforming growth factor beta binding protein 3 (KOIL et al. 2008)
MAPK8IP3 mitogen-activated protein kinase 8 interacting protein 3 (JIP) (Mackay et al. 2003)(Jiao et al. 2010)  (Meixner et al. 2010)
MMP matrix metallopeptidase (Hsu et al. 2006) 
NOTCH notch (Le Friec et al. 2012). 
PDCD4 programmed cell death 4 (neoplastic transformation inhibitor) (Zargar et al. 2011)(Baeckstro et al. 2000)(Huang et al. 2009)
RECK reversion-inducing-cysteine-rich protein with kazal motifs (Hsu et al. 2006) (Noda et al. 2003)(Yoshida et al. 2011)
SKP2 S-phase kinase-associated protein 2 (SKP2) (Yoshida et al. 2011)
TGFB1 Transforming growth factor beta (Wilson et al. 2005)(Frederick et al. 2004)
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PPARD  is implicated in developmental and metabolic regulation in several 
tissues and gene disruption is often lethal due to a placental defect (Luquet et al. 
2005) ,QDGLSRF\WHV 33$5į LQLWLDWHV WKH DGLSRJHQLF DFWLRQ RI ORQJ-chain fatty 
acids by stimulating preadipocyte proliferation (JEHL-PIETRI et al. 2000) and the 
iQGXFWLRQRI33$5ǄSURPRWHVH[SUHVVLRQRIDGLSRJHQHVLVSURJUDP(Bastie et al. 
1999). In keratinocytes, 33$5įXS-regulation results in increased resistance to 
71)Į-induced apoptosis and increases the rate of keratinocyte differentiation 
(Michalik et al. 2003). Luquet et al. (2005) GHPRQVWUDWHGWKDW33$5įLVLQYROYHG
in the control of cellular proliferation in intestinal crypts. In skeletal muscle, 
overexpresVLRQ RI 33$5į LQ VNHOHWDO PXVFOHV JUHDWO\ LQIOXHQFHG ERWK
development and metabolic capability of mouse muscles by promoting a net 
increase of fibres with an oxidative metabolic capability (Luquet et al. 2003). 
33$5į H[SUHVVLRQ LQ VNHOHWDO PXVFOH LV JUHDWHU WKDQ RWKHU 33$5V DQG KLJKHU
expression is observed in oxidative type I muscle fibres compared with glycolytic 
type II muscle fibres (Ehrenborg & Krook 2009) 7KH UROH RI 33$5į RQ WKH
regulation of lipid metabolism in skeletal muscle is documented (Krämer et al. 
2007; Jucker et al. 2007; Ehrenborg & Krook 2009). In this study a number of 
GRZQVWUHDP WDUJHWV RI 33$5į ZHUH DVVRFLated with lipid metabolism however 
the most significant pathway in terms of Z score that was predicted to be 
UHJXODWHGE\33$5įDFWLYDWLRQZDVDVVRFLDWHGZLWKFHOOSUROLIHUDWLRQ,QVXSSRUW
of this result, Angione et al. (2011) GHPRQVWUDWHGWKDW33$5įKDVDFULWLFDOUROH
in satellite cell proliferation and postnatal regeneration of skeletal muscles 
through reduction of Forkhead box class O transcription factor 1 (FoxO1) gene 
expression. The role of phosphatidylinositol 3-kinase and AKT pathways in 
mediation of cell proliferation of endothelial and skeletal muscle progenitor cells 
was reported by Han et al. (2008) and Chakravarthy et al. (2000), respectively. 
In addition, Bonala et al. (2012) UHSRUWHG WKDW DFWLYDWLRQ RI 33$5į OHG WR
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inhibition of myostatin activity and thus increased myogenesis. Myostatin is a 
secreted growth and differentiation factor that is a member of the TGF 
beta protein family which inhibits muscle differentiation and growth. 
Interestingly, ERBB2 overexpression inhibits TGF beta and BCL2 is also a 
GRZQVWUHDPWUDQVFULSWRI33$5įLQGLFDWHVWKDWXSVWUHDPUHJXODWRUVPD\DKDYH
a synergistic effect on cell proliferation.  
MAPK8 (JNK1) is another upstream regulator the expression of which is 
associated with cell proliferation, cell death and survival. MAPK kinase is involved 
in cell proliferation and transformation. Several studies have shown that 
overexpression of MEK1 alone can lead to up-regulation of cyclin D1 and down-
regulation of p27 (Yang et al. 2000). Interestingly, some genes which influenced 
by ERBB2 are also targets of MAPK8 such as CDK1, CDKN1B, BCL2. Upregulation 
of MMP by stress-activated MAPK signaling pathways was demonstrated by (Oh 
et al. 2001; Nielsen et al. 2008). Moreover, CDKN1B, NOTCH1 and BCL2 are also 
regulated by IL-3 as well as ERBB2.  
IL-3 is a cytokine which has a key role in cell proliferation and survival 
(Ebner et al. 2002). It is worth mentioning that ATF (activating transcription 
factor 5) is another downstream transcript of the upstream regulator IL-3. ATF is 
a member of the  ATF/CREB family of transcription factors which have  important 
roles in differentiation and regulation of the cell cycle (Gho et al. 2008). 
Persengiev et al. (2002) demonstrated that ATF suppresses apoptosis resulting 
from cytokine deprivation in an interleukin 3 (IL-3)-dependent cell line, which 
indicates that ATF is an anti-apoptotic factor. 
Collectively, treatment of human skeletal muscle cultured cells with the 
GPR40 antagonist induced activation of cell proliferation through different 
upstream regulators which seem to have different pathways although certain 
downstream transcripts were found to be common to several upstream factors.
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CHAPTER 6. General Discussion and Future 
Aspects 
The mechanisms behind the development of insulin resistance in skeletal 
muscle are very complex and have not being completely understood. The 
association between lipid over supply and insulin resistance is well established. 
The insulin resistance in skeletal muscle is of particular importance because 
muscle is the major site of insulin stimulated glucose uptake. Interference with 
insulin signal transduction by lipid activated signalling pathways is likely to play 
an important role in the initiation of insulin resistance which usually develops 
decades before overt diabetes (Dipl-Pharm & Zierath 2005). Isolated skeletal 
muscle preparations are short lived for experimental manipulation, and they are 
invasive for human studies. Several muscle cell lines of animal origin are 
currently available (rat L6 and mouse C2C12 of skeletal muscle origin and 
mouse BC3H1 of brain tumour origin). There are no muscle cell lines of human 
origin that have been equally characterized. Primary skeletal muscle cell 
cultures have been shown to retain the metabolic characteristics of the tissue 
donor and thus reflect alterations in metabolism as seen in specific disease 
states such as obesity and type 2 diabetes mellitus (Gaster et al. 
2004)(Steinberg et al. 2006). The human muscle cells were shown to have a 
saturable glucose uptake system and to be more sensitive to insulin than the 
rat cell line (Sarabia et al. 1992). However contamination by fibroblasts and the 
potential for spontanous differentiation of myoblasts to myotube are the main 
problems of primary culture (Gaster et al. 2001). Human muscle cells in culture 
as well as rat L6 muscle cell lines express higher ratios of GLUT1/GLUT4 
transporters than do adult rat or human muscles while other cell lines (BC3H1, 
C2C12, and G8) have been reported to express detectable levels of only GLUT1 
(Sarabia et al. 1992). Hence, it appears that human primary muscle cell 
cultures are the most suitable model for studying muscle mechanisms in vitro. 
In an attempt to define defects in insulin signalling in skeletal muscle, 
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characterized and to better understand the effects of GPRC ligands (in particular 
CB1 and GPR40 agonists/antagonist) in human muscle, we have used human 
and rat (Wistar and Zuckers) primary muscle cell cultures.  
In the present thesis, high-density oligonucleotide arrays were used mainly 
to characterize changes in global mRNA expression patterns during human 
myogenesis as well as to investigate potential differences in the expression of 
metabolic genes and GPRCRs between skeletal muscle tissue and primary 
cultured cells in a genome-wide perspective. Studying the difference between 
myoblast and myotubes as well as myotubes and skeletal muscle tissue shows 
that human cultured cell is a suitable model for studying myogenesis. This thesis 
showed that the myogenic markers (PAX7 and PAX3) and transcriptional 
regulator of myogenesis such as MYOD1, MYF5, CDK6 and Myogenin were higher 
in culture cells than tissue. Moreover, MYOD1 and MYF5, which are responsible 
for myogenin formation and CDK, were higher in myoblasts than myotubes. It is 
well known that the CDk level increases in the late stage of myoblasts 
proliferation to arrest cell cycle and starts the differentiation stage (Tomczak et 
al., 2004). Genes encoding cell adhesion molecules were expressed higher in 
myotubes compared to myoblasts and whole muscle tissue providing a clearer 
indication of how the plasma membrane and extracellular matrix may be 
modified prior to cell fusion and suggesting their potential role during the steps 
of myogenic differentiation.  
Human skeletal muscle culture has been used for the investigation of the 
biochemical and genetic basis of peripheral insulin resistance. Insulin 
enhancement of the rate of 2-deoxyglucose uptake in these cells is 2 fold less 
than insulin responsiveness typically observed in human forearm muscle balance 
studies  (Perriott et al. 2001). This low degree of insulin responsiveness makes 
these cells questionable for assessing insulin effects on glucose utilization and for 
establishing the mechanism of impaired insulin sensitivity. In the present thesis, 
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the MAPKs pathway was not affected in cultured cells compared to tissue whereas 
the PI3K/AKT pathway and the GLUT4 translocation were affected. Interestingly, 
most of the negative regulators of insulin transduction pathway had higher 
expression in myotubes compared to skeletal muscle tissue such as PTEN, SHIP2, 
SOSC3 and LAR. It is worth mentioning that not only the expression of GLUT4 
(SLC2A4) but also genes responsible for GLUT4 trafficking such as VAM2 and 
TC10 had lower expression in myotubes than skeletal muscle tissue. In addition, 
genes associated with carbohydrate, protein and lipid metabolisms as well as 
energy production were expressed at lower levels in myotubes compared to 
skeletal muscle tissue. In fact, genes encoding key regulators of glycogenolysis 
and glycolysis as well as most genes in TCA Cycle, ǃ oxidation, and oxidative 
phosphorylation were expressed at lower levels in myotubes when compared to 
skeletal muscle tissue. Interestingly, the expression of genes that are involved in 
the transcriptional control of fatty acid oxidation and glucose homeostasis such as 
PPARA, PPARG, PPARGCIA & PPARGC1B (Semple 2006; Wahli & Michalik 2012; 
Lefebvre & Chinetti 2006) was also lower in myotubes when compared to tissue. 
Collectively, this implies that cultured cells are in a non-functional stage that 
does not demand more energy for metabolism. The metabolic requirements of 
skeletal muscle are highly variable, the working contracting muscle is a high 
consumer of ATP, and is also under hormonal control. In the basal (fasting and 
resting) state, approximately 80% of blood glucose is metabolized in an insulin-
independent manner by the brain, gut, and red blood cells, whereas insulin-
sensitive tissues (skeletal muscle and fat) require only small quantities. However, 
after insulin stimulation, skeletal muscle accounts for 75% of glucose utilization 
(Ehrenborg & Krook 2009).  Not surprisingly, the expression of genes responsible 
for muscle structure subunit and phenotypes (Desmin, Tropomyosin, Troponin, 
Tropomodulin and myosin light and heavy chain) was higher in tissue than 
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cultured cells suggesting that cultured cells are relatively immature and specific 
transcriptional programs generating mature muscle phenotype are activated in 
vivo but not in cultured muscle cells. The ability of skeletal muscle to increase 
muscle size together with an ability to alter protein isoform expression, gives 
muscle the ability to adapt to the different challenges that may be placed up on it 
(use hypertrophy and disuse atrophy) (Harridge 2007). In fact, the decrease in 
metabolic genes and genes involved in muscle contraction demonstrated in 
cultured cells in this thesis, indicated a phenotype associated with disuse atrophy. 
Interestingly, a higher level of expression of metabolic genes in myotubes 
compared to myoblasts was also observed indicating an essential modification 
change (i.e cells are differentiated and gaining muscle phenotype) prior to fusion 
occurring. Collectively, the use of skeletal muscle culture cannot be used as a 
reliable model for a complete study of the insulin signalling pathway. In this 
work, the use of 100nM insulin in cultured cells induced ERK1/2, MAPK38, AKT 
DQG*6.ĮǃSKRVSKRU\ODWLRQDFWLYDWLRQDOWKRXJKQR*/87UHFUXLWPHQWWR WKH
membrane was observed. This may be due to the fact that GLUT4 transport is a 
complex process as discussed in previous chapters. The decreased expression of 
GLUT4, the increase of GLUT1, the decrease in actin remodelling genes and the 
decrease in genes involved in calcium signalling and consequently muscle 
contraction altogether lead to the suggestion that insulin stimulated GLUT4 
transport may also be impaired in those cells. The qualitative differences 
between cultured human muscle cells and adult human skeletal muscle may be 
related to the less mature state of the cells in culture, to the lack of innervation 
in culture, or to other conditions typical of the culture procedure. Therefore, 
better visualization method (GLUT4 photolabelling), intravital measurement of 
GLUT4-GFP chimeras, antibody-based determinations, exofacial tagged GLUT4, 
and affinity photolabeling techniques should be used to assess the regulation of 
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GLUT4 traffic.  Optimizations of culture methods (electrical stimulation and 
introduction of continuous flow) as well as co-culture with other cells such as 
adipose tissue to study the cross talk between tissues are required.  
The expression of cannabinoid and potential cannabinoid receptors as well 
as GPR40 was detected at the mRNA level by microarray, but their level of 
expression was low.  The microarray technology, whilst effective as a tool for 
analysis of global gene expression changes, can lack the sensitivity to detect 
transcripts expressed at low but functional levels. Therefore, the expression 
levels of GPCRs were further investigated using QRT-PCR, which is a more 
sensitive technique for the detection of mRNA.  
As illustrated in chapter 4, QRT-PCR analysis revealed the expression of 
CB1 in human and rat (Wistar and Zucker) skeletal muscle at different stage of 
differentiation and in different muscle phenotypes. In addition, CB1 mRNA 
expression was observed in rat heart, spleen, brain and adipose tissue.  To the 
best of our knowledge, this is the first study that characterized the CB1 
expression in this wide range of tissues by extracting mRNA from total RNA prior 
to cDNA synthesis as CB1 receptor is a single axon gene. The QRT-PCR findings 
from the present study also revealed the presence of CB2 mRNA expression in 
rat skeletal muscle tissue and cultured cells in agreement with  Cavuoto et al. 
(2007). However, human CB2 mRNA expression was detected in cultured cells 
only in contrast to  Cavuoto et al. (2007) who used 10 times over the standard 
loading amount for RT-PCR. The low level of CB2 in skeletal muscle tissue might 
be the reason for the underestimation of the role of CB2 in skeletal muscle. It is 
worth mentioning that (Bermudez-Silva et al. 2007) reported activation of 
cannabinoid CB2 receptors by CB2 agonist (JWH133) improved glucose tolerance 
after a glucose load, whereas blockade of cannabinoid CB2 receptors by AM630 
counteracted this effect, leading to glucose intolerance in rats. Moreover, 
CHAPTER Six 
 
 
 
    219 
 
 
  
(Rajesh et al. 2008) observed that CB2 agonists decrease vascular smooth 
muscle proliferation and migration LQGXFHGE\71)ĮDQGDVDUHVXOWclinically CB2 
agonists are under trial in post balloon implantation. The expression of the 
potential cannabinoid receptor GPR119 was also observed in human and rat 
skeletal muscle tissue and cultured cells. To the best of our knowledge, this is 
the first study revealing the presence of GPR119 in skeletal muscle using QRT-
PCR.  
High levels of circulatory endocannabinoids are well documented in obese 
and diabetic subjects (Serrano et al. 2008). However, the presence and role of 
skeletal muscle CB1 receptors in obesity and diabetes is poorly described. 
Pagotto et al. (2006) reported a high level of mRNA CB1 expression in soleus 
muscles from mice fed a high fat diet whereas Lindborg et al. (2010) observed a 
low CB1 protein expression in soleus muscles from ZFR.  In the present study, 
the expression levels of CB1, CB2 and GPR119 in muscle, liver, heart, spleen 
and adipose tissues were similar between 12week old Zucker Fat Rats (ZFR) and 
Zucker Lean Rats (ZLR), however at 20 weeks ZFR muscle and adipose tissues 
had a significantly higher expression of CB1 than ZLR. The expression of GPR119 
in skeletal muscle tissue was higher in Zucker than Wistar rats in contrast to 
CB1 which has higher expression in Wistar compared to Zuckers. However, the 
difference disappeared in myotubes cultured from the same animal, which 
indicates that removal of the physiological factors that differentiate the two 
strains of rat in cultured cells may cause the equalization of GPR119 and CB1 
expressions.  This hypothesis is supported by the fact that Brozinick, Roberts, & 
Dohm, (2003), Pender et al. (2005) and Berggren et al. (2005) did not observe 
a difference in insulin resistance between cultured cells from obese (insulin-
resistant patients) and control subjects. 
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The functionality of CB1 receptor in skeletal muscle was assessed by 
studying the effects of selective CB1 agonists and antagonists on ERK1/2 
phoshorylation. CB1 activation of members of the MAP family such as ERK1/2 
and MAPK38 is well documented and has been reviewed by (Demuth & Molleman 
2006) and (Pertwee & Ross 2002). As described in chapter 4, ACEA and AEA 
lead to time dependent increase in ERK1/2 phosphorylation with a peak at 10 
min in human and rat (Wistar and Zuckers) myotubes.  Treatment with a CB1 
selective antagonist (Rimonabant, RIM) alone attenuated ERK activation in cells 
obtained from Wistar and ZLR but not ZFR. The inability of rimonabant to inhibit 
CB1 agonist mediated ERK phosphorylation suggests altered ECS signalling in 
obesity and diabetes, however further investigation in terms of effects on 
metabolic gene expression and cell proliferation is needed. It is possible that the 
effects of endocannabinoids upon ERK signalling are unrelated to their metabolic 
effects and rather, are associated with cell proliferation or differentiation. The 
immunocytochemistry study using the proliferative marker Ki67 showed that 
ACEA induce cell proliferation in Wistar rat however, proliferation and 
differentiation assays are needed to confirm the role of CB1 activation in 
proliferation.    
To further investigate the role of CB1 receptor activation in the acute 
modulation of insulin signalling in rat and human myotubes, the effects of CB1 
agonists and antagonists on key proteins in the insulin signalling cascade were 
studied. The results from this thesis indicated that neither ACEA nor RIM affect 
insulin-stimulated phosphorylation of ERK1/2, MAPK38, PKB/$NW RU *6.Įǃ
indicating that modulation of CB1 receptor in skeletal muscle cultured cell does 
not have a role in insulin signalling. Previous findings in the literature regarding 
the role of the cannabinoid receptor activation or inhibition on AKT are 
controversial. Eckardt et al. (2009) found that AEA impaired insulin-stimulated 
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$.7EXWQRW*6.ĮǃSKRVSKorylation and pre-treatment with RIM completely 
abolished the AEA effect in human primary skeletal muscle cultured cells. In 
contrast, Lindborg et al. (2010) reported that neither CB1 receptor agonists nor 
DQWDJRQLVWVDOWHUHG$NWDQG*6.ǃSKRVSKRU\ODWLRQ in soleus muscle from lean 
and obese Zucker rats. (Song et al. 2011) reported that the CB1 agonist HU210 
induced insulin resistance in muscle of wild-type C57BL/6 mice through inhibition 
of AKT phosphorylation which was prevented by pretreatment with the CB1 
antagonist AM251. (Esposito et al. 2008) also demonstrated that RIM increased 
AKT phosphorylation and glucose uptake in L6 skeletal muscle cells. (Lipina et al. 
2010) showed that pharmacological activation or inhibition of CB1 receptor 
activity exerts a differential effect with regard to MAP kinase and PKB/Akt-
directed signalling in L6 cells. The discrepancy between this study and some 
earlier studies may be due to the different time points studied and the cell model 
used as previously discussed in chapter 4. It is interesting to note that even 
though the mRNA expression of CB1 and insulin signalling cascade genes were 
found to be low in cultured myotubes by micrroarray, the CB1 is functional (as 
indicated by the ACEA and AEA induced increase in ERK1/2 phosphorylation) and 
treatment with insulin can induce phosphorylation of ERK1/2, MAPK38, AKT and 
*6.Įǃ 7KH LQDELOLW\ RI LQVXOLQ WR LQGXFH*/87 WUDQVSRUWPD\EHGXH WR WKH
complexity of this transport process as discussed earlier. The findings of this 
thesis suggest that CB1 activation or inhibition has no role in modulating the 
activity of key proteins involved in insulin signalling. 
There is a growing body of evidence linking elevated FFA and the 
development of insulin resistance. The role of GPR40 in glucose homeostasis in 
pancreas has been extensively studied; however its role in skeletal muscle has 
not been reported. To the best of our knowledge, this is the first study to 
characterize the GPR40 receptors in human and rats (Wistar and Zuckers) in 
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different stage of muscle development and in different muscle phenotypes.  Even 
though the microarray data showed very low level of expression of GPR40 
mRNA, the QRT-PCR confirmed the expression of GPR40 in human and rat 
skeletal muscle tissue and cultured cells.  The higher level of GPR40 mRNA 
expression in myoblasts in comparison to myotubes and tissue suggested a 
possible role of GPR40 in cell proliferation. Human brain and spleen tissues also 
expressed GPR40 in agreement with Swaminath (2008) and Hirasawa et al. 
(2008). The GPR40 expression was also found in rat pancreas, spleen, adipose, 
heart and liver but not in rat brain in agreement with  Itoh et al. (2003) and 
Brownlie et al. (2008). Interestingly, Ma et al. (2007) detected GPR40 
expression in monkey brain. This indicates that the expression of GPR40 is not 
only tissue specific but also species specific.  
Decrease in GPR40 expression in response to a high fat diet in mice was 
observed by Kebede et al. (2012),  whereas Briscoe et al. (2003) detected a 
significant increase in expression of GPR40 mRNA in whole pancreas of ob/ob 
mice compared with control lean mice. In the present thesis, expression levels of 
GPR40 were similar at 12weeks for Zucker fat Rat (ZFR) and Zucker Lean Rat 
(ZLR), however at 20 weeks ZFR had higher expression of GPR40 than ZLR. Not 
surprisingly, cultured myotubes from ZFR, ZLR and Wistar rats had no significant 
difference in GPR40 expression, however cells cultured in 25mM glucose had a 
high level of GPR40 expression.  Kebede et al. (2012) also observed a higher 
GPR40 mRNA expression in human and rat islets cultured in high glucose and 
they concluded that the main effect of glucose on GPR40 expression does not lie 
at the level of mRNA stability but, rather, at the transcriptional level. In contrast, 
Fontés et al. (2010) found low expression of the GPR40 gene under 
glucolipotoxic conditions in rat ǃ FHOOV  and Del_Guerra et al. (2010) in islets 
from T2D patients. Interestingly, the addition GPR40 ligand for 6 hours, led to a 
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significant down-regulation of GPR40, i.e., G protein-coupled receptor-specific 
internalization (Kaplamadzhiev et al. 2010; Hu et al. 2009). Therefore, further 
confirmation and investigation is needed to see the effect of high glucose as well 
as GPR40 ligands on GPR40 mRNA expression in skeletal muscle. 
As discussed in chapter 5, even though a growing body of evidence 
suggested that the GPR40 receptRUFRXSOHVWRWKH*ĮTVXEXQLWRI*SURWHLQ
(Shapiro et al. 2005)(Carina P 2008), other studies suggested that GPR40 is 
coupled to Gi/o (Fujita et al. 2011), (Hidalgo et al. 2011) and (Yonezawa et al. 
2008). Studying the signalling mechanisms downstream of GPR40, we found 
that PTX (a Gi inhibitor) attenuates MAPK phosphorylation induced by GPR40 
agonists suggesting that GPR40 is a Gi coupled receptor in skeletal muscle. 
Moreover, GPR40 agonists had no effect on intracellular calcium release in 
Wistar rat myotubes and myoblasts while ATP produced a quick response. This 
indicates that even though cultured muscle cells are relatively immature and a 
decrease in the expression of calcium signalling and ryanodine receptor genes 
was observed by microarray analysis, the cells still responding to stimulation of 
calcium release. Calcium imaging assays might be unreliable methods to study 
the functional read out of GPR40 because it has a high constitutive activity 
(Stoddart & Milligan 2010). Thus, these results should be verified through the 
use of PLC inhibitors (such as 8*ĮTLQKLELWRUs (such as YM-254890) as 
well as measurements of cAMP production in skeletal muscle in response to 
treatment with GPR40 agonists and antagonits. 
Even though the role of GPR40 in the regulation of insulin secretion is well 
documented, it is still a matter of debate whether activation or inhibition of 
GPR40 would be beneficial for the treatment of type 2 diabetes (Ou et al. 2013). 
In humans, clinical trials with the GPR40 agonist TAK-875 improved glucose 
tolerance and glycaemic control significantly without causing hypoglycaemia. Ito 
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et al. (2013) observed a significant improvement of postprandial and fasting 
hyperglycaemia, as well as a decrease in glycosylated Hb, with the use of TAK-
875 in Zucker obese rats and additive improvements were also observed in 
combination with metformin. Lin et al. (2011) demonstrated that acute 
administration of AMG837 (a potent GPR40 partial agonist) lowered glucose 
excursions and increased glucose stimulated insulin secretion during glucose 
tolerance tests in both normal and Zucker obese rats. These finding support the 
potential use of GPR40 agonists for the treatment of type 2 diabetes.  However, 
Zhang et al. (2010) showed that the GPR40 antagonist DC260126 improves 
insulin tolerance and increase insulin signalling in diabetic Zucker rats. 
Collectively, these finding raise a question about the use of GPR40 in the 
treatment of diabetes, thus it is necessary to further investigate the role of 
GPR40 agonists and antagonists in other species and tissues. The current thesis 
is the first study to evaluate the role of GPR40 in skeletal muscle insulin 
resistance and cell proliferation. The main findings showed (1) Activation of 
ERK1/2 by GW9508, AZ921, and Oleic acid but not Palmitic acid, (2) Activation 
of MAPK38 by GW9508 only, (3) inhibition of ERK/2 phosphorylation induced by 
AZ921 only by the antagonists (AZ836 and AZ468) in human and rat (Wistar 
and Zuckers) myotubes. These findings were in agreement with previous reports 
as discussed in Chapter 5. The apparent difference between effects of the 
various GPR40 agonists is most likely attributable to activation of distinct 
allosteric sites on the receptor by different molecule structure. Interestingly, Lin 
et al. (2012) described three novel GPR40 allosteric agonists that bind to 
separate sites and display complex binding and function cooperatively with one 
another and with the endogenous GPR40 ligands docosahexaenoic acid and 
linoleic acid. Positive allosteric modulation of GPR40 activity presents an 
attractive therapeutic avenue that would offer additional advantages over 
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orthosteric GPR40 agonists (Mancini & Poitout 2013). The selective inhibitory 
effect of the 2 antagonists on AZ921 indicates the specificity of the Astra Zeneca 
compounds used in this thesis.  
Activation of ERK1/2 also plays a major role in cell proliferation, 
differentiation and transformation (Fredriksson R 2003).   Thus, this thesis also 
investigated the effect of GPR40 agonists and antagonists on key regulatory 
SURWHLQV LQ LQVXOLQ VLJQDOOLQJ QDPHO\ $.7 DQG *6.Įǃ.  The effect of GPR40 
agonists on the insulin stimulation of AKT in human and Wistar rat myotubes 
was inconsistent; GW9508 had no effect, AZ921 decreased the effect of insulin 
stimulation of AKT phosphorylation, and the GPR40 antagonist (AZ836) 
abolished the effect of AZ921 only. Furthermore, the GPR40 agonists had no 
HIIHFW RQ LQVXOLQ VWLPXODWLRQ RI *6.ǃ Shosphorylation while the GPR40 
antagonist significantly increased it. This indicates the modulation of GPR40 
receptors by the antagonist may have a stimulatory effect on insulin signalling. 
Other possible targets involved in the development of lipid-induced insulin 
resistance in skeletal muscle such as PDK4 (a molecular inhibitor of glucose 
R[LGDWLRQ DQG WKH SURLQIODPPDWRU\ F\WRNLQHV ,/ DQG 71)Į ZHUH DOVR
investigated.  The main finding was that the GPR40 agonist AZ921had no effect 
RQ,/71)ĮRU3'.P5NA expression in human and rat myotubes. This finding 
indicates that GPR40 receptor may not mediate skeletal muscle insulin 
resistance through induction of 71)Į, IL6 or PDK4 in skeletal muscle. 
The role of GPR40 agonists and antagonists in skeletal muscle were further 
investigated using Affymetrix microarrays.  Interestingly, no relationship was 
found between GPR40 activation or inhibition with alterations in the expression of 
metabolic genes suggesting that GPR40 may have other, as yet unidentified, 
roles in skeletal muscle. In fact, the GPR40 antagonist had a strong relationship 
with genes involved in cell proliferation particularly with ERBB2, an epidermal 
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growth factor receptor (EGFR).  Cross-talk between G protein-coupled receptors 
(GPCRs) and EGFR signalling systems is widely established in a variety of normal 
and transformed cell types. As discussed earlier in chapter 5, the GPR40 agonist 
AZ921had no significant affect which might due to the high constitutive activity of 
GPR40. In summary, treatment of human skeletal muscle cultured cells with a 
GPR40 antagonist induced activation of cell proliferation through different 
upstream regulators which seem to have different pathways as 2 to 4 
downstream transcripts were found to be in common. This study concluded that it 
is the GPR40 antagonist and not the agonist that leads to cell proliferation and 
suggested the potential use of GPR40 antagonist in treatment of human muscle 
disease. The role of the GPR40 agonists in human breast cancer cell line (MCF-7), 
mammary epithelial and human bronchial epithelial cells proliferation was 
previously demonstrated (Yonezawa et al. 2004) (Yonezawa et al. 2008) (Hardy 
et al. 2005) (Gras et al. 2009b).   One important aspect of any GPR40 agonist or 
antagonist that may be used to treat a chronic condition such as type 2 diabetes 
or muscle disease is the potential for GPR40 modulation to exert carcinogenic 
effects. This warrants further investigation as it might hold the key to the use of 
GPR40 agonists and antagonist in near future. Prolonged clinical studies will 
ultimately establish the long-term use of GPR40 agonists or antagonists by 
delineating the biological functions of GPR40 and whether these can be 
modulated to treat human disease. 
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Appendix 3: List of low expressed genes in myotube 
compared to skeletal muscle tissue  
Table 1: List of low expressed genes in myotube compared to skeletal muscle tissue related to 
Carbohydrate metabolism. 
 
Symbol Entrez Gene Name Fold Change
FBP2 fructose-1,6-bisphosphatase 2 -6480.477
PYGM phosphorylase, glycogen, muscle -4373.799
SLC2A4 solute carrier family 2 (facilitated glucose transporter), member 4 -3329.179
LPL lipoprotein lipase -2198.27
GPD1 glycerol-3-phosphate dehydrogenase 1 (soluble) -1028.407
PGAM2 phosphoglycerate mutase 2 (muscle) -779.711
mir-133 microRNA 133b -715.926
CXCL14 chemokine (C-X-C motif) ligand 14 -709.304
DLK1 delta-like 1 homolog (Drosophila) -511.989
PLCD4 phospholipase C, delta 4 -289.439
NOS1 nitric oxide synthase 1 (neuronal) -245.532
CD38 CD38 molecule -227.534
HRASLS HRAS-like suppressor -217.855
PRKCQ protein kinase C, theta -206.128
P2RY2 purinergic receptor P2Y, G-protein coupled, 2 -201.032
PDK4 pyruvate dehydrogenase kinase, isozyme 4 -176.367
PHKG1 phosphorylase kinase, gamma 1 (muscle) -173.694
CD36 CD36 molecule (thrombospondin receptor) -165.23
KLF15 Kruppel-like factor 15 -158.555
UCP3 uncoupling protein 3 (mitochondrial, proton carrier) -156.344
PHKA1 phosphorylase kinase, alpha 1 (muscle) -146.376
MLXIPL MLX interacting protein-like -113.783
PFKFB1 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 -112.554
ESRRG estrogen-related receptor gamma -91.59
HYAL1 hyaluronoglucosaminidase 1 -89.867
SLC25A12 solute carrier family 25 (aspartate/glutamate carrier), member 12 -88.9
CAMK2A calcium/calmodulin-dependent protein kinase II alpha -62.127
ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 -61.947
BMP5 bone morphogenetic protein 5 -60.751
EEF1A2 eukaryotic translation elongation factor 1 alpha 2 -54.824
PPARGC1A peroxisome proliferator-activated receptor gamma, coactivator 1 alpha -51.108
CKM creatine kinase, muscle -50.899
AQP1 aquaporin 1 (Colton blood group) -50.721
PPARGC1B peroxisome proliferator-activated receptor gamma, coactivator 1 beta -49.366
ESR1 estrogen receptor 1 -48.794
AGL amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase -47.748
EPM2A epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) -44.728
PRKAA2 protein kinase, AMP-activated, alpha 2 catalytic subunit -40.409
PFKM phosphofructokinase, muscle -30.145
EGF epidermal growth factor -29.058
PCDH12 protocadherin 12 -27.343
GHR growth hormone receptor -26.417
MGAT4A mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, 
isozyme A
-26.112
PARK2 parkinson protein 2, E3 ubiquitin protein ligase (parkin) -23.64
FABP3 fatty acid binding protein 3, muscle and heart (mammary-derived growth 
inhibitor)
-23.068
ACADM acyl-CoA dehydrogenase, C-4 to C-12 straight chain -20.62
IMPA2 inositol(myo)-1(or 4)-monophosphatase 2 -20.385
PTPRC protein tyrosine phosphatase, receptor type, C -20.365
GYG1 glycogenin 1 -20.24
S1PR1 sphingosine-1-phosphate receptor 1 -19.637
SORBS1 sorbin and SH3 domain containing 1 -19.187
ACACB acetyl-CoA carboxylase beta -18.902
AKR1B10 aldo-keto reductase family 1, member B10 (aldose reductase) -18.726
POMC proopiomelanocortin -17.947
ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 -17.736
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Table 1: (Continued) 
 
Symbol Entrez Gene Name Fold Change
CSF1R colony stimulating factor 1 receptor -17.608
APOD apolipoprotein D -16.216
PGM1 phosphoglucomutase 1 -16.089
RRAD Ras-related associated with diabetes -16.073
GOT1 glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase 1) -15.991
PDGFB platelet-derived growth factor beta polypeptide -15.917
USF2 upstream transcription factor 2, c-fos interacting -13.867
USP2 ubiquitin specific peptidase 2 -13.449
CEBPB CCAAT/enhancer binding protein (C/EBP), beta -12.894
PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) -12.874
HADH hydroxyacyl-CoA dehydrogenase -12.683
HFE hemochromatosis -12.505
SLC2A8 solute carrier family 2 (facilitated glucose transporter), member 8 -12.337
IL18 interleukin 18 (interferon-gamma-inducing factor) -12.335
ALDH2 aldehyde dehydrogenase 2 family (mitochondrial) -12.246
INPP5D inositol polyphosphate-5-phosphatase, 145kDa -12.031
PRKG1 protein kinase, cGMP-dependent, type I -11.739
TLR2 toll-like receptor 2 -11.465
SEPP1 selenoprotein P, plasma, 1 -11.444
PPP1R3C protein phosphatase 1, regulatory subunit 3C -11.32
LYVE1 lymphatic vessel endothelial hyaluronan receptor 1 -11.257
PLA2G4C phospholipase A2, group IVC (cytosolic, calcium-independent) -11.253
ACSL1 acyl-CoA synthetase long-chain family member 1 -11.063
NOS3 nitric oxide synthase 3 (endothelial cell) -10.848
NPY1R neuropeptide Y receptor Y1 -10.842
LIPE lipase, hormone-sensitive -10.644
VDAC1 voltage-dependent anion channel 1 -10.367
CSGALNACT1 chondroitin sulfate N-acetylgalactosaminyltransferase 1 -10.262
SERP1 stress-associated endoplasmic reticulum protein 1 -10.134
NT5C1A 5'-nucleotidase, cytosolic IA -10.024
ESRRA estrogen-related receptor alpha -9.987
NR4A1 nuclear receptor subfamily 4, group A, member 1 -9.941
CRY2 cryptochrome 2 (photolyase-like) -9.745
LTF lactotransferrin -9.532
PANK1 pantothenate kinase 1 -9.394
FABP4 fatty acid binding protein 4, adipocyte -9.354
CS citrate synthase -9.071
GBP5 guanylate binding protein 5 -8.982
ACTA1 actin, alpha 1, skeletal muscle -8.961
ABCC8 ATP-binding cassette, sub-family C (CFTR/MRP), member 8 -8.861
PRKCB protein kinase C, beta -8.791
ACVR2B activin A receptor, type IIB -8.528
ATP8A1 ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 -8.502
ZBTB20 zinc finger and BTB domain containing 20 -8.361
CRYAB crystallin, alpha B -8.196
SCP2 sterol carrier protein 2 -8.134
RTN2 reticulon 2 -8.074
AK1 adenylate kinase 1 -8.052
ARPP19 cAMP-regulated phosphoprotein, 19kDa -8.035
LIFR leukemia inhibitory factor receptor alpha -7.467
FOXO4 forkhead box O4 -7.382
TLR5 toll-like receptor 5 -7.337
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Table 1: (Continued) 
 
Symbol Entrez Gene Name Fold Change
ALDOA aldolase A, fructose-bisphosphate -7.33
ABCB4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 -7.187
HYAL4 hyaluronoglucosaminidase 4 -7.115
MLYCD malonyl-CoA decarboxylase -7.045
SLC37A4 solute carrier family 37 (glucose-6-phosphate transporter), member 4 -6.909
BAG1 BCL2-associated athanogene -6.864
NR1I3 nuclear receptor subfamily 1, group I, member 3 -6.849
ACADVL acyl-CoA dehydrogenase, very long chain -6.586
MFN2 mitofusin 2 -6.385
PRKAG3 protein kinase, AMP-activated, gamma 3 non-catalytic subunit -6.383
PPARA peroxisome proliferator-activated receptor alpha -6.153
COQ2 coenzyme Q2 homolog, prenyltransferase (yeast) -6.149
NR4A3 nuclear receptor subfamily 4, group A, member 3 -6.032
TNF tumor necrosis factor -5.997
PPP1CB protein phosphatase 1, catalytic subunit, beta isozyme -5.903
PHKB phosphorylase kinase, beta -5.899
PLIN2 perilipin 2 -5.836
GPLD1 glycosylphosphatidylinositol specific phospholipase D1 -5.824
CRAT carnitine O-acetyltransferase -5.58
HIF1AN hypoxia inducible factor 1, alpha subunit inhibitor -5.506
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha -5.429
RHOQ ras homolog family member Q -5.354
LNPEP leucyl/cystinyl aminopeptidase -5.155
IP6K3 inositol hexakisphosphate kinase 3 -5.098
FABP5 fatty acid binding protein 5 (psoriasis-associated) -4.991
DGKZ diacylglycerol kinase, zeta -4.964
UGP2 UDP-glucose pyrophosphorylase 2 -4.963
MAPK14 mitogen-activated protein kinase 14 -4.926
PRDX2 peroxiredoxin 2 -4.926
PRKAB2 protein kinase, AMP-activated, beta 2 non-catalytic subunit -4.918
PLD1 phospholipase D1, phosphatidylcholine-specific -4.905
FCGR2A Fc fragment of IgG, low affinity IIa, receptor (CD32) -4.812
PGR progesterone receptor -4.689
APPL1 adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper 
containing 1
-4.633
PPM1A protein phosphatase, Mg2+/Mn2+ dependent, 1A -4.623
PPARG peroxisome proliferator-activated receptor gamma -4.579
AKR1B1 aldo-keto reductase family 1, member B1 (aldose reductase) -4.567
CPE carboxypeptidase E -4.558
SIRT3 sirtuin 3 -4.53
B4GALNT1 beta-1,4-N-acetyl-galactosaminyl transferase 1 -4.479
ADCY5 adenylate cyclase 5 -4.381
ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 -4.339
ASPN asporin -4.33
SNRPN small nuclear ribonucleoprotein polypeptide N -4.288
PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 -4.239
MLXIP MLX interacting protein -4.217
WDTC1 WD and tetratricopeptide repeats 1 -4.185
CDO1 cysteine dioxygenase, type I -4.185
DECR1 2,4-dienoyl CoA reductase 1, mitochondrial -4.162
DAB2IP DAB2 interacting protein -4.151
PLA1A phospholipase A1 member A -4.125
FITM2 fat storage-inducing transmembrane protein 2 -3.94
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Table 1: (Continued) 
 
Symbol Entrez Gene Name Fold Change
PIK3CB phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta -3.899
CIDEA cell death-inducing DFFA-like effector a -3.886
RGS3 regulator of G-protein signaling 3 -3.844
APLN apelin -3.842
PITPNC1 phosphatidylinositol transfer protein, cytoplasmic 1 -3.82
SSTR2 somatostatin receptor 2 -3.796
SLC27A1 solute carrier family 27 (fatty acid transporter), member 1 -3.768
S1PR2 sphingosine-1-phosphate receptor 2 -3.738
TEK TEK tyrosine kinase, endothelial -3.734
ADRB2 adrenoceptor beta 2, surface -3.707
TFF1 trefoil factor 1 -3.702
NR1H4 nuclear receptor subfamily 1, group H, member 4 -3.695
PLEK pleckstrin -3.695
SH2B2 SH2B adaptor protein 2 -3.677
GYS1 glycogen synthase 1 (muscle) -3.65
HEXA hexosaminidase A (alpha polypeptide) -3.583
APOE apolipoprotein E -3.538
CAT catalase -3.532
PPP1CC protein phosphatase 1, catalytic subunit, gamma isozyme -3.474
ADIPOQ adiponectin, C1Q and collagen domain containing -3.45
ADIPOR2 adiponectin receptor 2 -3.401
PGK1 phosphoglycerate kinase 1 -3.365
IL1RN interleukin 1 receptor antagonist -3.328
PBX1 pre-B-cell leukemia homeobox 1 -3.322
SPI1 spleen focus forming virus (SFFV) proviral integration oncogene spi1 -3.284
O3FAR1 omega-3 fatty acid receptor 1 -3.274
TIRAP toll-interleukin 1 receptor (TIR) domain containing adaptor protein -3.257
GAPDH glyceraldehyde-3-phosphate dehydrogenase -3.254
BCAT2 branched chain amino-acid transaminase 2, mitochondrial -3.225
PPIP5K1 diphosphoinositol pentakisphosphate kinase 1 -3.178
TPI1 triosephosphate isomerase 1 -3.178
IGFBP5 insulin-like growth factor binding protein 5 -3.094
H6PD hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) -3.086
AKT2 v-akt murine thymoma viral oncogene homolog 2 -3.056
PARP1 poly (ADP-ribose) polymerase 1 -3.049
NPHS1 nephrosis 1, congenital, Finnish type (nephrin) -3.008
B3GALNT2 beta-1,3-N-acetylgalactosaminyltransferase 2 -2.951
OMA1 OMA1 zinc metallopeptidase homolog (S. cerevisiae) -2.884
TXNIP thioredoxin interacting protein -2.854
AGK acylglycerol kinase -2.821
IRS2 insulin receptor substrate 2 -2.787
RBP4 retinol binding protein 4, plasma -2.74
ATF3 activating transcription factor 3 -2.722
IGF2 insulin-like growth factor 2 (somatomedin A) -2.715
PPP3R2 protein phosphatase 3, regulatory subunit B, beta -2.713
ERN1 endoplasmic reticulum to nucleus signaling 1 -2.706
NRIP1 nuclear receptor interacting protein 1 -2.696
GALT galactose-1-phosphate uridylyltransferase -2.685
GRK5 G protein-coupled receptor kinase 5 -2.681
ATXN2 ataxin 2 -2.646
SRF serum response factor (c-fos serum response element-binding transcription 
factor)
-2.644
CCL5 chemokine (C-C motif) ligand 5 -2.637
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Table 1: (Continued)
 
Symbol Entrez Gene Name Fold Change
PTGER4 prostaglandin E receptor 4 (subtype EP4) -2.631
SOD2 superoxide dismutase 2, mitochondrial -2.61
MTRR 5-methyltetrahydrofolate-homocysteine methyltransferase reductase -2.569
PNPLA8 patatin-like phospholipase domain containing 8 -2.557
IKBKB inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta -2.548
TACR1 tachykinin receptor 1 -2.542
PLCH2 phospholipase C, eta 2 -2.506
LARGE like-glycosyltransferase -2.498
TNKS2 tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase 2 -2.494
CXADR coxsackie virus and adenovirus receptor -2.488
SQSTM1 sequestosome 1 -2.479
PRKD3 protein kinase D3 -2.478
FGF23 fibroblast growth factor 23 -2.43
IL10 interleukin 10 -2.416
CCRN4L CCR4 carbon catabolite repression 4-like (S. cerevisiae) -2.413
PCCA propionyl CoA carboxylase, alpha polypeptide -2.411
CAV3 caveolin 3 -2.405
NR2C2 nuclear receptor subfamily 2, group C, member 2 -2.397
PCYT1A phosphate cytidylyltransferase 1, choline, alpha -2.387
SRGN serglycin -2.384
ONECUT1 one cut homeobox 1 -2.382
SOCS7 suppressor of cytokine signaling 7 -2.379
G6PC glucose-6-phosphatase, catalytic subunit -2.376
ADRA1A adrenoceptor alpha 1A -2.375
IRS4 insulin receptor substrate 4 -2.372
IGF1R insulin-like growth factor 1 receptor -2.37
BTC betacellulin -2.37
CYP19A1 cytochrome P450, family 19, subfamily A, polypeptide 1 -2.369
ASIP agouti signaling protein -2.368
CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5 -2.362
IL6ST interleukin 6 signal transducer (gp130, oncostatin M receptor) -2.362
INSRR insulin receptor-related receptor -2.362
PCK1 phosphoenolpyruvate carboxykinase 1 (soluble) -2.36
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 -2.359
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 -2.359
ALDOB aldolase B, fructose-bisphosphate -2.348
PKLR pyruvate kinase, liver and RBC -2.346
F2 coagulation factor II (thrombin) -2.345
UGT2B28 UDP glucuronosyltransferase 2 family, polypeptide B28 -2.344
TAT tyrosine aminotransferase -2.341
HRH3 histamine receptor H3 -2.339
APOC3 apolipoprotein C-III -2.338
IL17F interleukin 17F -2.336
HTR2C 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled -2.335
ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 -2.334
MTNR1B melatonin receptor 1B -2.334
LRAT lecithin retinol acyltransferase (phosphatidylcholine--retinol O-acyltransferase) -2.333
B3GAT1 beta-1,3-glucuronyltransferase 1 (glucuronosyltransferase P) -2.322
ESR2 estrogen receptor 2 (ER beta) -2.321
CD22 CD22 molecule -2.317
CYP3A4 cytochrome P450, family 3, subfamily A, polypeptide 4 -2.316
GRB10 growth factor receptor-bound protein 10 -2.316
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Table 1: (Continued) 
 
 
Symbol Entrez Gene Name Fold Change
IL4 interleukin 4 -2.312
GPRC6A G protein-coupled receptor, family C, group 6, member A -2.312
RPS6KB1 ribosomal protein S6 kinase, 70kDa, polypeptide 1 -2.31
SLC30A8 solute carrier family 30 (zinc transporter), member 8 -2.309
IL1R2 interleukin 1 receptor, type II -2.308
LEP leptin -2.306
CNR2 cannabinoid receptor 2 (macrophage) -2.305
PRLR prolactin receptor -2.303
SOD1 superoxide dismutase 1, soluble -2.303
SLC13A1 solute carrier family 13 (sodium/sulfate symporters), member 1 -2.292
NTRK1 neurotrophic tyrosine kinase, receptor, type 1 -2.289
PLA2G10 phospholipase A2, group X -2.289
POFUT1 protein O-fucosyltransferase 1 -2.289
OBP2A odorant binding protein 2A -2.282
ACP1 acid phosphatase 1, soluble -2.279
SLC12A1 solute carrier family 12 (sodium/potassium/chloride transporters), member 1 -2.278
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma 
derived oncogene homolog (avian)
-2.277
CA5A carbonic anhydrase VA, mitochondrial -2.269
INPP5E inositol polyphosphate-5-phosphatase, 72 kDa -2.268
ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) -2.253
GCNT3 glucosaminyl (N-acetyl) transferase 3, mucin type -2.247
NEU3 sialidase 3 (membrane sialidase) -2.245
FGF10 fibroblast growth factor 10 -2.238
UCP1 uncoupling protein 1 (mitochondrial, proton carrier) -2.236
THRA thyroid hormone receptor, alpha -2.228
ABCB11 ATP-binding cassette, sub-family B (MDR/TAP), member 11 -2.225
CEL carboxyl ester lipase (bile salt-stimulated lipase) -2.222
TSHR thyroid stimulating hormone receptor -2.221
C1QBP complement component 1, q subcomponent binding protein -2.206
AGER advanced glycosylation end product-specific receptor -2.203
PTPRE protein tyrosine phosphatase, receptor type, E -2.198
MC2R melanocortin 2 receptor (adrenocorticotropic hormone) -2.174
PPP1R3D protein phosphatase 1, regulatory subunit 3D -2.124
TRHR thyrotropin-releasing hormone receptor -2.119
ARNT aryl hydrocarbon receptor nuclear translocator -2.117
DGAT1 diacylglycerol O-acyltransferase 1 -2.107
POMT1 protein-O-mannosyltransferase 1 -2.088
DGAT2 diacylglycerol O-acyltransferase 2 -2.068
PEX11B peroxisomal biogenesis factor 11 beta -2.067
TRPC3 transient receptor potential cation channel, subfamily C, member 3 -2.065
UCP2 uncoupling protein 2 (mitochondrial, proton carrier) -2.063
PPP3CA protein phosphatase 3, catalytic subunit, alpha isozyme -2.049
MECP2 methyl CpG binding protein 2 (Rett syndrome) -2.047
RELA v-rel reticuloendotheliosis viral oncogene homolog A (avian) -2.043
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Table 2: List of Low expressed genes in myotube compared to skeletal muscle tissue related to lipid 
metabolism. 
 
Symbol Entrez Gene Name Fold Change
GPIHBP1 glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 -4606.449
SLC2A4 solute carrier family 2 (facilitated glucose transporter), member 4 -3329.179
LPL lipoprotein lipase -2198.27
ANKRD23 ankyrin repeat domain 23 -1097.932
PLIN5 perilipin 5 -410.365
HRASLS HRAS-like suppressor -217.855
PDK4 pyruvate dehydrogenase kinase, isozyme 4 -176.367
CD36 CD36 molecule (thrombospondin receptor) -165.23
UCP3 uncoupling protein 3 (mitochondrial, proton carrier) -156.344
MLXIPL MLX interacting protein-like -113.783
FGR Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog -106.935
CPT1B carnitine palmitoyltransferase 1B (muscle) -97.448
CNTFR ciliary neurotrophic factor receptor -96.53
ERBB4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) -67.807
CD74 CD74 molecule, major histocompatibility complex, class II invariant chain -59.088
PPARGC1A peroxisome proliferator-activated receptor gamma, coactivator 1 alpha -51.108
PPARGC1B peroxisome proliferator-activated receptor gamma, coactivator 1 beta -49.366
ESR1 estrogen receptor 1 -48.794
ABCC6 ATP-binding cassette, sub-family C (CFTR/MRP), member 6 -46.906
ABCG1 ATP-binding cassette, sub-family G (WHITE), member 1 -44.984
PRKAA2 protein kinase, AMP-activated, alpha 2 catalytic subunit -40.409
ACSS1 acyl-CoA synthetase short-chain family member 1 -36.598
EGF epidermal growth factor -29.058
ACSL6 acyl-CoA synthetase long-chain family member 6 -26.642
GHR growth hormone receptor -26.417
THRB thyroid hormone receptor, beta -25.103
FABP3 fatty acid binding protein 3, muscle and heart (mammary-derived growth 
inhibitor)
-23.068
ACADS acyl-CoA dehydrogenase, C-2 to C-3 short chain -21.627
ACADM acyl-CoA dehydrogenase, C-4 to C-12 straight chain -20.62
ADH1C alcohol dehydrogenase 1C (class I), gamma polypeptide -20.238
PHYH phytanoyl-CoA 2-hydroxylase -20.072
S1PR1 sphingosine-1-phosphate receptor 1 -19.637
GOT2 glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate 
aminotransferase 2)
-19.42
ACACB acetyl-CoA carboxylase beta -18.902
POMC proopiomelanocortin -17.947
OSBPL1A oxysterol binding protein-like 1A -17.945
APOD apolipoprotein D -16.216
CEBPB CCAAT/enhancer binding protein (C/EBP), beta -12.894
LPIN1 lipin 1 -12.73
HADH hydroxyacyl-CoA dehydrogenase -12.683
PRKAR2B protein kinase, cAMP-dependent, regulatory, type II, beta -12.425
IL18 interleukin 18 (interferon-gamma-inducing factor) -12.335
LRPPRC leucine-rich pentatricopeptide repeat containing -11.873
CADM1 cell adhesion molecule 1 -11.814
TLR2 toll-like receptor 2 -11.465
PLA2G4C phospholipase A2, group IVC (cytosolic, calcium-independent) -11.253
SUCLA2 succinate-CoA ligase, ADP-forming, beta subunit -11.067
ACSL1 acyl-CoA synthetase long-chain family member 1 -11.063
SUCLG1 succinate-CoA ligase, alpha subunit -11.005
MDH2 malate dehydrogenase 2, NAD (mitochondrial) -10.709
LIPE lipase, hormone-sensitive -10.644
ACADL acyl-CoA dehydrogenase, long chain -10.286
SDHA succinate dehydrogenase complex, subunit A, flavoprotein (Fp) -10.212
ESRRA estrogen-related receptor alpha -9.987
KL klotho -9.957
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Table 2: (Continued)
 
Symbol Entrez Gene Name Fold Change
MITF microphthalmia-associated transcription factor -9.7
PDHA1 pyruvate dehydrogenase (lipoamide) alpha 1 -9.535
LTF lactotransferrin -9.532
FABP4 fatty acid binding protein 4, adipocyte -9.354
CS citrate synthase -9.071
CYCS cytochrome c, somatic -9.063
PEX5 peroxisomal biogenesis factor 5 -8.753
ATP8A1 ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 -8.502
SDHB succinate dehydrogenase complex, subunit B, iron sulfur (Ip) -8.425
ACSBG1 acyl-CoA synthetase bubblegum family member 1 -8.361
SCP2 sterol carrier protein 2 -8.134
SMPD3 sphingomyelin phosphodiesterase 3, neutral membrane (neutral 
sphingomyelinase II)
-8.13
ABCB4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 -7.187
MLYCD malonyl-CoA decarboxylase -7.045
OGDH oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide) -6.993
ACSL5 acyl-CoA synthetase long-chain family member 5 -6.667
ACADVL acyl-CoA dehydrogenase, very long chain -6.586
NUDT7 nudix (nucleoside diphosphate linked moiety X)-type motif 7 -6.508
IL16 interleukin 16 -6.484
IL33 interleukin 33 -6.448
FAAH fatty acid amide hydrolase -6.399
CNR1 cannabinoid receptor 1 (brain) -6.398
TEF thyrotrophic embryonic factor -6.389
NTRK2 neurotrophic tyrosine kinase, receptor, type 2 -6.337
IL18RAP interleukin 18 receptor accessory protein -6.301
DLAT dihydrolipoamide S-acetyltransferase -6.267
EDNRB endothelin receptor type B -6.243
PPARA peroxisome proliferator-activated receptor alpha -6.153
CYP27A1 cytochrome P450, family 27, subfamily A, polypeptide 1 -6.109
NR4A3 nuclear receptor subfamily 4, group A, member 3 -6.032
TNF tumor necrosis factor -5.997
PLIN2 perilipin 2 -5.836
CRAT carnitine O-acetyltransferase -5.58
SLC10A2 solute carrier family 10 (sodium/bile acid cotransporter family), member 2 -5.565
SUCLG2 succinate-CoA ligase, GDP-forming, beta subunit -5.432
ATP5J ATP synthase, H+ transporting, mitochondrial Fo complex, subunit F6 -5.321
PLA2G4F phospholipase A2, group IVF -5.286
IMMT inner membrane protein, mitochondrial -5.162
PLA2G16 phospholipase A2, group XVI -5.099
FABP5 fatty acid binding protein 5 (psoriasis-associated) -4.991
HOXA10 homeobox A10 -4.987
SLC22A5 solute carrier family 22 (organic cation/carnitine transporter), member 5 -4.978
FH fumarate hydratase -4.961
HADHB hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase 
(trifunctional protein), beta subunit
-4.935
MAPK14 mitogen-activated protein kinase 14 -4.926
SLC36A1 solute carrier family 36 (proton/amino acid symporter), member 1 -4.877
TECR trans-2,3-enoyl-CoA reductase -4.851
FCGR2A Fc fragment of IgG, low affinity IIa, receptor (CD32) -4.812
ECI1 enoyl-CoA delta isomerase 1 -4.794
PGR progesterone receptor -4.689
APPL1 adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper 
containing 1
-4.633
DBP D site of albumin promoter (albumin D-box) binding protein -4.618
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Table 2: (Continued)
 
Symbol Entrez Gene Name Fold Change
PPARG peroxisome proliferator-activated receptor gamma -4.579
AKR1B1 aldo-keto reductase family 1, member B1 (aldose reductase) -4.567
ECI2 enoyl-CoA delta isomerase 2 -4.485
B4GALNT1 beta-1,4-N-acetyl-galactosaminyl transferase 1 -4.479
ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 -4.339
HADHA hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase 
(trifunctional protein), alpha subunit
-4.295
IL15 interleukin 15 -4.269
DLD dihydrolipoamide dehydrogenase -4.198
MID1IP1 MID1 interacting protein 1 -4.191
WDTC1 WD and tetratricopeptide repeats 1 -4.185
ACOT1 acyl-CoA thioesterase 1 -4.18
DECR1 2,4-dienoyl CoA reductase 1, mitochondrial -4.162
FITM2 fat storage-inducing transmembrane protein 2 -3.94
PIK3CB phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta -3.899
PITPNC1 phosphatidylinositol transfer protein, cytoplasmic 1 -3.82
SLC27A1 solute carrier family 27 (fatty acid transporter), member 1 -3.768
ADRB2 adrenoceptor beta 2, surface -3.707
NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, 
alpha
-3.702
NR1H4 nuclear receptor subfamily 1, group H, member 4 -3.695
B4GALT6 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 6 -3.662
STAT5B signal transducer and activator of transcription 5B -3.662
ME2 malic enzyme 2, NAD(+)-dependent, mitochondrial -3.575
ME3 malic enzyme 3, NADP(+)-dependent, mitochondrial -3.574
APOE apolipoprotein E -3.538
CAT catalase -3.532
PTGES2 prostaglandin E synthase 2 -3.462
ADIPOQ adiponectin, C1Q and collagen domain containing -3.45
ADIPOR2 adiponectin receptor 2 -3.401
B3GALT4 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 4 -3.379
NFATC2 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 -3.371
IL1RN interleukin 1 receptor antagonist -3.328
OSBP oxysterol binding protein -3.282
PEBP1 phosphatidylethanolamine binding protein 1 -3.171
CASP8 caspase 8, apoptosis-related cysteine peptidase -3.082
AKT2 v-akt murine thymoma viral oncogene homolog 2 -3.056
CLEC7A C-type lectin domain family 7, member A -3.051
NR5A2 nuclear receptor subfamily 5, group A, member 2 -3.035
QKI QKI, KH domain containing, RNA binding -2.865
VEGFA vascular endothelial growth factor A -2.858
AGK acylglycerol kinase -2.821
IRS2 insulin receptor substrate 2 -2.787
ALOX5AP arachidonate 5-lipoxygenase-activating protein -2.75
RBP4 retinol binding protein 4, plasma -2.74
IGF2 insulin-like growth factor 2 (somatomedin A) -2.715
IDE insulin-degrading enzyme -2.684
CCL5 chemokine (C-C motif) ligand 5 -2.637
MECR mitochondrial trans-2-enoyl-CoA reductase -2.599
PNPLA8 patatin-like phospholipase domain containing 8 -2.557
TACR1 tachykinin receptor 1 -2.542
PCCB propionyl CoA carboxylase, beta polypeptide -2.52
MGLL monoglyceride lipase -2.513
LARGE like-glycosyltransferase -2.498
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Table 2: (Continued)
 
Symbol Entrez Gene Name Fold Change
HMGCL 3-hydroxymethyl-3-methylglutaryl-CoA lyase -2.463
ARV1 ARV1 homolog (S. cerevisiae) -2.444
IL10 interleukin 10 -2.416
CCRN4L CCR4 carbon catabolite repression 4-like (S. cerevisiae) -2.413
PLA2G2D phospholipase A2, group IID -2.412
PCCA propionyl CoA carboxylase, alpha polypeptide -2.411
PCYT1A phosphate cytidylyltransferase 1, choline, alpha -2.387
SLCO1A2 solute carrier organic anion transporter family, member 1A2 -2.371
IGF1R insulin-like growth factor 1 receptor -2.37
CYP19A1 cytochrome P450, family 19, subfamily A, polypeptide 1 -2.369
CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5 -2.362
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 -2.359
F2 coagulation factor II (thrombin) -2.345
FASLG Fas ligand (TNF superfamily, member 6) -2.341
APOC3 apolipoprotein C-III -2.338
ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 -2.334
ESR2 estrogen receptor 2 (ER beta) -2.321
ABCD2 ATP-binding cassette, sub-family D (ALD), member 2 -2.32
CYP3A4 cytochrome P450, family 3, subfamily A, polypeptide 4 -2.316
IL4 interleukin 4 -2.312
IL1R2 interleukin 1 receptor, type II -2.308
LEP leptin -2.306
SLCO6A1 solute carrier organic anion transporter family, member 6A1 -2.304
SOD1 superoxide dismutase 1, soluble -2.303
KLF2 Kruppel-like factor 2 (lung) -2.292
PLA2G10 phospholipase A2, group X -2.289
MAP3K1 mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase -2.286
OBP2A odorant binding protein 2A -2.282
CYP2C19 cytochrome P450, family 2, subfamily C, polypeptide 19 -2.279
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma 
derived oncogene homolog (avian)
-2.277
MAP2K1 mitogen-activated protein kinase kinase 1 -2.269
UCP1 uncoupling protein 1 (mitochondrial, proton carrier) -2.236
FA2H fatty acid 2-hydroxylase -2.228
THRA thyroid hormone receptor, alpha -2.228
PLA2G3 phospholipase A2, group III -2.226
ABCB11 ATP-binding cassette, sub-family B (MDR/TAP), member 11 -2.225
CEL carboxyl ester lipase (bile salt-stimulated lipase) -2.222
CYP46A1 cytochrome P450, family 46, subfamily A, polypeptide 1 -2.219
AGER advanced glycosylation end product-specific receptor -2.203
GSN gelsolin -2.198
HSPA8 heat shock 70kDa protein 8 -2.177
ALOX15 arachidonate 15-lipoxygenase -2.173
SLCO2A1 solute carrier organic anion transporter family, member 2A1 -2.134
DBI diazepam binding inhibitor (GABA receptor modulator, acyl-CoA binding 
protein)
-2.113
DGAT1 diacylglycerol O-acyltransferase 1 -2.107
ACAA1 acetyl-CoA acyltransferase 1 -2.082
HSD17B4 hydroxysteroid (17-beta) dehydrogenase 4 -2.075
NAA40 N(alpha)-acetyltransferase 40, NatD catalytic subunit, homolog (S. cerevisiae) -2.075
ME1 malic enzyme 1, NADP(+)-dependent, cytosolic -2.068
MAP2K4 mitogen-activated protein kinase kinase 4 -2.067
UCP2 uncoupling protein 2 (mitochondrial, proton carrier) -2.063
SLC16A1 solute carrier family 16, member 1 (monocarboxylic acid transporter 1) -2.058
ABCG5 ATP-binding cassette, sub-family G (WHITE), member 5 -2.053
RELA v-rel reticuloendotheliosis viral oncogene homolog A (avian) -2.043
RASGRP4 RAS guanyl releasing protein 4 -2.037
EPAS1 endothelial PAS domain protein 1 -2.018
APPENDICES 
 
 
 
  
Table 3: List of Low expressed genes in myotube compared to skeletal muscle tissue related to 
energy production.
 
Symbol Entrez Gene Name Fold Change
SLC2A4 solute carrier family 2 (facilitated glucose transporter), member 4 -3329.179
LPL lipoprotein lipase -2198.27
PLIN5 perilipin 5 -410.365
S100A1 S100 calcium binding protein A1 -374.526
NOS1 nitric oxide synthase 1 (neuronal) -245.532
PDK4 pyruvate dehydrogenase kinase, isozyme 4 -176.367
CD36 CD36 molecule (thrombospondin receptor) -165.23
UCP3 uncoupling protein 3 (mitochondrial, proton carrier) -156.344
MAPT microtubule-associated protein tau -141.057
MLXIPL MLX interacting protein-like -113.783
SLC25A12 solute carrier family 25 (aspartate/glutamate carrier), member 12 -88.9
PPARGC1A peroxisome proliferator-activated receptor gamma, coactivator 1 alpha -51.108
PPARGC1B peroxisome proliferator-activated receptor gamma, coactivator 1 beta -49.366
ABCG1 ATP-binding cassette, sub-family G (WHITE), member 1 -44.984
EPM2A epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) -44.728
RYR1 ryanodine receptor 1 (skeletal) -43.562
PRKAA2 protein kinase, AMP-activated, alpha 2 catalytic subunit -40.409
EGF epidermal growth factor -29.058
ACSL6 acyl-CoA synthetase long-chain family member 6 -26.642
THRB thyroid hormone receptor, beta -25.103
PARK2 parkinson protein 2, E3 ubiquitin protein ligase (parkin) -23.64
FABP3 fatty acid binding protein 3, muscle and heart (mammary-derived growth 
inhibitor)
-23.068
ACADS acyl-CoA dehydrogenase, C-2 to C-3 short chain -21.627
ACADM acyl-CoA dehydrogenase, C-4 to C-12 straight chain -20.62
ADH1C alcohol dehydrogenase 1C (class I), gamma polypeptide -20.238
SOX6 SRY (sex determining region Y)-box 6 -20.137
PHYH phytanoyl-CoA 2-hydroxylase -20.072
GOT2 glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate 
aminotransferase 2)
-19.42
ACACB acetyl-CoA carboxylase beta -18.902
POMC proopiomelanocortin -17.947
CREB5 cAMP responsive element binding protein 5 -14.264
LPIN1 lipin 1 -12.73
HADH hydroxyacyl-CoA dehydrogenase -12.683
IL18 interleukin 18 (interferon-gamma-inducing factor) -12.335
LRPPRC leucine-rich pentatricopeptide repeat containing -11.873
ACSL1 acyl-CoA synthetase long-chain family member 1 -11.063
NOS3 nitric oxide synthase 3 (endothelial cell) -10.848
NPY1R neuropeptide Y receptor Y1 -10.842
LIPE lipase, hormone-sensitive -10.644
NDUFS1 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa (NADH-coenzyme Q 
reductase)
-10.521
VDAC1 voltage-dependent anion channel 1 -10.367
ACADL acyl-CoA dehydrogenase, long chain -10.286
ESRRA estrogen-related receptor alpha -9.987
KL klotho -9.957
NR4A1 nuclear receptor subfamily 4, group A, member 1 -9.941
CYCS cytochrome c, somatic -9.063
PINK1 PTEN induced putative kinase 1 -8.965
ABCC8 ATP-binding cassette, sub-family C (CFTR/MRP), member 8 -8.861
PEX5 peroxisomal biogenesis factor 5 -8.753
ATP6 ATP synthase F0 subunit 6 -8.66
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Table 3: (Continued)
Symbol Entrez Gene Name Fold Change
CRYAB crystallin, alpha B -8.196
ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide -7.735
ALDOA aldolase A, fructose-bisphosphate -7.33
DES desmin -7.084
MLYCD malonyl-CoA decarboxylase -7.045
ACSL5 acyl-CoA synthetase long-chain family member 5 -6.667
COQ7 coenzyme Q7 homolog, ubiquinone (yeast) -6.59
ACADVL acyl-CoA dehydrogenase, very long chain -6.586
MFN2 mitofusin 2 -6.385
ATP5G1 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C1 (subunit 
9)
-6.265
PPARA peroxisome proliferator-activated receptor alpha -6.153
CYP27A1 cytochrome P450, family 27, subfamily A, polypeptide 1 -6.109
NR4A3 nuclear receptor subfamily 4, group A, member 3 -6.032
TNF tumor necrosis factor -5.997
COX8A cytochrome c oxidase subunit VIIIA (ubiquitous) -5.717
ATP5D ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit -5.679
RXRA retinoid X receptor, alpha -5.604
CRAT carnitine O-acetyltransferase -5.58
COX3 cytochrome c oxidase III -5.537
HIF1AN hypoxia inducible factor 1, alpha subunit inhibitor -5.506
IMMT inner membrane protein, mitochondrial -5.162
SLC22A5 solute carrier family 22 (organic cation/carnitine transporter), member 5 -4.978
HADHB hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase 
(trifunctional protein), beta subunit
-4.935
MAPK14 mitogen-activated protein kinase 14 -4.926
ECI1 enoyl-CoA delta isomerase 1 -4.794
NDUFAF1 NADH dehydrogenase (ubiquinone) complex I, assembly factor 1 -4.768
EEF2K eukaryotic elongation factor-2 kinase -4.656
APPL1 adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper 
containing 1
-4.633
PPARG peroxisome proliferator-activated receptor gamma -4.579
SIRT3 sirtuin 3 -4.53
ECI2 enoyl-CoA delta isomerase 2 -4.485
HADHA hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase 
(trifunctional protein), alpha subunit
-4.295
PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 -4.239
TH tyrosine hydroxylase -4.206
NAMPT nicotinamide phosphoribosyltransferase -4.186
DECR1 2,4-dienoyl CoA reductase 1, mitochondrial -4.162
FITM2 fat storage-inducing transmembrane protein 2 -3.94
NDUFS6 NADH dehydrogenase (ubiquinone) Fe-S protein 6, 13kDa (NADH-coenzyme Q 
reductase)
-3.887
SLC27A1 solute carrier family 27 (fatty acid transporter), member 1 -3.768
ADRB2 adrenoceptor beta 2, surface -3.707
APOE apolipoprotein E -3.538
CAT catalase -3.532
ADIPOQ adiponectin, C1Q and collagen domain containing -3.45
ADIPOR2 adiponectin receptor 2 -3.401
IL1RN interleukin 1 receptor antagonist -3.328
AKT2 v-akt murine thymoma viral oncogene homolog 2 -3.056
PARP1 poly (ADP-ribose) polymerase 1 -3.049
MNF1 mitochondrial nucleoid factor 1 -3.019
TYR tyrosinase (oculocutaneous albinism IA) -2.934
MEF2D myocyte enhancer factor 2D -2.906
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 Table 3: (Continued)
 
Symbol Entrez Gene Name Fold Change
OMA1 OMA1 zinc metallopeptidase homolog (S. cerevisiae) -2.884
NMNAT1 nicotinamide nucleotide adenylyltransferase 1 -2.873
TXNIP thioredoxin interacting protein -2.854
LDHA lactate dehydrogenase A -2.79
IRS2 insulin receptor substrate 2 -2.787
NRIP1 nuclear receptor interacting protein 1 -2.696
IDE insulin-degrading enzyme -2.684
PNPLA8 patatin-like phospholipase domain containing 8 -2.557
MSRA methionine sulfoxide reductase A -2.544
SQSTM1 sequestosome 1 -2.479
NR2C2 nuclear receptor subfamily 2, group C, member 2 -2.397
IGF1R insulin-like growth factor 1 receptor -2.37
CYP19A1 cytochrome P450, family 19, subfamily A, polypeptide 1 -2.369
CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5 -2.362
PKLR pyruvate kinase, liver and RBC -2.346
HRH3 histamine receptor H3 -2.339
ESR2 estrogen receptor 2 (ER beta) -2.321
ABCD2 ATP-binding cassette, sub-family D (ALD), member 2 -2.32
CYP3A4 cytochrome P450, family 3, subfamily A, polypeptide 4 -2.316
IL4 interleukin 4 -2.312
RBL1 retinoblastoma-like 1 (p107) -2.307
LEP leptin -2.306
SOD1 superoxide dismutase 1, soluble -2.303
ADK adenosine kinase -2.292
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog -2.284
OBP2A odorant binding protein 2A -2.282
CYP2C19 cytochrome P450, family 2, subfamily C, polypeptide 19 -2.279
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma 
derived oncogene homolog (avian)
-2.277
UCP1 uncoupling protein 1 (mitochondrial, proton carrier) -2.236
THRA thyroid hormone receptor, alpha -2.228
WNT3A wingless-type MMTV integration site family, member 3A -2.216
AGER advanced glycosylation end product-specific receptor -2.203
PTPMT1 protein tyrosine phosphatase, mitochondrial 1 -2.191
TFAM transcription factor A, mitochondrial -2.14
SLCO2A1 solute carrier organic anion transporter family, member 2A1 -2.134
DNM1L dynamin 1-like -2.125
DGAT1 diacylglycerol O-acyltransferase 1 -2.107
ACAA1 acetyl-CoA acyltransferase 1 -2.082
HSD17B4 hydroxysteroid (17-beta) dehydrogenase 4 -2.075
UCP2 uncoupling protein 2 (mitochondrial, proton carrier) -2.063
RELA v-rel reticuloendotheliosis viral oncogene homolog A (avian) -2.043
EPAS1 endothelial PAS domain protein 1 -2.018
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Table 4: List of Low expressed genes in myotube compared to skeletal muscle tissue related to 
protein metabolism.
 
Symbol Entrez Gene Name Fold Change
SLC2A4 solute carrier family 2 (facilitated glucose transporter), member 4 -3329.179
CKMT2 creatine kinase, mitochondrial 2 (sarcomeric) -985.349
NOS1 nitric oxide synthase 1 (neuronal) -245.532
PDK4 pyruvate dehydrogenase kinase, isozyme 4 -176.367
SLC25A4 solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), 
member 4
-69.464
CKM creatine kinase, muscle -50.899
PRKAA2 protein kinase, AMP-activated, alpha 2 catalytic subunit -40.409
EGF epidermal growth factor -29.058
GHR growth hormone receptor -26.417
ASPA aspartoacylase -25.332
THRB thyroid hormone receptor, beta -25.103
FABP3 fatty acid binding protein 3, muscle and heart (mammary-derived growth 
inhibitor)
-23.068
GAMT guanidinoacetate N-methyltransferase -20.568
GOT2 glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate 
aminotransferase 2)
-19.42
RXRG retinoid X receptor, gamma -18.255
POMC proopiomelanocortin -17.947
GOT1 glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase 1) -15.991
CD34 CD34 molecule -15.361
HOMER2 homer homolog 2 (Drosophila) -14.36
DDC dopa decarboxylase (aromatic L-amino acid decarboxylase) -14.194
HADH hydroxyacyl-CoA dehydrogenase -12.683
NOS3 nitric oxide synthase 3 (endothelial cell) -10.848
GATM glycine amidinotransferase (L-arginine:glycine amidinotransferase) -9.61
PANK1 pantothenate kinase 1 -9.394
ABCC8 ATP-binding cassette, sub-family C (CFTR/MRP), member 8 -8.861
SMPD3 sphingomyelin phosphodiesterase 3, neutral membrane (neutral 
sphingomyelinase II)
-8.13
GLUL glutamate-ammonia ligase -7.788
NR1I3 nuclear receptor subfamily 1, group I, member 3 -6.849
ACADVL acyl-CoA dehydrogenase, very long chain -6.586
LIAS lipoic acid synthetase -6.533
FAAH fatty acid amide hydrolase -6.399
PPARA peroxisome proliferator-activated receptor alpha -6.153
TNF tumor necrosis factor -5.997
SLC6A8 solute carrier family 6 (neurotransmitter transporter, creatine), member 8 -5.689
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha -5.429
PRODH proline dehydrogenase (oxidase) 1 -5.34
DDO D-aspartate oxidase -5.282
SLC22A5 solute carrier family 22 (organic cation/carnitine transporter), member 5 -4.978
HOMER1 homer homolog 1 (Drosophila) -4.765
SLC7A8 solute carrier family 7 (amino acid transporter light chain, L system), member 8 -4.25
TH tyrosine hydroxylase -4.206
CDO1 cysteine dioxygenase, type I -4.185
SPR sepiapterin reductase (7,8-dihydrobiopterin:NADP+ oxidoreductase) -4.129
FOS FBJ murine osteosarcoma viral oncogene homolog -4.026
PCYOX1 prenylcysteine oxidase 1 -3.72
CD86 CD86 molecule -3.63
ME2 malic enzyme 2, NAD(+)-dependent, mitochondrial -3.575
APOE apolipoprotein E -3.538
BCKDHA branched chain keto acid dehydrogenase E1, alpha polypeptide -3.467
MCCC2 methylcrotonoyl-CoA carboxylase 2 (beta) -3.415
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Table 4: (Continued)
 
Symbol Entrez Gene Name Fold Change
GSTZ1 glutathione S-transferase zeta 1 -3.321
BCAT2 branched chain amino-acid transaminase 2, mitochondrial -3.225
MUT methylmalonyl CoA mutase -3.002
EFNA5 ephrin-A5 -2.785
MTRR 5-methyltetrahydrofolate-homocysteine methyltransferase reductase -2.569
MSRA methionine sulfoxide reductase A -2.544
PCCB propionyl CoA carboxylase, beta polypeptide -2.52
IL10 interleukin 10 -2.416
PCCA propionyl CoA carboxylase, alpha polypeptide -2.411
DBT dihydrolipoamide branched chain transacylase E2 -2.391
PCYT1A phosphate cytidylyltransferase 1, choline, alpha -2.387
IGF1R insulin-like growth factor 1 receptor -2.37
PCK1 phosphoenolpyruvate carboxykinase 1 (soluble) -2.36
CGA glycoprotein hormones, alpha polypeptide -2.345
TAT tyrosine aminotransferase -2.341
IL4 interleukin 4 -2.312
MCHR1 melanin-concentrating hormone receptor 1 -2.309
LEP leptin -2.306
PRLR prolactin receptor -2.303
PRKCE protein kinase C, epsilon -2.259
CD80 CD80 molecule -2.259
UCP1 uncoupling protein 1 (mitochondrial, proton carrier) -2.236
THRA thyroid hormone receptor, alpha -2.228
TSHR thyroid stimulating hormone receptor -2.221
NFS1 NFS1 nitrogen fixation 1 homolog (S. cerevisiae) -2.181
TRHR thyrotropin-releasing hormone receptor -2.119
MTHFR methylenetetrahydrofolate reductase (NAD(P)H) -2.087
MECP2 methyl CpG binding protein 2 (Rett syndrome) -2.047
PSPH phosphoserine phosphatase -2.043
BCKDHB branched chain keto acid dehydrogenase E1, beta polypeptide -2.032
MTHFD1 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1, 
methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthetase
-2.032
PICK1 protein interacting with PRKCA 1 -2.001
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 Table 5: List of Low expressed genes in myotube compared to skeletal muscle tissue related to 
mitochondria dysfunction.
 
Symbol Entrez Gene Name Fold Change
MAOB monoamine oxidase B -2484.776
CPT1B carnitine palmitoyltransferase 1B (muscle) -97.448
MAPK12 mitogen-activated protein kinase 12 -46.432
COX7B cytochrome c oxidase subunit VIIb -24.49
PARK2 parkinson protein 2, E3 ubiquitin protein ligase (parkin) -23.64
COX7A1 cytochrome c oxidase subunit VIIa polypeptide 1 (muscle) -22.431
COX4I2 cytochrome c oxidase subunit IV isoform 2 (lung) -20.916
MAOA monoamine oxidase A -15.857
COX6A2 cytochrome c oxidase subunit VIa polypeptide 2 -13.739
NDUFB10 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10, 22kDa -12.022
NDUFS7 NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20kDa (NADH-coenzyme Q 
reductase)
-11.716
NDUFS1 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa (NADH-coenzyme Q 
reductase)
-10.521
SDHA succinate dehydrogenase complex, subunit A, flavoprotein (Fp) -10.212
UQCRFS1 ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 -9.909
NDUFS3 NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa (NADH-coenzyme Q 
reductase)
-9.536
PDHA1 pyruvate dehydrogenase (lipoamide) alpha 1 -9.535
ATP5A1 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, 
cardiac muscle
-9.496
NDUFS2 NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa (NADH-coenzyme Q 
reductase)
-9.197
CYCS cytochrome c, somatic -9.063
PINK1 PTEN induced putative kinase 1 -8.965
COX5A cytochrome c oxidase subunit Va -8.902
COX5B cytochrome c oxidase subunit Vb -8.764
SDHB succinate dehydrogenase complex, subunit B, iron sulfur (Ip) -8.425
COX1 cytochrome c oxidase subunit I -8.379
UQCRC1 ubiquinol-cytochrome c reductase core protein I -8.298
LRRK2 leucine-rich repeat kinase 2 -8.038
ND5 NADH dehydrogenase, subunit 5 (complex I) -7.88
NDUFA10 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 10, 42kDa -7.744
ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide -7.735
NDUFV2 NADH dehydrogenase (ubiquinone) flavoprotein 2, 24kDa -7.692
NDUFB9 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9, 22kDa -7.566
CYC1 cytochrome c-1 -7.474
NDUFA6 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 14kDa -7.393
NDUFB3 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3, 12kDa -7.188
CYTB cytochrome b -7.149
OGDH oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide) -6.993
NDUFA5 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5, 13kDa -6.663
SDHD succinate dehydrogenase complex, subunit D, integral membrane protein -6.624
NDUFV3 NADH dehydrogenase (ubiquinone) flavoprotein 3, 10kDa -6.212
ATP5C1 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 
1
-6.051
COX8A cytochrome c oxidase subunit VIIIA (ubiquitous) -5.717
NDUFA12 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 -5.695
NDUFA9 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39kDa -5.598
COX3 cytochrome c oxidase III -5.537
COX2 cytochrome c oxidase subunit II -5.47
COX4I1 cytochrome c oxidase subunit IV isoform 1 -5.378
ATP5J ATP synthase, H+ transporting, mitochondrial Fo complex, subunit F6 -5.321
NDUFA7 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7, 14.5kDa -5.227
NDUFB7 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 18kDa -4.947
NDUFB5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 16kDa -4.932
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 Table 5: (Continued)
 
Symbol Entrez Gene Name Fold Change
NDUFS4 NADH dehydrogenase (ubiquinone) Fe-S protein 4, 18kDa (NADH-coenzyme Q 
reductase)
-4.819
COX6B1 cytochrome c oxidase subunit VIb polypeptide 1 (ubiquitous) -4.811
UQCRC2 ubiquinol-cytochrome c reductase core protein II -4.799
NDUFV1 NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kDa -4.77
NDUFAF1 NADH dehydrogenase (ubiquinone) complex I, assembly factor 1 -4.768
PRDX3 peroxiredoxin 3 -4.695
NDUFA2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 8kDa -4.652
UQCR11 ubiquinol-cytochrome c reductase, complex III subunit XI -4.543
UQCRH ubiquinol-cytochrome c reductase hinge protein -4.452
NDUFA8 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8, 19kDa -4.394
COX7C cytochrome c oxidase subunit VIIc -4.391
NDUFS6 NADH dehydrogenase (ubiquinone) Fe-S protein 6, 13kDa (NADH-coenzyme Q 
reductase)
-3.887
NDUFA3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 9kDa -3.871
NDUFB4 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 15kDa -3.66
COX6C cytochrome c oxidase subunit VIc -3.636
CAT catalase -3.532
NDUFS8 NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa (NADH-coenzyme Q 
reductase)
-3.481
AIFM1 apoptosis-inducing factor, mitochondrion-associated, 1 -3.425
COX17 COX17 cytochrome c oxidase assembly homolog (S. cerevisiae) -3.199
NDUFB6 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa -3.11
CASP8 caspase 8, apoptosis-related cysteine peptidase -3.082
NDUFS5 NADH dehydrogenase (ubiquinone) Fe-S protein 5, 15kDa (NADH-coenzyme Q 
reductase)
-2.945
NDUFA13 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 -2.851
SOD2 superoxide dismutase 2, mitochondrial -2.61
FIS1 fission 1 (mitochondrial outer membrane) homolog (S. cerevisiae) -2.446
COX6A1 cytochrome c oxidase subunit VIa polypeptide 1 -2.225
MAP2K4 mitogen-activated protein kinase kinase 4 -2.067
UCP2 uncoupling protein 2 (mitochondrial, proton carrier) -2.063
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Table 6: List of Low expressed genes in myotube compared to skeletal muscle tissue related to 
calcium signalling. 
 
Symbol Entrez Gene Name Fold Change
CASQ1 calsequestrin 1 (fast-twitch, skeletal muscle) -3128.116
MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow -2435.062
ATP2A1 ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 -672.378
TRDN triadin -308.202
TNNI2 troponin I type 2 (skeletal, fast) -135.175
TNNI3 troponin I type 3 (cardiac) -87.453
MYH11 myosin, heavy chain 11, smooth muscle -80.244
MYL2 myosin, light chain 2, regulatory, cardiac, slow -63.976
CAMK2A calcium/calmodulin-dependent protein kinase II alpha -62.127
ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 -61.947
TPM3 tropomyosin 3 -49.685
RYR3 ryanodine receptor 3 -44.983
RYR1 ryanodine receptor 1 (skeletal) -43.562
MYH2 myosin, heavy chain 2, skeletal muscle, adult -40.062
TNNT3 troponin T type 3 (skeletal, fast) -27.717
TNNC2 troponin C type 2 (fast) -22.838
MYL1 myosin, light chain 1, alkali; skeletal, fast -20.491
TNNC1 troponin C type 1 (slow) -19.648
TNNT1 troponin T type 1 (skeletal, slow) -14.543
CREB5 cAMP responsive element binding protein 5 -14.264
TP63 tumor protein p63 -12.987
MYH7 myosin, heavy chain 7, cardiac muscle, beta -12.585
PRKAR2B protein kinase, cAMP-dependent, regulatory, type II, beta -12.425
MYH1 myosin, heavy chain 1, skeletal muscle, adult -12.397
ACTA1 actin, alpha 1, skeletal muscle -8.961
HDAC9 histone deacetylase 9 -8.74
CAMK2G calcium/calmodulin-dependent protein kinase II gamma -7.294
PRKAR2A protein kinase, cAMP-dependent, regulatory, type II, alpha -5.954
PPP3CB protein phosphatase 3, catalytic subunit, beta isozyme -5.865
ASPH aspartate beta-hydroxylase -5.802
NFATC1 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 -5.798
TNNI1 troponin I type 1 (skeletal, slow) -5.744
MEF2C myocyte enhancer factor 2C -4.756
ACTC1 actin, alpha, cardiac muscle 1 -4.724
HDAC5 histone deacetylase 5 -4.65
CHRNA5 cholinergic receptor, nicotinic, alpha 5 (neuronal) -4.114
ACTA2 actin, alpha 2, smooth muscle, aorta -3.836
NFATC3 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 -3.765
HDAC10 histone deacetylase 10 -3.672
HDAC4 histone deacetylase 4 -3.585
NFATC2 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 -3.371
HDAC11 histone deacetylase 11 -3.103
MEF2D myocyte enhancer factor 2D -2.906
MYH14 myosin, heavy chain 14, non-muscle -2.898
PRKAG1 protein kinase, AMP-activated, gamma 1 non-catalytic subunit -2.803
PPP3R2 protein phosphatase 3, regulatory subunit B, beta -2.713
PRKACA protein kinase, cAMP-dependent, catalytic, alpha -2.634
CALM1 calmodulin 1 (phosphorylase kinase, delta) -2.532
HDAC8 histone deacetylase 8 -2.418
GRIN2A glutamate receptor, ionotropic, N-methyl D-aspartate 2A -2.359
CAMK1G calcium/calmodulin-dependent protein kinase IG -2.34
TRPV6 transient receptor potential cation channel, subfamily V, member 6 -2.313
ATP2A3 ATPase, Ca++ transporting, ubiquitous -2.298
TRPC2 transient receptor potential cation channel, subfamily C, member 2 -2.298
TRPC6 transient receptor potential cation channel, subfamily C, member 6 -2.29
CALML5 calmodulin-like 5 -2.28
MYH4 myosin, heavy chain 4, skeletal muscle -2.231
TRPC3 transient receptor potential cation channel, subfamily C, member 3 -2.065
PPP3CA protein phosphatase 3, catalytic subunit, alpha isozyme -2.049
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Appendix 4: List of up regulated genes in mytube vs skeletal 
muscle tissue. 
Table 1: List of up regulated genes in MT vs skeletal muscle TIS related to skeletal muscle 
proliferation. 
 
ID
Prediction (based on 
expression direction)
Fold 
Change
Findings Entrez Gene Name
POSTN Increased 2432.253 Increases (1) periostin, osteoblast specific factor
IL6 Increased 456.32 Increases (6) interleukin 4 receptor
GATA6 Increased 198.633 Increases (2) GATA binding protein 6
RGS4 Decreased 131.933 Decreases (1) regulator of G-protein signaling 4
IGFBP3 Decreased 98.432 Decreases (1) insulin-l ike growth factor binding protein 3
FN1 Increased 73.187 Increases (1) fibronectin 1
MMP14 Increased 60.372 Increases (1) matrix metallopeptidase 14 (membrane-inserted)
TNC Increased 47.24 Increases (1) tenascin C
VCAN Increased 39.177 Increases (1) versican
HMGA2 Increased 37.237 Increases (2) high mobility group AT-hook 2
PAPPA Increased 30.67 Increases (2) pregnancy-associated plasma protein A, pappalysin 1
CDKN1A Decreased 30.432 Decreases (4) cyclin-dependent kinase 2 associated protein 2
NRG1 Increased 28.718 Increases (1) neuregulin 1
IL1B Increased 25.016 Increases (4) inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma
HIF1A Increased 23.93 Increases (2)
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix 
transcription factor)
ELN Decreased 21.355 Decreases (4) elastin
FGF2 Increased 20.559 Increases (29) fibroblast growth factor 2 (basic)
FGF1 Increased 19.66 Increases (1) fibroblast growth factor 1 (acidic)
LRP1 Decreased 17.488 Decreases (1) low density l ipoprotein receptor-related protein 1
KLF5 Increased 17.369 Increases (2) Kruppel-l ike factor 5 (intestinal)
FGFR2 Increased 12.255 Increases (2) fibroblast growth factor receptor 2
TNFRSF12A Increased 10.952 Increases (1) tumor necrosis factor receptor superfamily, member 12A
IGFBP4 Increased 10.278 Increases (1) insulin-l ike growth factor binding protein 4
ID2 Increased 10.192 Increases (3) inhibitor of DNA binding 2, dominant negative helix-loop-helix protein
PTGS2 Increased 9.967 Increases (1)
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and 
cyclooxygenase)
SPARC Decreased 9.857 Decreases (1) secreted protein, acidic, cysteine-rich (osteonectin)
MYF5 Affected 9.234 Affects (1) myogenic factor 5
GJA1 Affected 8.995 Affects (1) gap junction protein, alpha 1, 43kDa
MIF Increased 8.941 Increases (2) macrophage migration inhibitory factor (glycosylation-inhibiting factor)
MYC Affected 7.943 Affects (5) v-myc myelocytomatosis viral oncogene homolog (avian)
TNFRSF10B Affected 6.99 Affects (1) tumor necrosis factor receptor superfamily, member 10b
NQO1 Decreased 6.5 Decreases (1) NAD(P)H dehydrogenase, quinone 1
TFPI2 Decreased 6.439 Decreases (1) tissue factor pathway inhibitor 2
SLC9A1 Increased 6.422 Increases (1) solute carrier family 9, subfamily A (NHE1, cation proton antiporter 1), 
F3 Increased 6.409 Increases (1) coagulation factor II (thrombin) receptor-l ike 2
SOCS3 Decreased 5.694 Decreases (4) suppressor of cytokine signaling 3
SHC1 Increased 5.685 Increases (3) SHC (Src homology 2 domain containing) transforming protein 1
IRAK4 Increased 5.475 Increases (1) interleukin-1 receptor-associated kinase 4
TP53 Decreased 4.933 Decreases (5) tumor protein p53
TGFBR2 Affected 4.882 Affects (2) transforming growth factor, beta receptor II (70/80kDa)
ATP2B1 Decreased 4.779 Decreases (1) ATPase, Ca++ transporting, plasma membrane 1
CTNNB1 Increased 4.767 Increases (3) catenin (cadherin-associated protein), beta 1, 88kDa
PLAT Increased 4.667 Increases (1) plasminogen activator, tissue
S1PR2 Increased 4.538 Increases (3) sphingosine-1-phosphate receptor 2
HEYL Affected 4.375 Affects (1) hairy/enhancer-of-split related with YRPW motif-l ike
BDNF Increased 4.198 Increases (1) brain-derived neurotrophic factor
FOXP1 Decreased 3.958 Decreases (3) forkhead box P1
ITGB1 Decreased 3.865 Decreases (2)
integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 
includes MDF2, MSK12)
TXN Decreased 3.849 Decreases (1) thioredoxin
DNAJB6 Decreased 3.693 Decreases (2) DnaJ (Hsp40) homolog, subfamily B, member 11
PRNP Increased 3.661 Increases (1) prion protein
MYD88 Increased 3.517 Increases (1) myeloid differentiation primary response gene (88)
IGFBP1 Increased 3.414 Increases (1) insulin-l ike growth factor binding protein 1
GNAQ Increased 3.138 Increases (2) guanine nucleotide binding protein (G protein), q polypeptide
ABCC2 Decreased 3.024 Decreases (1) ATP-binding cassette, sub-family C (CFTR/MRP), member 2
GSK3B Decreased 3.019 Decreases (5) glycogen synthase kinase 3 beta
CREB1 Decreased 2.988 Decreases (1) cAMP responsive element binding protein 1
FBLN5 Affected 2.978 Affects (2) fibulin 5
ROCK1 Increased 2.976 Increases (1) Rho-associated, coiled-coil  containing protein kinase 1
PPIA Increased 2.899 Increases (6) peptidylprolyl isomerase A (cyclophilin A)
TGM2 Increased 2.889 Increases (1) transglutaminase 2 (C polypeptide, protein-glutamine-gamma-
TNFRSF1A Decreased 2.883 Decreases (2) tumor necrosis factor receptor superfamily, member 1A
H19 Affected 2.833 Affects (1) H19, imprinted maternally expressed transcript (non-protein coding)
EDN1 Increased 2.827 Increases (10) endothelin 1
IRAK1 Increased 2.724 Increases (1) interleukin-1 receptor-associated kinase 1
ITGA6 Decreased 2.695 Decreases (1) integrin, alpha 11
BMPR2 Decreased 2.652 Decreases (2) bone morphogenetic protein receptor, type II (serine/threonine kinase)
RAB1A Increased 2.636 Increases (7) RAB13, member RAS oncogene family
NFE2L2 Decreased 2.576 Decreases (1) nuclear factor (erythroid-derived 2)-l ike 2
PTPN11 Increased 2.485 Increases (1)
protein tyrosine phosphatase-like (proline instead of catalytic arginine), 
member b
KRAS Affected 2.418 Affects (1) v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
ABCC4 Increased 2.232 Increases (1) ATP-binding cassette, sub-family C (CFTR/MRP), member 4
TLR4 Increased 2.216 Increases (1) toll-l ike receptor 4
NOG Decreased 2.168 Decreases (3) noggin
YAP1 Increased 2.113 Increases (3) Yes-associated protein 1
PLCE1 Increased 2.103 Increases (9) phospholipase C, epsilon 1
EPC1 Affected 2.1 Affects (1) enhancer of polycomb homolog 1 (Drosophila)
MYOG Increased 2.096 Increases (1) myogenin (myogenic factor 4)
TNFAIP3 Decreased 2.05 Decreases (1) tumor necrosis factor, alpha-induced protein 3
CCDC88A Increased 2.048 Increases (1) coiled-coil  domain containing 88A
PTEN Decreased 2.048 Decreases (1) phosphatase and tensin homolog
HMGB1 Increased 2.034 Increases (1) high mobility group box 1
MKL1 Affected 2.02 Affects (1) megakaryoblastic leukemia (translocation) 1
PRKCA Increased 2.001 Increases (4) protein kinase C, alpha
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Appendix 5: RNA Electorpherogram Summary. 
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Appendix 6: List of genes regulated by GPR40 agonist. 
Table 1: The effect of GPR40 agonist (100nM AZ921) on mRNA expression in himan myotubes  
 
ID Fold Change Entrez Gene Name
PCSK1 3.702 proprotein convertase subtilisin/kexin type 1
BMP6 3.049 bone morphogenetic protein 6
CENPF 2.390 centromere protein F, 350/400kDa (mitosin)
LOC100131564 2.086 uncharacterized LOC100131564
MALAT1 2.063 metastasis associated lung adenocarcinoma transcript 1 (non-protein 
coding)
HNRNPA2B1 2.057 heterogeneous nuclear ribonucleoprotein A2/B1
PDE4D 2.057 phosphodiesterase 4D, cAMP-specific
AHSA2 2.001 AHA1, activator of heat shock 90kDa protein ATPase homolog 2 (yeast)
RPL10 1.999 ribosomal protein L10
ASPM 1.971 asp (abnormal spindle) homolog, microcephaly associated (Drosophila)
FGF7 1.951 fibroblast growth factor 7
SFRS3 1.911 serine/arginine-rich splicing factor 3
P4HA3 1.907 prolyl 4-hydroxylase, alpha polypeptide III
ZBTB20 1.893 zinc finger and BTB domain containing 20
HES1 1.869 hairy and enhancer of split 1, (Drosophila)
NEAT1 1.846 nuclear paraspeckle assembly transcript 1 (non-protein coding)
RBM25 1.843 RNA binding motif protein 25
ATRX 1.842 alpha thalassemia/mental retardation syndrome X-linked
SFRS18 1.840 PNN-interacting serine/arginine-rich protein
PLD1 1.805 phospholipase D1, phosphatidylcholine-specific
PHIP 1.799 pleckstrin homology domain interacting protein
COL3A1 1.789 collagen, type III, alpha 1
DST 1.784 dystonin
PNN 1.779 pinin, desmosome associated protein
HNRNPD 1.756 heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding protein 1, 37kDa)
BNC2 1.754 basonuclin 2
TOP2A 1.739 topoisomerase (DNA) II alpha 170kDa
EFHC1 1.735 EF-hand domain (C-terminal) containing 1
NOTCH2NL 1.724 notch 2 N-terminal like
DTWD1 1.722 DTW domain containing 1
PDK3 1.711 pyruvate dehydrogenase kinase, isozyme 3
MEG3 1.696 maternally expressed 3 (non-protein coding)
RASEF 1.691 RAS and EF-hand domain containing
MIR214 1.684 microRNA 214
ANGPTL2 1.680 angiopoietin-like 2
REV3L 1.661 REV3-like, polymerase (DNA directed), zeta, catalytic subunit
OBSL1 1.645 obscurin-like 1
ABCA1 1.644 ATP-binding cassette, sub-family A (ABC1), member 1
NKTR 1.644 natural killer-tumor recognition sequence
CCNL1 1.639 cyclin L1
RBBP6 1.635 retinoblastoma binding protein 6
EML4 1.632 echinoderm microtubule associated protein like 4
CCNL2 1.631 cyclin L2
C7orf63 1.628 chromosome 7 open reading frame 63
NFIA 1.624 nuclear factor I/A
PDE7B 1.624 phosphodiesterase 7B
ZNF696 1.619 zinc finger protein 696
ARGLU1 1.605 arginine and glutamate rich 1
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Benjamini-Hochberg test) 
Table 1: (Continued)
 
ID Fold Change Entrez Gene Name
CADM4 1.605 cell adhesion molecule 4
CRYBG3 1.601 beta-gamma crystallin domain containing 3
EIF3B 1.599 eukaryotic translation initiation factor 3, subunit B
SNHG12 1.597 small nucleolar RNA host gene 12 (non-protein coding)
AHI1 1.587 Abelson helper integration site 1
ARID4B 1.582 AT rich interactive domain 4B (RBP1-like)
PPAP2B 1.579 phosphatidic acid phosphatase type 2B
CCDC14 1.573 coiled-coil domain containing 14
SF3B1 1.567 splicing factor 3b, subunit 1, 155kDa
TMEM161B 1.560 transmembrane protein 161B
ZNF638 1.560 zinc finger protein 638
ZSCAN5A 1.559 zinc finger and SCAN domain containing 5A
PLEKHN1 1.555 pleckstrin homology domain containing, family N member 1
RPL18 1.555 ribosomal protein L18
SRSF7 1.552 serine/arginine-rich splicing factor 7
GOLGA8A 1.550 golgin A8 family, member B
LUC7L3 1.546 LUC7-like 3 (S. cerevisiae)
ITGA8 1.545 integrin, alpha 8
SLK 1.545 STE20-like kinase
LRCH4 1.540 leucine-rich repeats and calponin homology (CH) domain containing 4
FAM176B 1.538 eva-1 homolog B (C. elegans)
SMC4 1.529 structural maintenance of chromosomes 4
NIPBL 1.528 Nipped-B homolog (Drosophila)
NCRNA00107 1.524 long intergenic non-protein coding RNA 685
ZFC3H1 1.523 zinc finger, C3H1-type containing
CEP350 1.522 centrosomal protein 350kDa
RORA 1.519 RAR-related orphan receptor A
FLJ44342 1.517 uncharacterized LOC645460
DYNC2H1 1.516 dynein, cytoplasmic 2, heavy chain 1
PLAGL1 1.516 pleiomorphic adenoma gene-like 1
ABCC5 1.515 ATP-binding cassette, sub-family C (CFTR/MRP), member 5
KTN1 1.512 kinectin 1 (kinesin receptor)
EIF5B 1.505 eukaryotic translation initiation factor 5B
RRP9 1.503 ribosomal RNA processing 9, small subunit (SSU) processome 
component, homolog (yeast)
SIP1 -1.501 gem (nuclear organelle) associated protein 2
FAM43A -1.502 family with sequence similarity 43, member A
MRS2 -1.502 MRS2 magnesium homeostasis factor homolog (S. cerevisiae)
CDK8 -1.503 cyclin-dependent kinase 8
CARS -1.504 cysteinyl-tRNA synthetase
SMEK1 -1.514 SMEK homolog 1, suppressor of mek1 (Dictyostelium)
BRAP -1.520 BRCA1 associated protein
MEGF6 -1.531 multiple EGF-like-domains 6
CLIC3 -1.534 chloride intracellular channel 3
SIGLEC15 -1.535 sialic acid binding Ig-like lectin 15
NHLRC3 -1.537 NHL repeat containing 3
CMKLR1 -1.540 chemokine-like receptor 1
KCND3 -1.544 potassium voltage-gated channel, Shal-related subfamily, member 3
C16orf72 -1.550 chromosome 16 open reading frame 72
HS6ST2 -1.553 heparan sulfate 6-O-sulfotransferase 2
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ID Fold Change Entrez Gene Name
MYO5B -1.554 myosin VB
CXorf38 -1.555 chromosome X open reading frame 38
IL32 -1.556 interleukin 32
ZNF599 -1.560 zinc finger protein 599
PDGFA -1.568 platelet-derived growth factor alpha polypeptide
DKK2 -1.578 dickkopf 2 homolog (Xenopus laevis)
ANXA3 -1.590 annexin A3
ARHGAP26 -1.590 Rho GTPase activating protein 26
CHST7 -1.593 carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7
NEDD9 -1.598 neural precursor cell expressed, developmentally down-regulated 9
ATP8B1 -1.603 ATPase, aminophospholipid transporter, class I, type 8B, member 1
BCAT1 -1.610 branched chain amino-acid transaminase 1, cytosolic
CCBE1 -1.613 collagen and calcium binding EGF domains 1
APBB2 -1.617 amyloid beta (A4) precursor protein-binding, family B, member 2
SUMO1 -1.620 SMT3 suppressor of mif two 3 homolog 1 (S. cerevisiae)
JAG1 -1.621 jagged 1
DOPEY2 -1.623 dopey family member 2
PCDH19 -1.626 protocadherin 19
INHBE -1.629 inhibin, beta E
PAQR5 -1.632 progestin and adipoQ receptor family member V
C5orf46 -1.639 chromosome 5 open reading frame 46
HDAC9 -1.639 histone deacetylase 9
PRR16 -1.639 proline rich 16
SDPR -1.649 serum deprivation response
FRMD4B -1.654 FERM domain containing 4B
SRD5A1 -1.656 steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1)
HERPUD2 -1.686 HERPUD family member 2
ADRA2A -1.728 adrenoceptor alpha 2A
EHD1 -1.729 EH-domain containing 1
COL13A1 -1.737 collagen, type XIII, alpha 1
MKX -1.742 mohawk homeobox
LPXN -1.746 leupaxin
LYPD6B -1.752 LY6/PLAUR domain containing 6B
DTX4 -1.754 deltex homolog 4 (Drosophila)
KLF5 -1.755 Kruppel-like factor 5 (intestinal)
CDC42EP5 -1.764 CDC42 effector protein (Rho GTPase binding) 5
COL11A1 -1.764 collagen, type XI, alpha 1
TGFB2 -1.769 transforming growth factor, beta 2
C14orf28 -1.777 chromosome 14 open reading frame 28
LASS6 -1.810 ceramide synthase 6
SLC24A3 -1.876 solute carrier family 24 (sodium/potassium/calcium exchanger), 
member 3
C1orf85 -1.892 chromosome 1 open reading frame 85
CITED2 -1.914 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-
terminal domain, 2
NRXN3 -1.930 neurexin 3
RGS4 -1.958 regulator of G-protein signaling 4
OPCML -2.047 opioid binding protein/cell adhesion molecule-like
